<SEC-DOCUMENT>0001347178-20-000013.txt : 20200507
<SEC-HEADER>0001347178-20-000013.hdr.sgml : 20200507
<ACCEPTANCE-DATETIME>20200507070111
ACCESSION NUMBER:		0001347178-20-000013
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200507
DATE AS OF CHANGE:		20200507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vanda Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001347178
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				030491827
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34186
		FILM NUMBER:		20854503

	BUSINESS ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
		BUSINESS PHONE:		202-734-3400

	MAIL ADDRESS:	
		STREET 1:		2200 PENNSYLVANIA AVE NW
		STREET 2:		SUITE 300E
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20037
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vnda331202010q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:9f137b986e9648798e802fa2f947eefb,x:73e42857080a4cca9e1c2a1a9015fdb9-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:vnda="http://www.vandapharmaceuticals.com/20200331" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:AmendmentFlag" id="Fact-DF94991DB43C9033F5ACA3EA1A386533-wk-Fact-DF94991DB43C9033F5ACA3EA1A386533" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-310E06BF556A8BC3455CA3EA1A3D7457-wk-Fact-310E06BF556A8BC3455CA3EA1A3D7457">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-46000437BC781EE856C9A3EA1A3B8CDA-wk-Fact-46000437BC781EE856C9A3EA1A3B8CDA">Q1</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalYearFocus" id="Fact-75CDF076E22FA6CBF858A3EA1A39436A-wk-Fact-75CDF076E22FA6CBF858A3EA1A39436A">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:EntityCentralIndexKey" id="Fact-0DE4695AC94D1F1BCFCCA3EA1A3A8EE1-wk-Fact-0DE4695AC94D1F1BCFCCA3EA1A3A8EE1">0001347178</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q1QTD" name="us-gaap:AmortizationOfIntangibleAssets" id="Fact-3F7B774A03B63EFC9065A3EA1A017354-wk-Fact-3F7B774A03B63EFC9065A3EA1A017354">400000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-C3E5043AC6CDFABBDAABA3EA1A049BB8-wk-Fact-C3E5043AC6CDFABBDAABA3EA1A049BB8">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-41347909997BD91B2CA4A3EA1A07D800-wk-Fact-41347909997BD91B2CA4A3EA1A07D800">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-CD9C74E954D9973C72ADA3EA19FFD442-wk-Fact-CD9C74E954D9973C72ADA3EA19FFD442">150000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesAuthorized" id="Fact-913BEA859641E55F3E64A3EA1A02D5A1-wk-Fact-913BEA859641E55F3E64A3EA1A02D5A1">150000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-39545F43F790BBF0B90BA3EA1A031FEB-wk-Fact-39545F43F790BBF0B90BA3EA1A031FEB">53549612</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesIssued" id="Fact-CBFEC17C0432DB9E7C15A3EA1A00D158-wk-Fact-CBFEC17C0432DB9E7C15A3EA1A00D158">54132336</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-817C990DE84F7E6D9124A3EA1A01709B-wk-Fact-817C990DE84F7E6D9124A3EA1A01709B">53549612</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesOutstanding" id="Fact-77BDDCF88804655BC0CAA3EA19FE8564-wk-Fact-77BDDCF88804655BC0CAA3EA19FE8564">54132336</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_FanaptMember" name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact-6D68E75717AA59D91F09A3EA1A0127B5-wk-Fact-6D68E75717AA59D91F09A3EA1A0127B5">27900000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-E7B487579B20F8B6672DA3EA19FEAB0C-wk-Fact-E7B487579B20F8B6672DA3EA19FEAB0C">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-53C9099F1309DFA9D3DFA3EA1A007F74-wk-Fact-53C9099F1309DFA9D3DFA3EA1A007F74">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-0C87E675D4AEF6F884C0A3EA1A0AB7AD-wk-Fact-0C87E675D4AEF6F884C0A3EA1A0AB7AD">20000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-434953ECF09358C770EAA3EA1A059D47-wk-Fact-434953ECF09358C770EAA3EA1A059D47">20000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-D1E1C7747409D3B968D1A3EA1A0928C4-wk-Fact-D1E1C7747409D3B968D1A3EA1A0928C4">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesIssued" id="Fact-8A16133D9A4B1597F2D3A3EA1A019AFE-wk-Fact-8A16133D9A4B1597F2D3A3EA1A019AFE">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-CF2874BD32DBC1C456C8A3EA19FD5442-wk-Fact-CF2874BD32DBC1C456C8A3EA19FD5442">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-9115BA664A6B2E0F390BA3EA1A015A99-wk-Fact-9115BA664A6B2E0F390BA3EA1A015A99">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" id="Fact-0BF7CE577C300C268B17A3EA1A185DE9-wk-Fact-0BF7CE577C300C268B17A3EA1A185DE9">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="vnda-20200331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q1YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q2Apr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_FanaptMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_vnda_FanaptMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2015Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_vnda_FanaptMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_SalesMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:SalesMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Apr2012March2020_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-04-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Mar2017Mar2020_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="vnda:StatementScenarioSecondaryAxis">vnda:ScenarioFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1March2019_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:FutureRegulatoryApprovalAndSalesMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Feb1Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2004-02-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_VQW765Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:VQW765Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1July2018_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001347178</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="Customer">
		<xbrli:measure>vnda:Customer</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="Segment">
		<xbrli:measure>vnda:Segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="installment">
		<xbrli:measure>vnda:installment</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s64529A648E6257D7A7D1F8F9C82661BA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.366471734892787%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">Form </span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"><span><ix:nonNumeric id="d6355e368-wk-Fact-48D5B06D341FC0BEE34BA3EA19F408B3" name="dei:DocumentType" contextRef="FD2020Q1YTD">10-Q</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.366471734892787%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</span></div><div style="line-height:120%;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:16pt;"><span style="font-family:Arial Unicode MS;font-size:16pt;"><span><ix:nonNumeric id="d6355e402-wk-Fact-18635621C2F1A8188D4CA3EA1A3D86A9" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d6355e412-wk-Fact-4099032E2E2CAC202B7BA3EA1A372CC1" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q1YTD" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">or</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:16pt;"><span style="font-family:Arial Unicode MS;font-size:16pt;"><span><ix:nonNumeric id="d6355e434-wk-Fact-A2BD001CA71390123FB8A3EA19FBC0C0" name="dei:DocumentTransitionReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> to </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d6355e455-wk-Fact-BA4ABF3F27315C94B6A6A3EA1A3A9C8E" name="dei:EntityFileNumber" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">001-34186</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.366471734892787%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:24pt;"><span><ix:nonNumeric id="d6355e476-wk-Fact-831276FEC64142296144A3EA1A366BE9" name="dei:EntityRegistrantName" contextRef="FD2020Q1YTD"><span style="font-size:24pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:24pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.366471734892787%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:30%;"></td><td style="width:22%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6355e510-wk-Fact-9E82DF2E30A6B2CEBBA2A3EA1A0A8D75" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6355e520-wk-Fact-F6BDE2A34EF6AAD47B7FA3EA1A0B0E6A" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q1YTD">03-0491827</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d6355e546-wk-Fact-E851B2F9FAE13D93356BA3EA1A0D4D0E" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">2200 Pennsylvania Avenue NW</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d6355e551-wk-Fact-DFC49C06A6269ED49AF3A3EA19F20E65" name="dei:EntityAddressAddressLine2" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">Suite 300 E </span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d6355e557-wk-Fact-BEDB7135DA29D303BB11A3EA1A38F7E0" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">Washington</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d6355e562-wk-Fact-D7D6CAF89614D753761BA3EA1A358289" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">DC</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d6355e567-wk-Fact-99D33C4995F122D563E6A3EA1A293E1D" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">20037</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d6355e575-wk-Fact-CA13162507809056726DA3EA19EEFDA7" name="dei:CityAreaCode" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">202</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d6355e580-wk-Fact-BD8D28238947CFE87B97A3EA1A32B3F9" name="dei:LocalPhoneNumber" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">734-3400</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:24.366471734892787%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Exchange Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:37%;"></td><td style="width:26%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Title of Each Class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Trading Symbol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Name of Exchange on Which Registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6355e633-wk-Fact-AA83CC2BB5A56A82E82CA3EA1A38CB6C" name="dei:Security12bTitle" contextRef="FD2020Q1YTD">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6355e638-wk-Fact-305C92A940A1769AE245A3EA1A381279" name="dei:TradingSymbol" contextRef="FD2020Q1YTD">VNDA</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d6355e643-wk-Fact-08F211992DE4F8212625A3EA1A370F7E" name="dei:SecurityExchangeName" contextRef="FD2020Q1YTD" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d6355e650-wk-Fact-DB163F990645DBAD318FA3EA19EFEF55" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q1YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d6355e665-wk-Fact-8F630ADD012022CBD1E3A3EA1A36642A" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q1YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.14230019493176%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d6355e701-wk-Fact-30C5347BE6EF737C4ACAA3EA1A2C4540" name="dei:EntityFilerCategory" contextRef="FD2020Q1YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">x</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d6355e803-wk-Fact-09B582D81522E2E67803A3EA1A2D53C1" name="dei:EntitySmallBusiness" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging&#160;growth&#160;company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d6355e875-wk-Fact-5AA34741C3D1281B2436A3EA1A364BC0" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d6355e887-wk-Fact-C40867033B6C1B37660AA3EA1A3FFF4F" name="dei:EntityShellCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">x</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">April&#160;30, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d6355e903-wk-Fact-59AC751C306D558085D4A3EA1A19C379" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2Apr30" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">54,550,461</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the registrant&#8217;s common stock issued and outstanding.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s43749DCED2A75F9787DAB212383DDBE9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Vanda Pharmaceuticals Inc.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Report on Form 10-Q</span></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">For the Quarter Ended </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:87%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s988CFDFD51A85F088714320585B1270F"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1CBC45944C9256B58C6ECE8D88FCBF2D"><span style="font-family:inherit;font-size:10pt;">Financial Statements (Unaudited)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1CBC45944C9256B58C6ECE8D88FCBF2D"> 5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s222A95751BA95AAC93B7ADDB0DD577DA"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets as of March 31, 2020 and December&#160;31, 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s222A95751BA95AAC93B7ADDB0DD577DA"> 5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA4EF862ACB5050C9AFD65F3D8211293B"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA4EF862ACB5050C9AFD65F3D8211293B"> 6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE8700535EAA35C3E879076270B82C5BB"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE8700535EAA35C3E879076270B82C5BB"> 7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s163019044C21586B88CB8E8DF42E2049"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statement of Changes in Stockholders&#8217; Equity for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s163019044C21586B88CB8E8DF42E2049"> 8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDE6B839C059A55C9B9D2B9BBA5EF35BC"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sDE6B839C059A55C9B9D2B9BBA5EF35BC"> 9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAD20E2A330CE5224B4A40B64CC1AA5C9"><span style="font-family:inherit;font-size:10pt;">Notes to the Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAD20E2A330CE5224B4A40B64CC1AA5C9"> 10</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4B3FBA3207275B6386D502EAFDA29298"><span style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4B3FBA3207275B6386D502EAFDA29298"> 22</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;3</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E3EC5E873735ACF9E33C7B0F8F11275"><span style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5E3EC5E873735ACF9E33C7B0F8F11275"> 30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;4</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD6F606401923505AAC539FAA3ED3D058"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD6F606401923505AAC539FAA3ED3D058"> 31</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#s30300DF8A77853A1A4BA357A56BBDAF4"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART&#160;II&#160;&#8211; OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F40A6AFB31857CC9BF70016761EF7DA"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2F40A6AFB31857CC9BF70016761EF7DA"> 31</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;1A</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A20EA5FDBD55683B80C1C4645DDD3BD"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A20EA5FDBD55683B80C1C4645DDD3BD"> 34</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s06E63EA43547510B8A7FC0DE2023A656"><span style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s06E63EA43547510B8A7FC0DE2023A656"> 35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;3</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD266263AA381541EBED79E8BF0CAD4C5"><span style="font-family:inherit;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD266263AA381541EBED79E8BF0CAD4C5"> 35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;4</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD0D443A1079C5B9AB6A56ABAB5613C65"><span style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD0D443A1079C5B9AB6A56ABAB5613C65"> 35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;5</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8D7896B1686350EAB95212CC0254FC68"><span style="font-family:inherit;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8D7896B1686350EAB95212CC0254FC68"> 35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ITEM&#160;6</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68330179D12D5A6A99DB319596368FCA"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68330179D12D5A6A99DB319596368FCA"> 37</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD43394A1FB825224806C40093EFDE0AF"><span style="font-family:inherit;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD43394A1FB825224806C40093EFDE0AF"> 38</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s732A0439624559A5B1B8A0F77BBED424"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This quarterly report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act) and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act). Words such as, but not limited to, &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;likely,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and &#8220;could,&#8221; or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The forward-looking statements in this quarterly report on Form 10-Q may include, among other things, statements about:</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) to continue to commercialize HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (tasimelteon) for the treatment of Non-24-hour Sleep-Wake Disorder (Non-24) in the United States (U.S.) and Europe;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to increase market awareness of Non-24 and the market acceptance of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to continue to generate U.S. sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (iloperidone) for the treatment of schizophrenia;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of the novel coronavirus (COVID-19) on our business and operations, including our revenues, our supply chain, our commercial activities, our ongoing and planned clinical trials and our regulatory activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our dependence on third-party manufacturers to manufacture HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in sufficient quantities and quality;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our level of success in commercializing HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in new markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to reach agreement with the U.S. Food and Drug Administration (FDA) regarding our regulatory approval strategy, preclinical animal testing requirements or proposed path to approval for tradipitant; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to prepare, file, prosecute, defend and enforce any patent claims and other intellectual property rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to maintain rights to develop and commercialize our products under our license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain approval from the FDA for HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of jet lag disorder;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to obtain and maintain regulatory approval of our products, and the labeling for any approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations regarding the timing and success of preclinical studies and clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of our products to be demonstrably safe and effective;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limitations on our ability to utilize some or all of our prior net operating losses and orphan drug and research and development credits;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the size and growth of the potential markets for our products and the ability to serve those markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations regarding trends with respect to our revenues, costs, expenses, liabilities and cash, cash equivalents and marketable securities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, progress, expansion and costs of developing and commercializing our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to identify or obtain rights to new products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to attract and retain key scientific or management personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost and effects of litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain the capital necessary to fund our research and development or commercial activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory developments in the United States (U.S.), Europe and other jurisdictions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">potential losses incurred from product liability claims made against us; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the use of our existing cash, cash equivalents and marketable securities.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All written and verbal forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained throughout this report. We caution investors not to rely too heavily on the forward-looking statements we make or that are made on our behalf. We undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 3</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We encourage you to read </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:inherit;font-size:10pt;"> and our unaudited condensed consolidated financial statements contained in this quarterly report on Form 10-Q. In addition to the risks described below and in Item&#160;1A of Part I of our annual report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission from time to time, including on Form&#160;10-Q and Form 8-K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s988CFDFD51A85F088714320585B1270F"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Part I &#8212; FINANCIAL INFORMATION</span><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><div><a id="s1CBC45944C9256B58C6ECE8D88FCBF2D"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements (Unaudited)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s222A95751BA95AAC93B7ADDB0DD577DA"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e491-wk-Fact-4228AC9E19BF97A38573A3EA1A2B0B37" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">64,950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e510-wk-Fact-8E2D08A95D585801AF2FA3EA1A241F60" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,072</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e525-wk-Fact-F1BA8FAED271957B1943A3EA1A208C5B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e544-wk-Fact-9143B7175A0BBCF10587A3EA1A30FCFC" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">267,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e564-wk-Fact-B06BDF39FEDD9D08BA3DA3EA1A267A5B" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e583-wk-Fact-D62B9F60CC251E01E6A6A3EA1A2F309B" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e603-wk-Fact-E5FF2D4D3DC41E7CEBFFA3EA1A27D432" name="us-gaap:InventoryNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e622-wk-Fact-7C2C530DB3097BE332E1A3EA1A30AED6" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e642-wk-Fact-22C497826033D82C7E61A3EA1A1EDB67" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e661-wk-Fact-21010E0DEC1FA14F5EDDA3EA1A32ADF1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e681-wk-Fact-EFDF5F23764CBAC41363A3EA1A27D157" name="us-gaap:AssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">360,746</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e700-wk-Fact-E7E5B8B6EBECFDAFAA6EA3EA1A296F9F" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">354,136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e720-wk-Fact-F3B7EA1AFAC40B855332A3EA1A316E0B" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e739-wk-Fact-7244D41ACE337ABA4D99A3EA1A31916A" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,864</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e759-wk-Fact-7BEDF3B0A4F56400BBF0A3EA1A2FC12A" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e778-wk-Fact-0A9A2E66C008C0AF7E17A3EA1A3358D9" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e799-wk-Fact-DFB14DBF6F0A2D953F54A3EA1A33CBEE" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e818-wk-Fact-956CD90D4D56AEB4918FA3EA1A2A6BB1" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e838-wk-Fact-02F1F5D4C3B25D741762A3EA1A29BE38" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e857-wk-Fact-15C40C64874549314A7CA3EA1A1DCE6E" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,680</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current inventory and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e877-wk-Fact-76D21FC534D96850055BA3EA1A1DB3B6" name="vnda:InventoryAndOtherNonCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e896-wk-Fact-FAFDE562E44A619F3892A3EA1A29E891" name="vnda:InventoryAndOtherNonCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e921-wk-Fact-1AF15008BB721FEA9251A3EA1A234BDF" name="us-gaap:Assets" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">488,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e940-wk-Fact-5512FA690C0E994A8EC0A3EA1A2E8A08" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">483,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1042-wk-Fact-1B412832705ADE87477EA3EA1A2FE88C" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1061-wk-Fact-469A7B7FB4E36FA99A83A3EA1A1EA055" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,590</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1076-wk-Fact-7520C137D0690C03213DA3EA1A1F4F7E" name="vnda:ProductRevenueAllowancesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,177</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1095-wk-Fact-11D9EA390DF7FDF1B2D8A3EA1A2F1276" name="vnda:ProductRevenueAllowancesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1115-wk-Fact-511C136BBA26AD45ED19A3EA1A1CEB0D" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1134-wk-Fact-804644B7A23B7310AD21A3EA1A2C4575" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">59,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1154-wk-Fact-CD30A214B5DF969ABCC3A3EA1A2B16C7" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1173-wk-Fact-CFF5337B5F2767ED247FA3EA1A259AA2" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1193-wk-Fact-9533E1F4DB68767201DAA3EA1A21C932" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">778</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1212-wk-Fact-ED509968E6AB001E378EA3EA1A2C290B" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1233-wk-Fact-52024AFF9DE5B59642D5A3EA1A260F47" name="us-gaap:Liabilities" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1252-wk-Fact-30916798DA94BF8C39FEA3EA1A201C4A" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and contingencies (Notes 8 and 13)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1272-wk-Fact-9D303604F7526C0D1BD0A3EA1A1CD63C" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2020Q1" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1291-wk-Fact-158B81F43C83C82BD1D8A3EA1A2A34B2" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at March 31, 2020 and December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1352-wk-Fact-678960C448803D75E3A2A3EA1A216E98" name="us-gaap:PreferredStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1371-wk-Fact-7BCF1BEC7AD593D45608A3EA1A246CC6" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value; 150,000,000 shares authorized; 54,132,336 and 53,549,612 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1391-wk-Fact-A76805292372A160B447A3EA1A28B218" name="us-gaap:CommonStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1410-wk-Fact-94CAF70212322162D138A3EA1A223DF8" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1430-wk-Fact-23E1637362CFCD0AD710A3EA1A3041DA" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">635,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1449-wk-Fact-C9D5AF3142285B4BCE56A3EA1A22EF37" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">631,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1469-wk-Fact-8CF55ACDEE4088629324A3EA1A265B32" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1488-wk-Fact-3EF41A751627B000C675A3EA1A2413D3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8383e1508-wk-Fact-5AEA32F2EE5415A827E9A3EA1A2C7766" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">220,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8383e1528-wk-Fact-88C099E1C13ABE4C944EA3EA1A1FCC8C" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">220,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1549-wk-Fact-83A230F9E60CB342F6D8A3EA1A2B6CD0" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">416,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1568-wk-Fact-4DA19984309DAB17A8CBA3EA1A1DBC32" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">410,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1593-wk-Fact-D200FBF649A8AECDD723A3EA1A242C93" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">488,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8383e1612-wk-Fact-5852E0B8134E94AD2192A3EA1A2DC785" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">483,748</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 5</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA4EF862ACB5050C9AFD65F3D8211293B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net product sales</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e490-wk-Fact-48A15EB70D764791142CA3EA1A1F7848" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e509-wk-Fact-F9383CA5E946C3635BA1A3EA1A17C792" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e524-wk-Fact-C34AD2BD4963A5C3CC5CA3EA1A18651D" name="us-gaap:Revenues" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e543-wk-Fact-85D2ADFDDC6EC99D2712A3EA1A177C53" name="us-gaap:Revenues" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of goods sold excluding amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e604-wk-Fact-23AFA8996003643C036AA3EA1A16B253" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e623-wk-Fact-AFA212BEC3B152DAE8F5A3EA1A170383" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e643-wk-Fact-90119094ECE04BA93F9AA3EA1A1DC275" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,527</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e662-wk-Fact-3E92294BCEB69FF1F6C2A3EA1A1E9A01" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e682-wk-Fact-4690F2F35C2FF5BD4581A3EA1A223530" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e701-wk-Fact-55FE6034FDEF2208C2FDA3EA1A22FD76" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,029</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e721-wk-Fact-5ED0E1074A1989F6D77FA3EA1A1D01C7" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e740-wk-Fact-CD02064756DA0ECE870BA3EA1A1FBA68" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e760-wk-Fact-DB8FA31F99890413DFA7A3EA1A1A2B72" name="us-gaap:CostsAndExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e779-wk-Fact-0F24100F73D3C42098D7A3EA1A1675BF" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7443e800-wk-Fact-B2B07A4302A4A7EF417BA3EA1A1BA612" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7443e820-wk-Fact-5FC4797256DEB4A27C20A3EA1A1EE374" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e841-wk-Fact-4BA70488227BD7A22592A3EA1A210299" name="us-gaap:OtherIncome" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e860-wk-Fact-E813B5D43264C166CDFAA3EA1A1A5D4D" name="us-gaap:OtherIncome" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e880-wk-Fact-51AFD070F52B6443A323A3EA1A1A70B0" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7443e899-wk-Fact-22B76CD143EC5C5DA78DA3EA1A18A2ED" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e920-wk-Fact-C2FD22ABAA83876770D6A3EA1A19A65E" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">755</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e939-wk-Fact-5345D17DC7A21A0E6FE1A3EA1A219C43" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e964-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7443e983-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e1045-wk-Fact-DB56EAA2B2E84199C268A3EA1A15480C" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7443e1064-wk-Fact-69AA522C761FDD2E53F9A3EA1A157FF6" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e1085-wk-Fact-EC58C28E514512EF12DBA3EA1A22D909" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7443e1104-wk-Fact-4B0A6AF5514CED92404CA3EA1A20F671" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e1161-wk-Fact-B2E6B312D839F80D888CA3EA1A1B571D" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">53,806,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e1180-wk-Fact-B7D1F0FAAF7A9D852EC7A3EA1A1EBD64" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">52,752,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e1200-wk-Fact-5BB133E9BFC696DB03CEA3EA1A230D7B" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">54,870,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7443e1219-wk-Fact-9276896B58A7C4180CE3A3EA1A1614BE" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">52,752,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE8700535EAA35C3E879076270B82C5BB"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7266e449-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7266e468-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net foreign currency translation loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7266e525-wk-Fact-480E4E9C7B3927674E40A3EA1A0E0646" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7266e545-wk-Fact-ECF89EE3E5D433F7E098A3EA1A08E194" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in net unrealized gain on marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7266e566-wk-Fact-3124E2B3AEF18936C522A3EA1A04F203" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7266e585-wk-Fact-0D8F5697B56F0AF1403FA3EA1A0E3791" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax provision on other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7266e605-wk-Fact-B84E7C74A0182EB5F567A3EA1A0CD62D" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7266e625-wk-Fact-905FDD7D49A9CED5BAE6A3EA1A030008" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income, net of tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7266e645-wk-Fact-E633AC2B2373F67CDFFCA3EA1A0B9598" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7266e664-wk-Fact-147629AB8F1E38B7D0D1A3EA1A033657" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7266e689-wk-Fact-0D6F80C2769B59FE7E65A3EA1A08A8E4" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d7266e708-wk-Fact-3918AD663CFBFC0B2050A3EA1A04828F" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 7</span></div></div><hr style="page-break-after:always"></hr><div><a id="s163019044C21586B88CB8E8DF42E2049"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Unaudited)</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:30%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e626-wk-Fact-04DFD4F90A11833E3999A3EA1A2026DE" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">53,549,612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e645-wk-Fact-42F26B36160364947D85A3EA1A2281AB" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e664-wk-Fact-B8A5D2868804553E2D6CA3EA1A29E50F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">631,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e684-wk-Fact-963206457842DAF7C999A3EA1A285C3C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8411e703-wk-Fact-BD8C1A85E8389678C737A3EA1A1F9B23" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">220,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e723-wk-Fact-4DA19984309DAB17A8CBA3EA1A1DBC32" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">410,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e739-wk-Fact-D14A0AF58BBC7694D150A3EA1A22E30F" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">582,724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e753-wk-Fact-0A885A368F3A2B4B9A25A3EA1A38AB55" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e772-wk-Fact-E2BBC975AFBED9CC093AA3EA1A1E6EBB" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e830-wk-Fact-D727CED6A6B766BCA10FA3EA1A2D6DEC" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e884-wk-Fact-EA3071DC2B7C4BDE1C58A3EA1A21F0B8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e942-wk-Fact-68ADF435A62EB567E288A3EA1A2D4EB0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1035-wk-Fact-F79CCFE6A973F8703A1BA3EA1A20A220" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1054-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income, net of tax</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1128-wk-Fact-0A5035C0C5A91CF8C46FA3EA1A3330EE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1166-wk-Fact-E633AC2B2373F67CDFFCA3EA1A0B9598" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1187-wk-Fact-6D26FA1FB0EB9CA761CCA3EA1A26931C" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">54,132,336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1201-wk-Fact-FBC9588CEBD7C086DA31A3EA1A1CA383" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1220-wk-Fact-1D9ED48F9EE152094E3CA3EA1A26EF08" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">635,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1240-wk-Fact-B3B4618A971E6F3D5797A3EA1A25BC6C" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8411e1259-wk-Fact-52F2B1262C9C7012B1C1A3EA1A273FF5" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">220,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1279-wk-Fact-83A230F9E60CB342F6D8A3EA1A2B6CD0" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">416,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:30%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other<br/>Comprehensive Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par&#160;Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1567-wk-Fact-2003B9285769ECE55D8DA3EA1A3276E6" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">52,477,593</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1586-wk-Fact-FE3F4731DFEF6F667F4AA3EA1A3B2D2D" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1605-wk-Fact-1372045FCCDCD671305AA3EA1A37CED8" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">611,587</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1625-wk-Fact-DAADBBC18E747567154EA3EA1A362360" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8411e1644-wk-Fact-9DFD930F605D7A36C7F2A3EA1A3A0CD6" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">336,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1664-wk-Fact-08DE27984B0477BFEB2CA3EA1A35CB51" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">275,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1680-wk-Fact-B936A3119C67C11A791CA3EA1A30F32F" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">485,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1694-wk-Fact-6BDE0DBEED63DCE26939A3EA1A3BD39C" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1713-wk-Fact-684D8D13789E2E75BAD6A3EA1A351238" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1771-wk-Fact-523ED0FEAFB084A013ACA3EA1A3DCD45" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1825-wk-Fact-E9D3C5364E76A69ED36EA3EA1A3B6490" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e1883-wk-Fact-F8CE57A009E657123877A3EA1A3CFC04" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8411e1976-wk-Fact-662AB9936A7975EBB21DA3EA1A39680D" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8411e1996-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income, net of tax</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e2071-wk-Fact-826CEBFA7B975790F014A3EA1A39BD79" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e2109-wk-Fact-147629AB8F1E38B7D0D1A3EA1A033657" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e2130-wk-Fact-D9D5D74A9072D0E582ECA3EA1A3B61C4" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">52,962,676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e2144-wk-Fact-16C5990928AE9B1491E6A3EA1A36951E" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e2163-wk-Fact-16862802FFD8FF9429AFA3EA1A320989" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">615,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e2183-wk-Fact-D13EF8FF234542946B21A3EA1A380AF8" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8411e2202-wk-Fact-3F61A484462E7A68E229A3EA1A39385C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">336,830</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8411e2222-wk-Fact-E9205C029ABD494CE750A3EA1A37D593" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278,405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 8</span></div></div><hr style="page-break-after:always"></hr><div><a id="sDE6B839C059A55C9B9D2B9BBA5EF35BC"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from operating activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e489-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e508-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e565-wk-Fact-F9376F913FD20E2C9167A3EA1A2FB80D" name="us-gaap:Depreciation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e584-wk-Fact-CA469E78FC91537D4F6DA3EA1A35892C" name="us-gaap:Depreciation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e604-wk-Fact-5274B1A9C69197A6EA20A3EA1A2ECDFF" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e623-wk-Fact-2E237962A71A6C602A60A3EA1A28F981" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of discounts and premiums on marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e643-wk-Fact-EC3B34476B945885FC5EA3EA1A3CC9BF" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e663-wk-Fact-C731D879BDA83891EE38A3EA1A2BA78D" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e684-wk-Fact-5ED0E1074A1989F6D77FA3EA1A1D01C7" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e703-wk-Fact-CD02064756DA0ECE870BA3EA1A1FBA68" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e723-wk-Fact-FD9CC5F7095BF1279568A3EA1A2BB0CD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e742-wk-Fact-67EBDA6B27DC40D156F8A3EA1A33C441" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other non-cash adjustments, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e762-wk-Fact-EC91F8B7BD3CFFE067EBA3EA1A27DBE0" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e781-wk-Fact-C0079F83C8240480E980A3EA1A328005" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e843-wk-Fact-E5D84925FC4E46807BF6A3EA1A2B1040" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e863-wk-Fact-8AAA0056F323B800AC89A3EA1A2C70E1" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e883-wk-Fact-5FE929F5B951F6E1FCBBA3EA1A3017CC" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e903-wk-Fact-11A1FB0E7B42DC459B96A3EA1A23F4D2" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e923-wk-Fact-077819D3AD0A968784FDA3EA1A323031" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e942-wk-Fact-97939A1632999D1B4B1EA3EA1A357BD1" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e963-wk-Fact-AD2C1ACDA36BB310A396A3EA1A2F18F1" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e983-wk-Fact-CC988CABC907405719B2A3EA1A312B7F" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,507</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product revenue allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1003-wk-Fact-4D637904F3AAA7C3B633A3EA1A2BAF5E" name="vnda:IncreaseDecreaseProductRevenueAllowances" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1022-wk-Fact-42F45213130D59B56196A3EA1A325511" name="vnda:IncreaseDecreaseProductRevenueAllowances" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e1042-wk-Fact-2491660D6B43EE8DA13DA3EA1A2C7016" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1062-wk-Fact-F6443A1127F73A4CDE69A3EA1A2DC575" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,643</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e1123-wk-Fact-DAF2AE0088226C64E3EDA3EA1A2EBD01" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e1143-wk-Fact-B00F30E20F1FA743F635A3EA1A2A4038" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e1164-wk-Fact-D7FA4EC681A1AB4B420CA3EA1A308EC8" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e1184-wk-Fact-F9D4884444784AD5B820A3EA1A348FB7" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1205-wk-Fact-06959C19FCF79B376B6BA3EA1A2E3CCC" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1224-wk-Fact-28B9C34B9CA183F714C1A3EA1A2A9F5D" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">64,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1245-wk-Fact-D8C5C9A00C723D5DA3F1A3EA1A2D1381" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e1264-wk-Fact-2F978B7579AE257BE649A3EA1A25E692" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from the exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1326-wk-Fact-1EF6EF0BB6A1F2BB8110A3EA1A33D833" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1345-wk-Fact-2EFB5B5B7A238D13EAF8A3EA1A31990D" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1365-wk-Fact-6A55CBEAD54B67524815A3EA1A31775F" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1384-wk-Fact-3AC7D5D9AC610B10B6D3A3EA1A314CB4" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1404-wk-Fact-8DA87EFA96297CDF0F6BA3EA1A2BCADF" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1423-wk-Fact-7CFD4686CF584E5DD5F3A3EA1A2EEB8E" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net change in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1443-wk-Fact-EDE38E19A714800EAF2EA3EA1A23330F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,877</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d8387e1462-wk-Fact-4F548C6B67A01B12480CA3EA1A277093" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">26,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash, cash equivalents and restricted cash</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1524-wk-Fact-E4E1780F7B6CD43E418CA3EA1A36009B" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1543-wk-Fact-25F773D7314E39733EA1A3EA1A23D2CF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">End of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1568-wk-Fact-09920F22E2D171F61078A3EA1A3BB38E" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,527</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8387e1587-wk-Fact-3332953422FBE70E7CB7A3EA1A2BC287" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 9</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAD20E2A330CE5224B4A40B64CC1AA5C9"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)</span></div><div><a id="s4D7FF81BFD5A55EF9BC2FB51FE702629"></a></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-0-wk-Fact-4C9021DD594B985F372AA3EA1A3356BC" continuedAt="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-1" escape="true">Business Organization and Presentation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-1" continuedAt="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business organization</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vanda Pharmaceuticals Inc. (the Company) </span><span style="font-family:inherit;font-size:10pt;">is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.</span><span style="font-family:inherit;font-size:10pt;"> The Company commenced its operations in 2003 and operates in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d8394e350-wk-Fact-AC01E1FD07BC209F070FA3EA1A3B1A48" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2020Q1YTD" unitRef="Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> reporting segment. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span>The Company&#8217;s commercial portfolio is currently comprised of two products, HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span> for the treatment of Non-24 Hour Sleep-Wake Disorder (Non-24) and Fanapt</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span> for the treatment of schizophrenia. HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span> is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span>&#160;(tasimelteon) for the treatment of jet lag disorder (JLD), Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>Fanapt</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span>&#160;(iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, motion sickness and COVID-19 Acute Respiratory Distress Syndrome (ARDS);</span><span style="font-family:inherit;font-size:10pt;">  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-A2DB99865A4D5F9544EEA3EA1A4A2042-0-wk-Fact-DFB3B7BEAF5B41D7E8C7A3EA1A2935B3" continuedAt="TextSelection-A2DB99865A4D5F9544EEA3EA1A4A2042-1" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div></ix:nonNumeric></ix:continuation><ix:continuation id="TextSelection-A2DB99865A4D5F9544EEA3EA1A4A2042-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><ix:continuation id="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-2" continuedAt="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-3"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (Annual Report) for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The financial information as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-3"> was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company&#8217;s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.</ix:continuation> </span></div></ix:continuation><div><a id="sD8562589C5555E50A4B4FDABB350E9B8"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="TextSelection-F5040665F35EF2C8E189A3EA1A4A5981-0-wk-Fact-9AB87185374FA7CA85CCA3EA1A04003D" continuedAt="TextSelection-F5040665F35EF2C8E189A3EA1A4A5981-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F5040665F35EF2C8E189A3EA1A4A5981-1" continuedAt="TextSelection-F5040665F35EF2C8E189A3EA1A4A5981-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material changes to the significant accounting policies previously disclosed in the Annual Report. </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:UseOfEstimates" id="TextSelection-EB720926A199D22A5DE8A3EA1A4AB164-0-wk-Fact-15B33A1AF9B956D3BEEFA3EA1A03D19B" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#8217;s evaluation could change. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="TextSelection-5D9004DE442FBDA3F5BFA3EA1A4A6D89-0-wk-Fact-2109A061E861F5AC01F9A3EA1A06DEB2" continuedAt="TextSelection-5D9004DE442FBDA3F5BFA3EA1A4A6D89-1" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F5040665F35EF2C8E189A3EA1A4A5981-2"><ix:continuation id="TextSelection-5D9004DE442FBDA3F5BFA3EA1A4A6D89-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#8217;s Washington, D.C. headquarters.&#160;</span></div></ix:continuation><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="TextSelection-3B64B1D65E98FDDFDB05A3EA1A4A6998-0-wk-Fact-9C5341609B9BC66EB825A3EA1A068636" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statement of Cash Flows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e447-wk-Fact-4228AC9E19BF97A38573A3EA1A2B0B37" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">64,950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e466-wk-Fact-68003F3A286586DC2AA0A3EA1A16C36F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,379</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e522-wk-Fact-3065F75DDF9B65DF646CA3EA1A129977" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e541-wk-Fact-111B7B703AD56B24D975A3EA1A12883B" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current inventory and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e561-wk-Fact-A69E303F6AF75927EBF4A3EA1A13570C" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e580-wk-Fact-554D990EAFBCEA0BC9D1A3EA1A12DC32" name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e605-wk-Fact-09920F22E2D171F61078A3EA1A3BB38E" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,527</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e624-wk-Fact-3332953422FBE70E7CB7A3EA1A2BC287" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue from Net Product Sales</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="TextSelection-7FD0252DF79FB2A846ECA3EA1A4A7CB2-0-wk-Fact-94C807D45D8F48DC3979A3EA1A04A4AF" escape="true"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. Net sales by product for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e791-wk-Fact-C9C5B09CF31130CF06CAA3EA1A3A7398" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e810-wk-Fact-457217D8F47ACEB74FCAA3EA1A33E3B8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,957</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e829-wk-Fact-B1E33774BE8A2DCEB3B8A3EA1A39F7A5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e848-wk-Fact-E6108D3A241ABD58ACC3A3EA1A39C929" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_FanaptMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e873-wk-Fact-48A15EB70D764791142CA3EA1A1F7848" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e892-wk-Fact-F9383CA5E946C3635BA1A3EA1A17C792" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:MajorCustomersPolicyPolicyTextBlock" id="TextSelection-53016270A3A3ADB0A10CA3EA1A4AF5A2-0-wk-Fact-983809A495617CF945E3A3EA1A04C933" escape="true"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Major Customers</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e924-wk-Fact-DA9DADB073FE6AF7D778A3EA1A0753BE" name="vnda:NumberOfMajorCustomersAccountedForRevenue" contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="Customer" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of total revenues and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e928-wk-Fact-FB67E16B7F3363E7488FA3EA1A029B8D" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">96</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e941-wk-Fact-F31B8466DF3A14D04E6DA3EA1A0761AF" name="vnda:NumberOfMajorCustomersAccountedForTradeAccountsReceivable" contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="Customer" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of accounts receivable and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d7280e945-wk-Fact-618B68FB70D819C6788EA3EA1A059812" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">94</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of total accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-E19E13664F3B92D34E08A3EA1A4A7345-0-wk-Fact-A853532356E7569EADD0A3EA1A068025" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12,&#160;Income Taxes (Topic 740), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">,&#160;which clarifies and simplifies certain aspects of the accounting for income taxes.&#160;The standard is effective&#160;for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments &#8211; Credit Losses</span><span style="font-family:inherit;font-size:10pt;">, which changes the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#8220;expected loss&#8221; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's condensed consolidated financial results.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 11</span></div></div><hr style="page-break-after:always"></hr><div><a id="s31B0F69039A55D08BB6C0B321B2C38F8"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="TextSelection-D3702DBD6402A2234BC7A3EA1A4B26A0-0-wk-Fact-A579F2D8328BEC1D0358A3EA1A361B6F" continuedAt="TextSelection-D3702DBD6402A2234BC7A3EA1A4B26A0-1" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="TextSelection-F4497B6CBB59184FDC7AA3EA1A4B834A-0-wk-Fact-E0BFB9DAAB1E12FAFA23A3EA1A368970" escape="true"><ix:continuation id="TextSelection-D3702DBD6402A2234BC7A3EA1A4B26A0-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than two years:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e574-wk-Fact-CE62B48256D0409F63D1A3EA19F845B5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e593-wk-Fact-FD8E51D42F367B947DB1A3EA19F25485" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e612-wk-Fact-6232FF856B4297755107A3EA19FC9B80" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e632-wk-Fact-87A99025B665A49C7D11A3EA1A00A9E1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e647-wk-Fact-1F03C14D2FCDD33EF896A3EA1A02BBC0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e666-wk-Fact-7387FA60783F5D35E0BAA3EA19FA7A29" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d11895e685-wk-Fact-B0253641728D94AE84BFA3EA1A2AD73E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e706-wk-Fact-DF9E0C1F13F77BF53C2BA3EA1A2A43E0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">123,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e726-wk-Fact-E545CCAEADC047F90BECA3EA19FB2423" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e745-wk-Fact-B63319798AFE0850217AA3EA19F506B9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d11895e764-wk-Fact-496EEA0858DED37297D6A3EA19F95D4A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e785-wk-Fact-E1E662FBE5CBC5D9A89BA3EA19F14E89" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e810-wk-Fact-FB8938FE7D67F0445F9DA3EA19FF0F14" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">246,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e829-wk-Fact-8650D9AC7DF3740CD964A3EA19F2E2A3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d11895e848-wk-Fact-3FBAFFB9F61923006179A3EA19F86079" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e869-wk-Fact-F2CB06C2A492B0CD2BE3A3EA19F44B1A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than two years:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1107-wk-Fact-EB3F02F3EA1239DF37C0A3EA1A087A5A" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1126-wk-Fact-D59550B3622071F96BC0A3EA1A0DC410" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d11895e1145-wk-Fact-D5B6F9420C1F48AD2C2AA3EA1A0C5329" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1166-wk-Fact-CD6161E91438AFE72F43A3EA1A0C150B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1181-wk-Fact-D4531A46E77FFD9DED04A3EA1A09C046" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">129,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1200-wk-Fact-59D3DBFB8603AC5CB084A3EA1A0BCA3B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d11895e1219-wk-Fact-DA31774A41C22309812DA3EA1A06CCBC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1240-wk-Fact-C2EC0DF64DA107C7AA26A3EA1A0B998C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">130,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1260-wk-Fact-4E59DD8014930ECC017FA3EA1A098E42" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1279-wk-Fact-DE061EDBA7AEE0CE2893A3EA1A09EF3A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d11895e1298-wk-Fact-5F8E5DE98DE12084F7AEA3EA1A0D6B87" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1319-wk-Fact-487A041F365F435DA99BA3EA1A0A4454" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1344-wk-Fact-6FFDA3F0A632D6E70B22A3EA1A08EAAA" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1363-wk-Fact-02DF4B9969339D3D72B0A3EA1A0979D2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d11895e1382-wk-Fact-D67D6832F08F6AEF9653A3EA1A07EE76" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11895e1403-wk-Fact-ABBEE8CD00D38A85C781A3EA1A0A0C1B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">267,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="sA26B62B6AF4A51A1A610FCF1D2BFEF9E"></a></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-ABB9C3EF695D47E02C9EA3EA1A4B0B8D-0-wk-Fact-7C9AB0A30E77F69F17B1A3EA19EF8B33" continuedAt="TextSelection-ABB9C3EF695D47E02C9EA3EA1A4B0B8D-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-ABB9C3EF695D47E02C9EA3EA1A4B0B8D-1" continuedAt="TextSelection-ABB9C3EF695D47E02C9EA3EA1A4B0B8D-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 &#8212; defined as observable inputs such as quoted prices in active markets</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;2 &#8212; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;3 &#8212; defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions</span></div></td></tr></table><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:MarketableSecuritiesPolicy" id="TextSelection-08763BB2371190C2BDAAA3EA1A4BD2EC-0-wk-Fact-64D863A8CC15F6845FEDA3EA1A3EB045" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities classified in Level&#160;1 and Level&#160;2 as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level&#160;2 is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="TextSelection-40D7DB0FDA52769216B5A3EA1A4BB012-0-wk-Fact-8F227EA233564D3BF70EA3EA19EE9923" continuedAt="TextSelection-40D7DB0FDA52769216B5A3EA1A4BB012-1" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of March 31, 2020 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active&#160;Markets&#160;for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e691-wk-Fact-0FE3245FE485C65A36B3A3EA1A3EBD70" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e710-wk-Fact-D5A47B06FCC4EB319F3EA3EA1A3E246E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e729-wk-Fact-3B8DE5B8FF87AB6DDD9DA3EA1A3D43C9" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e749-wk-Fact-E00EFCBE4612AD4CB450A3EA1A3E7115" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e764-wk-Fact-9D34225DBF5D51F66CC1A3EA1A3A0324" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">123,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e783-wk-Fact-2E666820FDA15E1B2E49A3EA1A3CD4B6" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e802-wk-Fact-880181D9BFDF00A8ACDCA3EA1A395F49" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">123,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e822-wk-Fact-364B77A3CF7E91998FF9A3EA1A3C3484" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e842-wk-Fact-5EE4B9223587838AA3F3A3EA1A3F7425" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e861-wk-Fact-B273899505907089EB92A3EA1A3D0136" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e880-wk-Fact-3400EDA03BB33B0B71D0A3EA19F119B6" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e900-wk-Fact-0C1A83EABE0D5EBAB27EA3EA1A3F8523" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e925-wk-Fact-EFB10B5C9D193E1F3591A3EA1A3EE244" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e944-wk-Fact-DB2E55C8CF72C03C02A7A3EA1A3BF920" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e963-wk-Fact-41870874ACF2124C6CE6A3EA1A3EAE0F" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e983-wk-Fact-CFCF4C0AE4C1E596BF7CA3EA1A3F3E72" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-ABB9C3EF695D47E02C9EA3EA1A4B0B8D-2"><ix:continuation id="TextSelection-40D7DB0FDA52769216B5A3EA1A4BB012-1"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of December 31, 2019 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in<br/>Active&#160;Markets&#160;for<br/>Identical Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other<br/>Observable&#160;Inputs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1279-wk-Fact-8DD181FE0CA09DABDC48A3EA19F6E1BE" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1298-wk-Fact-AA4E2C86E5308656211EA3EA19F7F8E4" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1317-wk-Fact-045A6AB3511FB0D70FCBA3EA19F510FA" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1337-wk-Fact-521D8762F68F118E708DA3EA19F354B1" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1352-wk-Fact-AE3DF8464FF942224F25A3EA19F5A171" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">137,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1371-wk-Fact-FC376CB9ADE0E2F6EC03A3EA19F6B59D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1390-wk-Fact-00D083239C0CA66B8041A3EA19F5C773" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">137,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1410-wk-Fact-B1B0410A137B39EF9DD6A3EA19FC6164" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1430-wk-Fact-C867A6430CCC9DCA9302A3EA19F05C02" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1449-wk-Fact-3195E294EE3E6C50430FA3EA19F72A32" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1468-wk-Fact-0795D298F5C6EDE59791A3EA19F520D3" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1488-wk-Fact-05EC2745C18F8D39FD51A3EA19F4A8B4" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1513-wk-Fact-66414FAE6C43F17C7E75A3EA19F3848C" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">274,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1532-wk-Fact-7EA3775C8E8BEF24C82DA3EA19F39503" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1551-wk-Fact-0D1727DA2191BCAAA27EA3EA19F3E902" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">185,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12568e1571-wk-Fact-1E6B8B3FF0D3832407D1A3EA19F2C69F" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> include </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12568e1590-wk-Fact-E20C4EE358814C6924A1A3EA1A3C1352" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash equivalents.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.</span></div></ix:continuation><div><a id="sFC0B361F91D3545299819966E8141A7C"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-4FDD5DF00531860FA5E8A3EA1A4B64D0-0-wk-Fact-3614B16B41068EA2F766A3EA1A064F93" continuedAt="TextSelection-4FDD5DF00531860FA5E8A3EA1A4B64D0-1" escape="true"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-63CC47735B56F708D948A3EA1A4BF621-0-wk-Fact-6B411217EEC58630F4C3A3EA1A0AC4E7" continuedAt="TextSelection-63CC47735B56F708D948A3EA1A4BF621-1" escape="true">Inventory</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-4FDD5DF00531860FA5E8A3EA1A4B64D0-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-63CC47735B56F708D948A3EA1A4BF621-1">The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current.</ix:continuation> </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="vnda:ScheduleOfInventoriesTableTextBlock" id="TextSelection-B7768477DDA7BB7376A4A3EA1A4B6A65-0-wk-Fact-C9E12C51E0BC3A964C3CA3EA1A06D46E" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e477-wk-Fact-932C3FA73DC1E5530381A3EA1A17DE01" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e496-wk-Fact-5DF31B92F4FA59E5A1BFA3EA1A12A2F9" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e516-wk-Fact-E5FF2D4D3DC41E7CEBFFA3EA1A27D432" name="us-gaap:InventoryNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e535-wk-Fact-7C2C530DB3097BE332E1A3EA1A30AED6" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e596-wk-Fact-3C7671938F982C531BEFA3EA1A128811" name="vnda:InventoryRawMaterialsNetOfReservesNonCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e615-wk-Fact-B991349C1AD070367ACEA3EA1A17E6FA" name="vnda:InventoryRawMaterialsNetOfReservesNonCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e630-wk-Fact-AD4428E18D5829185759A3EA1A151B0A" name="vnda:InventoryWorkInProcessNetOfReservesNonCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e649-wk-Fact-4D039A5B188244985EF3A3EA1A12F96C" name="vnda:InventoryWorkInProcessNetOfReservesNonCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e669-wk-Fact-528D9CCE5152D728F7B8A3EA1A187E1E" name="vnda:InventoryFinishedGoodsNetOfReservesNonCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">934</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e688-wk-Fact-3F1C8BBA56A61479B458A3EA1A11BAE7" name="vnda:InventoryFinishedGoodsNetOfReservesNonCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e708-wk-Fact-FECA35EB310F422DDFD7A3EA1A165F02" name="us-gaap:InventoryNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e727-wk-Fact-E1F7F702284BBF89F672A3EA1A15740D" name="us-gaap:InventoryNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,824</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e752-wk-Fact-B1D173A4133E6BE5AB67A3EA1A14FA00" name="vnda:Inventory" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11872e771-wk-Fact-8D385B253AB3B5BC1445A3EA1A19AF48" name="vnda:Inventory" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="s3A42CE2C0AE3509595AAA956323395B7"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-4B02119E4B1541662E1FA3EA1A4CCDB6-0-wk-Fact-439F1585F4A7BC015BECA3EA1A3FE809" continuedAt="TextSelection-4B02119E4B1541662E1FA3EA1A4CCDB6-1" escape="true">Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4B02119E4B1541662E1FA3EA1A4CCDB6-1" continuedAt="TextSelection-4B02119E4B1541662E1FA3EA1A4CCDB6-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;">&#160;In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e353-wk-Fact-79BFE1C1AC66F55A6B10A3EA19FA985B" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to BMS. The </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e357-wk-Fact-79BFE1C1AC66F55A6B10A3EA19FA985B" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, the Company met its final milestone under its license agreement when cumulative worldwide sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;reached </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e373-wk-Fact-8E74A75D34F96D01C0D3A3EA19F9D570" name="vnda:CumulativeNetSalesToAchieveMilestone" contextRef="D2018Q2Apr_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of the achievement of this milestone, the Company made a payment to BMS of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e377-wk-Fact-D9A2DAFB58F524C83BB0A3EA19F63388" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2018. The </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e381-wk-Fact-27747297C12960A5D536A3EA1A3FA85F" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="FD2015Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4B02119E4B1541662E1FA3EA1A4CCDB6-2"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated economic useful life of both the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e397-wk-Fact-79BFE1C1AC66F55A6B10A3EA19FA985B" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e401-wk-Fact-27747297C12960A5D536A3EA1A3FA85F" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="FD2015Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> intangible assets were changed from </span><span style="font-family:inherit;font-size:10pt;">February 2035</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;"> based on the July 2035 expiration date of U.S. patent number 10,376,487&#160;('487 Patent) issued by the U.S. Patent and Trademark Office in August 2019.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-506C63AD3F43394EE1FAA3EA1A4C41F3-0-wk-Fact-A988F74BCCC74A284593A3EA19F16767" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:41%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e639-wk-Fact-A437D35C3D9CB62078AAA3EA19FC4220" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e658-wk-Fact-12CD91D091205299C64BA3EA19F87713" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e678-wk-Fact-D09B8602B8D736A8FBE4A3EA1A0B5090" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:41%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e906-wk-Fact-DD72DF9586CC085E6167A3EA19FDA635" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e925-wk-Fact-EA06810B0E9EA89C2572A3EA19FFC57C" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e945-wk-Fact-E76842ECBD2FAE6D5572A3EA19F40461" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company also had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e967-wk-Fact-E5D5F23DE823AAFB1D0CA3EA19F00741" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_FanaptMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">27.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of fully amortized intangible assets related to Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d11954e979-wk-Fact-339E7158F42412018E7DA3EA19EFD4F5" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for each of the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-9CD8A87DEB6F129E5CF8A3EA1A4CDF75-0-wk-Fact-3F1BF73C8EC52CD373C8A3EA19F2C1DF" continuedAt="TextSelection-9CD8A87DEB6F129E5CF8A3EA1A4CDF75-1" escape="true">The following is a summary of the future intangible asset amortization schedule as of </ix:nonNumeric></span><ix:continuation id="TextSelection-9CD8A87DEB6F129E5CF8A3EA1A4CDF75-1" continuedAt="TextSelection-9CD8A87DEB6F129E5CF8A3EA1A4CDF75-2"><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></ix:continuation></div><ix:continuation id="TextSelection-9CD8A87DEB6F129E5CF8A3EA1A4CDF75-2"><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e1199-wk-Fact-D09B8602B8D736A8FBE4A3EA1A0B5090" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e1218-wk-Fact-A3337D1C4C0257C58627A3EA1A0B3283" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e1237-wk-Fact-EE48B5819DEB31531846A3EA1A0E673D" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e1257-wk-Fact-460A8942C168AB7B2DE3A3EA1A0AFB57" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e1276-wk-Fact-6684C915F356BC5370FFA3EA1A0A518A" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e1296-wk-Fact-7FDD208B5872A70C0473A3EA1A0E25DE" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d11954e1315-wk-Fact-C8EB95BD2343248A1274A3EA1A0ABF85" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="sE27B7976D890553FABE0253486C5C506"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="TextSelection-1AE3F5437A534E205B73A3EA1A4CB77B-0-wk-Fact-BCEA013EE0A9E892275CA3EA19FAD436" continuedAt="TextSelection-1AE3F5437A534E205B73A3EA1A4CB77B-1" escape="true">Accounts Payable and Accrued Liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="TextSelection-7A4803B3EC1358240568A3EA1A4CD39C-0-wk-Fact-37EE8764A4BDDEBDEB3DA3EA19FBFA1E" escape="true"><ix:continuation id="TextSelection-1AE3F5437A534E205B73A3EA1A4CB77B-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s accounts payable and accrued liabilities as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and other professional fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e426-wk-Fact-D98076011D4017863161A3EA19FC8C7F" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e445-wk-Fact-D2A212B09A5D30E7350BA3EA1A0D15C8" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e460-wk-Fact-88B5280E7B109CE1E26CA3EA19FBB68A" name="vnda:AccruedResearchAndDevelopmentExpense" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e479-wk-Fact-FE1C5AD34AA5C748B437A3EA19FAAA6E" name="vnda:AccruedResearchAndDevelopmentExpense" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,893</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e499-wk-Fact-7A94713F87B975CA2593A3EA1A002199" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,912</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e518-wk-Fact-B068C552D03CB995CB11A3EA19FC4511" name="us-gaap:AccruedRoyaltiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,904</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e538-wk-Fact-9158E8862BA0FD22113BA3EA19FED5CA" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e556-wk-Fact-6CF173876FA2635D0EE2A3EA1A03C83C" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e576-wk-Fact-30F2AD8BCFC172D8F21AA3EA19FFFEE6" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e595-wk-Fact-DA8EDE01449B61B2F289A3EA19FFB717" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e615-wk-Fact-138D7D3EAE7F42188A17A3EA19FD48AA" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e634-wk-Fact-7B6F36E8FE35B79EA9C7A3EA1A009295" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e659-wk-Fact-1B412832705ADE87477EA3EA1A2FE88C" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13731e678-wk-Fact-469A7B7FB4E36FA99A83A3EA1A1EA055" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,590</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><a id="s550B9DC528B558A89230C5F0F3A5501E"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-0-wk-Fact-BAF8BB956AEE5A1CD7A4A3EA19F7505B" continuedAt="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-1" continuedAt="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual from the date of </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-2" continuedAt="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-3"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;">&#160;In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.  As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has paid BMS </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e378-wk-Fact-EB718DB0B78F73118A0AA3EA1A0C86BA" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D2020Q1Feb1Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">37.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and milestone obligations, including </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e382-wk-Fact-3C0783136302E9C5C9B9A3EA1A03AFD2" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" contextRef="D2020Q1Feb1Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of regulatory approval and commercial milestones capitalized as intangible assets (see Note </span><span style="font-family:inherit;font-size:10pt;">6</span><span style="font-family:inherit;font-size:10pt;">). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;net sales to BMS in any territory where the Company commercializes HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;for a period equal to the greater of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13962e399-wk-Fact-4AD83537EAC605D351FDA3EA19FC8818" name="vnda:RoyaltyPeriod" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13962e403-wk-Fact-B82C56913CEDB0556C2EA3EA1A03B54E" name="vnda:RoyaltyPayableOnNetSalesPercentage" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> royalty on net sales in that territory.&#160;The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13962e408-wk-Fact-D4914691762A38B18643A3EA19FF7931" name="vnda:PercentageOfFutureSublicenseFeesPayable" contextRef="FD2020Q1YTD">mid-twenties</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">.&#160;The Company has agreed with BMS in the license agreement for HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;to use its commercially reasonable efforts to develop and commercialize HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;">&#160;Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> franchise to the Company on December&#160;31, 2014. The Company paid directly to Sanofi S.A (Sanofi) a fixed royalty of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13962e433-wk-Fact-6FB9A7B43BB989A7FB68A3EA1A0091D9" name="vnda:RoyaltyPayableOnNetSalesPercentage" contextRef="FD2020Q1YTD_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of net sales through December&#160;2019 related to manufacturing&#160;know-how.&#160;The Company is also obligated to pay Sanofi a fixed royalty on Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;net sales equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d13962e441-wk-Fact-33767FEAA726E08A2A77A3EA19FEDB2D" name="vnda:RoyaltyPayableOnNetSalesPercentage" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> on Sanofi&#160;know-how&#160;not related to manufacturing under certain conditions for a period of up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13962e446-wk-Fact-FCE8D53BDFDCECD07541A3EA1A04D80B" name="vnda:RoyaltyPeriod" contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tradipitant.</span><span style="font-family:inherit;font-size:10pt;">&#160;In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an&#160;NK-1R&#160;antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13962e455-wk-Fact-0DCAF0CAAE2AB4EBA5B4A3EA19F8F33D" name="vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">low double digits</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has paid Lilly </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e463-wk-Fact-9D21DA85EBD08118EFBEA3EA1A1C61E6" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" contextRef="D2020Q1Apr2012March2020_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and development milestones, including a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e467-wk-Fact-F350827016BBEEBB3200A3EA1A05C1A5" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" contextRef="D2018Q1July2018_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment in July 2018 as a result of enrolling the first subject into a Phase III study for tradipitant. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, remaining milestone obligations include a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e476-wk-Fact-8DF6CE7403B589FC7C22A3EA19FFDFAC" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or European Union (E.U.), </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e480-wk-Fact-D3C97DAEE594DDB70D44A3EA1A1924BF" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e484-wk-Fact-00E282CB3725C7A98F71A3EA1A05F675" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e488-wk-Fact-9AA9EA80DA32C2E45EB9A3EA1A1BFE86" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_SalesMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">VQW-765.</span><span style="font-family:inherit;font-size:10pt;">&#160;In connection with a settlement agreement with Novartis relating to Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765,&#160;a Phase II&#160;alpha-7&#160;nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize&#160;VQW-765&#160;and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13962e501-wk-Fact-C0A09342388FA8B988A2A3EA19FAE827" name="vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_VQW765Member">mid-teens</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Portfolio of CFTR activators and inhibitors</span><span style="font-family:inherit;font-size:10pt;">. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as&#160;</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13962e510-wk-Fact-C40DCC669FB05F6CAD4BA3EA1A0A19AD" name="vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember">single-digit</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">&#160;royalties on net sales. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has paid UCSF </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e518-wk-Fact-34D9E9210367FE900861A3EA1A036A22" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" contextRef="D2020Q1Mar2017Mar2020_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and development milestones, including an upfront license fee payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e522-wk-Fact-1C210AF15FEB664A83CAA3EA1A04BE53" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2017 and a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e526-wk-Fact-0258CF357D9886AEA06EA3EA19F80498" name="vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty" contextRef="D2019Q1March2019_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone payment in March 2019. As of </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-3" continuedAt="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-4"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, remaining milestone obligations include </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e537-wk-Fact-45B670E390105C49CF94A3EA1A1BDE3C" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;for development milestones and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e541-wk-Fact-D558C4B57EAE40140956A3EA1A0237A7" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;for future regulatory approval and sales milestones. Included in the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e545-wk-Fact-45B670E390105C49CF94A3EA1A1BDE3C" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160; in development milestones is a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e549-wk-Fact-AC31A5FF4D2F05C4F6E1A3EA1A1B6AB6" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">350,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e553-wk-Fact-E21D825051C1B2C76F88A3EA19F7C964" name="vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;in total for the CFTR portfolio. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</span></div></ix:continuation><div style="line-height:120%;padding-top:8px;font-size:10pt;"><ix:continuation id="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-4" continuedAt="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-5"><span style="font-family:inherit;font-size:10pt;">In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company&#8217;s current agreements for clinical, marketing, and other services may be terminated on generally </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d13962e564-wk-Fact-F58900D6143D39B1F64BA3EA1A1D6849" name="vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" contextRef="FD2020Q1YTD" format="ixt-sec:durday">90</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company&#8217;s contractors in closing out work in progress as of the effective date of termination. Noncancellable long-term contractual cash obligations include noncancellable purchase commitments longer than one year and primarily relate to commitments for media and data services, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e568-wk-Fact-6D39440C871C17090DACA3EA19FE0BE9" name="us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e572-wk-Fact-B406185421B67347F532A3EA19FBE725" name="us-gaap:PurchaseObligationDueInSecondYear" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d13962e576-wk-Fact-3068F12CEE55B51EEDAFA3EA1A0E1A86" name="us-gaap:PurchaseObligationDueInThirdYear" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> are expected to be paid in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2022</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-5">, respectively.</ix:continuation> </span></div><div><a id="s905C296865F358B6A83B58923239F03E"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="TextSelection-CE5E0E3F11DABF2D2600A3EA1A4DC87C-0-wk-Fact-9295E86A75EFE631AEA6A3EA19F18E0D" continuedAt="TextSelection-CE5E0E3F11DABF2D2600A3EA1A4DC87C-1" escape="true">Accumulated Other Comprehensive Income </ix:nonNumeric></span></div><ix:continuation id="TextSelection-CE5E0E3F11DABF2D2600A3EA1A4DC87C-1"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-5A9912C8287A7F0FA9E6A3EA1A4D1E99-0-wk-Fact-02EDED3F1C98811979E7A3EA19F14948" escape="true"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14227e425-wk-Fact-BE1E6BE7B8F972904A40A3EA1A0AE1C2" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14227e444-wk-Fact-DBE68530CA77D018A123A3EA1A09A51E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14227e459-wk-Fact-6E0EAA942997FA991F77A3EA1A0B2591" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14227e478-wk-Fact-8C101476E8AB660FCA0FA3EA1A14FA6A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14227e503-wk-Fact-8CF55ACDEE4088629324A3EA1A265B32" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14227e522-wk-Fact-3EF41A751627B000C675A3EA1A2413D3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14227e536-wk-Fact-52A2E2D722F0312A982FA3EA19F0D86B" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2020Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> reclassifications out of accumulated other comprehensive income for either of the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="sFFB3A809F9D55159B03BBFA512F4909B"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-0-wk-Fact-A4FAE4A06B8764B6CDB0A3EA1A11DA27" continuedAt="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-1" continuedAt="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e345-wk-Fact-CD234F84CC6BCE10FD34A3EA1A0F91DB" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,335,548</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares that were subject to outstanding options and restricted stock units (RSUs) under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April 2016, and the Company adopted the 2016 Plan. Outstanding options and RSUs under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company&#8217;s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated twice to increase the number of shares reserved for issuance, among other administrative changes. Both amendments and restatements of the 2016 Plan were approved by the Company's stockholders. There are a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e349-wk-Fact-0D92A6FC4BB9BB43F1DBA3EA1A0F2361" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,100,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock reserved for issuance under the 2016 Plan, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e353-wk-Fact-2062CE26BA4D7DAA04A3A3EA1A14C2DC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,153,920</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of which remained available for future grant as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e367-wk-Fact-27EF5E16BFA63A26005EA3EA1A0C3CA4" name="vnda:ShareBasedCompensationOptionAwardsContractualTerm" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">10</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e371-wk-Fact-4DF931DFD9FAD025CC87A3EA1A09FCC1" name="vnda:ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" contextRef="FD2020Q1YTD" format="ixt-sec:durwordsen">four years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> with the first </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e375-wk-Fact-1BBB18C25A15D04392EBA3EA1A1D57CB" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" contextRef="FD2020Q1YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares subject to service option awards vesting on the first anniversary of the grant date and remaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e379-wk-Fact-5483345DE8C4A673BB17A3EA1A0F27CD" name="vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" contextRef="FD2020Q1YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares subject to the service option awards in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e383-wk-Fact-6799757D6A22677EF722A3EA1A0E0DA5" name="vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" contextRef="FD2020Q1YTD" unitRef="installment" decimals="INF" scale="0" format="ixt:numdotdecimal">36</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards to executives and directors provide for accelerated vesting if there is a change in control of the Company. Certain service option awards to employees and executives provide for accelerated vesting if the respective employee&#8217;s or executive&#8217;s service is terminated by the Company for any reason other than cause or permanent disability.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d16557e394-wk-Fact-C06E4F29C50920A6989AA3EA1A0E8375" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e398-wk-Fact-CFCA98D5AE922FF82631A3EA1A0DFDAF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember" format="ixt-sec:duryear">1.5</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. No option awards are classified as a liability as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-2" continuedAt="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-3"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-6FE943D39AB48D4F5779A3EA1A4DD7BB-0-wk-Fact-B3CA5B01FE8E139CF21AA3EA1A0F1F2A" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of option activity under the Plans for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2006 and 2016 Plans</span><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price&#160;at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining&#160;Term</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e547-wk-Fact-361D49F66DE59CC2F4D8A3EA1A198A72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,495,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e566-wk-Fact-5CECC0471943F7CADDF1A3EA1A1EB5ED" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e580-wk-Fact-361FF7F5427DADB82F3DA3EA1A1201BC" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" format="ixt-sec:duryear">5.58</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e596-wk-Fact-ED3415767ECB190AE39DA3EA19FDBE6E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e611-wk-Fact-2F39DF841E57DCA01107A3EA1A10E7CE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">487,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e625-wk-Fact-173657467AD9C8CFF05FA3EA1A214950" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16557e676-wk-Fact-23A4635C50D39C82AC97A3EA1A11DC1B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">225,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e691-wk-Fact-C90C6BFE021D65E7CF53A3EA1A1C8422" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16557e742-wk-Fact-F9DB220FE2157E69D12DA3EA1A22653A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="FD2020Q1YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e757-wk-Fact-5F08A3063C01CC66EB90A3EA1A297705" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16557e808-wk-Fact-B2D1DB51FA8D82D7AB4BA3EA1A221603" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">172,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e823-wk-Fact-512E55984242FC802A2AA3EA19FFD6BD" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e852-wk-Fact-9B098A9D656E186CDBE9A3EA1A266C28" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e873-wk-Fact-4AC2F3511B9690C0896AA3EA1A203B9D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,575,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e887-wk-Fact-1D7D7ED1753A611DEE9FA3EA1A1A82E5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e906-wk-Fact-5F25E0980709EC1E39F4A3EA19FE1303" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" format="ixt-sec:duryear">5.81</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e916-wk-Fact-5BE28605A9F0E00716D5A3EA1A134C14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e937-wk-Fact-CDC9337BE98C461B144AA3EA1A1D91E5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,379,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e951-wk-Fact-09C2144C4EB69D79FD81A3EA1A035825" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.02</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e970-wk-Fact-7B4A643555063CE8C553A3EA1A02DDB8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" format="ixt-sec:duryear">4.63</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e980-wk-Fact-D6A68F5B3AAEED8BB399A3EA1A019DAF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1001-wk-Fact-8E56055439B670EB37B7A3EA1A19711F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,340,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1015-wk-Fact-3834981E4D3F0EBF2204A3EA1A0255E8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e1034-wk-Fact-9BF8C28F0D90C9806401A3EA1A02C4F5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" format="ixt-sec:duryear">5.60</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1044-wk-Fact-B52EE424B012A1723B63A3EA1A256A5C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant-date fair value of options granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d16557e1064-wk-Fact-DD2C02F171AB39156598A3EA1A11B79E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.73</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d16557e1068-wk-Fact-D967D5765FA33F31BD8BA3EA1A07413B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Proceeds from the exercise of stock options amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d16557e1085-wk-Fact-C9BF1D7A580CBC4EDC3FA3EA1A108E26" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d16557e1089-wk-Fact-4206E4AC7437B351A7C9A3EA1A10C579" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An RSU is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that vest in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1111-wk-Fact-31D4059084A2761C9B70A3EA1A109293" name="vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="installment" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> equal annual installments provided that the employee remains employed with the Company. Annual service RSUs granted to directors vest on the first anniversary of the grant date. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d16557e1123-wk-Fact-C06E8D41DEAB3CCA1BEBA3EA1A0F47EC" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">25.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e1127-wk-Fact-2008D04AC76572F72DD1A3EA1A0807F5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.0</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. No RSUs are classified as a liability as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="TextSelection-B70BC66B42DA1E202866A3EA1A4DC240-0-wk-Fact-1DE01A8159B4A5D4E551A3EA1A07DA43" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of RSU activity under the Plans for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2006 and 2016 Plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1227-wk-Fact-BC50ED6B2EC4821183AAA3EA1A009369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,649,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1246-wk-Fact-98A399BB92FD43B9CDC2A3EA19FAF847" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1261-wk-Fact-7AE9F648C3BC5D8523DFA3EA1A11C8DE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">745,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1275-wk-Fact-EFBEAB58A0561C078D0AA3EA1A06567E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16557e1295-wk-Fact-15660B5EE049ED3060FDA3EA1A104DA7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">136,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1310-wk-Fact-58B0C293CCF86A9AC779A3EA1A0CAB1D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16557e1330-wk-Fact-C0EBA581C4AC021A46AAA3EA1A014FEB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">498,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1345-wk-Fact-48FDA469E2CE5DF87BFAA3EA19EE39A8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1365-wk-Fact-390AC642C8F7C5471A95A3EA1A07915B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,760,507</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1379-wk-Fact-29BC832BC6B41BB7FD42A3EA1A080A14" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant date fair value for the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1398-wk-Fact-C0EBA581C4AC021A46AAA3EA1A014FEB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">498,505</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares underlying RSUs that vested during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d16557e1410-wk-Fact-EB96F3CC6F697B190473A3EA1A12A179" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-436F11950DFA591E490BA3EA1A4DD6C3-0-wk-Fact-B2C68A26EE2B5EF2C8A6A3EA1A115F69" escape="true"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense recognized for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was comprised of the following:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1549-wk-Fact-90CBADDEB4D9D6365DCDA3EA1A2361C7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1568-wk-Fact-A0A864113EE2CD01EFC3A3EA1A2A6590" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1583-wk-Fact-EDD12BE0253524C42EC1A3EA1A2A449B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1602-wk-Fact-4467A92BD34C6CD228B2A3EA1A1B197D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1627-wk-Fact-459243CD666622B7A209A3EA1A21FC65" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1646-wk-Fact-5672F5EC537FB68CC8D4A3EA1A2E57BA" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-3"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company&#8217;s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-6F1E83B2E0E2D41A9949A3EA1A4DB6B8-0-wk-Fact-072007C3A878D46CB6A2A3EA1A0CB6F3" continuedAt="TextSelection-6F1E83B2E0E2D41A9949A3EA1A4DB6B8-1" escape="true">Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the </ix:nonNumeric></span><ix:continuation id="TextSelection-6F1E83B2E0E2D41A9949A3EA1A4DB6B8-1" continuedAt="TextSelection-6F1E83B2E0E2D41A9949A3EA1A4DB6B8-2"><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></ix:continuation></div><ix:continuation id="TextSelection-6F1E83B2E0E2D41A9949A3EA1A4DB6B8-2"><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1764-wk-Fact-93BE1C4849296BED442BA3EA1A1709F8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2020Q1YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1779-wk-Fact-F08DF8632407B27B4A16A3EA1A163452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q1QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1795-wk-Fact-17587E8F2A743FB6E098A3EA1A1E3826" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2020Q1YTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1810-wk-Fact-9B3D75E3F96540C14A0EA3EA1A17FCB8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q1QTD" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e1826-wk-Fact-86729A36E982150DF201A3EA1A1CCB98" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2020Q1YTD" format="ixt-sec:duryear">6.09</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d16557e1840-wk-Fact-BA327367B04560C830B7A3EA1A169004" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q1QTD" format="ixt-sec:duryear">5.92</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average risk-free rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1855-wk-Fact-CB535B604682965A1708A3EA1A182E46" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2020Q1YTD" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16557e1870-wk-Fact-F61B9B6DEB3982EC6D3DA3EA1A182747" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q1QTD" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="s3B12E8543D405BD0AAE474B67BB09CE0"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-0-wk-Fact-B2B4A7E8586C06C5327EA3EA1A24BD63" continuedAt="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-1" continuedAt="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded income tax expense of&#160;$</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d14337e349-wk-Fact-B18784F3BB5F8E4E89D2A3EA1A1B790B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million&#160;and less than </span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. The income tax expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by the estimated effective tax rate for the year and the discrete impact of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d14337e362-wk-Fact-BC3D5F8F533A50463E05A3EA1A1CCBC7" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of net shortfall tax expense related to stock-based compensation activity during the quarter. As a result of the tax valuation allowance against deferred tax assets in the U.S., there was no benefit for federal income taxes associated with the loss before taxes for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Income taxes were recorded related to certain U.S. state and foreign jurisdictions for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div style="line-height:120%;padding-top:16px;font-size:10pt;"><ix:continuation id="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-2" continuedAt="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-3"><span style="font-family:inherit;font-size:10pt;">The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During the third quarter of 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance was retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-3">.</ix:continuation> </span></div><div><a id="sFCB161A627415D35B2D2533D73642875"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-4379DF582D9681878027A3EA1A4E61DB-0-wk-Fact-3311852334FD3B74208BA3EA1A1BB083" continuedAt="TextSelection-4379DF582D9681878027A3EA1A4E61DB-1" escape="true"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-585130E19FBDBE8CE266A3EA1A4E428E-0-wk-Fact-F1981BA49CC0ABDA9AF1A3EA1A199109" continuedAt="TextSelection-585130E19FBDBE8CE266A3EA1A4E428E-1" escape="true">Earnings per Share</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-4379DF582D9681878027A3EA1A4E61DB-1" continuedAt="TextSelection-4379DF582D9681878027A3EA1A4E61DB-2"><ix:continuation id="TextSelection-585130E19FBDBE8CE266A3EA1A4E428E-1"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-4379DF582D9681878027A3EA1A4E61DB-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-3C4B65E6AE7D6F37E524A3EA1A4D8719-0-wk-Fact-A46776D483C5956EBD3BA3EA1A1A5AD5" escape="true"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e520-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16548e539-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e596-wk-Fact-B2E6B312D839F80D888CA3EA1A1B571D" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">53,806,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e615-wk-Fact-B7D1F0FAAF7A9D852EC7A3EA1A1EBD64" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">52,752,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e635-wk-Fact-8114E0E04FE5A1164832A3EA1A11BA9F" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,063,829</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e654-wk-Fact-EE28F486D7A27761E8D2A3EA1A0CD9E0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e674-wk-Fact-5BB133E9BFC696DB03CEA3EA1A230D7B" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">54,870,146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e693-wk-Fact-9276896B58A7C4180CE3A3EA1A1614BE" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">52,752,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic and diluted:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e759-wk-Fact-DB56EAA2B2E84199C268A3EA1A15480C" name="us-gaap:EarningsPerShareBasic" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16548e778-wk-Fact-69AA522C761FDD2E53F9A3EA1A157FF6" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e799-wk-Fact-EC58C28E514512EF12DBA3EA1A22D909" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d16548e818-wk-Fact-4B0A6AF5514CED92404CA3EA1A20F671" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Antidilutive securities excluded from calculations of diluted net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e835-wk-Fact-5E25431A2FC241605019A3EA1A1504D2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,095,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d16548e854-wk-Fact-94D67636037F9325C55EA3EA1A0D2D24" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,068,806</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurred a net loss for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.</span></div></ix:continuation><div><a id="s8DD35C7A86FC5D4B839137A161F16105"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-0-wk-Fact-4CDBB935AB62B9633605A3EA1A214A92" continuedAt="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-1" escape="true">Legal Matters</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-1" continuedAt="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-2"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The Company has been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since the Company filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014.  The lawsuit was filed in response to Roxane&#8217;s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;prior to the expiration of certain of the Company&#8217;s patents covering Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, including U.S. Patent No. 8,586,610 (&#8216;610 Patent). In August 2016, the Delaware District Court ruled in the Company&#8217;s favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane&#8217;s ANDA until the expiration of the &#8216;610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court&#8217;s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the&#160;Delaware District Court&#8217;s&#160;ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward&#8217;s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit&#8217;s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants of ANDAs for generic versions of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;prior to the expiration of the &#8216;610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025.  The Company entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The parties are scheduled to provide the court with a status report on May 28, 2020 with respect to the remaining lawsuits against the other Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. In April and May 2018, the Company filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants alleging that certain of the Company's patents covering HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (collectively, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, as described in the ANDAs submitted to </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-2" continuedAt="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-3"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA by each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants, prior to the expiration of the latest to expire of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents in 2034. Each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents are listed in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="font-family:inherit;font-size:10pt;"> (Orange Book). In December 2018, the Company filed amended complaints against each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning its Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, April 2019, and May 2019, the Company filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from each concerning its Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants and are also scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November and December 2019, the Company filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of its Orange Book listed U.S. Patent No. 10,376,487 (&#8216;487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the &#8216;487 Patent is invalid. The Company answered Teva&#8217;s counterclaim by denying their allegation that the &#8216;487 Patent is invalid. In January 2020, the Company filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of its Orange Book-listed U.S. Patent No. 10,449,176 (&#8216;176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the &#8216;176 Patent, which expires in January 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants and are also scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020 and February 2020, the Company received additional Paragraph IV Letters from MSN concerning the '487 patent and the '176 Patent, respectively, in which MSN alleges that the &#8216;487 and the '176 Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of MSN's generic version of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as described in MSN's ANDA. In February and March 2020 the Company filed two additional lawsuits in the Delaware District Court against MSN for infringement of its &#8216;487 Patent and &#8216;176 Patent. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants and are also scheduled for trial in July 2021. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters</span><span style="font-family:inherit;font-size:10pt;">.  In April 2018, the Company submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, the Company amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, the Company submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, the Company did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on the two proposed studies, stating that the Company is required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed the Company that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 5, 2019, the Company filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA&#8217;s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA&#8217;s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until the Company has adequate safety data from a nine-month non-rodent toxicity study. In May 2019, the Company filed an amended complaint, and in July 2019, the Company filed a Motion for Summary Judgment based on its continuing belief after review of the FDA&#8217;s remand response that additional chronic toxicity studies are unjustified, and that it has provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held in December 2019. In January 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on the Company's claims. The Company has elected not to appeal the Court's ruling.  </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a qui tam action filed against the Company was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-3"><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">alleged that the Company violated these laws through the promotion and marketing of its products Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys&#8217; fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. In March 2020, the DC District Court vacated the scheduled hearing on the Company's motion to dismiss and will notify the parties of a new hearing date if one is deemed necessary by the DC District Court. The Company intends to vigorously defend itself in the case. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a securities class action, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon v. Vanda Pharmaceuticals Inc.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company&#8217;s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">and the Company&#8217;s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. On March 23, 2020, the Company filed a motion to dismiss the complaint. The plaintiff is expected to file its reply by May 7, 2020. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Samuel Williams vs. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Michael Bavaro v. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro </span><span style="font-family:inherit;font-size:10pt;">case to the Eastern District of New York, where the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> cases are pending. In March 2020, the Delaware District Court transferred the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro</span><span style="font-family:inherit;font-size:10pt;"> case to the Eastern District of New York, consolidating the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro</span><span style="font-family:inherit;font-size:10pt;"> cases, and the plaintiffs filed a consolidated complaint on April 24, 2020. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company&#8217;s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend these lawsuits. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA&#8217;s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. In February 2020, the Company filed an appeal of this judgment with the Court of Justice of the E.U.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 21</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4B3FBA3207275B6386D502EAFDA29298"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vanda Pharmaceuticals Inc. (we, our or Vanda) </span><span style="font-family:inherit;font-size:10pt;">is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We strive to advance novel approaches to bring important, new medicines to market through responsible innovation. We are committed to the use of technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and the commercial positioning of our products.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial portfolio is currently comprised of two products, HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of Non-24 Hour Sleep-Wake Disorder (Non-24) and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> for the treatment of schizophrenia. HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, we have a number of drugs in development, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span>&#160;(tasimelteon) for the treatment of jet lag disorder (JLD), Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>Fanapt</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span>&#160;(iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, motion sickness and COVID-19 Acute Respiratory Distress Syndrome (ARDS);</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operational Highlights</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are working proactively across our business and research units to protect employees and customers, and to maintain business continuity as a result of the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-left:4px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Products</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are encouraged by the strong performance of our commercial products during the first quarter of 2020, driving 22% year-over-year growth. We are implementing marketing and sales strategies aimed at overcoming the disruptions caused by the pandemic. We remain committed to continue innovating and bringing value to patients and prescribers, while advancing and strengthening the awareness and use of our products.</span></div><div style="line-height:120%;padding-left:4px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pipeline</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic has impacted clinical research globally, including our previously reported clinical trials. New recruitment for the tradipitant atopic dermatitis, gastroparesis and motion sickness programs, as well as the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> DSPD and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> bipolar disorder and LAI studies, is currently on hold.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradipitant </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ongoing atopic dermatitis and gastroparesis studies, have been adapted in accordance with FDA guidance to protect the health and safety of currently enrolled patients and healthcare providers.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of the recent atopic dermatitis (EPIONE), gastroparesis (VLY686-2301) and motion sickness (Motion Sifnos) studies have all been submitted to peer-review publications.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See below for details on our clinical study, ODYSSEY VLY-686-3501, for the treatment of patients with COVID-19 ARDS.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup>&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discussions with the FDA are ongoing regarding the supplemental New Drug Applications for HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the treatments of JLD and SMS.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">COVID-19 Therapeutic Program</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We initiated the following activities aimed at combating COVID-19:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We announced the initiation of ODYSSEY VLY-686-3501, a Phase III double-blind placebo-controlled trial investigating the efficacy and safety of tradipitant for the treatment of patients with COVID-19 ARDS. Results of this study are expected in the third quarter of 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also announced the initiation of the CALYPSO genetics study to evaluate the role of human and viral genetic variations in COVID-19 infection and disease severity.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and the University of Illinois at Chicago announced a research partnership to identify small molecule inhibitors of cathepsin-L, a host enzyme required for viral processing.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since we began operations, we have devoted substantially all of our resources to the in-licensing, clinical development and commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends on our level of success in commercializing HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the U.S. and Europe, on our ability, alone or with others, to complete the development of our products, and to obtain the regulatory approvals for and to manufacture, market and sell our products. The results of our operations will vary significantly from year-to-year and quarter-to-quarter and depend on a number of factors, including risks related to our business, risks related to our industry, and other risks which are detailed in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:inherit;font-size:10pt;"> reported in Item&#160;1A of Part I of our annual report on Form 10-K (Annual Report) for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and Item 1A of Part II of this quarterly report on Form 10-Q.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of our condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported revenues and expenses during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no significant changes in our critical accounting policies including estimates, assumptions and judgments from those described in Item&#160;7, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:inherit;font-size:10pt;">, included in the Annual Report.&#160;A summary of our significant accounting policies appears in the notes to our audited consolidated financial statements included in the Annual Report. We believe that the following accounting policies are important to understanding and evaluating our reported financial results, and we have accordingly included them in this discussion.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net Product Sales</span><span style="font-family:inherit;font-size:10pt;">. Our net product sales consist of sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. In accordance with Accounting Standards Codification (ASC) 606, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">, we account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. We recognize revenue when control of the product is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. We invoice and record revenue when customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. Revenues and accounts receivable are concentrated with these customers. Outside the U.S., we commercially launched HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;in Germany in August 2016. We have also entered into a distribution agreement with Megapharm Ltd. for the commercialization of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;in Israel. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price is determined based upon the consideration to which we will be entitled in exchange for transferring product to the customer. Our product sales are recorded net of applicable product revenue allowances for which reserves are </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">established and include discounts, rebates, chargebacks, service fees, co-pay assistance and product returns that are applicable for various government and commercial payors. We estimate the amount of variable consideration that should be included in the transaction price utilizing the most likely amount method and update our estimate at each reporting date. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable consideration is included in the transaction price if, in our judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Allowances for rebates, chargebacks and co-pay assistance are based upon the insurance benefits of the end customer, which are estimated using historical activity and, where available, actual and pending prescriptions for which we have validated the insurance benefits.&#160;Reserves for variable consideration are classified as product revenue allowances on our Condensed Consolidated Balance Sheets, with the exception of prompt-pay discounts which are classified as reductions of accounts receivable. The reserve for product returns for which the product may not be returned for a period of greater than one year from the balance sheet date is included as a component of other non-current liabilities on our Condensed Consolidated Balance Sheets. Uncertainties related to variable consideration are generally resolved in the quarter subsequent to period end, with the exception of Medicaid rebates, which are dependent upon the timing of when states submit reimbursement claims, and product returns which are resolved during the product expiry period specified in the customer contract. We currently record sales allowances for the following:</span></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt-pay:</span><span style="font-family:inherit;font-size:10pt;"> Specialty pharmacies and wholesalers are offered discounts for prompt payment. We expect that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deduct the full amount of these discounts from total product sales when revenues are recognized.</span></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Rebates:</span><span style="font-family:inherit;font-size:10pt;"> Allowances for rebates include mandated discounts under the Medicaid Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and estimated patient utilization.</span></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Chargebacks:</span><span style="font-family:inherit;font-size:10pt;"> Chargebacks are discounts that occur when contracted indirect customers purchase directly from specialty pharmacies and wholesalers. Contracted indirect customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the contracted customer.</span></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medicare Part D Coverage Gap:</span><span style="font-family:inherit;font-size:10pt;">&#160;Medicare Part&#160;D prescription drug benefit mandates manufacturers to fund approximately 70% of the Medicare Part&#160;D insurance coverage gap for prescription drugs sold to eligible patients for applicable drugs. We account for the Medicare Part D coverage gap using a point of sale model.&#160;Estimates for expected Medicare Part&#160;D coverage gap are based in part on historical activity and, where available, actual and pending prescriptions when we have validated the insurance benefits.</span></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Service Fees:</span><span style="font-family:inherit;font-size:10pt;"> We receive sales order management, data and distribution services from certain customers. These fees are based on contracted terms and are known amounts. We accrue service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it is a payment for a distinct good or service from the customer in which case the fair value of those distinct goods or services are recorded as selling, general and administrative expense.</span></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Co-payment Assistance:</span><span style="font-family:inherit;font-size:10pt;"> Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. Co-pay assistance utilization is based on information provided by our third-party administrator.</span></div><div style="line-height:120%;padding-top:8px;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns:</span><span style="font-family:inherit;font-size:10pt;"> We generally offer direct customers a limited right to return as contractually defined with our customers. We consider several factors in the estimation process, including expiration dates of product shipped to customers, inventory levels within the distribution channel, product shelf life, historical return activity, including activity for product sold for which the return period has past, prescription trends and other relevant factors. We do not expect returned goods to be resalable. There was no right of return asset as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes sales discounts and allowance activity for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Rebates &amp; Chargebacks</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Discounts,</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Returns&#160;and Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,392</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,151</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32,543</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision related to current period sales</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,245</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,872</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,117</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments for prior period sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(531</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(231</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(762</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Credits/payments made</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(14,701</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(7,286</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(21,987</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balances at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,405</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,506</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33,911</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The provision of </span><span style="font-family:inherit;font-size:10pt;">$17.2 million</span><span style="font-family:inherit;font-size:10pt;"> for rebates and chargebacks for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> primarily represents Medicaid rebates applicable to sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The provision of </span><span style="font-family:inherit;font-size:10pt;">$6.9 million</span><span style="font-family:inherit;font-size:10pt;">&#160;for discounts, returns and other for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> primarily represents wholesaler distribution fees applicable to sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and, to a lesser extent, estimated product returns of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, and co-pay assistance costs and prompt pay discounts applicable to the sales of both HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:9pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation</span><span style="font-family:inherit;font-size:10pt;">. Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and recognized over the period during which the employee or director is required to perform service in exchange for the award. We use the Black-Scholes-Merton option pricing model to determine the fair value of stock options. The determination of the fair value of stock options on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the expected stock price volatility over the expected term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility rates are based on the historical volatility of our publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have never paid cash dividends to our stockholders since our inception and do not plan to pay dividends in the foreseeable future. As stock-based compensation expense recognized in the Condensed Consolidated Statements of Operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses</span><span style="font-family:inherit;font-size:10pt;">. Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials, costs of contract manufacturing services for clinical trial use, milestone payments made under licensing agreements prior to regulatory approval, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. We expense research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments made under license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with our research and development efforts and has no alternative future use.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials are inherently complex, often involve multiple service providers, and can include payments made to investigator physicians at study sites. Because billing for services often lags delivery of service by a substantial amount of time, we often are required to estimate a significant portion of our accrued clinical expenses. Our assessments include, but are not limited to: (i)&#160;an evaluation by the project manager of the work that has been completed during the period, (ii)&#160;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&#160;analyses of data that justify the progress, and (iv)&#160;management&#8217;s judgment. In the event that we do not identify certain costs that have begun to be incurred or we under- or over-estimate the level of services performed or the costs of such services, our reported expenses for such period would be too low or too high.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible Assets</span><span style="font-family:inherit;font-size:10pt;">. Our intangible assets consist of capitalized license costs for products approved by the FDA. We amortize our intangible assets on a straight-line basis over the estimated useful economic life of the related product patents. We assess the impairment of intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important which could trigger an impairment review include significant underperformance relative to expected historical or projected future operating results, a significant adverse change in legal or regulatory factors that could affect the value or patent life including our ability to defend and enforce patent claims and other intellectual property </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rights and significant negative industry or economic trends. When we determine that the carrying value of our intangible assets may not be recoverable based upon the existence of one or more of the indicators of impairment, we measure any impairment based on the amount that carrying value exceeds fair value. No impairments have been recognized on our intangible assets.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income taxes.</span><span style="font-family:inherit;font-size:10pt;">&#160;We assess the need for a valuation allowance against our deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis is highly dependent upon historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During the third quarter of 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, we concluded that it was more likely than not that substantially all of our deferred tax assets in the U.S. are realizable in future periods.  A valuation allowance has been retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.  Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> footnote to the condensed consolidated financial statements included in Part I of this quarterly report on Form 10-Q for information on recent accounting pronouncements.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including our and our partners&#8217; ability to successfully commercialize our products, any possible payments made or received pursuant to license or collaboration agreements, progress of our research and development efforts, the timing and outcome of clinical trials and related possible regulatory approvals. Since our inception, we have incurred significant losses resulting in an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$220.2 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Our total stockholders&#8217; equity was </span><span style="font-family:inherit;font-size:10pt;">$416.4 million</span><span style="font-family:inherit;font-size:10pt;">&#160;as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Three months ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> compared to three months ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenues</span><span style="font-family:inherit;font-size:10pt;">. Total revenues </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$10.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">22%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$58.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$47.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Revenues were as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Percent</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35,336</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28,957</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,379</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22,664</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18,756</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,908</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58,000</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47,713</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,287</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> product sales, net </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$6.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">22%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$35.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$29.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> to net product sales was attributable to an increase in volume and an increase in price net of deductions.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> product sales, net </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$3.9 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">21%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$22.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$18.8 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> to net product sales was attributable to an increase in volume and an increase in price net of deductions. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of goods sold.</span><span style="font-family:inherit;font-size:10pt;"> Cost of goods sold </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">2%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$5.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$5.1 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Cost of goods sold includes third-party manufacturing costs of product sold, third-party royalty costs and distribution and other costs. Third-party royalty costs were 10% and 5% of net product sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> in the U.S. and Germany, respectively. Third-party royalty costs on net product sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> decreased from 9% to 6% beginning January 2020.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to third-party royalty costs, HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;cost of goods sold as a percentage of revenue depends upon our cost to manufacture inventory at normalized production levels with our third-party manufacturers. We expect that, in the future, total HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;manufacturing costs included in cost of goods sold will continue to be less than 2% of our net product sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. We expect that, in the future, total Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;manufacturing costs included in cost of goods sold will continue to be less than 3% of our net product sales of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development expenses.</span><span style="font-family:inherit;font-size:10pt;"> Research and development expenses were </span><span style="font-family:inherit;font-size:10pt;">$15.5 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$13.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in clinical trial expenses was primarily associated with our&#160;Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> development programs. The following table summarizes the costs of our product development initiatives for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Direct project costs (1)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,898</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,097</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:26px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,685</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,081</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradipitant</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,193</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,652</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VTR-297</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">368</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">390</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CFTR</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">780</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,367</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">471</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,395</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,692</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indirect project costs (1)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,111</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">728</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other indirect overhead</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">858</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,132</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,586</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total research and development expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15,527</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13,278</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:40px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:16px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to incur significant research and development expenses as we continue to develop our products. In addition, we expect to incur licensing costs in the future that could be substantial, as we continue our efforts to expand our product pipeline.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses.</span><span style="font-family:inherit;font-size:10pt;"> Selling, general and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$6.0 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">19%</span><span style="font-family:inherit;font-size:10pt;">, to </span><span style="font-family:inherit;font-size:10pt;">$37.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$31.0 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> was primarily the result of increased spending on marketing activities for our commercial products. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible asset amortization</span><span style="font-family:inherit;font-size:10pt;">. Intangible asset amortization was </span><span style="font-family:inherit;font-size:10pt;">$0.4 million</span><span style="font-family:inherit;font-size:10pt;"> for each of the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other income</span><span style="font-family:inherit;font-size:10pt;">. Other income was </span><span style="font-family:inherit;font-size:10pt;">$1.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$1.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Other income primarily relates to investment income on our marketable securities.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for income taxes.</span><span style="font-family:inherit;font-size:10pt;"> For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded income tax expense of&#160;$</span><span style="font-family:inherit;font-size:10pt;">0.8</span><span style="font-family:inherit;font-size:10pt;"> million&#160;and less than $0.1 million, respectively.  The income tax expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by the estimated effective tax rate for the year and the discrete impact of </span><span style="font-family:inherit;font-size:10pt;">$0.4 million</span><span style="font-family:inherit;font-size:10pt;"> of net shortfall tax expense related to stock-based compensation activity during the quarter. As a result of the tax valuation allowance against deferred tax assets in the U.S., there was no benefit for federal income taxes associated with the loss before taxes for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Income taxes were recorded related to certain U.S. state and foreign jurisdictions for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, our total cash and cash equivalents and marketable securities were </span><span style="font-family:inherit;font-size:10pt;">$312.3 million</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$312.1 million</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Our cash and cash equivalents are deposits in operating accounts and highly liquid investments with an original maturity of 90 days or less at date of purchase and consist of investments in money market funds with commercial banks and financial institutions and commercial paper of high-quality corporate issuers. Our marketable securities consist of investments in government sponsored and corporate enterprises, commercial paper and asset-backed securities.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our liquidity resources as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are summarized as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64,950</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45,072</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87,572</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88,601</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">123,426</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130,055</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36,378</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48,401</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">247,376</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">267,057</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">312,326</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">312,129</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we maintained all of our Cash in two financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits, but we do not anticipate any losses with respect to such deposits.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to incur substantial costs and expenses throughout the remainder of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and beyond in connection with our continued clinical development of tradipitant and our other products, U.S. commercial activities for HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, the European commercial launch activities for HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and payments due upon achievement of milestones under our license agreements. Additionally, we continue to pursue market approval of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;in other regions. The actual costs to advance tradipitant and our research and development projects and commercial activities for HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;are difficult to estimate and may vary significantly. We believe that our existing funds will be sufficient to meet our operating plans for at least the next twelve months. Our future capital requirements and the adequacy of our available funds will depend on many factors, primarily including our ability to generate revenue, the scope and costs of our commercial, manufacturing and process development activities, the magnitude of our discovery, preclinical and clinical development programs, and potential costs to acquire or license the rights to additional products. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may need or desire to obtain additional capital to finance our operations through debt, equity or alternative financing arrangements. We may also seek capital through collaborations or partnerships with other companies. The issuance of debt could require us to grant liens on certain of our assets that may limit our flexibility and debt securities may be convertible into common stock. If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may significantly dilute the ownership of our existing stockholders. If we are unable to obtain additional financing, we may be required to reduce the scope of our future activities which could harm our business, financial condition and operating results. There can be no assurance that any additional financing required in the future will be available on acceptable terms, if at all.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flow</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our net cash flows from operating, investing and financing activities for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by (used in):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">486</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(612</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,098</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-cash charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,571</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,405</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,166</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net change in operating assets and liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(6,964</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6,850</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(13,814</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(907</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,643</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(10,550</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(373</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(393</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net maturities (purchases) of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,673</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(36,058</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56,731</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20,300</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(36,451</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56,751</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Proceeds from the exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">479</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">179</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">300</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">479</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">179</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">300</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net change in cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,877</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(26,627</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46,504</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities:</span><span style="font-family:inherit;font-size:10pt;"> Cash flows used in operating activities during the </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">$0.9 million</span><span style="font-family:inherit;font-size:10pt;">, a decrease of </span><span style="font-family:inherit;font-size:10pt;">$10.6 million</span><span style="font-family:inherit;font-size:10pt;"> compared to cash flows provided by operating activities of </span><span style="font-family:inherit;font-size:10pt;">$9.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The decrease reflects a decrease&#160;of </span><span style="font-family:inherit;font-size:10pt;">$13.8 million</span><span style="font-family:inherit;font-size:10pt;"> from the net change in operating assets and liabilities, partially offset by an increase of </span><span style="font-family:inherit;font-size:10pt;">$1.1 million</span><span style="font-family:inherit;font-size:10pt;"> in net income and an increase of </span><span style="font-family:inherit;font-size:10pt;">$2.2 million</span><span style="font-family:inherit;font-size:10pt;"> in non-cash charges. The decrease of </span><span style="font-family:inherit;font-size:10pt;">$13.8 million</span><span style="font-family:inherit;font-size:10pt;"> from the net change in operating assets and liabilities primarily relates to an increase in accounts receivable attributable to the timing of shipments and payments, an increase in prepaid expenses and other assets attributable to the timing of activities and payments, partially offset by a decrease in accounts payable and other liabilities attributable to the timing of activities and payments. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities:</span><span style="font-family:inherit;font-size:10pt;"> Cash flows provided by investing activities during the </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;">$20.3 million</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$56.8 million</span><span style="font-family:inherit;font-size:10pt;"> compared to cash flows used in investing activities of </span><span style="font-family:inherit;font-size:10pt;">$36.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Investing activities primarily include purchases and maturities of marketable securities. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities:</span><span style="font-family:inherit;font-size:10pt;"> Cash flows provided by financing activities during the </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;">$0.5 million</span><span style="font-family:inherit;font-size:10pt;">, an increase of </span><span style="font-family:inherit;font-size:10pt;">$0.3 million</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$0.2 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;font-style:normal;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Financing activities include proceeds from exercises of stock options. </span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have no off-balance sheet arrangements, as defined in Item&#160;303(a)(4)&#160;of the Securities and Exchange Commission&#8217;s Regulation&#160;S-K.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Commitments</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of our noncancellable long-term contractual cash obligations as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="27" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash Payments Due by Year (3)(4)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases(1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19,445</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,671</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,329</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,355</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,420</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,488</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,182</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase commitments(2) </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,665</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,218</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">966</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">481</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total noncancellable long-term contractual cash obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24,110</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,889</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,295</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,836</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,420</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,488</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8,182</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-bottom:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating leases include the minimum lease payments for our operating lease liabilities. This table does not include obligations under short-term lease agreements, variable payments for building maintenance and other services and executory costs associated with our operating lease agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase commitments include noncancellable purchase commitments for agreements longer than one year and primarily relate to commitments for media and data services. This table does not include various other long-term agreements entered into for services with other third-party vendors, such as inventory purchase commitments, due to the cancelable nature of the services or variable terms within the agreement. Additionally, this table does not include rebates, chargebacks or discounts recorded as liabilities at the time that product sales are recognized as revenue.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This table does not include potential future milestone obligations under our license agreements for which we have not deemed it probable that the milestone event will occur as of&#160;</span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. See </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;"> footnote to the condensed consolidated financial statements included in Part I of this quarterly report on Form 10-Q for a description of our licensing arrangements and remaining milestone obligations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(4)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This table does not include liabilities related to uncertain tax positions taken as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Due to the uncertainties in the timing of potential tax audits, the timing associated with the resolution of these positions is also uncertain. </span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s5E3EC5E873735ACF9E33C7B0F8F11275"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate risks</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our exposure to market risk is currently confined to our cash and cash equivalents, marketable securities and restricted cash. We currently do not hedge interest rate exposure. We have not used derivative financial instruments for speculation or trading purposes. Because of the short-term maturities of our cash and cash equivalents and marketable securities, we do not believe that an increase in market rates would have any significant impact on the realized value of our investments.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of credit risk</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We deposit our cash with financial institutions that we consider to be of high credit quality and purchase marketable securities which are generally investment grade, liquid, short-term fixed income securities and money-market instruments denominated in U.S. dollars. Our marketable securities consist of certificates of deposit, commercial paper, corporate notes, asset-backed securities and U.S. government agency notes.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues and accounts receivable are concentrated with specialty pharmacies and wholesalers. There were </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of total revenues and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;">96%</span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. There were </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of accounts receivable and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;">94%</span><span style="font-family:inherit;font-size:10pt;"> of total accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. We mitigate our credit risk relating to accounts receivable from customers by performing ongoing credit evaluations.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign currency risk</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to risks related to changes in foreign currency exchange rates relating to our foreign operations. The functional currency of our international subsidiaries is the local currency. We are exposed to foreign currency risk to the extent that we enter into transactions denominated in currencies other than our subsidiaries&#8217; respective functional currencies. We are also exposed to unfavorable fluctuations of the U.S. dollar, which is our reporting currency, against the currencies of our operating subsidiaries when their respective financial statements are translated into U.S. dollars for inclusion in our condensed </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">consolidated financial statements. We do not currently hedge our foreign currency exchange rate risk. Foreign currency has not had a material impact on our results of operations.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effects of inflation</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inflation has not had a material impact on our results of operations.</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sD6F606401923505AAC539FAA3ED3D058"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Controls and Procedures</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)) as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Based upon that evaluation, our Chief Executive Officer and Acting Chief Financial Officer concluded that our disclosure controls and procedures are effective as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the end of the period covered by this quarterly report, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Acting Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="line-height:120%;padding-top:8px;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;"><br/></span></div><div><a id="s30300DF8A77853A1A4BA357A56BBDAF4"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II &#8212; OTHER INFORMATION</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><div><a id="s2F40A6AFB31857CC9BF70016761EF7DA"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.46875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:36%;"></td><td style="width:64%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. We have been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since we filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014.  The lawsuit was filed in response to Roxane&#8217;s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;prior to the expiration of certain of our patents covering Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, including U.S. Patent No. 8,586,610 (&#8216;610 Patent). In August 2016, the Delaware District Court ruled in our favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane&#8217;s ANDA until the expiration of the &#8216;610 Patent in November 2027, or May 2028 if we obtain pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court&#8217;s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the&#160;Delaware District Court&#8217;s&#160;ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward&#8217;s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit&#8217;s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, we filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants of ANDAs for generic versions of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;prior to the expiration of the &#8216;610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025.  We entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The parties are scheduled to provide the court with a status report on May 28, 2020 with respect to the remaining lawsuits against the other Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. In April and May 2018, we filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants alleging that certain of our patents covering HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (collectively, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, as described in the ANDAs submitted to the FDA by each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants, prior to the expiration of the latest to expire of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents in 2034. Each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents are listed in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="font-family:inherit;font-size:10pt;"> (Orange Book). In December 2018, we filed amended complaints against each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning our Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, April 2019, and May 2019, we filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from each concerning our Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants and are also scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November and December 2019, we filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of our Orange Book listed U.S. Patent No. 10,376,487 (&#8216;487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the &#8216;487 Patent is invalid. We answered Teva&#8217;s counterclaim by denying their allegation that the &#8216;487 Patent is invalid. In January 2020, we filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of our Orange Book-listed U.S. Patent No. 10,449,176 (&#8216;176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the &#8216;176 Patent, which expires in January 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants and are also scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020 and February 2020, we received additional Paragraph IV Letters from MSN concerning the '487 patent and the '176 Patent, respectively, in which MSN alleges that the &#8216;487 and the '176 Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of MSN's generic version of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as described in MSN's ANDA. In February and March 2020 we filed two additional lawsuits in the Delaware District Court against MSN for infringement of our &#8216;487 Patent and &#8216;176 Patent. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants and are also scheduled for trial in July 2021. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters</span><span style="font-family:inherit;font-size:10pt;">.  In April 2018, we submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, we amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, we submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, we did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on the two proposed studies, stating that we are required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed us that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 5, 2019, we filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA&#8217;s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA&#8217;s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until we have adequate safety data from a nine-month non-rodent toxicity study. In May 2019, we filed an amended complaint, and in July 2019, we filed a Motion for Summary Judgment based on our continuing belief after review of the FDA&#8217;s remand response that additional chronic toxicity studies are unjustified, and that we have provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held in December 2019. In January 2020, the Court granted the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on our claims. We have elected not to appeal the Court's ruling.  </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a qui tam action filed against us was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by one of our former employees on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint alleged that we violated these laws through the promotion and marketing of our products Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys&#8217; fees and costs. By virtue of the DC District Court having unsealed the original complaint, we learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, we filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. In March 2020, the DC District Court vacated the scheduled hearing on our motion to dismiss and will notify the parties of a new hearing date if one is deemed necessary by the DC District Court. We intend to vigorously defend itself in the case. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a securities class action, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon v. Vanda Pharmaceuticals Inc.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming us and certain of our officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased our publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">and our interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. On March 23, 2020, we filed a motion to dismiss the complaint. The plaintiff is expected to file its reply by May 7, 2020. We believe that it has meritorious defenses and intends to vigorously defend this lawsuit. We do not anticipate that this litigation will have a material adverse effect on our business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and we may not prevail. We believe we are entitled to coverage under our relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Samuel Williams vs. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former of our directors and officers as defendants. In September 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Michael Bavaro v. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the Delaware District Court naming certain current and former of our directors and officers as defendants. In October 2019, we filed a motion to transfer the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro </span><span style="font-family:inherit;font-size:10pt;">case to the Eastern District of New York, where the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> cases are pending. In March 2020, the Delaware District Court transferred the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro</span><span style="font-family:inherit;font-size:10pt;"> case to the Eastern District of New York, consolidating the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro</span><span style="font-family:inherit;font-size:10pt;"> cases, and the plaintiffs filed a consolidated complaint on April 24, 2020. These complaints, filed on behalf of purported stockholders, derivatively on behalf of us, assert claims for alleged breach of fiduciary duties by certain of our current and former directors and officers. We believe that it has meritorious defenses and intends to vigorously defend these lawsuits. We do not anticipate that this litigation will have a material adverse effect on our business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and we may not prevail. We believe we are entitled to coverage under our relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> did not outweigh its risks and recommended against marketing authorization. In March 2018, we filed an application seeking annulment of the EMA&#8217;s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. In February 2020, we filed an appeal of this judgment with the Court of Justice of the E.U.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 33</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8A20EA5FDBD55683B80C1C4645DDD3BD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1A</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk Factors</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We previously disclosed in Part I, Item&#160;1A of our annual report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, filed with the Securities and Exchange Commission on February&#160;26, 2020, important factors which could affect our business, financial condition, results of operations and future operations under the heading </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Factors</span><span style="font-family:inherit;font-size:10pt;">. Our business, financial condition and operating results can be affected by a number of factors, whether current known or unknown, including but not limited to those described as risk factors, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from past, or anticipated future, operating results and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock. Except as set forth below, there have been no material changes in our risk factors subsequent to the filing of our annual report on Form 10-K for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Global health crises and pandemics, such as the global outbreak of the novel coronavirus (COVID-19), may adversely impact our business.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, a novel strain of coronavirus (COVID-19) surfaced in Wuhan, China. Since then, COVID-19 has spread to nearly every country in the world, including the U.S. The COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The effects of shelter-in-place orders and our work-from-home policies may negatively impact productivity and disrupt our business, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our sales force has had physical access to healthcare providers curtailed, which may have an impact on our future revenues.&#160;While we are implementing marketing and sales strategies aimed at overcoming the disruptions caused by the pandemic, we cannot ensure that these methods will be effective. Additionally, patients who might be currently using our products, or might otherwise be eligible to use our products, may be unable to meet with their healthcare providers, which may reduce the number of prescription refills or new patient starts, thereby adversely affecting our revenues.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic has impacted clinical research globally, including our previously reported clinical trials. New recruitment for the tradipitant atopic dermatitis, gastroparesis, and motion sickness programs, as well as the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> delayed sleep phase disorder and Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> bipolar disorder and long acting injectable studies, is currently on hold. We may further experience disruptions that could adversely impact our supply chain, our ongoing and planned clinical trials, and other regulatory activities, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interruption of, or delays in receiving, supplies of the active pharmaceutical ingredients that our contract manufacturing organizations use to manufacture our products and any related interruption of, or delays in receiving, supplies of our products from these organizations, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">delays or difficulties in enrolling patients in our clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as procedures that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limitations on our employee resources or those of third-party clinical research organizations towards the development of our products, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">interruption or delays in the operations of regulatory agencies, which may impact review and approval timelines.</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak may impact our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, travel restrictions and social distancing practices, business closures or business disruptions and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease.</span></div><div><a id="s06E63EA43547510B8A7FC0DE2023A656"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None</span></div><div style="line-height:120%;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;"><br/></span></div><div><a id="sD266263AA381541EBED79E8BF0CAD4C5"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Defaults Upon Senior Securities</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None</span></div><div><a id="sD0D443A1079C5B9AB6A56ABAB5613C65"></a></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Mine Safety Disclosures</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable</span></div><div style="line-height:120%;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;"><br/></span></div><div><a id="s8D7896B1686350EAB95212CC0254FC68"></a></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;5</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Information</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Approval of Amended and Restated 2016 Equity Incentive Plan</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 20, 2020 our Board of Directors approved, subject to stockholder approval, an amendment and restatement of our Amended and Restated 2016 Equity Incentive Plan (the 2016 Plan). The amendment and restatement of the 2016 Plan, if approved by the stockholders, will increase the aggregate number of shares of common stock that may be issued by us pursuant to awards under the 2016 Plan by 1,690,000 shares.</span></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amended and Restated Employment Agreement with Kevin Moran</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 5, 2020, we entered into an amended and restated employment agreement (the Employment Agreement) with Kevin Moran, our Vice President, Acting Chief Financial Officer and Treasurer, which amends and restates his prior employment agreement. The Employment Agreement provides for an annual base salary of not less than $270,113 and the possibility of an annual target cash incentive bonus amount equal to 30% of his annual base salary upon achievement of certain performance criteria, in accordance with his previously approved base salary and target cash bonus. The Employment Agreement provides that if we terminate Mr. Moran&#8217;s employment for any reason other than cause or permanent disability, or, if he terminates his employment within six months after the occurrence of any event constituting good reason (as defined below), Mr. Moran will receive the following severance benefits following termination: (1) base salary for a period of 12 months; (2) his annual target bonus, payable in a lump sum; and (3) an additional three months of service credit under all options held by him and all such options shall be exercisable for six months following his termination.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Employment Agreement, the following terms are defined as follows:</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8220;Good reason&#8221; means: (i) a change in Mr. Moran&#8217;s position with us that materially reduces his level of authority or responsibility from what it was prior to his elevation to the position of Acting Chief Financial Officer and Treasurer; (ii) a material reduction in his base compensation; or (iii) receipt of notice that his principal workplace will be relocated by more than 30 miles. A condition shall not be considered &#8220;good reason&#8221; unless Mr. Moran gives us written notice of such condition within 90 days after such condition comes into existence and we fail to remedy such condition within 30 days after receiving such written notice.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8220;Cause&#8221; means: (i) an unauthorized use or disclosure of our confidential information or trade secrets, which use or disclosure causes material harm to us; (ii) a material breach of any agreement between Mr. Moran and us; (iii) a material failure to comply with our written policies or rules; (iv) conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the U.S. or any state thereof; (v) Mr. Moran&#8217;s gross negligence or willful misconduct; (vi) a continuing failure to perform assigned duties after receiving written notification of such failure from the Board; or (vii) a failure by Mr. Moran to cooperate in good faith with a governmental or internal investigation of us or our directors, officers or employees, if we have requested Mr. Moran&#8217;s cooperation.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The foregoing summary of the Employment Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Employment Agreement, a copy of which is attached hereto as Exhibit 10.42, and the terms of which are incorporated herein by reference.</span></div><div style="line-height:120%;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 36</span></div></div><hr style="page-break-after:always"></hr><div><a id="s68330179D12D5A6A99DB319596368FCA"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibits</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:92%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-align:center;">Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1347178/000095013306001354/w15453a2exv3w8.htm"><span style="font-family:inherit;font-size:10pt;">Form of Amended and Restated Certificate of Incorporation of the registrant (filed as Exhibit 3.8 to Amendment No. 2 to the registrant&#8217;s registration statement on Form S-1 (File No.&#160;333-130759) on March&#160;17, 2006 and incorporated herein by reference).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1347178/000119312515409169/d106778dex31.htm"><span style="font-family:inherit;font-size:10pt;">Fourth Amended and Restated Bylaws of the registrant, as amended and restated on December&#160;17, 2015 (filed as Exhibit&#160;3.1 to the registrant&#8217;s current report on Form 8-K (File No.&#160;001-34186) on December&#160;21, 2015 and incorporated herein by reference).</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.42</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vndaex1042331202010q.htm"><span style="font-family:inherit;font-size:10pt;">Amended and Restated Employment Agreement, dated May 5, 2020, by and between Kevin Moran and the registrant.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vndaex311331202010q.htm"><span style="font-family:inherit;font-size:10pt;">Certification of the Chief Executive Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vndaex312331202010q.htm"><span style="font-family:inherit;font-size:10pt;">Certification of the Acting Chief Financial Officer, as required by Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="vndaex321331202010q.htm"><span style="font-family:inherit;font-size:10pt;">Certification of the Chief Executive Officer (Principal Executive Officer) and Acting Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer), as required by Section&#160; 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following financial information from this quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2020 formatted in Inline Extensible Business Reporting Language (iXBRL) and filed electronically herewith: (i)&#160;Condensed Consolidated Balance Sheets as of March 31, 2020 and December&#160;31, 2019; (ii) Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019; (iii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the three months ended March 31, 2020 and 2019; (iv) Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the three months ended March 31, 2020 and 2019; (v) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019; and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 37</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD43394A1FB825224806C40093EFDE0AF"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:inherit;font-size:8pt;font-weight:bold;" href="#s43749DCED2A75F9787DAB212383DDBE9"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:4%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Vanda Pharmaceuticals Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;Mihael H. Polymeropoulos, M.D.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Mihael H. Polymeropoulos, M.D.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/&#160;Kevin Moran</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Kevin Moran</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Acting&#160;Chief&#160;Financial&#160;Officer (Principal&#160;Financial&#160;Officer&#160;and&#160;Principal&#160;Accounting&#160;Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> 38</span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>2
<FILENAME>vndaex1042331202010q.htm
<DESCRIPTION>EXHIBIT 10.42
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s92DE57397F63E40F2BF8E01BF2CE47E0"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 10.42</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:13pt;"><font style="font-family:inherit;font-size:12pt;">This Employment Agreement (this &#8220;Agreement&#8221;) by and between </font><font style="font-family:inherit;font-size:13pt;font-weight:bold;">KEVIN MORAN</font><font style="font-family:inherit;font-size:12pt;">&#32;(the &#8220;Executive&#8221;) and </font><font style="font-family:inherit;font-size:13pt;font-weight:bold;">VANDA PHARMACEUTICALS INC.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware corporation (the &#8220;Company&#8221;) was originally entered into as of August 6, 2010.  This Agreement is hereby amended and restated as of May 5, 2020.</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:48px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Duties and Scope of Employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Position</font><font style="font-family:inherit;font-size:12pt;">.  During his employment under this Agreement (&#8220;Employment&#8221;), the Company agrees to employ the Executive in the position of VP, Acting Chief Financial Officer and Treasurer.  The Executive shall be subject to the supervision of, and shall have such authority as is delegated to him by, the Company&#8217;s Chief Executive Officer.  The Executive hereby accepts such employment and agrees to undertake the duties and responsibilities normally inherent in such position and such other duties and responsibilities as the Company&#8217;s Chief Executive Officer shall from time to time reasonably assign to him. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Obligations to the Company</font><font style="font-family:inherit;font-size:12pt;">.  During his Employment, the Executive shall devote his full business efforts and time to the Company.  In addition, during his Employment, without the prior written approval of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;), the Executive shall not render services in any capacity to any other person or entity and shall not act as a sole proprietor or partner of any other person or entity or as a shareholder owning more than five percent of the voting power of any other entity.  The Executive shall comply with the Company&#8217;s policies and rules, as they may be in effect from time to time during his Employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">No Conflicting Obligations</font><font style="font-family:inherit;font-size:12pt;">.  The Executive represents and warrants to the Company that he is under no obligations or commitments, whether contractual or otherwise, that are inconsistent with his obligations under this Agreement.  The Executive represents and warrants that he will not use or disclose, in connection with his Employment, any trade secrets or other proprietary information or intellectual property in which the Executive or any other person has any right, title or interest and that his Employment as contemplated by this Agreement will not infringe or violate the rights of any other person or entity.  The Executive represents and warrants to the Company that he has returned all property and confidential information belonging to any prior employers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cash and Incentive Compensation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Salary</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall pay the Executive as compensation for his services a base salary at a gross annual rate of not less than $270,113.  Such salary shall be payable in accordance with the Company&#8217;s standard payroll procedures.  The annual compensation specified in this Subsection&#160;(a), together with any increases in such compensation that the Company may grant from time to time, is referred to in this Agreement as &#8220;Base Compensation.&#8221;</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incentive Bonuses</font><font style="font-family:inherit;font-size:12pt;">.  The Executive shall be eligible for an annual incentive bonus with a target amount equal to 30% of his Base Compensation (the &#8220;Annual Target Bonus&#8221;).  Such Annual Target Bonus (if any) shall be awarded based on objective or subjective criteria established in advance by the Board or the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;).  Any Annual Target Bonus for a fiscal year shall in no event be paid later than 2&#189; months after the close of such fiscal year.  Except as provided in Section 6, such Annual Target Bonus shall be paid only if the Executive is employed by the Company at the time of payment.  The determinations of the Board or the Compensation Committee with respect to such Annual Target Bonus shall be final and binding.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Equity Awards</font><font style="font-family:inherit;font-size:12pt;">.  The Executive has previously been granted options to purchase shares of the Company&#8217;s common stock and restricted stock units.  In addition, the Executive will be eligible to receive annual equity awards, if any, subject to the approval of the Board or the Compensation Committee in their sole discretion.  The timing and size of the annual equity awards, if any, shall be determined in the sole discretion of the Board or the Compensation Committee based on the Executive&#8217;s and/or the Company&#8217;s performance.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Vacation and Employee Benefits.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Company has adopted an unlimited paid time off policy, as such, during his Employment, the Executive shall be eligible for an unlimited number of paid vacation days each year, subject to the unlimited paid time off policy as in effect from time to time.  In accordance with such policy, the Executive shall not be entitled to any accrued vacation upon termination of employment for any reason.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">During his Employment, the Executive shall be eligible to participate in any employee benefit plans maintained by the Company for similarly situated employees, subject in each case to the generally applicable terms and conditions of the plan in question and to the determinations of any person or committee administering such plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Business Expenses.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;During his Employment, the Executive shall be authorized to incur necessary and reasonable travel, entertainment and other business expenses in connection with his duties hereunder.  The Company shall reimburse the Executive for such expenses upon presentation of an itemized account and appropriate supporting documentation, all in accordance with the Company&#8217;s generally applicable policies.  Any reimbursement shall (a)&#160;be paid promptly but not later than the last day of the calendar year following the year in which the expense was incurred, (b)&#160;not be affected by any other expenses that are eligible for reimbursement in any calendar year and (c)&#160;not be subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term of Employment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Employment at Will</font><font style="font-family:inherit;font-size:12pt;">.  The Executive&#8217;s Employment with the Company shall be &#8220;at will,&#8221; meaning that either the Executive or the Company may terminate the Executive&#8217;s Employment at any time and for any reason, with or without Cause.  Any contrary representations which may have been made to the Executive shall be superseded by this Agreement.  This Agreement shall constitute the full and complete agreement between the Executive and the </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Company on the &#8220;at will&#8221; nature of the Executive&#8217;s Employment, which may only be changed in an express written agreement signed by the Executive and a duly authorized officer of the Company (other than the Executive).  The termination of Executive&#8217;s Employment shall not limit or otherwise affect his obligations under Section 7 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Termination</font><font style="font-family:inherit;font-size:12pt;">.  The Company may terminate the Executive&#8217;s Employment at any time and for any reason (or no reason), and with or without Cause, by giving the Executive notice in writing.  The Executive may terminate his Employment by giving the Company 14 days&#8217; advance notice in writing.  The Executive&#8217;s Employment shall terminate automatically in the event of his death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rights Upon Termination</font><font style="font-family:inherit;font-size:12pt;">.  Except as expressly provided in Section&#160;6, upon the termination of the Executive&#8217;s Employment pursuant to this Section&#160;5, the Executive shall only be entitled to accrued and unpaid compensation, benefits and expense reimbursements described in Sections&#160;2, 3 and&#160;4 for the period preceding the effective date of the termination.  The payments under this Agreement shall fully discharge all responsibilities of the Company to the Executive.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Termination Benefits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Preconditions</font><font style="font-family:inherit;font-size:12pt;">.  Any other provision of this Agreement notwithstanding, the remaining Subsections&#160;of this Section 6 shall not apply unless each of the following requirements is satisfied:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Executive has executed a general release of all known and unknown claims that the Executive may then have against the Company or persons affiliated with the Company in a form prescribed by the Company, without alterations.  The Executive shall execute and return the release on or before the date specified by the Company in the prescribed form (the &#8220;Release Deadline&#8221;).  The Release Deadline shall in no event be later than 50 days after the Executive&#8217;s Separation.  If the Executive fails to return the release on or before the Release Deadline, or if the Executive revokes the release, then the Executive shall not be entitled to the benefits described in this Section&#160;6.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">The Executive has returned all property of the Company in the Executive&#8217;s possession.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Severance Pay</font><font style="font-family:inherit;font-size:12pt;">.  If, during the term of this Agreement, the Executive is subject to an Involuntary Termination, then the Company shall pay the Executive both of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Base Compensation</font><font style="font-family:inherit;font-size:12pt;">.  The Company shall continue to pay Executive his Base Compensation for a period of 12 months following the Separation (the &#8220;Continuation Period&#8221;).  Such severance payments shall be paid at the Base Compensation rate in effect at the time of the Separation and in accordance with the Company&#8217;s standard payroll procedures.  The severance payments shall </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">commence within 60 days after the Executive&#8217;s Separation and, once they commence (the &#8220;Payment Commencement&#8221;), shall include any unpaid amounts accrued from the date of the Employee&#8217;s Separation.  However, if the 60-day period described in the preceding sentence spans two calendar years, then the Payment Commencement shall in any event begin on the first payroll period following expiration of any applicable revocation period in the second calendar year.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Target Bonus</font><font style="font-family:inherit;font-size:12pt;">.  An amount equal to his Annual Target Bonus at the rate in effect at the time of the Separation.  Such amount shall be payable in a lump sum on the Company&#8217;s next regularly scheduled payroll that occurs following the Payment Commencement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Options</font><font style="font-family:inherit;font-size:12pt;">.  If, during the term of this Agreement, Executive is subject to an Involuntary Termination, then (i)&#160;the vested portion of the shares of the Company&#8217;s Common Stock subject to all options held by the Executive at the time of his Separation shall be determined by adding three months to the actual period of service that he has completed with the Company and (ii)&#160;such options shall be exercisable for up to six months after the Executive&#8217;s Separation (provided, however, that the Option shall remain subject to the terms of the Plan in the event the Company is subject to a Change in Control, and further provided that the Option in any event shall expire no later than the Expiration Date set forth in the Notice of Stock Option Grant evidencing the Option).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Solicitation, Non-Disclosure and Non-Competition.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;The Executive has entered into a Proprietary Information and Inventions Agreement with the Company, which agreement is incorporated herein by reference.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Successors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Company&#8217;s Successors</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement shall be binding upon any successor (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and/or assets.  For all purposes under this Agreement, the term &#8220;Company&#8221; shall include any successor to the Company&#8217;s business and/or assets which becomes bound by this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Executive&#8217;s Successors</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement and all rights of the Executive hereunder shall inure to the benefit of, and be enforceable by, the Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Definitions.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#32;For all purposes under this Agreement:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cause</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;An unauthorized use or disclosure by the Executive of the Company&#8217;s confidential information or trade secrets, which use or disclosure causes material harm to the Company;</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;A material breach by the Executive of any agreement between the Executive and the Company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;A material failure by the Executive to comply with the Company&#8217;s written policies or rules;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;The Executive&#8217;s conviction of, or plea of &#8220;guilty&#8221; or &#8220;no contest&#8221; to, a felony under the laws of the United States or any State thereof;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)&#160;&#160;&#160;&#160;The Executive&#8217;s gross negligence or willful misconduct;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)&#160;&#160;&#160;&#160;A continuing failure by the Executive to perform assigned duties after receiving written notification of such failure from the Board; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)&#160;&#160;&#160;&#160;A failure by the Executive to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested the Executive&#8217;s cooperation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Change in Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)&#160;&#160;&#160;&#160;The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if persons who were not stockholders of the Company immediately prior to such merger, consolidation or other reorganization own immediately after such merger, consolidation or other reorganization 50% or more of the voting power of the outstanding securities of each of (i)&#160;the continuing or surviving entity and (ii)&#160;any direct or indirect parent corporation of such continuing or surviving entity;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)&#160;&#160;&#160;&#160;The sale, transfer or other disposition of all or substantially all of the Company&#8217;s assets;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)&#160;&#160;&#160;&#160;A change in the composition of the Board, as a result of which fewer than 50% of the incumbent directors are directors who either:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)&#160;&#160;&#160;&#160;Had been directors of the Company on the date 24 months prior to the date of such change in the composition of the Board (the &#8220;Original Directors&#8221;); or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)&#160;&#160;&#160;&#160;Were appointed to the Board, or nominated for election to the Board, with the affirmative votes of at least a majority of the aggregate of (A)&#160;the Original Directors who were in office at the time of their appointment or nomination and (B)&#160;the directors whose appointment or nomination was previously approved in a manner consistent with this Subsection (c)(ii); or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)&#160;&#160;&#160;&#160;Any transaction as a result of which any person is the &#8220;beneficial owner&#8221; (as defined in Rule&#160;13d-3 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), directly or indirectly, of securities of the Company representing at least 50% of the total voting power represented by the Company&#8217;s then outstanding voting securities.  For </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">purposes of this Subsection&#160;(d), the term &#8220;person&#8221; shall have the same meaning as when used in Sections&#160;13(d) and&#160;14(d) of the Exchange Act but shall exclude (i)&#160;a trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a parent or subsidiary of the Company and (ii)&#160;a corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the Common Stock of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">A transaction shall not constitute a Change in Control if its sole purpose is to change the State of the Company&#8217;s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately before such transaction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Code</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the Internal Revenue Code of 1986, as amended.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Reason</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean Executive&#8217;s resignation within 6 months after one of the following conditions has come into existence without Executive&#8217;s consent: (i)&#160;a change in the Executive&#8217;s position with the Company that materially reduces his level of authority or responsibility from what it was prior to his elevation to the position of Acting Chief Financial Officer and Treasurer, (ii)&#160;a material reduction in his Base Compensation or (iii)&#160;receipt of notice that his principal workplace will be relocated by more than 30 miles.  A condition shall not be considered &#8220;Good Reason&#8221; unless the Executive gives the Company written notice of such condition within 90 days after the initial existence of such condition and the Company fails to remedy such condition within 30 days after receiving the Executive&#8217;s written notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Involuntary Termination</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean a Separation resulting from either (i)&#160;the Executive&#8217;s involuntary discharge by the Company for reasons other than Cause, Executive&#8217;s death or Permanent Disability or (ii)&#160;the Executive&#8217;s voluntary resignation for Good Reason.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Permanent Disability</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean the Executive&#8217;s inability to perform the essential functions of the Executive&#8217;s position, with or without reasonable accommodation, for a period of at least 120 consecutive days because of a physical or mental impairment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Separation</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean a &#8220;separation from service,&#8221; as defined in the regulations under Section&#160;409A of the Code.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Miscellaneous Provisions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notice</font><font style="font-family:inherit;font-size:12pt;">.  Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by overnight courier, U.S. registered or certified mail, return receipt requested and postage prepaid.  In the case of the Executive, mailed notices shall be addressed to him at the home address that he most recently communicated to the Company in writing.  In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Modifications and Waivers</font><font style="font-family:inherit;font-size:12pt;">.  No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">writing and signed by the Executive and by an authorized officer of the Company (other than the Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Whole Agreement</font><font style="font-family:inherit;font-size:12pt;">.  No other agreements, representations or understandings (whether oral or written and whether express or implied) which are not expressly set forth in this Agreement have been made or entered into by either party with respect to the subject matter hereof.  This Agreement and the Proprietary Information and Inventions Agreement contain the entire understanding of the parties with respect to the subject matter hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax Matters</font><font style="font-family:inherit;font-size:12pt;">.  All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be withheld by law.  For purposes of Section&#160;409A of the Code, each payment under Section&#160;6(b) is hereby designated as a separate payment.  If the Company determines that the Executive is a &#8220;specified employee&#8221; within the meaning of Section&#160;409A(a)(2)(B)(i) of the Code and the regulations thereunder at the time of his Separation, then:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any salary continuation payments under Section&#160;6(b)(i), to the extent not exempt from Section&#160;409A of the Code, shall commence with the Company&#8217;s first regularly scheduled payroll that occurs following the earlier of (x) expiration of the six-month period measured from Executive&#8217;s Separation or (y) the date of Executive&#8217;s death and, once such payments commence, any amounts accrued from the Separation date shall be paid in a lump sum on the first payment date; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Any lump-sum payment under Section&#160;6(b)(ii), to the extent not exempt from Section&#160;409A of the Code, shall be made with the Company&#8217;s first regularly scheduled payroll that occurs following the earlier of (x) expiration of the six-month period measured from Executive&#8217;s Separation or (y) the date of Executive&#8217;s death.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Company shall not have a duty to design its compensation policies in a manner that minimizes the Executive&#8217;s tax liabilities, and the Executive shall not make any claim against the Company or the Board related to tax liabilities arising from the Executive&#8217;s compensation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Choice of Law</font><font style="font-family:inherit;font-size:12pt;">.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the District of Columbia (except its provisions governing the choice of law).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Severability</font><font style="font-family:inherit;font-size:12pt;">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">No Assignment</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement and all rights and obligations of the Executive hereunder are personal to the Executive and may not be transferred or assigned by </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the Executive at any time.  The Company may assign its rights under this Agreement to any entity that assumes the Company&#8217;s obligations hereunder in connection with any sale or transfer of all or a substantial portion of the Company&#8217;s assets to such entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">[REMAINDER OF PAGE LEFT BLANK INTENTIONALLY]</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:80px;text-align:justify;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:12pt;">, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the date first written above.</font></div><div style="line-height:120%;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;/s/ Kevin Moran                                            &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:40px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Kevin Moran</font></div><div style="line-height:120%;padding-bottom:40px;text-align:justify;padding-left:288px;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">VANDA PHARMACEUTICALS INC.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;&#32;&#160;&#160;&#160;&#160;/s/ Mihael H. Polymeropoulos, M.D.           &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">&#32;&#32;&#160;&#160;&#160;&#160;President and Chief Executive Officer         &#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>vndaex311331202010q.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAA8DA2AECE7B5BF5B587B7318B04918A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Mihael H. Polymeropoulos, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Vanda Pharmaceuticals Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:4%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Mihael H. Polymeropoulos, M.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mihael H. Polymeropoulos, M.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>vndaex312331202010q.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEFCD98682EC05167A03CF28A32D3B040"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF ACTING CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Kevin Moran, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this quarterly report on Form 10-Q of Vanda Pharmaceuticals Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">c.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">d.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">a.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">b.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:4%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Kevin Moran</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Kevin Moran</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vice&#160;President,&#160;Acting Chief&#160;Financial&#160;Officer&#160;and&#160;Treasurer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal&#160;Financial&#160;Officer&#160;and&#160;Principal&#160;Accounting&#160;Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>vndaex321331202010q.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7D414A8150DF50E3BA9594DF394BC6FA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND ACTING CHIEF FINANCIAL OFFICER</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Subsections (a)&#160;and (b)&#160;of Section&#160;1350, Chapter 63 of Title 18, United States Code)</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Vanda Pharmaceuticals Inc. (the Company), does hereby certify, to the best of such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Quarterly Report on Form 10-Q for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;(the Form 10-Q) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:4%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Mihael H. Polymeropoulos, M.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mihael H. Polymeropoulos, M.D.</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May&#160;7, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;Kevin Moran</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Kevin Moran</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vice&#160;President,&#160;Acting Chief&#160;Financial&#160;Officer&#160;and&#160;Treasurer (Principal&#160;Financial&#160;Officer&#160;and&#160;Principal&#160;Accounting&#160;Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification &#8220;accompanies&#8221; the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vnda-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vandapharmaceuticals.com/20200331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:vnda="http://www.vandapharmaceuticals.com/20200331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vnda-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccountsPayableAndAccruedLiabilities" roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities">
        <link:definition>2110100 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedLiabilitiesDetail" roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail">
        <link:definition>2410402 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedLiabilitiesTables" roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>2310301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>2116100 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail">
        <link:definition>2416403 - Disclosure - Accumulated Other Comprehensive Income - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail">
        <link:definition>2416402 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>2316301 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOrganizationAndPresentation" roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation">
        <link:definition>2101100 - Disclosure - Business Organization and Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOrganizationAndPresentationDetail" roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail">
        <link:definition>2401401 - Disclosure - Business Organization and Presentation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies">
        <link:definition>2114100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail">
        <link:definition>2414405 - Disclosure - Commitments and Contingencies - (CFTR Activators and Inhibitors) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesFanaptAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail">
        <link:definition>2414402 - Disclosure - Commitments and Contingencies - (Fanapt) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesHetliozAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail">
        <link:definition>2414401 - Disclosure - Commitments and Contingencies - (HETLIOZ) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesPurchaseCommitmentsDetails" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails">
        <link:definition>2414406 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail">
        <link:definition>2414403 - Disclosure - Commitments and Contingencies - (Tradipitant) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesVqw765AdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail">
        <link:definition>2414404 - Disclosure - Commitments and Contingencies - (VQW-765) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited">
        <link:definition>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
        <link:definition>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.vandapharmaceuticals.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShare">
        <link:definition>2125100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetail" roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail">
        <link:definition>2425402 - Disclosure - Earnings per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables">
        <link:definition>2325301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements">
        <link:definition>2106100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>2406402 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes">
        <link:definition>2124100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails">
        <link:definition>2424401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets">
        <link:definition>2109100 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail">
        <link:definition>2409404 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsFanaptAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail">
        <link:definition>2409403 - Disclosure - Intangible Assets - (Fanapt) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsHetliozAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail">
        <link:definition>2409402 - Disclosure - Intangible Assets - (HETLIOZ) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail">
        <link:definition>2409406 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsSummaryOfIntangibleAssetsDetail" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail">
        <link:definition>2409405 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables">
        <link:definition>2309301 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.vandapharmaceuticals.com/role/Inventory">
        <link:definition>2108100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetail" roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail">
        <link:definition>2408402 - Disclosure - Inventory (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables">
        <link:definition>2308301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalMatters" roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters">
        <link:definition>2126100 - Disclosure - Legal Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities">
        <link:definition>2104100 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail">
        <link:definition>2404402 - Disclosure - Marketable Securities Available-For-Sale Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables">
        <link:definition>2304301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation">
        <link:definition>2119100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail">
        <link:definition>2419408 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRsuAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail">
        <link:definition>2419404 - Disclosure - Stock-Based Compensation - (RSU) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail">
        <link:definition>2419402 - Disclosure - Stock-Based Compensation - (Stock-Based Compensation) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionAdditionalInformationDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail">
        <link:definition>2419403 - Disclosure - Stock-Based Compensation - (Stock Option) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail">
        <link:definition>2419405 - Disclosure - Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryOfRsuActivityPlanDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail">
        <link:definition>2419406 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables">
        <link:definition>2319301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTotalStockBasedCompensationExpenseDetail" roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail">
        <link:definition>2419407 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Major Customers (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Tables" roleURI="http://www.vandapharmaceuticals.com/role/Tables">
        <link:definition>2306301 - Disclosure - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="vnda_AccruedResearchAndDevelopmentExpense" name="AccruedResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" name="AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_CftrActivatorsAndInhibitorsAbstract" name="CftrActivatorsAndInhibitorsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_CftrActivatorsAndInhibitorsMember" name="CftrActivatorsAndInhibitorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_CumulativeNetSalesToAchieveMilestone" name="CumulativeNetSalesToAchieveMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" name="DevelopmentAndMilestoneObligationsPaidToThirdParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" name="DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" name="DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_FanaptAbstract" name="FanaptAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_FanaptMember" name="FanaptMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" name="FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" name="FutureRegulatoryApprovalAndSalesMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_HetliozAbstract" name="HetliozAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_HetliozMember" name="HetliozMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_IncreaseDecreaseProductRevenueAllowances" name="IncreaseDecreaseProductRevenueAllowances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="vnda_Inventory" name="Inventory" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vnda_InventoryAndOtherNonCurrent" name="InventoryAndOtherNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" name="InventoryFinishedGoodsNetOfReservesNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vnda_InventoryRawMaterialsNetOfReservesNonCurrent" name="InventoryRawMaterialsNetOfReservesNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="vnda_InventoryWorkInProcessNetOfReservesNonCurrent" name="InventoryWorkInProcessNetOfReservesNonCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="vnda_NoncurrentInventoryAndOtherMember" name="NoncurrentInventoryAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_NoncurrentInvestmentsMember" name="NoncurrentInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_NumberOfMajorCustomersAccountedForRevenue" name="NumberOfMajorCustomersAccountedForRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable" name="NumberOfMajorCustomersAccountedForTradeAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_PercentageOfFutureSublicenseFeesPayable" name="PercentageOfFutureSublicenseFeesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_ProductRevenueAllowancesCurrent" name="ProductRevenueAllowancesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="vnda_RegulatoryApprovalMilestoneMember" name="RegulatoryApprovalMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_RoyaltyPayableOnNetSalesPercentage" name="RoyaltyPayableOnNetSalesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_RoyaltyPeriod" name="RoyaltyPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_SalesMilestoneMember" name="SalesMilestoneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_ScenarioFourMember" name="ScenarioFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_ScheduleOfInventoriesTableTextBlock" name="ScheduleOfInventoriesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" name="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_ServiceOptionAwardsMember" name="ServiceOptionAwardsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" name="ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_ShareBasedCompensationOptionAwardsContractualTerm" name="ShareBasedCompensationOptionAwardsContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" name="SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_StatementScenarioSecondaryAxis" name="StatementScenarioSecondaryAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_StatementScenarioSecondaryDomain" name="StatementScenarioSecondaryDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" name="StockOptionsAndRestrictedStockUnitsRSUsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_TradipitantMember" name="TradipitantMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" name="TwoThousandSixPlanAndTwoThousandSixteenPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_TwoThousandSixteenPlanMember" name="TwoThousandSixteenPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="vnda_VQW765Member" name="VQW765Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>vnda-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:href="vnda-20200331.xsd#BusinessOrganizationAndPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:href="vnda-20200331.xsd#BusinessOrganizationAndPresentationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="vnda-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="vnda-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:href="vnda-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:href="vnda-20200331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:href="vnda-20200331.xsd#EarningsPerShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:href="vnda-20200331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:href="vnda-20200331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="vnda-20200331.xsd#FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:href="vnda-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:href="vnda-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:href="vnda-20200331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="vnda-20200331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:href="vnda-20200331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:href="vnda-20200331.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:href="vnda-20200331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:href="vnda-20200331.xsd#LegalMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:href="vnda-20200331.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:href="vnda-20200331.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:href="vnda-20200331.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:href="vnda-20200331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:href="vnda-20200331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Tables" xlink:href="vnda-20200331.xsd#Tables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_AccruedResearchAndDevelopmentExpense" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_9dcf13d3-42c0-31d7-bf57-a3ea274a5678" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_vnda_AccruedResearchAndDevelopmentExpense_9dcf13d3-42c0-31d7-bf57-a3ea274a5678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_7d4777c3-e41b-9b63-699f-d86dc2fc13b0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_7d4777c3-e41b-9b63-699f-d86dc2fc13b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_4d245d7e-ad6c-dd35-41be-465e2f0e7195" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_4d245d7e-ad6c-dd35-41be-465e2f0e7195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58dbb131-3dd4-8ecf-cb87-48dc5113246d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_58dbb131-3dd4-8ecf-cb87-48dc5113246d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryAndOtherNonCurrent" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_642fcaf6-e6e5-d08b-edfe-a3ea2764d288" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_vnda_InventoryAndOtherNonCurrent_642fcaf6-e6e5-d08b-edfe-a3ea2764d288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ProductRevenueAllowancesCurrent" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_5d3f72e4-680b-2107-f481-a3ea27324819" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_vnda_ProductRevenueAllowancesCurrent_5d3f72e4-680b-2107-f481-a3ea27324819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_848cd271-4e03-8c13-d21d-e6ec9c3916f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_Depreciation_848cd271-4e03-8c13-d21d-e6ec9c3916f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c8905fa8-9b6b-867f-c840-12e5f98e855d" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_c8905fa8-9b6b-867f-c840-12e5f98e855d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_IncreaseDecreaseProductRevenueAllowances" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_d3de10f2-57bd-47e0-b8d0-a3ea27430d37" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_vnda_IncreaseDecreaseProductRevenueAllowances_d3de10f2-57bd-47e0-b8d0-a3ea27430d37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_10f4e187-d236-b8a3-b3b6-e65153fa455e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_10f4e187-d236-b8a3-b3b6-e65153fa455e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_c4ac2521-eb1a-fa8f-6a84-e79d4c95e1da" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_c4ac2521-eb1a-fa8f-6a84-e79d4c95e1da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_78cb6bac-3d73-8ac6-d64e-50b167d6c0fa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_78cb6bac-3d73-8ac6-d64e-50b167d6c0fa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_b36cbb9c-3cb7-e834-cb02-aac35e8dbc1b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_d71649eb-5769-933d-7982-2a2ada9ea257" xlink:to="loc_us-gaap_OtherIncome_b36cbb9c-3cb7-e834-cb02-aac35e8dbc1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_161efa93-4fc3-b3e6-9a97-d8d9aeebe0cc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_161efa93-4fc3-b3e6-9a97-d8d9aeebe0cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_Inventory" xlink:label="loc_vnda_Inventory_9bd326ad-c756-ad00-7024-a3ea2763a7ea" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_99c58bac-792a-ada8-97dd-388f2515a1b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_9bd326ad-c756-ad00-7024-a3ea2763a7ea" xlink:to="loc_us-gaap_InventoryNoncurrent_99c58bac-792a-ada8-97dd-388f2515a1b4" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_70acc0ab-a912-1c0c-1fe5-a3ea273947d3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_99c58bac-792a-ada8-97dd-388f2515a1b4" xlink:to="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_70acc0ab-a912-1c0c-1fe5-a3ea273947d3" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_f913dfe0-328f-20f2-e5b4-a3ea27598f69" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_99c58bac-792a-ada8-97dd-388f2515a1b4" xlink:to="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_f913dfe0-328f-20f2-e5b4-a3ea27598f69" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_e74d97cd-733e-1049-5b9d-a3ea27538357" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNoncurrent_99c58bac-792a-ada8-97dd-388f2515a1b4" xlink:to="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_e74d97cd-733e-1049-5b9d-a3ea27538357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_vnda_Inventory_9bd326ad-c756-ad00-7024-a3ea2763a7ea" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ae11e3b1-839b-d0b0-a04b-b35611528b8c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ae11e3b1-839b-d0b0-a04b-b35611528b8c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.vandapharmaceuticals.com/role/Tables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>vnda-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:href="vnda-20200331.xsd#BusinessOrganizationAndPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:href="vnda-20200331.xsd#BusinessOrganizationAndPresentationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="vnda-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="vnda-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:href="vnda-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:href="vnda-20200331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:href="vnda-20200331.xsd#EarningsPerShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:href="vnda-20200331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:href="vnda-20200331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="vnda-20200331.xsd#FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:href="vnda-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:href="vnda-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:href="vnda-20200331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="vnda-20200331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:href="vnda-20200331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:href="vnda-20200331.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:href="vnda-20200331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:href="vnda-20200331.xsd#LegalMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:href="vnda-20200331.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:href="vnda-20200331.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:href="vnda-20200331.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:href="vnda-20200331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:href="vnda-20200331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Tables" xlink:href="vnda-20200331.xsd#Tables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:to="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:to="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:to="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:to="loc_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RegulatoryApprovalMilestoneMember" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:label="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:to="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_74B4415D85190FA084E8A3EA4EB9D117" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:to="loc_srt_ProductOrServiceAxis_74B4415D85190FA084E8A3EA4EB9D117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_74B4415D85190FA084E8A3EA4EB9D117" xlink:to="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_74B4415D85190FA084E8A3EA4EB9D117" xlink:to="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CftrActivatorsAndInhibitorsMember" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_CC3672B20DB30FEFADD4A3EA4EB918BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_CC3672B20DB30FEFADD4A3EA4EB918BD" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CftrActivatorsAndInhibitorsAbstract" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_37514F8272215F2F80A9A3EA4F5913B5" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_37514F8272215F2F80A9A3EA4F5913B5" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_85DA61FEE0CE12AB5E00A3EA4F574BD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:to="loc_srt_ProductOrServiceAxis_85DA61FEE0CE12AB5E00A3EA4F574BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_85DA61FEE0CE12AB5E00A3EA4F574BD4" xlink:to="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_85DA61FEE0CE12AB5E00A3EA4F574BD4" xlink:to="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3" xlink:to="loc_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StatementScenarioSecondaryAxis" xlink:label="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:to="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StatementScenarioSecondaryDomain" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:to="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636_default" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StatementScenarioSecondaryDomain" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:to="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScenarioFourMember" xlink:label="loc_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:to="loc_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptAbstract" xlink:label="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_37514F8272215F2F80A9A3EA4F5913B5" xlink:to="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPayableOnNetSalesPercentage" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPeriod" xlink:label="loc_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:to="loc_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_464BA5E60EA5D6CC8EBDA3EA4F25AE01" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_70D9317BEEFB5BC2FA3EA3EA4F24B036" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_464BA5E60EA5D6CC8EBDA3EA4F25AE01" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_70D9317BEEFB5BC2FA3EA3EA4F24B036" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_13CAF33B951927F2B756A3EA4F251F98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_70D9317BEEFB5BC2FA3EA3EA4F24B036" xlink:to="loc_srt_ProductOrServiceAxis_13CAF33B951927F2B756A3EA4F251F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_13CAF33B951927F2B756A3EA4F251F98" xlink:to="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_13CAF33B951927F2B756A3EA4F251F98" xlink:to="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_4CB10DDA372FB98A1981A3EA4F258C09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49" xlink:to="loc_vnda_HetliozMember_4CB10DDA372FB98A1981A3EA4F258C09" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozAbstract" xlink:label="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_464BA5E60EA5D6CC8EBDA3EA4F25AE01" xlink:to="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPeriod" xlink:label="loc_vnda_RoyaltyPeriod_57A95626C76668EC7583A3EA4F26CB35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_vnda_RoyaltyPeriod_57A95626C76668EC7583A3EA4F26CB35" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPayableOnNetSalesPercentage" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_0B8A8F80A5A025D7C950A3EA4F263264" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_0B8A8F80A5A025D7C950A3EA4F263264" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_PercentageOfFutureSublicenseFeesPayable" xlink:label="loc_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:to="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:to="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:to="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:to="loc_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:to="loc_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15D367F7581189F3B692A3EA4F640FE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15D367F7581189F3B692A3EA4F640FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15D367F7581189F3B692A3EA4F640FE6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15D367F7581189F3B692A3EA4F640FE6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TradipitantMember" xlink:label="loc_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77" xlink:to="loc_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4E8198E1B5E3ED602A37A3EA4F653F15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4E8198E1B5E3ED602A37A3EA4F653F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4E8198E1B5E3ED602A37A3EA4F653F15" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4E8198E1B5E3ED602A37A3EA4F653F15" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RegulatoryApprovalMilestoneMember" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_A9223637421F5FAECFA1A3EA4F652C94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_A9223637421F5FAECFA1A3EA4F652C94" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SalesMilestoneMember" xlink:label="loc_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:to="loc_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_970C4A88C79E174FD43EA3EA4F66407D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_970C4A88C79E174FD43EA3EA4F66407D" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_C73200F1CEBA58FA7031A3EA4F660A1E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_C73200F1CEBA58FA7031A3EA4F660A1E" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_731F3F2E40429C58F0C7A3EA4F674835" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_731F3F2E40429C58F0C7A3EA4F674835" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_VQW765Member" xlink:label="loc_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:to="loc_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:to="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:to="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:to="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4A458EAE483FDC50B8E9A3EA4E422789" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4A458EAE483FDC50B8E9A3EA4E422789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4A458EAE483FDC50B8E9A3EA4E422789" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4A458EAE483FDC50B8E9A3EA4E422789" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C" xlink:to="loc_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_751EAE5A5E93B8092BF8A3EA4E4442B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_751EAE5A5E93B8092BF8A3EA4E4442B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_751EAE5A5E93B8092BF8A3EA4E4442B3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_751EAE5A5E93B8092BF8A3EA4E4442B3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_DFEBCA28E18C1267409DA3EA4E45669F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_DFEBCA28E18C1267409DA3EA4E45669F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3C5C5EB20FDFE8D1BF21A3EA4E4549C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3C5C5EB20FDFE8D1BF21A3EA4E4549C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_C14CA2EABB630C7B5255A3EA4E45ADA7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_C14CA2EABB630C7B5255A3EA4E45ADA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FCE8652574F2EF34733EA3EA4E1404C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D803C1C80170E7BA4E24A3EA4E139845" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FCE8652574F2EF34733EA3EA4E1404C5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D803C1C80170E7BA4E24A3EA4E139845" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9232DAB697A9651BA3C1A3EA4E14965E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D803C1C80170E7BA4E24A3EA4E139845" xlink:to="loc_srt_ProductOrServiceAxis_9232DAB697A9651BA3C1A3EA4E14965E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9232DAB697A9651BA3C1A3EA4E14965E" xlink:to="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9232DAB697A9651BA3C1A3EA4E14965E" xlink:to="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_910817F88F43BAE7477CA3EA4E141B26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA" xlink:to="loc_vnda_FanaptMember_910817F88F43BAE7477CA3EA4E141B26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FCE8652574F2EF34733EA3EA4E1404C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C675E8FD67A08456E101A3EA4F79B89D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C675E8FD67A08456E101A3EA4F79B89D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_37EF300AAE93A6675873A3EA4F794832" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C675E8FD67A08456E101A3EA4F79B89D" xlink:to="loc_srt_ProductOrServiceAxis_37EF300AAE93A6675873A3EA4F794832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_37EF300AAE93A6675873A3EA4F794832" xlink:to="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_37EF300AAE93A6675873A3EA4F794832" xlink:to="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_EFE599F6371EA35EDA4DA3EA4F7AA73A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40" xlink:to="loc_vnda_HetliozMember_EFE599F6371EA35EDA4DA3EA4F7AA73A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_04F16CE5C3F65A162863A3EA4F7A313A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_04F16CE5C3F65A162863A3EA4F7A313A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CumulativeNetSalesToAchieveMilestone" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:to="loc_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_C49EBCA9A925BC1CDC7BA3EA4F7B4419" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_C49EBCA9A925BC1CDC7BA3EA4F7B4419" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C1D3ED6ED7AE7D1CC825A3EA4E4F382C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C1D3ED6ED7AE7D1CC825A3EA4E4F382C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_45D3307BF4144D4B6BC6A3EA4E50363D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C1D3ED6ED7AE7D1CC825A3EA4E4F382C" xlink:to="loc_srt_ProductOrServiceAxis_45D3307BF4144D4B6BC6A3EA4E50363D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_45D3307BF4144D4B6BC6A3EA4E50363D" xlink:to="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_45D3307BF4144D4B6BC6A3EA4E50363D" xlink:to="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_C7848767D43EB0E43225A3EA4E509B5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE" xlink:to="loc_vnda_HetliozMember_C7848767D43EB0E43225A3EA4E509B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A44F9C5CDE9432978CDA3EA4E51F245" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A44F9C5CDE9432978CDA3EA4E51F245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:to="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:to="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:to="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:to="loc_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:to="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NoncurrentInvestmentsMember" xlink:label="loc_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:to="loc_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BFDBF6CDB48B7F1BA9F5A3EA4F946ABB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BFDBF6CDB48B7F1BA9F5A3EA4F946ABB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_44E8471EEBE1BFB99638A3EA4F94D52A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BFDBF6CDB48B7F1BA9F5A3EA4F946ABB" xlink:to="loc_us-gaap_AwardTypeAxis_44E8471EEBE1BFB99638A3EA4F94D52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_44E8471EEBE1BFB99638A3EA4F94D52A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_44E8471EEBE1BFB99638A3EA4F94D52A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_278A67787CB0A0A770C9A3EA4F9516F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_278A67787CB0A0A770C9A3EA4F9516F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4DD8B50D776EF0B98248A3EA4F96BAE2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4DD8B50D776EF0B98248A3EA4F96BAE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:to="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:to="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:to="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:to="loc_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:to="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:label="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:to="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E79E0578BA4D7A74EB61A3EA4E766D97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E79E0578BA4D7A74EB61A3EA4E766D97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9014FCEC1DC97C4D4CFDA3EA4E7603E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E79E0578BA4D7A74EB61A3EA4E766D97" xlink:to="loc_us-gaap_AwardTypeAxis_9014FCEC1DC97C4D4CFDA3EA4E7603E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9014FCEC1DC97C4D4CFDA3EA4E7603E0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9014FCEC1DC97C4D4CFDA3EA4E7603E0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ServiceOptionAwardsMember" xlink:label="loc_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40" xlink:to="loc_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:label="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:label="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F7916D5F7F93D496DBDA3EA4E37A0B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F7916D5F7F93D496DBDA3EA4E37A0B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_77FED8102A51C1F018ECA3EA4E374321" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F7916D5F7F93D496DBDA3EA4E37A0B2" xlink:to="loc_us-gaap_PlanNameAxis_77FED8102A51C1F018ECA3EA4E374321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_77FED8102A51C1F018ECA3EA4E374321" xlink:to="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_77FED8102A51C1F018ECA3EA4E374321" xlink:to="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_1527002EE86433470551A3EA4E38C3C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_1527002EE86433470551A3EA4E38C3C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A40577ABF50A3DF18759A3EA4EADF278" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:to="loc_us-gaap_AwardTypeAxis_A40577ABF50A3DF18759A3EA4EADF278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A40577ABF50A3DF18759A3EA4EADF278" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A40577ABF50A3DF18759A3EA4EADF278" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_85194233612B49359C5CA3EA4EAE2991" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_85194233612B49359C5CA3EA4EAE2991" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NoncurrentInventoryAndOtherMember" xlink:label="loc_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:to="loc_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:type="extended">
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:to="loc_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:to="loc_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NumberOfMajorCustomersAccountedForRevenue" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EB0DEC3B1DE567A16CF1A3EA4E6586E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:to="loc_srt_ProductOrServiceAxis_EB0DEC3B1DE567A16CF1A3EA4E6586E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_EB0DEC3B1DE567A16CF1A3EA4E6586E9" xlink:to="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_EB0DEC3B1DE567A16CF1A3EA4E6586E9" xlink:to="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:to="loc_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:to="loc_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.vandapharmaceuticals.com/role/Tables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>vnda-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32EA235A530E7D35521AA3EA4F3AF247_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32EA235A530E7D35521AA3EA4F3AF247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32EA235A530E7D35521AA3EA4F3AF247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32EA235A530E7D35521AA3EA4F3AF247" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32EA235A530E7D35521AA3EA4F3AF247" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:to="lab_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:to="lab_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:type="arc" />
    <link:label id="lab_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0_verboseLabel_en-US" xlink:label="lab_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">HETLIOZ&#174;</link:label>
    <link:label id="lab_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0_label_en-US" xlink:label="lab_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hetlioz [Member]</link:label>
    <link:label id="lab_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0_documentation_en-US" xlink:label="lab_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hetlioz [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:to="lab_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DFB08CA60F6B9EEC420EA3EA4F33230D_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DFB08CA60F6B9EEC420EA3EA4F33230D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DFB08CA60F6B9EEC420EA3EA4F33230D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DFB08CA60F6B9EEC420EA3EA4F33230D" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DFB08CA60F6B9EEC420EA3EA4F33230D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A_label_en-US" xlink:label="lab_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="lab_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6_terseLabel_en-US" xlink:label="lab_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6_label_en-US" xlink:label="lab_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6" xlink:to="lab_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97" xlink:to="lab_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176" xlink:to="lab_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1" xlink:to="lab_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8_label_en-US" xlink:label="lab_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8" xlink:to="lab_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC_label_en-US" xlink:label="lab_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC" xlink:to="lab_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41" xlink:to="lab_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0" xlink:to="lab_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37" xlink:to="lab_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C" xlink:to="lab_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D" xlink:to="lab_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7" xlink:to="lab_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6" xlink:to="lab_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94_label_en-US" xlink:label="lab_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94" xlink:to="lab_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2" xlink:to="lab_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA_label_en-US" xlink:label="lab_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA" xlink:to="lab_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56_label_en-US" xlink:label="lab_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56" xlink:to="lab_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87_label_en-US" xlink:label="lab_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87" xlink:to="lab_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4" xlink:to="lab_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B" xlink:to="lab_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596_label_en-US" xlink:label="lab_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596" xlink:to="lab_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18" xlink:to="lab_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3" xlink:to="lab_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E_label_en-US" xlink:label="lab_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E" xlink:to="lab_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3" xlink:to="lab_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D" xlink:to="lab_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6" xlink:to="lab_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85" xlink:to="lab_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538_label_en-US" xlink:label="lab_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538" xlink:to="lab_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_171B2DB576ADB09BB02DA3EA4F50B8A3_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_171B2DB576ADB09BB02DA3EA4F50B8A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_171B2DB576ADB09BB02DA3EA4F50B8A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_171B2DB576ADB09BB02DA3EA4F50B8A3" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_171B2DB576ADB09BB02DA3EA4F50B8A3" xlink:type="arc" />
    <link:label id="lab_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A_terseLabel_en-US" xlink:label="lab_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A_label_en-US" xlink:label="lab_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A_documentation_en-US" xlink:label="lab_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:to="lab_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:to="lab_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:to="lab_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:to="lab_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:type="arc" />
    <link:label id="lab_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26_terseLabel_en-US" xlink:label="lab_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26_label_en-US" xlink:label="lab_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26_documentation_en-US" xlink:label="lab_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="lab_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:type="arc" />
    <link:label id="lab_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9_terseLabel_en-US" xlink:label="lab_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of major customers that each accounted for more than 10% of total revenues</link:label>
    <link:label id="lab_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9_label_en-US" xlink:label="lab_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Major Customers Accounted For Revenue</link:label>
    <link:label id="lab_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9_documentation_en-US" xlink:label="lab_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of major customers that each accounted for more than 10% of total revenues.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NumberOfMajorCustomersAccountedForRevenue" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:to="lab_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:type="arc" />
    <link:label id="lab_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD_terseLabel_en-US" xlink:label="lab_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of major customers that each accounted for more than 10% of total accounts receivable</link:label>
    <link:label id="lab_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD_label_en-US" xlink:label="lab_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Major Customers Accounted For Trade Accounts Receivable</link:label>
    <link:label id="lab_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD_documentation_en-US" xlink:label="lab_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of major customers that each accounted for more than 10% of total accounts receivable.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:to="lab_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:to="lab_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F_label_en-US" xlink:label="lab_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F" xlink:to="lab_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Current assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrentAbstract" xlink:label="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:to="lab_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:type="arc" />
    <link:label id="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30_terseLabel_en-US" xlink:label="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30_label_en-US" xlink:label="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves, Non Current</link:label>
    <link:label id="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30_documentation_en-US" xlink:label="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:to="lab_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:type="arc" />
    <link:label id="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755_terseLabel_en-US" xlink:label="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755_label_en-US" xlink:label="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves, Non Current</link:label>
    <link:label id="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755_documentation_en-US" xlink:label="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:to="lab_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:type="arc" />
    <link:label id="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C_terseLabel_en-US" xlink:label="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C_label_en-US" xlink:label="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves, Non Current</link:label>
    <link:label id="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C_documentation_en-US" xlink:label="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:to="lab_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory, non-current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32" xlink:to="lab_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32" xlink:type="arc" />
    <link:label id="lab_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3_totalLabel_en-US" xlink:label="lab_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3_label_en-US" xlink:label="lab_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">inventory</link:label>
    <link:label id="lab_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3_documentation_en-US" xlink:label="lab_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">inventory</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_Inventory" xlink:label="loc_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:to="lab_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:type="arc" />
    <link:label id="lab_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C_label_en-US" xlink:label="lab_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Inventories [Table Text Block]</link:label>
    <link:label id="lab_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C_documentation_en-US" xlink:label="lab_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of inventories.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfInventoriesTableTextBlock" xlink:label="loc_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:to="lab_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48" xlink:to="lab_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers</link:label>
    <link:label id="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94_label_en-US" xlink:label="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Customers, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94" xlink:to="lab_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DAA5D126E57ECC38FDFA3EA4F754AE5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DAA5D126E57ECC38FDFA3EA4F754AE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DAA5D126E57ECC38FDFA3EA4F754AE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DAA5D126E57ECC38FDFA3EA4F754AE5" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DAA5D126E57ECC38FDFA3EA4F754AE5" xlink:type="arc" />
    <link:label id="lab_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691_terseLabel_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691_label_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691_documentation_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:to="lab_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:to="lab_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:type="arc" />
    <link:label id="lab_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9_terseLabel_en-US" xlink:label="lab_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VQW-765</link:label>
    <link:label id="lab_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9_label_en-US" xlink:label="lab_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VQW-765 [Member]</link:label>
    <link:label id="lab_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9_documentation_en-US" xlink:label="lab_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VQW-765 [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_VQW765Member" xlink:label="loc_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:to="lab_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:type="arc" />
    <link:label id="lab_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7_terseLabel_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7_label_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7_documentation_en-US" xlink:label="lab_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:to="lab_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:type="arc" />
    <link:label id="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B_terseLabel_en-US" xlink:label="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future percentage of royalty payments based net sales</link:label>
    <link:label id="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B_label_en-US" xlink:label="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Percentage Of Royalty Payments Based On Net Sales</link:label>
    <link:label id="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B_documentation_en-US" xlink:label="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Percentage Of Royalty Payments Based On Net Sales.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:to="lab_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Sales by Product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D87D68019C7ADB4AE4F0A3EA4F5C971A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D87D68019C7ADB4AE4F0A3EA4F5C971A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D87D68019C7ADB4AE4F0A3EA4F5C971A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D87D68019C7ADB4AE4F0A3EA4F5C971A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D87D68019C7ADB4AE4F0A3EA4F5C971A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Option Activity Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of RSU Activity for 2006 Plan and 2016 Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14" xlink:type="arc" />
    <link:label id="lab_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108_terseLabel_en-US" xlink:label="lab_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fanapt&#174;</link:label>
    <link:label id="lab_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108_label_en-US" xlink:label="lab_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fanapt [Member]</link:label>
    <link:label id="lab_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108_documentation_en-US" xlink:label="lab_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fanapt.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:to="lab_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:type="arc" />
    <link:label id="lab_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895_terseLabel_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Scenario Secondary [Axis]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895_label_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement, Scenario Secondary [Axis]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895_documentation_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statement, Scenario Secondary [Axis]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StatementScenarioSecondaryAxis" xlink:label="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:to="lab_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:type="arc" />
    <link:label id="lab_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636_terseLabel_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Scenario Secondary [Domain]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636_label_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement, Scenario Secondary [Domain]</link:label>
    <link:label id="lab_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636_documentation_en-US" xlink:label="lab_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statement, Scenario Secondary [Domain]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StatementScenarioSecondaryDomain" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:to="lab_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:type="arc" />
    <link:label id="lab_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951_terseLabel_en-US" xlink:label="lab_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">November 16,2016 through December 31,2019</link:label>
    <link:label id="lab_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951_label_en-US" xlink:label="lab_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario 4 [Member]</link:label>
    <link:label id="lab_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951_documentation_en-US" xlink:label="lab_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Scenario 4 [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScenarioFourMember" xlink:label="loc_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:to="lab_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:type="arc" />
    <link:label id="lab_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE_terseLabel_en-US" xlink:label="lab_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fanapt</link:label>
    <link:label id="lab_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE_label_en-US" xlink:label="lab_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fanapt [Abstract]</link:label>
    <link:label id="lab_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE_documentation_en-US" xlink:label="lab_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fanapt [Abstract]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptAbstract" xlink:label="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:to="lab_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:type="arc" />
    <link:label id="lab_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1_terseLabel_en-US" xlink:label="lab_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payable percentage on net sales</link:label>
    <link:label id="lab_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1_label_en-US" xlink:label="lab_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payable On Net Sales Percentage</link:label>
    <link:label id="lab_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1_documentation_en-US" xlink:label="lab_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPayableOnNetSalesPercentage" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:to="lab_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:type="arc" />
    <link:label id="lab_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0_terseLabel_en-US" xlink:label="lab_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment period</link:label>
    <link:label id="lab_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0_label_en-US" xlink:label="lab_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Period</link:label>
    <link:label id="lab_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0_documentation_en-US" xlink:label="lab_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Period</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPeriod" xlink:label="loc_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:to="lab_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_E546C36289BC516A698DA3EA4F17E898_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_E546C36289BC516A698DA3EA4F17E898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E546C36289BC516A698DA3EA4F17E898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E546C36289BC516A698DA3EA4F17E898" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_E546C36289BC516A698DA3EA4F17E898" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Future Intangible Asset Amortization</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4587ABFFFD00750EF19CA3EA4E91C5D9_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4587ABFFFD00750EF19CA3EA4E91C5D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4587ABFFFD00750EF19CA3EA4E91C5D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4587ABFFFD00750EF19CA3EA4E91C5D9" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4587ABFFFD00750EF19CA3EA4E91C5D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Organization and Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:type="arc" />
    <link:label id="lab_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549_terseLabel_en-US" xlink:label="lab_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current inventory and other</link:label>
    <link:label id="lab_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549_label_en-US" xlink:label="lab_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Inventory and Other [Member]</link:label>
    <link:label id="lab_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549_documentation_en-US" xlink:label="lab_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Inventory and Other [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NoncurrentInventoryAndOtherMember" xlink:label="loc_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:to="lab_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in:</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:to="lab_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:to="lab_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:type="arc" />
    <link:label id="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29_terseLabel_en-US" xlink:label="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2006 Plan and 2016 Plan</link:label>
    <link:label id="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29_label_en-US" xlink:label="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]</link:label>
    <link:label id="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29_documentation_en-US" xlink:label="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:to="lab_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:type="arc" />
    <link:label id="lab_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5_terseLabel_en-US" xlink:label="lab_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5_label_en-US" xlink:label="lab_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Plan [Member]</link:label>
    <link:label id="lab_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5_documentation_en-US" xlink:label="lab_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Plan [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:to="lab_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:to="lab_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:type="arc" />
    <link:label id="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9_terseLabel_en-US" xlink:label="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding options and RSUs granted (RSUs)</link:label>
    <link:label id="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9_label_en-US" xlink:label="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9_documentation_en-US" xlink:label="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options and Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:label="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:to="lab_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares subject to outstanding options and RSUs (in shares)</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units (RSUs) Outstanding Number</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of common stock available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A_totalLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A" xlink:type="arc" />
    <link:label id="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2_terseLabel_en-US" xlink:label="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreements for clinical and marketing services, termination notice period</link:label>
    <link:label id="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2_label_en-US" xlink:label="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreements For Clinical And Marketing Services, Termination Notice Period</link:label>
    <link:label id="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2_documentation_en-US" xlink:label="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreements For Clinical And Marketing Services, Termination Notice Period</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:label="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:to="lab_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:to="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4" xlink:to="lab_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Second Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Third Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7418A192CD21BAC3FB34A3EA4E566B8C_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_7418A192CD21BAC3FB34A3EA4E566B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7418A192CD21BAC3FB34A3EA4E566B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7418A192CD21BAC3FB34A3EA4E566B8C" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_7418A192CD21BAC3FB34A3EA4E566B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D_label_en-US" xlink:label="lab_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:to="lab_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="lab_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:to="lab_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:to="lab_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:to="lab_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:to="lab_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock form the exercise of stock options and settlement of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:to="lab_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_32071E87CE3F8821573EA3EA4E5A4CFC_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_32071E87CE3F8821573EA3EA4E5A4CFC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_32071E87CE3F8821573EA3EA4E5A4CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_32071E87CE3F8821573EA3EA4E5A4CFC" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_32071E87CE3F8821573EA3EA4E5A4CFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_1895C872363CFEE5867DA3EA4E5A1075_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_1895C872363CFEE5867DA3EA4E5A1075" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1895C872363CFEE5867DA3EA4E5A1075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_1895C872363CFEE5867DA3EA4E5A1075" xlink:to="lab_us-gaap_StockholdersEquity_1895C872363CFEE5867DA3EA4E5A1075" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0" xlink:to="lab_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0" xlink:type="arc" />
    <link:label id="lab_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028_terseLabel_en-US" xlink:label="lab_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service option awards</link:label>
    <link:label id="lab_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028_label_en-US" xlink:label="lab_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service Option Awards [Member]</link:label>
    <link:label id="lab_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028_documentation_en-US" xlink:label="lab_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Service Option Awards [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ServiceOptionAwardsMember" xlink:label="loc_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:to="lab_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation option awards contractual term</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Option Awards Contractual Term</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual term of stock option awards.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:label="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:to="lab_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion of initial stock options granted to employees that vests on employee's first anniversary</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of new hire stock option award that vests after one year of service.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of new hire stock option award that vests monthly after one year of service.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:type="arc" />
    <link:label id="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575_terseLabel_en-US" xlink:label="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of vesting equal installments</link:label>
    <link:label id="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575_label_en-US" xlink:label="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</link:label>
    <link:label id="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575_documentation_en-US" xlink:label="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:to="lab_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period for subsequent stock options granted to directors</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Annual Award Vesting Period Employees and New Directors</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:label="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:to="lab_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expenses, weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, weighted average fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of employee stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_C9096A59056524F8F29EA3EA4E887913_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_C9096A59056524F8F29EA3EA4E887913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C9096A59056524F8F29EA3EA4E887913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C9096A59056524F8F29EA3EA4E887913" xlink:to="lab_us-gaap_EarningsPerShareAbstract_C9096A59056524F8F29EA3EA4E887913" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and Diluted Net Loss Per Share of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9D342BC6A343B3534E3EA3EA4E8B00A0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_9D342BC6A343B3534E3EA3EA4E8B00A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9D342BC6A343B3534E3EA3EA4E8B00A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9D342BC6A343B3534E3EA3EA4E8B00A0" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_9D342BC6A343B3534E3EA3EA4E8B00A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSU)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expenses related to unvested RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value of common stock granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value of common stock vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:type="arc" />
    <link:label id="lab_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A_terseLabel_en-US" xlink:label="lab_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HETLIOZ&#174; product sales, net</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:to="lab_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:type="arc" />
    <link:label id="lab_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D_verboseLabel_en-US" xlink:label="lab_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fanapt&#174; product sales, net</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:to="lab_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_541A13B650D1C47B896CA3EA4E5E0833_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_541A13B650D1C47B896CA3EA4E5E0833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_541A13B650D1C47B896CA3EA4E5E0833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_541A13B650D1C47B896CA3EA4E5E0833" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_541A13B650D1C47B896CA3EA4E5E0833" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:to="lab_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:type="arc" />
    <link:label id="lab_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88_terseLabel_en-US" xlink:label="lab_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent Investments</link:label>
    <link:label id="lab_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88_label_en-US" xlink:label="lab_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Investments [Member]</link:label>
    <link:label id="lab_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88_documentation_en-US" xlink:label="lab_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Investments [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NoncurrentInvestmentsMember" xlink:label="loc_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:to="lab_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:to="lab_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government agencies</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_CC638D0F998DD36ED1E7CBE0062EDFCB_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_CC638D0F998DD36ED1E7CBE0062EDFCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CC638D0F998DD36ED1E7CBE0062EDFCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_CC638D0F998DD36ED1E7CBE0062EDFCB" xlink:to="lab_us-gaap_NetIncomeLoss_CC638D0F998DD36ED1E7CBE0062EDFCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82_label_en-US" xlink:label="lab_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82" xlink:to="lab_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12" xlink:to="lab_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of discounts and premiums on marketable securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-cash adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0" xlink:type="arc" />
    <link:label id="lab_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931_terseLabel_en-US" xlink:label="lab_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue allowances</link:label>
    <link:label id="lab_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931_label_en-US" xlink:label="lab_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Product Revenue Allowances</link:label>
    <link:label id="lab_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931_documentation_en-US" xlink:label="lab_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_IncreaseDecreaseProductRevenueAllowances" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:to="lab_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of intangible asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6D149C4F017DD9C84881CBE0063253AC_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_6D149C4F017DD9C84881CBE0063253AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6D149C4F017DD9C84881CBE0063253AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_6D149C4F017DD9C84881CBE0063253AC" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_6D149C4F017DD9C84881CBE0063253AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17FDCDF351C860E0B3E6CBE0063304EE_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17FDCDF351C860E0B3E6CBE0063304EE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17FDCDF351C860E0B3E6CBE0063304EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17FDCDF351C860E0B3E6CBE0063304EE" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17FDCDF351C860E0B3E6CBE0063304EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF718913F4C89A68B471CBE00633F0EB_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF718913F4C89A68B471CBE00633F0EB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF718913F4C89A68B471CBE00633F0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF718913F4C89A68B471CBE00633F0EB" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF718913F4C89A68B471CBE00633F0EB" xlink:type="arc" />
    <link:label id="lab_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7_terseLabel_en-US" xlink:label="lab_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HETLIOZ</link:label>
    <link:label id="lab_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7_label_en-US" xlink:label="lab_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hetlioz [Abstract]</link:label>
    <link:label id="lab_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7_documentation_en-US" xlink:label="lab_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hetlioz [Abstract]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozAbstract" xlink:label="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="lab_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets capitalized</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:type="arc" />
    <link:label id="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C_terseLabel_en-US" xlink:label="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future sublicense fees payable to third-party</link:label>
    <link:label id="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C_label_en-US" xlink:label="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Future Sublicense Fees Payable</link:label>
    <link:label id="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C_documentation_en-US" xlink:label="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_PercentageOfFutureSublicenseFeesPayable" xlink:label="loc_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:to="lab_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fully amortized intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5_label_en-US" xlink:label="lab_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:to="lab_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533_terseLabel_en-US" xlink:label="lab_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533_label_en-US" xlink:label="lab_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:to="lab_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159_label_en-US" xlink:label="lab_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:to="lab_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:type="arc" />
    <link:label id="lab_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F_terseLabel_en-US" xlink:label="lab_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone</link:label>
    <link:label id="lab_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F_label_en-US" xlink:label="lab_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:label id="lab_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F_documentation_en-US" xlink:label="lab_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Approval Milestone [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RegulatoryApprovalMilestoneMember" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:to="lab_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:type="arc" />
    <link:label id="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F_terseLabel_en-US" xlink:label="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Regulatory Approval And Sales Milestones</link:label>
    <link:label id="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F_label_en-US" xlink:label="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Regulatory Approval And Sales Milestones [Member]</link:label>
    <link:label id="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F_documentation_en-US" xlink:label="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Regulatory Approval And Sales Milestones [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:label="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:to="lab_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:type="arc" />
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388_terseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development And Milestone Payment, Conclusion Of Phase I Study</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388_label_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Milestone Payment, Conclusion Of Phase I Study [Member]</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388_documentation_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Milestone Payment, Conclusion Of Phase I Study [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:to="lab_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:type="arc" />
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569_terseLabel_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CFTR Activators and Inhibitors</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569_label_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CFTR activators and inhibitors [Member]</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569_documentation_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CFTR activators and inhibitors [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CftrActivatorsAndInhibitorsMember" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:to="lab_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:type="arc" />
    <link:label id="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73_terseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and milestone obligations paid to third party</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73_label_en-US" xlink:label="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Milestone Obligations Paid To Third Party</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73_documentation_en-US" xlink:label="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Milestone Obligations Paid To Third Party</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:to="lab_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:type="arc" />
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B_terseLabel_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CFTR activators and inhibitors</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B_label_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CFTR activators and inhibitors [Abstract]</link:label>
    <link:label id="lab_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B_documentation_en-US" xlink:label="lab_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CFTR activators and inhibitors [Abstract]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CftrActivatorsAndInhibitorsAbstract" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:to="lab_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:type="arc" />
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3_verboseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Possible future milestone payments</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3_label_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Milestone Payments Potentially Due To Third Party</link:label>
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3_documentation_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:to="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discrete impact of net shortfall tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="lab_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:to="lab_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A350CF77A8E22EACD128A3EA4F8931DC_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A350CF77A8E22EACD128A3EA4F8931DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A350CF77A8E22EACD128A3EA4F8931DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A350CF77A8E22EACD128A3EA4F8931DC" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A350CF77A8E22EACD128A3EA4F8931DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_D3FC947C41677F210545A3EA4F8AABF1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_D3FC947C41677F210545A3EA4F8AABF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D3FC947C41677F210545A3EA4F8AABF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_D3FC947C41677F210545A3EA4F8AABF1" xlink:to="lab_us-gaap_InventoryNet_D3FC947C41677F210545A3EA4F8AABF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64" xlink:to="lab_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_605D0634ADCCDE90F991A3EA4F8A9B9B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_605D0634ADCCDE90F991A3EA4F8A9B9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_605D0634ADCCDE90F991A3EA4F8A9B9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_605D0634ADCCDE90F991A3EA4F8A9B9B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_605D0634ADCCDE90F991A3EA4F8A9B9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77" xlink:type="arc" />
    <link:label id="lab_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5_terseLabel_en-US" xlink:label="lab_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current inventory and other</link:label>
    <link:label id="lab_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5_label_en-US" xlink:label="lab_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory and Other Non Current</link:label>
    <link:label id="lab_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5_documentation_en-US" xlink:label="lab_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryAndOtherNonCurrent" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:to="lab_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6_label_en-US" xlink:label="lab_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6" xlink:to="lab_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA" xlink:type="arc" />
    <link:label id="lab_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F_terseLabel_en-US" xlink:label="lab_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue allowances</link:label>
    <link:label id="lab_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F_label_en-US" xlink:label="lab_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Revenue Allowances, Current</link:label>
    <link:label id="lab_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F_documentation_en-US" xlink:label="lab_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Revenue Allowances, Current</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ProductRevenueAllowancesCurrent" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:to="lab_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B" xlink:to="lab_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A_label_en-US" xlink:label="lab_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A" xlink:to="lab_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Notes 8 and 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5" xlink:to="lab_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:to="lab_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at March 31, 2020 and December 31, 2019</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF" xlink:to="lab_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 150,000,000 shares authorized; 54,132,336 and 53,549,612 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A" xlink:to="lab_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6F8901BBFD5F95FB51FA3EA4F8E1652_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6F8901BBFD5F95FB51FA3EA4F8E1652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6F8901BBFD5F95FB51FA3EA4F8E1652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6F8901BBFD5F95FB51FA3EA4F8E1652" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6F8901BBFD5F95FB51FA3EA4F8E1652" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A7FC8C058AD416190332A3EA4F8E254E_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A7FC8C058AD416190332A3EA4F8E254E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A7FC8C058AD416190332A3EA4F8E254E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A7FC8C058AD416190332A3EA4F8E254E" xlink:to="lab_us-gaap_StockholdersEquity_A7FC8C058AD416190332A3EA4F8E254E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="lab_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:to="lab_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D_label_en-US" xlink:label="lab_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D" xlink:to="lab_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold excluding amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D" xlink:to="lab_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B" xlink:to="lab_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53_label_en-US" xlink:label="lab_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53" xlink:to="lab_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_A0877C518536DEF77ACCCBE0068B2B66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_A0877C518536DEF77ACCCBE0068B2B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A0877C518536DEF77ACCCBE0068B2B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_A0877C518536DEF77ACCCBE0068B2B66" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_A0877C518536DEF77ACCCBE0068B2B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_EDE88C9A1BD8D656AA0ACBE0068B5630_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_EDE88C9A1BD8D656AA0ACBE0068B5630" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EDE88C9A1BD8D656AA0ACBE0068B5630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_EDE88C9A1BD8D656AA0ACBE0068B5630" xlink:to="lab_us-gaap_NetIncomeLoss_EDE88C9A1BD8D656AA0ACBE0068B5630" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:to="lab_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470" xlink:to="lab_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:to="lab_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications out of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consulting and other professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A" xlink:type="arc" />
    <link:label id="lab_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C_terseLabel_en-US" xlink:label="lab_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C_label_en-US" xlink:label="lab_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense</link:label>
    <link:label id="lab_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C_documentation_en-US" xlink:label="lab_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_AccruedResearchAndDevelopmentExpense" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:to="lab_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties payable</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5B05553C6D8B190522EBA3EA4F72B343_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5B05553C6D8B190522EBA3EA4F72B343" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5B05553C6D8B190522EBA3EA4F72B343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5B05553C6D8B190522EBA3EA4F72B343" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5B05553C6D8B190522EBA3EA4F72B343" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net foreign currency translation loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in net unrealized gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax provision on other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C3FBB635F37F15B58774A3EA4F80FE5F_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C3FBB635F37F15B58774A3EA4F80FE5F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C3FBB635F37F15B58774A3EA4F80FE5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C3FBB635F37F15B58774A3EA4F80FE5F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C3FBB635F37F15B58774A3EA4F80FE5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Matters</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:to="lab_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:to="lab_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:type="arc" />
    <link:label id="lab_country_US_80C899DFC8355B678D2FA3EA4F64BC95_terseLabel_en-US" xlink:label="lab_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_80C899DFC8355B678D2FA3EA4F64BC95_label_en-US" xlink:label="lab_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:to="lab_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F_label_en-US" xlink:label="lab_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:to="lab_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:type="arc" />
    <link:label id="lab_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58_terseLabel_en-US" xlink:label="lab_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tradipitant</link:label>
    <link:label id="lab_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58_label_en-US" xlink:label="lab_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tradipitant [Member]</link:label>
    <link:label id="lab_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58_documentation_en-US" xlink:label="lab_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tradipitant [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TradipitantMember" xlink:label="loc_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:to="lab_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:type="arc" />
    <link:label id="lab_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101_terseLabel_en-US" xlink:label="lab_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101_label_en-US" xlink:label="lab_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101_documentation_en-US" xlink:label="lab_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SalesMilestoneMember" xlink:label="loc_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:to="lab_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:type="arc" />
    <link:label id="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34_terseLabel_en-US" xlink:label="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Possible future milestone payment</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:to="lab_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:type="arc" />
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230_label_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230_documentation_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:to="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:type="arc" />
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D_terseLabel_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D_label_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]</link:label>
    <link:label id="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D_documentation_en-US" xlink:label="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:to="lab_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares Unvested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A9AAE9F07A15CAAC32B7A3EA4EAFA49C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A9AAE9F07A15CAAC32B7A3EA4EAFA49C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A9AAE9F07A15CAAC32B7A3EA4EAFA49C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A9AAE9F07A15CAAC32B7A3EA4EAFA49C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A9AAE9F07A15CAAC32B7A3EA4EAFA49C" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Price/Share Unvested</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8BF8BC582AD7286329BBA3EA4EB01D9B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8BF8BC582AD7286329BBA3EA4EB01D9B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8BF8BC582AD7286329BBA3EA4EB01D9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8BF8BC582AD7286329BBA3EA4EB01D9B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8BF8BC582AD7286329BBA3EA4EB01D9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14" xlink:to="lab_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678" xlink:to="lab_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6932845E5647806D0A60A3EA4F3162CE_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_6932845E5647806D0A60A3EA4F3162CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6932845E5647806D0A60A3EA4F3162CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_6932845E5647806D0A60A3EA4F3162CE" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_6932845E5647806D0A60A3EA4F3162CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1F3DB6EF272E27DEECEEA3EA4E3A0334_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1F3DB6EF272E27DEECEEA3EA4E3A0334" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1F3DB6EF272E27DEECEEA3EA4E3A0334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1F3DB6EF272E27DEECEEA3EA4E3A0334" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1F3DB6EF272E27DEECEEA3EA4E3A0334" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price at Grant Date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B75F5AA88CC3C7B4A006A3EA4E3B845D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B75F5AA88CC3C7B4A006A3EA4E3B845D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B75F5AA88CC3C7B4A006A3EA4E3B845D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B75F5AA88CC3C7B4A006A3EA4E3B845D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B75F5AA88CC3C7B4A006A3EA4E3B845D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Term (Years)</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:type="arc" />
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B_terseLabel_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B_label_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B_documentation_en-US" xlink:label="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="lab_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FE42AAB7AC5FE59E13FEA3EA4E3DAF5B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FE42AAB7AC5FE59E13FEA3EA4E3DAF5B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FE42AAB7AC5FE59E13FEA3EA4E3DAF5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FE42AAB7AC5FE59E13FEA3EA4E3DAF5B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FE42AAB7AC5FE59E13FEA3EA4E3DAF5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:to="lab_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_68D54899A615DC168881CBE004F616C5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_68D54899A615DC168881CBE004F616C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_68D54899A615DC168881CBE004F616C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_68D54899A615DC168881CBE004F616C5" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_68D54899A615DC168881CBE004F616C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82156FCC39338E7B66D4CBE004F6EA84_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82156FCC39338E7B66D4CBE004F6EA84" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82156FCC39338E7B66D4CBE004F6EA84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82156FCC39338E7B66D4CBE004F6EA84" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82156FCC39338E7B66D4CBE004F6EA84" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic and diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from calculations of diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D" xlink:type="arc" />
    <link:label id="lab_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9_terseLabel_en-US" xlink:label="lab_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative worldwide sales milestone</link:label>
    <link:label id="lab_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9_label_en-US" xlink:label="lab_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Net Sales To Achieve Milestone</link:label>
    <link:label id="lab_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9_documentation_en-US" xlink:label="lab_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation.</link:label>
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CumulativeNetSalesToAchieveMilestone" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:to="lab_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Available-for-Sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>vnda-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:href="vnda-20200331.xsd#AccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:href="vnda-20200331.xsd#AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:href="vnda-20200331.xsd#BusinessOrganizationAndPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:href="vnda-20200331.xsd#BusinessOrganizationAndPresentationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:href="vnda-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:href="vnda-20200331.xsd#CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="vnda-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vnda-20200331.xsd#CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:href="vnda-20200331.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:href="vnda-20200331.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:href="vnda-20200331.xsd#EarningsPerShareDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:href="vnda-20200331.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:href="vnda-20200331.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="vnda-20200331.xsd#FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:href="vnda-20200331.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:href="vnda-20200331.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:href="vnda-20200331.xsd#IntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:href="vnda-20200331.xsd#IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:href="vnda-20200331.xsd#IntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Inventory" xlink:href="vnda-20200331.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:href="vnda-20200331.xsd#InventoryDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:href="vnda-20200331.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:href="vnda-20200331.xsd#LegalMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:href="vnda-20200331.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:href="vnda-20200331.xsd#MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:href="vnda-20200331.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:href="vnda-20200331.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:href="vnda-20200331.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:href="vnda-20200331.xsd#StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="vnda-20200331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.vandapharmaceuticals.com/role/Tables" xlink:href="vnda-20200331.xsd#Tables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_D9BA51A2A16269493867A3EA4E7CC101" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_D9BA51A2A16269493867A3EA4E7CC101" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_914136E5A31B1891D647A3EA4E7D8C69" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5F57A63B4882199C7EE7A3EA4F70D20A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_AccruedResearchAndDevelopmentExpense" xlink:label="loc_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="loc_vnda_AccruedResearchAndDevelopmentExpense_EEE90A49CF658A8360CDA3EA4F71035C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_38CB3E22601D177152D7A3EA4F712C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_438076BA4D3B7501BF2AA3EA4F711EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4CA1AEA37CE0051EC199A3EA4F7174DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_CF68A756C3D8DB342056A3EA4F71A575" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5B05553C6D8B190522EBA3EA4F72B343" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A393065A61A45762B5B6A3EA4F702262" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5B05553C6D8B190522EBA3EA4F72B343" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_B80748F3DE5660620B6EA3EA4E8D899A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_B80748F3DE5660620B6EA3EA4E8D899A" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_EE87839DD17E2B46F8E5A3EA4E8D056D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_0A5DB6B426054BA902D4A3EA4E1E0D4F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_0A5DB6B426054BA902D4A3EA4E1E0D4F" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_5F0160079006B9DB0716A3EA4E1EEA8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6135412896DD5C70AAF0A3EA4F2B661A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_6135412896DD5C70AAF0A3EA4F2B661A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_98C2E44AACED025B0F23A3EA4F2C218A" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_08CE97E932CE59BF199DA3EA4F2C0856" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_5A21C4D4AE3DC9F942B6A3EA4F2D25B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_9DDDFA365EEE1D3E504EA3EA4F2C9C17" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_E0E62C9B2CDBAB6055D4A3EA4F2DE864" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_6930311F741C0AD322AFA3EA4F2DE138" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_076C6E6CB3D77A6FEB56A3EA4DE44B10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_076C6E6CB3D77A6FEB56A3EA4DE44B10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_DC0016F1A1CE84DE1603A3EA4DE5852F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_076C6E6CB3D77A6FEB56A3EA4DE44B10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_E929B97965B8C20E0400A3EA4DE59144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_076C6E6CB3D77A6FEB56A3EA4DE44B10" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_34C424373EA5627289A4A3EA4DE5733A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DFB08CA60F6B9EEC420EA3EA4F33230D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_DFB08CA60F6B9EEC420EA3EA4F33230D" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29780CF87F35E9C45808A3EA4F33DF29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4587ABFFFD00750EF19CA3EA4E91C5D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4587ABFFFD00750EF19CA3EA4E91C5D9" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8F86010C1006AC299AB6A3EA4E91EEE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE2A97C6FA06BA84A82DA3EA4EB27DE3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE2A97C6FA06BA84A82DA3EA4EB27DE3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_8A3C3D7F9DBE02078447A3EA4EB27DF0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17C4A5BF2952DA3B69B7A3EA4EA42B94" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_17C4A5BF2952DA3B69B7A3EA4EA42B94" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1843C1500DF4AFBA8036A3EA4EA47E55" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FA3B7B3E71EF16FC7420A3EA4EB6F1CF" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FA3B7B3E71EF16FC7420A3EA4EB6F1CF" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:to="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ED48E693BECF2AA984F0A3EA4EB7BAC5" xlink:to="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8499F0FFC66BA8E2CC6BA3EA4EB7F533" xlink:to="loc_srt_MaximumMember_2EC31DBCB772E9F6FA50A3EA4EB75159" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4C93E54C76EE8355F953A3EA4EB7E300" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RegulatoryApprovalMilestoneMember" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_96E22DE952103D499817A3EA4EB8446F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FutureRegulatoryApprovalAndSalesMilestonesMember" xlink:label="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:to="loc_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember_F517A81D5CC288B052F1A3EA4EB8A28F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_3B1B6EF83F24B9F46000A3EA4EB8AC5C" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember_2F5B4B46D504E5DE6D85A3EA4EB81388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_74B4415D85190FA084E8A3EA4EB9D117" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:to="loc_srt_ProductOrServiceAxis_74B4415D85190FA084E8A3EA4EB9D117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_74B4415D85190FA084E8A3EA4EB9D117" xlink:to="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CftrActivatorsAndInhibitorsMember" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F3DFA9A1AFE09EFF57BFA3EA4EB9866B" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsMember_27ABCEB707BE7F768253A3EA4EB98569" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_A7C768A3ED5E470D9AA4A3EA4EB63558" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_CC3672B20DB30FEFADD4A3EA4EB918BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_CC3672B20DB30FEFADD4A3EA4EB918BD" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_6A866CB8625B3F764984A3EA4EBAEE73" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CftrActivatorsAndInhibitorsAbstract" xlink:label="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_09F8DDFCC11C2AC2749EA3EA4EB9986F" xlink:to="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CftrActivatorsAndInhibitorsAbstract_939938DF536C283A8E7AA3EA4EBAEC3B" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_06AEAC8949CB71BDABDFA3EA4F047DD3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A56DFFA60F7940E77E41A3EA4F573D74" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A56DFFA60F7940E77E41A3EA4F573D74" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_85DA61FEE0CE12AB5E00A3EA4F574BD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:to="loc_srt_ProductOrServiceAxis_85DA61FEE0CE12AB5E00A3EA4F574BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_85DA61FEE0CE12AB5E00A3EA4F574BD4" xlink:to="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_BF103392574CA6FA6831A3EA4F5724A3" xlink:to="loc_vnda_FanaptMember_1A7BE1362A7F8D424F82A3EA4F589108" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StatementScenarioSecondaryAxis" xlink:label="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:to="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StatementScenarioSecondaryDomain" xlink:label="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_StatementScenarioSecondaryAxis_4DA506339882623D8F9DA3EA4F587895" xlink:to="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScenarioFourMember" xlink:label="loc_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_StatementScenarioSecondaryDomain_767E8FE7525DE16D5711A3EA4F58B636" xlink:to="loc_vnda_ScenarioFourMember_1FF8981459AE19C488C9A3EA4F582951" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_37514F8272215F2F80A9A3EA4F5913B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_81D03AB4FD2D17F69573A3EA4F573663" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_37514F8272215F2F80A9A3EA4F5913B5" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptAbstract" xlink:label="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_37514F8272215F2F80A9A3EA4F5913B5" xlink:to="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPayableOnNetSalesPercentage" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_CDEE566C1EF1A96D1A5AA3EA4F59BCC1" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPeriod" xlink:label="loc_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_FanaptAbstract_2C847D23DDD0975ACD05A3EA4F5980FE" xlink:to="loc_vnda_RoyaltyPeriod_8EC12AF9B430D9C734EBA3EA4F5981B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_335BAC9B6A45EC8AFA2FA3EA4F247F26" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_70D9317BEEFB5BC2FA3EA3EA4F24B036" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_335BAC9B6A45EC8AFA2FA3EA4F247F26" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_70D9317BEEFB5BC2FA3EA3EA4F24B036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_13CAF33B951927F2B756A3EA4F251F98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_70D9317BEEFB5BC2FA3EA3EA4F24B036" xlink:to="loc_srt_ProductOrServiceAxis_13CAF33B951927F2B756A3EA4F251F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_13CAF33B951927F2B756A3EA4F251F98" xlink:to="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_4CB10DDA372FB98A1981A3EA4F258C09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_654A88F722A7AEFF53D3A3EA4F250F49" xlink:to="loc_vnda_HetliozMember_4CB10DDA372FB98A1981A3EA4F258C09" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_464BA5E60EA5D6CC8EBDA3EA4F25AE01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_70D9317BEEFB5BC2FA3EA3EA4F24B036" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_464BA5E60EA5D6CC8EBDA3EA4F25AE01" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozAbstract" xlink:label="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_464BA5E60EA5D6CC8EBDA3EA4F25AE01" xlink:to="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8F6A5E2FC5B4D0C7C1F0A3EA4F26757C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_57882D4C52AC7AF5CC58A3EA4F26195C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPeriod" xlink:label="loc_vnda_RoyaltyPeriod_57A95626C76668EC7583A3EA4F26CB35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_vnda_RoyaltyPeriod_57A95626C76668EC7583A3EA4F26CB35" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RoyaltyPayableOnNetSalesPercentage" xlink:label="loc_vnda_RoyaltyPayableOnNetSalesPercentage_0B8A8F80A5A025D7C950A3EA4F263264" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_vnda_RoyaltyPayableOnNetSalesPercentage_0B8A8F80A5A025D7C950A3EA4F263264" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_PercentageOfFutureSublicenseFeesPayable" xlink:label="loc_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_HetliozAbstract_054AA617206067B4818BA3EA4F26CBF7" xlink:to="loc_vnda_PercentageOfFutureSublicenseFeesPayable_3BDBBEDC3120251F7A2BA3EA4F277C3C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDF0309B25EF67B52B23A3EA4F1C9A87" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod" xlink:label="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDF0309B25EF67B52B23A3EA4F1C9A87" xlink:to="loc_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod_AF2348277D5ADEF2BD01A3EA4F1CC3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DDF0309B25EF67B52B23A3EA4F1C9A87" xlink:to="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:to="loc_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear_0DC8FF30101334AACDDEA3EA4F1DE6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_51752122B886B39B011DA3EA4F1DA51C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_C09BEB643228FE35B5DEA3EA4F1C9697" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_1FB35EEA17F909FD5659A3EA4F1D254E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22A3DDF3A3A018B76C16A3EA4F62529D" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_22A3DDF3A3A018B76C16A3EA4F62529D" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:to="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_CB8A0FEC9895AED31E0EA3EA4F63D249" xlink:to="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:to="loc_country_US_80C899DFC8355B678D2FA3EA4F64BC95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_82F91B6189BECA55818AA3EA4F63ABB9" xlink:to="loc_srt_EuropeMember_F37188FB20A0533D68F5A3EA4F64C28F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15D367F7581189F3B692A3EA4F640FE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15D367F7581189F3B692A3EA4F640FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15D367F7581189F3B692A3EA4F640FE6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TradipitantMember" xlink:label="loc_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3EBF80274562177D0AEA3EA4F64CE77" xlink:to="loc_vnda_TradipitantMember_8F15BD06EFF87D0452F8A3EA4F655D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4E8198E1B5E3ED602A37A3EA4F653F15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4E8198E1B5E3ED602A37A3EA4F653F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_4E8198E1B5E3ED602A37A3EA4F653F15" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_RegulatoryApprovalMilestoneMember" xlink:label="loc_vnda_RegulatoryApprovalMilestoneMember_A9223637421F5FAECFA1A3EA4F652C94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:to="loc_vnda_RegulatoryApprovalMilestoneMember_A9223637421F5FAECFA1A3EA4F652C94" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SalesMilestoneMember" xlink:label="loc_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_CB1723B0074AB3781933A3EA4F65C45A" xlink:to="loc_vnda_SalesMilestoneMember_DD1BD61A9A997D0E8900A3EA4F666101" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_D86A867FA4FDF432D4B7A3EA4F62FE5B" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_970C4A88C79E174FD43EA3EA4F66407D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_970C4A88C79E174FD43EA3EA4F66407D" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_C73200F1CEBA58FA7031A3EA4F660A1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty_C73200F1CEBA58FA7031A3EA4F660A1E" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty" xlink:label="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty_AE55C933D4F49747B08CA3EA4F660C34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_731F3F2E40429C58F0C7A3EA4F674835" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_629AB9FC25999F96EC94A3EA4F665EA9" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_731F3F2E40429C58F0C7A3EA4F674835" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DAA5D126E57ECC38FDFA3EA4F754AE5" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesTable" xlink:label="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1DAA5D126E57ECC38FDFA3EA4F754AE5" xlink:to="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:to="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_59DC861F56C7BA5DD2D3A3EA4F75DE8F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_VQW765Member" xlink:label="loc_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7E0F8EA7989B667E81D9A3EA4F7572CC" xlink:to="loc_vnda_VQW765Member_9B8370179CA7E7B0D3E9A3EA4F763FF9" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CommitmentsAndContingenciesLineItems" xlink:label="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesTable_214BEC423CC3DA6F02ACA3EA4F759691" xlink:to="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales" xlink:label="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_CommitmentsAndContingenciesLineItems_6D8BA0F1E8CD5D5DC493A3EA4F76A3E7" xlink:to="loc_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales_0A2900B7DC17DA8E80BBA3EA4F76B30B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659" xlink:to="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A350CF77A8E22EACD128A3EA4F8931DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A350CF77A8E22EACD128A3EA4F8931DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_DC01B0D6CB57D8EC1349A3EA4F89F864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_187233643DC30A8BCBA5A3EA4F89A305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D3FC947C41677F210545A3EA4F8AABF1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:to="loc_us-gaap_InventoryNet_D3FC947C41677F210545A3EA4F8AABF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5198B6131217E0FFC731A3EA4F8A8600" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9D2712998BFA54E56B95A3EA4F88FCD6" xlink:to="loc_us-gaap_AssetsCurrent_10ACA727B2C90CB677B5A3EA4F8ACF64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_D3B03999D2296968959EA3EA4F8A42E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_AC31B97F9FAB948281F8A3EA4F8AAB08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_605D0634ADCCDE90F991A3EA4F8A9B9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_605D0634ADCCDE90F991A3EA4F8A9B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_35733C819D4C8016B5EAA3EA4F8BEB77" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryAndOtherNonCurrent" xlink:label="loc_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="loc_vnda_InventoryAndOtherNonCurrent_32BD895C01D34F04E03AA3EA4F8B2DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_EC116F3AB43A2EF62822A3EA4F881A2A" xlink:to="loc_us-gaap_Assets_97D29633D1EBC0FE8D9AA3EA4F8B7FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D299EAA6332DBC7AB8DAA3EA4F88F659" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_E2B547DB1B3577B0BB54A3EA4F8C32DA" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ProductRevenueAllowancesCurrent" xlink:label="loc_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:to="loc_vnda_ProductRevenueAllowancesCurrent_0EAAD2F4F917EA8F372CA3EA4F8CC68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_CC84FD167E1F79298940A3EA4F8BB471" xlink:to="loc_us-gaap_LiabilitiesCurrent_1D078F1AEAAEE63794B1A3EA4F8C3A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7584DDE592A86AD38196A3EA4F8C51F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4BFB3C94C0EE88F09086A3EA4F8C1009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="loc_us-gaap_Liabilities_9DD88FB5505231BD179DA3EA4F8C2E2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="loc_us-gaap_CommitmentsAndContingencies_F3DE89FAB4FC6AD35642A3EA4F8D61D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:to="loc_us-gaap_PreferredStockValue_4A5216653DBB7A85D180A3EA4F8D0AAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:to="loc_us-gaap_CommonStockValue_314734B2FE9B31C20AD8A3EA4F8D933A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8F63A1C15F26B3233E7FA3EA4F8EED99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6F8901BBFD5F95FB51FA3EA4F8E1652" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F6F8901BBFD5F95FB51FA3EA4F8E1652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6324D3064F5A0A01AE9FA3EA4F8E6295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A7FC8C058AD416190332A3EA4F8E254E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_D5C2C6B5E9DB325FA0FBA3EA4F8D5CA0" xlink:to="loc_us-gaap_StockholdersEquity_A7FC8C058AD416190332A3EA4F8E254E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_C8782FFC3BE59A0C45BCA3EA4F8BE9BE" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_8E8D1E8CD8B1ABA25F8CA3EA4F8EABF2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6073E032A47DC5B0C93BA3EA4F30D0AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9157F9112CA4A103777EA3EA4F30CCA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_PreferredStockSharesIssued_BEF5EC625A16C68365FFA3EA4F310D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6AA06D676FCB3495159CA3EA4F316381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_F5EAD991114B22B7D07DA3EA4F312DC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_053FFC783E40165A8B48A3EA4F31F887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_CommonStockSharesIssued_CA36223F2BDE4ACC6398A3EA4F31F678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6932845E5647806D0A60A3EA4F3162CE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D06911DB2BAAA2E494B2A3EA4F30D42F" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6932845E5647806D0A60A3EA4F3162CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CC638D0F998DD36ED1E7CBE0062EDFCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:to="loc_us-gaap_NetIncomeLoss_CC638D0F998DD36ED1E7CBE0062EDFCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="loc_us-gaap_Depreciation_D29D5D5B2AAFBE27A61FCBE0062F0A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="loc_us-gaap_ShareBasedCompensation_8FB97A82E2B8F30242F2CBE0062FAD12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_44DCEF676BB5E55AE463CBE0062F0EC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3F02C9661C30E37E4335CBE0062FB362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7488B21AE283816F2255CBE0062FA52C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_75C396F98697250843DACBE00630146F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B2FFC9ECE4652D1F0C05CBE0062F4C99" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_D68DA288D342ACB62F72CBE0063009E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5918F80D902F5786214BCBE006306351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_E5397050C6C9DEE64242CBE006309727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B72563E405AF5A46BDA2CBE006304AD0" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_IncreaseDecreaseProductRevenueAllowances" xlink:label="loc_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_03EEFF9D14D8661D74B1CBE0063047F0" xlink:to="loc_vnda_IncreaseDecreaseProductRevenueAllowances_65924DEF6B6E266C7F85CBE00631F931" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_768BE2D898429C825479CBE0062E4A81" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C978387ED0861E78396ECBE006316487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_874A0B36258D598D628ACBE006310167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C2E2C7BBBB3F144CFFFBCBE00631EC36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1E83EEEA3392EC0A4A31CBE00632D28A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_F7CE5D5CFDFAF9D645E6CBE00632D6CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_EB642B2C8795EB86FC14CBE006314569" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99C741C4A5E598C4DEDCCBE006321603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6D149C4F017DD9C84881CBE0063253AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6D149C4F017DD9C84881CBE0063253AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_F146C3BD6DDCFBD17EFACBE00632C0CE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_BEC5204B83B95F1FFBE1CBE006320B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0C7B180B4855ECE610C3CBE00633CE4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3413FEA3A4C43630B0BDCBE00633F68A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DD03F7D715E38B196073CBE0062ECF6B" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17FDCDF351C860E0B3E6CBE0063304EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_17FDCDF351C860E0B3E6CBE0063304EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF718913F4C89A68B471CBE00633F0EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_FFE3B6B59EDAEB575023CBE00633743C" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_CF718913F4C89A68B471CBE00633F0EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7418A192CD21BAC3FB34A3EA4E566B8C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7418A192CD21BAC3FB34A3EA4E566B8C" xlink:to="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_71354AFF46A4B4897A44A3EA4E57A09A" xlink:to="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_CommonStockMember_0F950CB33E67689CE813A3EA4E586A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_29E6E1F5700B16DD1AA5A3EA4E58E3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_13F1DA8667FA21915C3FA3EA4E581FAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2E0AC46202A0651525DFA3EA4E57623F" xlink:to="loc_us-gaap_RetainedEarningsMember_6D0D2A20046B8A5B3493A3EA4E58584C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_262204392FB43A9D697CA3EA4E57CE6D" xlink:to="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8DD94B7D59EEE5441349A3EA4E580D7E" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_62DD042A6D412BF1EB59A3EA4E59A035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_StockholdersEquity_F4C174310C24944071D7A3EA4E5917FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_875C293662AF89A75A99A3EA4E5940B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_AABC7FC2281E6C166958A3EA4E59B7B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_F925D73A0FB43F88BB5EA3EA4E5A792E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_NetIncomeLoss_5BDBA07A43DFB56D930AA3EA4E5ABFEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6D7E19ED82DB6CE855C6A3EA4E5A9988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_32071E87CE3F8821573EA3EA4E5A4CFC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_32071E87CE3F8821573EA3EA4E5A4CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_1895C872363CFEE5867DA3EA4E5A1075" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_B8ACE0A2D2828A8C9F8FA3EA4E587712" xlink:to="loc_us-gaap_StockholdersEquity_1895C872363CFEE5867DA3EA4E5A1075" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C6A99F9EB3B3F67BA7FAA3EA4F7FB4D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:to="loc_us-gaap_NetIncomeLoss_C6A99F9EB3B3F67BA7FAA3EA4F7FB4D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_0D3859D5D997CF40E62DA3EA4F806326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_576FECE159FA1DCD352FA3EA4F80FB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_9F57BC03F31B7F7DC59CA3EA4F80E855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C3FBB635F37F15B58774A3EA4F80FE5F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract_43F41535629869634EA1A3EA4F80AF28" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_C3FBB635F37F15B58774A3EA4F80FE5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_10B327484E3DFCFE32E4A3EA4F7F53E3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_DE740F06FAC7F821B545A3EA4F80805C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C8965E8C0727C3F01F1ECBE006887A41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C8965E8C0727C3F01F1ECBE006887A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_300F43A2AE69700709B9CBE00688C0BE" xlink:to="loc_us-gaap_Revenues_EAF1D1EC031521709A31CBE00689981D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_049C4F4F2CD900FC4BB3CBE006892EF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2AF57C0E4DA9C0F64ECFCBE00689E491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_31108216D5C08BEF5674CBE0068A8B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_583CDF85FADB8FDE2BB1CBE0068AE0EB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_583CDF85FADB8FDE2BB1CBE0068AE0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_AF26CBED648C0699D153CBE0068969A3" xlink:to="loc_us-gaap_CostsAndExpenses_DBCAD595D25A742476F8CBE0068A685D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_OperatingIncomeLoss_3E0693FB3C2C6AB2E2E0CBE0068A6A4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_OtherIncome_91A56D2D457527874716CBE0068A1C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_32E4A49AEEAE2C2EEB21CBE0068A7119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_A0877C518536DEF77ACCCBE0068B2B66" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_A0877C518536DEF77ACCCBE0068B2B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EDE88C9A1BD8D656AA0ACBE0068B5630" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_NetIncomeLoss_EDE88C9A1BD8D656AA0ACBE0068B5630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:to="loc_us-gaap_EarningsPerShareBasic_F1C8BDD07E87776C90CCCBE0068BE470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_44D9683E29419D224EB4CBE0068B6891" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0137B101DB0194B23AF7CBE0068B6D90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4F5EBEA01CA48D3F10C2CBE00688AAF7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2E434F5AAB6A897B1D4FCBE0068C3DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9AF83824BD845DC9AF05CBE0068CDF7A" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7B5880B5FDFDC254BFCECBE0068C7766" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_DocumentType_83F6FA2C877F948B177DE025DC4803F6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_DocumentQuarterlyReport_4B29EDB530B850ED63DCE025DC487B97" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_DocumentPeriodEndDate_F5C8759E33F3EE373718E025DC48E176" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_DocumentTransitionReport_746C6391FCB7D5815098E025DC4804E1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityFileNumber_21645BB6C9D4FC31C769E025DC4866D8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityRegistrantName_61DB0B0763179F464026E025DC4873FC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5072CB79531DB88CCA87E025DC49CD41" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityTaxIdentificationNumber_47FA9F743E12183A34E5E025DC4901B0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityAddressAddressLine1_377F377DCC58118F396EE025DC495E37" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityAddressAddressLine2_98D0ACD7F58D4FCB4CF3E025DC49577C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityAddressCityOrTown_72186130DDFF1459121FE025DC49C98D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityAddressStateOrProvince_47BBCFFC9306E8F1F759E025DC4983E7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityAddressPostalZipCode_74CBE661F80264EE0BFCE025DC4AA0E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_CityAreaCode_8E7E0EF537AF2CF9D222E025DC4ABB94" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_LocalPhoneNumber_CAD6F56E32BAD4D891D9E025DC4A91A2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_Security12bTitle_29F47B967278BA40CA3CE025DC4A58AA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_TradingSymbol_56E4E6D0429FEED4085AE025DC4A1E56" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_SecurityExchangeName_9A3F970A548562E1EDB6E025DC4A7A87" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityCurrentReportingStatus_EF9DF768E8B5AC9BCA1EE025DC4B57E4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityInteractiveDataCurrent_197213CD8FB2FB29B862E025DC4B7F9B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityFilerCategory_AE80FAF67EA14F671534E025DC4BB596" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntitySmallBusiness_4F7A6261252040D8F169E025DC4BBD18" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityEmergingGrowthCompany_34A62EEAE921A25252B5E025DC4B22F3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityShellCompany_4D364552B6F43578EE46E025DC4BCC8E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0BD967199FF37C6782B7E025DC4C751B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_EntityCentralIndexKey_208BA3A063A86DFC6938E025DC4CAAC3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_CurrentFiscalYearEndDate_E71A8E7E79EFCBA6CF04E025DC4C2D5D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_DocumentFiscalYearFocus_FFC6643E874B55AE7F2BE025DC4C53E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_DocumentFiscalPeriodFocus_17B35679ADDDF65F6ABCE025DC4CCB85" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_03F3090DE00A6B905403E025DC47F11A" xlink:to="loc_dei_AmendmentFlag_F3422622402CD513D8A7E025DC4C8538" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B186A1D7537408705A13A3EA4F21B915" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B186A1D7537408705A13A3EA4F21B915" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2FA6A4B65EA99CA1647CA3EA4F21794B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_F0B88352A60F21C4CBDFCBE004F53B77" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_F0B88352A60F21C4CBDFCBE004F53B77" xlink:to="loc_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AE41BA7179E014610292CBE004F5C58A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_D0D571ACD89AFCFA10BDCBE004F5B501" xlink:to="loc_us-gaap_NetIncomeLoss_AE41BA7179E014610292CBE004F5C58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_F0B88352A60F21C4CBDFCBE004F53B77" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_68D54899A615DC168881CBE004F616C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_68D54899A615DC168881CBE004F616C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_F493ED911C6AA4E64C7BCBE004F6BDE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82156FCC39338E7B66D4CBE004F6EA84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_A71F2371BECAE038F11ACBE004F6941E" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_82156FCC39338E7B66D4CBE004F6EA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_F0B88352A60F21C4CBDFCBE004F53B77" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_83C9EB73746CD1D87499CBE004F7088D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:to="loc_us-gaap_EarningsPerShareBasic_83C9EB73746CD1D87499CBE004F7088D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C3615012927785741CF1CBE004FC6AD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C3615012927785741CF1CBE004FC6AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_34922B326D45E2BD0FAACBE004F61C5E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_161A7A00A407DE8DC35DCBE004FC8233" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_C9096A59056524F8F29EA3EA4E887913" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_C9096A59056524F8F29EA3EA4E887913" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2D66710EF6B827953150A3EA4E8983BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E546C36289BC516A698DA3EA4F17E898" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E546C36289BC516A698DA3EA4F17E898" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_C67C3C87B5369EDA2A7BA3EA4F173427" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_F41539B3850325F0FFCDA3EA4E42AD88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_F41539B3850325F0FFCDA3EA4E42AD88" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4A458EAE483FDC50B8E9A3EA4E422789" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4A458EAE483FDC50B8E9A3EA4E422789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4A458EAE483FDC50B8E9A3EA4E422789" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24DC2602217D577059B7A3EA4E43934C" xlink:to="loc_us-gaap_CashEquivalentsMember_6250EBFABDB2E66BE430A3EA4E4376AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_D16D404097A82546A44EA3EA4E434436" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_D41DEBE3D08DB8274AF6A3EA4E447FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4D373A1C1083A3DD2170A3EA4E4493C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3EA2BBCBEEA69B2ACF51A3EA4E437695" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5402D48D937C3A2CC730A3EA4E447CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_751EAE5A5E93B8092BF8A3EA4E4442B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_751EAE5A5E93B8092BF8A3EA4E4442B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_751EAE5A5E93B8092BF8A3EA4E4442B3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_DFEBCA28E18C1267409DA3EA4E45669F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_DFEBCA28E18C1267409DA3EA4E45669F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3C5C5EB20FDFE8D1BF21A3EA4E4549C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3C5C5EB20FDFE8D1BF21A3EA4E4549C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_C14CA2EABB630C7B5255A3EA4E45ADA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7A3FBCB958890D268B4BA3EA4E441268" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_C14CA2EABB630C7B5255A3EA4E45ADA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4314762B3393CE411701A3EA4E4261A7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8AE9182538B2104C7310A3EA4E45B873" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_BC88D9ED1CF8B68C5B48A3EA4E453354" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9D342BC6A343B3534E3EA3EA4E8B00A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9D342BC6A343B3534E3EA3EA4E8B00A0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_49E4DA27FA518F6F127DA3EA4E8B9F71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F3E4FC96CF00F47AFFCDD1319008F4ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F3E4FC96CF00F47AFFCDD1319008F4ED" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ADDDB677770042C7A4B3D13190088ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F3E4FC96CF00F47AFFCDD1319008F4ED" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_C1B776D6E82839CC6116D1319008145E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_594A72B87B2C753B16ADA3EA4F49F4B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_594A72B87B2C753B16ADA3EA4F49F4B8" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_39A6887BDD89CAC344E4A3EA4F49ECBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F9CA55C2925B296D5AF4A3EA4F1FDA45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2657941E58B35B836B13A3EA4F1F7ECE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F9CA55C2925B296D5AF4A3EA4F1FDA45" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2657941E58B35B836B13A3EA4F1F7ECE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6A5E07D9B93C16DB1835A3EA4E13557E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D803C1C80170E7BA4E24A3EA4E139845" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6A5E07D9B93C16DB1835A3EA4E13557E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D803C1C80170E7BA4E24A3EA4E139845" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9232DAB697A9651BA3C1A3EA4E14965E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D803C1C80170E7BA4E24A3EA4E139845" xlink:to="loc_srt_ProductOrServiceAxis_9232DAB697A9651BA3C1A3EA4E14965E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9232DAB697A9651BA3C1A3EA4E14965E" xlink:to="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_910817F88F43BAE7477CA3EA4E141B26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_45F090B68D14E4E69817A3EA4E1474EA" xlink:to="loc_vnda_FanaptMember_910817F88F43BAE7477CA3EA4E141B26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FCE8652574F2EF34733EA3EA4E1404C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_D803C1C80170E7BA4E24A3EA4E139845" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FCE8652574F2EF34733EA3EA4E1404C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_FCE8652574F2EF34733EA3EA4E1404C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_DBFF95F25BC8F7C2932FA3EA4E152D57" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DD341A1EC2267689C34AA3EA4F796E37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C675E8FD67A08456E101A3EA4F79B89D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DD341A1EC2267689C34AA3EA4F796E37" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C675E8FD67A08456E101A3EA4F79B89D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_37EF300AAE93A6675873A3EA4F794832" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C675E8FD67A08456E101A3EA4F79B89D" xlink:to="loc_srt_ProductOrServiceAxis_37EF300AAE93A6675873A3EA4F794832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_37EF300AAE93A6675873A3EA4F794832" xlink:to="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_EFE599F6371EA35EDA4DA3EA4F7AA73A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_539998E27AD1120172E6A3EA4F7A1C40" xlink:to="loc_vnda_HetliozMember_EFE599F6371EA35EDA4DA3EA4F7AA73A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C675E8FD67A08456E101A3EA4F79B89D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_04F16CE5C3F65A162863A3EA4F7A313A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_04F16CE5C3F65A162863A3EA4F7A313A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_CumulativeNetSalesToAchieveMilestone" xlink:label="loc_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:to="loc_vnda_CumulativeNetSalesToAchieveMilestone_AC445714AB5822479DEAA3EA4F7BF5A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_C49EBCA9A925BC1CDC7BA3EA4F7B4419" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_CBDCEF08079CCE6A466CA3EA4F7A8223" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_C49EBCA9A925BC1CDC7BA3EA4F7B4419" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A8E33F8A57B7EB992A68A3EA4E4FF483" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C1D3ED6ED7AE7D1CC825A3EA4E4F382C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A8E33F8A57B7EB992A68A3EA4E4FF483" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C1D3ED6ED7AE7D1CC825A3EA4E4F382C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_45D3307BF4144D4B6BC6A3EA4E50363D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C1D3ED6ED7AE7D1CC825A3EA4E4F382C" xlink:to="loc_srt_ProductOrServiceAxis_45D3307BF4144D4B6BC6A3EA4E50363D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_45D3307BF4144D4B6BC6A3EA4E50363D" xlink:to="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_C7848767D43EB0E43225A3EA4E509B5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_29413C69979FD45B8590A3EA4E507FDE" xlink:to="loc_vnda_HetliozMember_C7848767D43EB0E43225A3EA4E509B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_C1D3ED6ED7AE7D1CC825A3EA4E4F382C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A44F9C5CDE9432978CDA3EA4E51F245" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2A44F9C5CDE9432978CDA3EA4E51F245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_CC16638E383354B673C2A3EA4E514FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_19604318C4B66637FFB0A3EA4E5109B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_F03D32A8E6865256A931A3EA4E51779B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_B59D222295CA44E6FDD5A3EA4E510522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5B92992ED17259047EBFA3EA4E52A6A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3A79807BEDE3B5E30845A3EA4E501496" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_957922235D375B199DBBA3EA4E525065" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32EA235A530E7D35521AA3EA4F3AF247" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_32EA235A530E7D35521AA3EA4F3AF247" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:to="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_C3984563A1694280BE1EA3EA4F3BA274" xlink:to="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7E272068F8156DCE3308A3EA4F3B6401" xlink:to="loc_vnda_HetliozMember_023ABF3B21207873FF1EA3EA4F3BADF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_919721F70AD7B9B46B40A3EA4F3BFC48" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7CF149E40B69165649A6A3EA4F3CE138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_787D64613BB0EF45ECADA3EA4F3C2D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_415B6CCFC156CCE6E158A3EA4F3CA6C7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0540EA1B9E200FB28E15A3EA4F3C9122" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DFD33DF635A206A0A8F6A3EA4E170F0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DFD33DF635A206A0A8F6A3EA4E170F0C" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05CB627DBA5219C976E7A3EA4E173857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DFD33DF635A206A0A8F6A3EA4E170F0C" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7FCBD478ACF2D588EE04A3EA4E170F0C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_01D71C5034D767730D57A3EA4F154CC8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_01D71C5034D767730D57A3EA4F154CC8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_FAD969BEF12ED5BF967DA3EA4F156713" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:to="loc_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_993A7118B38E870A630BCBE005E8B58F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_DCCAA45A737855B75A04CBE005E8E906" xlink:to="loc_us-gaap_InventoryNet_79AD29C8E3EF5A27260DCBE005E9BE2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrentAbstract" xlink:label="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:to="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryRawMaterialsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:to="loc_vnda_InventoryRawMaterialsNetOfReservesNonCurrent_DF7ED527D947AB816074CBE005E9DC30" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryWorkInProcessNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:to="loc_vnda_InventoryWorkInProcessNetOfReservesNonCurrent_F6E8D81DD907C50A2BCACBE005E9B755" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_InventoryFinishedGoodsNetOfReservesNonCurrent" xlink:label="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:to="loc_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent_A27473EB614B16D38D58CBE005E93A4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNoncurrentAbstract_688607DC2DB6C1FC9909CBE005E94201" xlink:to="loc_us-gaap_InventoryNoncurrent_E5A016040454C6AA595ACBE005E9AA32" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_Inventory" xlink:label="loc_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_7138B192C64A51F619E6CBE005E885C8" xlink:to="loc_vnda_Inventory_D55C905C705AC941D6E9CBE005EA6CC3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_084B3F43883FC11817D2A3EA4F3E4389" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfInventoriesTableTextBlock" xlink:label="loc_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_084B3F43883FC11817D2A3EA4F3E4389" xlink:to="loc_vnda_ScheduleOfInventoriesTableTextBlock_53E9F8CB81DEB8FD8FF4A3EA4F3F905C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/LegalMatters" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58FF066502571511B790A3EA4F198E5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58FF066502571511B790A3EA4F198E5C" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_81EC41F3D7FD58E615C8A3EA4F195259" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0656FAAE29321A16F806A3EA4F37F5C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0656FAAE29321A16F806A3EA4F37F5C8" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_22E778ADB7CC3BDE111CA3EA4F37EC8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_541A13B650D1C47B896CA3EA4E5E0833" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_541A13B650D1C47B896CA3EA4E5E0833" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:to="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_E6DD93C23A5C12DC41C9A3EA4E5EBCFD" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NoncurrentInvestmentsMember" xlink:label="loc_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_E42C9E85F3B9F1842B47A3EA4E5FDA2A" xlink:to="loc_vnda_NoncurrentInvestmentsMember_BCCED72B778B658FF74FA3EA4E5F5C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E39EC0F9732158740A4DA3EA4E5F55E5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_3B21285960554D034FFAA3EA4E609F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_B7EBC9FA0830DB9C20A8A3EA4E606532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_B32B08DA4444163FC7E0A3EA4E5F470C" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_E74DA78E6F1DF4F6AAA5A3EA4E60B3A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6F9379217FD3ABABC831A3EA4E5EFFA3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_AA9F0C1C2A7B2F03A46CA3EA4E61F0BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1066C19DFB33C731CF14A3EA4E612BF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9402D857AC9D3835F806A3EA4E618141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_F89BD30962C7B7929E81A3EA4E60701C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DFD3DD56D49481D20F44A3EA4E61A586" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EB9DE5D719634D7CB78BA3EA4F35C6E4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EB9DE5D719634D7CB78BA3EA4F35C6E4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_E5D8AAFF176A074EC8D9A3EA4F35338D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_672FB3AC5DA21B8DEE14A3EA4E684676" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_672FB3AC5DA21B8DEE14A3EA4E684676" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B9F85939B6C4AC19F98AA3EA4E68520C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_835CC893B0EE42F3F768A3EA4F4BAE1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_835CC893B0EE42F3F768A3EA4F4BAE1F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FF2A277B145CE5620492A3EA4F4BEA94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_835CC893B0EE42F3F768A3EA4F4BAE1F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_63622DABA777A741A7FDA3EA4F4CEDC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_835CC893B0EE42F3F768A3EA4F4BAE1F" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D1DAC839347EB27FDF1CA3EA4F4C91FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_835CC893B0EE42F3F768A3EA4F4BAE1F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_C6D84FBC73E1C493A40FA3EA4F4C3AE2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8383673E95E73CB2A1B4A3EA4F94F2E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BFDBF6CDB48B7F1BA9F5A3EA4F946ABB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8383673E95E73CB2A1B4A3EA4F94F2E8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BFDBF6CDB48B7F1BA9F5A3EA4F946ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_44E8471EEBE1BFB99638A3EA4F94D52A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BFDBF6CDB48B7F1BA9F5A3EA4F946ABB" xlink:to="loc_us-gaap_AwardTypeAxis_44E8471EEBE1BFB99638A3EA4F94D52A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_44E8471EEBE1BFB99638A3EA4F94D52A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_FF028CE16DAC95B474B6A3EA4F9488A9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_D7F03582E1EC86E3CB1DA3EA4F95D42D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_BFDBF6CDB48B7F1BA9F5A3EA4F946ABB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_278A67787CB0A0A770C9A3EA4F9516F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_278A67787CB0A0A770C9A3EA4F9516F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B423315D43FE184FF791A3EA4F96157A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4DD8B50D776EF0B98248A3EA4F96BAE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4DD8B50D776EF0B98248A3EA4F96BAE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1F7F1860F0FB3251B3A2A3EA4F9615C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E944D7C9EE38A56F6953A3EA4F951F92" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_47E00FFBA3BA23AB2036A3EA4F96ABE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_149039F2046FB640212BA3EA4E82BF72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_149039F2046FB640212BA3EA4E82BF72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:to="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_30E44D9D33C1B4BF45F3A3EA4E830D8C" xlink:to="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_12E2701982F7F736D29BA3EA4E837E29" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_E55FFB140C4BE9EFF362A3EA4E83ACA2" xlink:to="loc_vnda_TwoThousandSixteenPlanMember_EAB8C994033204182B7FA3EA4E841AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:to="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D50E5D4B4918F46DD843A3EA4E846EEA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_StockOptionsAndRestrictedStockUnitsRSUsMember" xlink:label="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5F0BBF5590772B72FC98A3EA4E8429EA" xlink:to="loc_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_ACB7D128400D533D6E7BA3EA4E84B6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_AD1D7474922516DDF9B8A3EA4E8239CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber_9C04EB002BB3B1F5A615A3EA4E84CAB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_154D92362B865016C8D3A3EA4E85925D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6CF5B86B2B6EE7BDCF16A3EA4E845D2B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_5B853C81C11AAD457B43A3EA4E85C3C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C69D42E79E5DAE4C28D2A3EA4E766209" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E79E0578BA4D7A74EB61A3EA4E766D97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C69D42E79E5DAE4C28D2A3EA4E766209" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E79E0578BA4D7A74EB61A3EA4E766D97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9014FCEC1DC97C4D4CFDA3EA4E7603E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E79E0578BA4D7A74EB61A3EA4E766D97" xlink:to="loc_us-gaap_AwardTypeAxis_9014FCEC1DC97C4D4CFDA3EA4E7603E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9014FCEC1DC97C4D4CFDA3EA4E7603E0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ServiceOptionAwardsMember" xlink:label="loc_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73289F1E20550BABD4BCA3EA4E770B40" xlink:to="loc_vnda_ServiceOptionAwardsMember_FEEBBEFA82B643ED2791A3EA4E77F028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E79E0578BA4D7A74EB61A3EA4E766D97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationOptionAwardsContractualTerm" xlink:label="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationOptionAwardsContractualTerm_470AA424B76F2D87D68CA3EA4E77F9FC" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards_310B6C5D30BCB623B314A3EA4E7796C1" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards_4E644B7D2FA6EE76F6A4A3EA4E786325" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments" xlink:label="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments_37EDE77D771FA510BF82A3EA4E787575" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors" xlink:label="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors_EA0255D04E29B6A6D6C0A3EA4E78A719" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_806FB409470823E64B65A3EA4E780569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B15AB131A6DF63BF6A1CA3EA4E78056E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E06EE52C0A29B0E7C78CA3EA4E78705C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5696B8C64FA5924B1672A3EA4E77B615" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_AC7A6BBF5D69AFA644F9A3EA4E79A301" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFB63CC803400912D45FA3EA4E3073F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F7916D5F7F93D496DBDA3EA4E37A0B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CFB63CC803400912D45FA3EA4E3073F0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F7916D5F7F93D496DBDA3EA4E37A0B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_77FED8102A51C1F018ECA3EA4E374321" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F7916D5F7F93D496DBDA3EA4E37A0B2" xlink:to="loc_us-gaap_PlanNameAxis_77FED8102A51C1F018ECA3EA4E374321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_77FED8102A51C1F018ECA3EA4E374321" xlink:to="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember" xlink:label="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_1527002EE86433470551A3EA4E38C3C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33EF60CA0B4541720986A3EA4E388593" xlink:to="loc_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember_1527002EE86433470551A3EA4E38C3C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7F7916D5F7F93D496DBDA3EA4E37A0B2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_DDF1AFE9E971703B4609A3EA4E39C724" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_81CB6BC3CAE6F7B49DEBA3EA4E39D822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_299D2CF0B862AC3BF2B4A3EA4E39D41C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9722E59430EE3A25DF90A3EA4E3966E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E4FA40A98406D983F65FA3EA4E3986E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1F3DB6EF272E27DEECEEA3EA4E3A0334" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6CBEBFC4820B3AE2AE32A3EA4E382B49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1F3DB6EF272E27DEECEEA3EA4E3A0334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_32DCBDB5EB68E474F2C4A3EA4E3A0B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_93ADF0337DD759E4026DA3EA4E3A2921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_622D66AF26D5BADE4B69A3EA4E3A3AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_FF2CAB76C21358DD96A9A3EA4E3BBCBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8E5F5D812A2FB26BD9BDA3EA4E3B4140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4B0E5BF5F36258D9D83FA3EA4E3B7C8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_64E4D4BA397344735A1DA3EA4E3B5255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B75F5AA88CC3C7B4A006A3EA4E3B845D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3B98BBB58E26644D490FA3EA4E3AC4B8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B75F5AA88CC3C7B4A006A3EA4E3B845D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_685B0DFAFB53D88FE9BFA3EA4E3B0F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_F659CB649E51ED4D9557A3EA4E3BE132" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B220C5680F5606381D3DA3EA4E3CD1A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_B7010D8459E62AA3AF16A3EA4E3C4824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_95CFE95877B9683240BBA3EA4E3C9C4A" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_36BE67F6AD8E3C2864A7A3EA4E3CDE10" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_506733C38E3E1936AD25A3EA4E381356" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3327D3FFA0F5729A6097A3EA4E3C25C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_916E46D6B8B2ED9F1BC0A3EA4E3DA335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FE42AAB7AC5FE59E13FEA3EA4E3DAF5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FE42AAB7AC5FE59E13FEA3EA4E3DAF5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_76EBE7A409C124C8A87FA3EA4E3D1BF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_558D21C5B084386E77C6A3EA4E3CB51B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_86945E1D614DDBF076CEA3EA4E3D5668" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_371EC511CD4A81691A1CA3EA4EAD8C26" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_371EC511CD4A81691A1CA3EA4EAD8C26" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A40577ABF50A3DF18759A3EA4EADF278" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:to="loc_us-gaap_AwardTypeAxis_A40577ABF50A3DF18759A3EA4EADF278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A40577ABF50A3DF18759A3EA4EADF278" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_85194233612B49359C5CA3EA4EAE2991" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_CB7C9D208471E6AE1EACA3EA4EAD0348" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_85194233612B49359C5CA3EA4EAE2991" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems" xlink:label="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable_EC18A3960C5125D20102A3EA4EAD6230" xlink:to="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A3523DFCBAA88C964556A3EA4EAF1B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CDB03424E75287213D55A3EA4EAFDA6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_C2E73C214F7D329C992AA3EA4EAFA5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0E2B4B86ECF34D20F6E1A3EA4EAFBB8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A9AAE9F07A15CAAC32B7A3EA4EAFA49C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3AD8D84C14F1EB3B5079A3EA4EAE29AC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A9AAE9F07A15CAAC32B7A3EA4EAFA49C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems_A58030AC071ED7B72C2EA3EA4EAE213D" xlink:to="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_751C55B8B079A1E14837A3EA4EB03538" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57AEB525558F5174BB86A3EA4EB0C42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_CACF768F86AE1480649DA3EA4EB0E1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_A43A47019AAF955A47DBA3EA4EB01883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8BF8BC582AD7286329BBA3EA4EB01D9B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract_64BDEFCBD00308642AA9A3EA4EAF0DFC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8BF8BC582AD7286329BBA3EA4EB01D9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D0C688F5E6D0006340D5A3EA4E8F60B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D0C688F5E6D0006340D5A3EA4E8F60B7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4D34503980877F2A6C0CA3EA4E8FBB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D0C688F5E6D0006340D5A3EA4E8F60B7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_C42827C0C1B19FF8D1C3A3EA4E8F56B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D0C688F5E6D0006340D5A3EA4E8F60B7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_DAD0B26201CA97C86BF7A3EA4E900A5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D0C688F5E6D0006340D5A3EA4E8F60B7" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_488F214D9452578B8B95A3EA4E902F14" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D87D68019C7ADB4AE4F0A3EA4F5C971A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D87D68019C7ADB4AE4F0A3EA4F5C971A" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_D6CB195042005D24EA0DA3EA4F5DC11C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_DB088FEC2F4FF288A9B6A3EA4F5D41CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_BC863E82337D14CA2703A3EA4F5D7641" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_56A47E8E69B4F199EC39A3EA4F5D808A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_6F9C31912677A2D90BBBA3EA4F5C782E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_D33148B7078FFFA78C99A3EA4F5D68D2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_44B3CD7DD6356F8F0FA9A3EA4F5E8D90" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BAFCFD9D3E3177460224A3EA4EA2E3A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BAFCFD9D3E3177460224A3EA4EA2E3A2" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_E8726CD3096A6F218CE8A3EA4EA2C35D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DC6FC0D6A1F9F3EDEFB4CBE006151F92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DC6FC0D6A1F9F3EDEFB4CBE006151F92" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_16C436C251D52C52BF35CBE00615A61D" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_62FF82007B7E8EDB6A7FCBE006165AE4" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NoncurrentInventoryAndOtherMember" xlink:label="loc_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8BA4E7902E8E538243DBCBE00615FD13" xlink:to="loc_vnda_NoncurrentInventoryAndOtherMember_D21B2EDACA0751AAF772CBE006166549" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_E122202861FA85CFC0F7CBE006154419" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_F4970E0CC34CBEB657F6CBE0061661E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAbstract_B3DE17B09A48E03D5F34CBE006174EDC" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3A03FBA7B0C94CA86702CBE0061729CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_6A57EBB5E24409300DADCBE0061604A9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1332917CA0EF75D9DC5DCBE00617238E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_171B2DB576ADB09BB02DA3EA4F50B8A3" xlink:type="locator" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_171B2DB576ADB09BB02DA3EA4F50B8A3" xlink:to="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_32C7B4EE1DC114C42680A3EA4F500D0C" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_E1C867D5DE8CA97A45AFA3EA4F51BBD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_D9EC5C1CCDFA251E3F6EA3EA4F504924" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_281F198807295A5211CDA3EA4F51BEF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ED1C8C22692D4F40DAF8A3EA4F5146EC" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:to="loc_us-gaap_SalesRevenueNetMember_44F826ACBCBD22ED0BEAA3EA4F520796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_BE151337798AAFE2EE4EA3EA4F518C85" xlink:to="loc_us-gaap_AccountsReceivableMember_2D28BE4692E373926D6BA3EA4F52851C" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesTable_07F95F9510B1FAB198A5A3EA4F50C64A" xlink:to="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NumberOfMajorCustomersAccountedForRevenue" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="loc_vnda_NumberOfMajorCustomersAccountedForRevenue_D34C612BE249F19633C3A3EA4F525CC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_F5B03DBDB6D7E1D18BE6A3EA4F5308CC" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable" xlink:label="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vnda_SummaryOfSignificantAccountingPoliciesLineItems_D064CED58B3E2F54A7B7A3EA4F524C26" xlink:to="loc_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable_A15DC3CDCB11110BE010A3EA4F539ABD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3E205203E0D1491BDE4AA3EA4E64475B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3E205203E0D1491BDE4AA3EA4E64475B" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EB0DEC3B1DE567A16CF1A3EA4E6586E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:to="loc_srt_ProductOrServiceAxis_EB0DEC3B1DE567A16CF1A3EA4E6586E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_EB0DEC3B1DE567A16CF1A3EA4E6586E9" xlink:to="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_HetliozMember" xlink:label="loc_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:to="loc_vnda_HetliozMember_F71CE575FE47C1978429A3EA4E653D5A" xlink:type="arc" />
    <link:loc xlink:href="vnda-20200331.xsd#vnda_FanaptMember" xlink:label="loc_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_15C9397DED75494F890EA3EA4E6573B9" xlink:to="loc_vnda_FanaptMember_42A75E7FB0CB59BFC55FA3EA4E65B16D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_C3A38B3D5A1FFAF04A45A3EA4E64B6DB" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7153F35FB4CE65FD3089A3EA4E663AF0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C1BAFED19B2B9BA22FC1A3EA4E66583A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17D0C21221738F694739A3EA4DFFCDD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_UseOfEstimates_BEE36E638E5F376E36A8A3EA4DFF2E48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_645E7A7AE34CEF76058DA3EA4E00E33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:label="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_MajorCustomersPolicyPolicyTextBlock_4D1744AA98FF836522F4A3EA4E008F94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_C5FA8A652AE578508B2BA3EA4E007623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_596AA8167F1BEE089D01A3EA4E0004AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_B47C4D673A83321084F3A3EA4E003E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_656BCEA8CC60D98638ABA3EA4DFF7B5B" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_44F43EF806C93EB2D786A3EA4E00945F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1F6B0869D4762DCA21BAA3EA4E7BF849" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1F6B0869D4762DCA21BAA3EA4E7BF849" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_3D616AB05855ACE7436DA3EA4E7B6882" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1F6B0869D4762DCA21BAA3EA4E7BF849" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_879FDA57095FE43D1BADA3EA4E7B4DFF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vandapharmaceuticals.com/role/Tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63D56E4744EB618A274FA3EA4F7C7422" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63D56E4744EB618A274FA3EA4F7C7422" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_763F1B65651E23A81007A3EA4F7CA30E" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894511008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 64,950<span></span>
</td>
<td class="nump">$ 45,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">247,376<span></span>
</td>
<td class="nump">267,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">29,272<span></span>
</td>
<td class="nump">26,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,828<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">360,746<span></span>
</td>
<td class="nump">354,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,877<span></span>
</td>
<td class="nump">3,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,875<span></span>
</td>
<td class="nump">11,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">22,667<span></span>
</td>
<td class="nump">23,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">86,641<span></span>
</td>
<td class="nump">87,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryAndOtherNonCurrent', window );">Non-current inventory and other</a></td>
<td class="nump">3,719<span></span>
</td>
<td class="nump">3,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">488,525<span></span>
</td>
<td class="nump">483,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">26,045<span></span>
</td>
<td class="nump">27,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ProductRevenueAllowancesCurrent', window );">Product revenue allowances</a></td>
<td class="nump">33,177<span></span>
</td>
<td class="nump">31,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">59,222<span></span>
</td>
<td class="nump">59,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">12,139<span></span>
</td>
<td class="nump">12,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">778<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">72,139<span></span>
</td>
<td class="nump">72,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 8 and 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at March 31, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 150,000,000 shares authorized; 54,132,336 and 53,549,612 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">635,730<span></span>
</td>
<td class="nump">631,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(220,179)<span></span>
</td>
<td class="num">(220,665)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">416,386<span></span>
</td>
<td class="nump">410,945<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 488,525<span></span>
</td>
<td class="nump">$ 483,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryAndOtherNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryAndOtherNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ProductRevenueAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Revenue Allowances, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ProductRevenueAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894592528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,477,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 275,422<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 611,587<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (336,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock form the exercise of stock options and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(612)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,962,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">$ 278,405<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">615,047<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="num">(336,830)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">53,549,612<span></span>
</td>
<td class="nump">53,549,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 410,945<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">631,307<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="num">(220,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock form the exercise of stock options and settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock from the exercise of stock options and settlement of restricted stock units</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">54,132,336<span></span>
</td>
<td class="nump">54,132,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 416,386<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">$ 635,730<span></span>
</td>
<td class="nump">$ 781<span></span>
</td>
<td class="num">$ (220,179)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796748256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883612320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Matters<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Matters</a></td>
<td class="text">Legal Matters<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The Company has been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since the Company filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014.  The lawsuit was filed in response to Roxane&#8217;s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;prior to the expiration of certain of the Company&#8217;s patents covering Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, including U.S. Patent No. 8,586,610 (&#8216;610 Patent). In August 2016, the Delaware District Court ruled in the Company&#8217;s favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane&#8217;s ANDA until the expiration of the &#8216;610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court&#8217;s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the&#160;Delaware District Court&#8217;s&#160;ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward&#8217;s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit&#8217;s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, the Company filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants of ANDAs for generic versions of Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;prior to the expiration of the &#8216;610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025.  The Company entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. The parties are scheduled to provide the court with a status report on May 28, 2020 with respect to the remaining lawsuits against the other Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. In April and May 2018, the Company filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants alleging that certain of the Company's patents covering HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (collectively, the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, as described in the ANDAs submitted to </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA by each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants, prior to the expiration of the latest to expire of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents in 2034. Each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Patents are listed in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="font-family:inherit;font-size:10pt;"> (Orange Book). In December 2018, the Company filed amended complaints against each of the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning its Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, April 2019, and May 2019, the Company filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants following the receipt of additional Paragraph IV Letters from each concerning its Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants and are also scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November and December 2019, the Company filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of its Orange Book listed U.S. Patent No. 10,376,487 (&#8216;487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the &#8216;487 Patent is invalid. The Company answered Teva&#8217;s counterclaim by denying their allegation that the &#8216;487 Patent is invalid. In January 2020, the Company filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of its Orange Book-listed U.S. Patent No. 10,449,176 (&#8216;176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the &#8216;176 Patent, which expires in January 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">Defendants and are also scheduled for trial in July 2021.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020 and February 2020, the Company received additional Paragraph IV Letters from MSN concerning the '487 patent and the '176 Patent, respectively, in which MSN alleges that the &#8216;487 and the '176 Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of MSN's generic version of HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> as described in MSN's ANDA. In February and March 2020 the Company filed two additional lawsuits in the Delaware District Court against MSN for infringement of its &#8216;487 Patent and &#8216;176 Patent. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> Defendants and are also scheduled for trial in July 2021. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Matters</span><span style="font-family:inherit;font-size:10pt;">.  In April 2018, the Company submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, the Company amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, the Company submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, the Company did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on the two proposed studies, stating that the Company is required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed the Company that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 5, 2019, the Company filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA&#8217;s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA&#8217;s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until the Company has adequate safety data from a nine-month non-rodent toxicity study. In May 2019, the Company filed an amended complaint, and in July 2019, the Company filed a Motion for Summary Judgment based on its continuing belief after review of the FDA&#8217;s remand response that additional chronic toxicity studies are unjustified, and that it has provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held in December 2019. In January 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on the Company's claims. The Company has elected not to appeal the Court's ruling.  </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a qui tam action filed against the Company was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">alleged that the Company violated these laws through the promotion and marketing of its products Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys&#8217; fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. In March 2020, the DC District Court vacated the scheduled hearing on the Company's motion to dismiss and will notify the parties of a new hearing date if one is deemed necessary by the DC District Court. The Company intends to vigorously defend itself in the case. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, a securities class action, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon v. Vanda Pharmaceuticals Inc.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company&#8217;s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, HETLIOZ</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></span><span style="font-family:inherit;font-size:10pt;">and the Company&#8217;s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. On March 23, 2020, the Company filed a motion to dismiss the complaint. The plaintiff is expected to file its reply by May 7, 2020. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. </span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Samuel Williams vs. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Michael Bavaro v. Mihael Polymeropoulos, et al.</span><span style="font-family:inherit;font-size:10pt;">, was filed in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro </span><span style="font-family:inherit;font-size:10pt;">case to the Eastern District of New York, where the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gordon </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> cases are pending. In March 2020, the Delaware District Court transferred the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro</span><span style="font-family:inherit;font-size:10pt;"> case to the Eastern District of New York, consolidating the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Williams</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bavaro</span><span style="font-family:inherit;font-size:10pt;"> cases, and the plaintiffs filed a consolidated complaint on April 24, 2020. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company&#8217;s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend these lawsuits. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA&#8217;s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. In February 2020, the Company filed an appeal of this judgment with the Court of Justice of the E.U.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885140992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>(Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of March 31, 2020 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active&#160;Markets&#160;for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of December 31, 2019 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in<br/>Active&#160;Markets&#160;for<br/>Identical Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other<br/>Observable&#160;Inputs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893519424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - (Fanapt) - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_StatementScenarioSecondaryAxis=vnda_ScenarioFourMember', window );">November 16,2016 through December 31,2019</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FanaptAbstract', window );"><strong>Fanapt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPayableOnNetSalesPercentage', window );">Royalty payable percentage on net sales</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_FanaptMember', window );">Fanapt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FanaptAbstract', window );"><strong>Fanapt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPayableOnNetSalesPercentage', window );">Royalty payable percentage on net sales</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPeriod', window );">Royalty payment period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_FanaptAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fanapt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_FanaptAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPayableOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPayableOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_StatementScenarioSecondaryAxis=vnda_ScenarioFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_StatementScenarioSecondaryAxis=vnda_ScenarioFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_FanaptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_FanaptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6880948896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Summary of Intangible Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 22,667<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">33,000<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">10,333<span></span>
</td>
<td class="nump">9,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 22,667<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792932320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Purchase Commitments (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod', window );">Agreements for clinical and marketing services, termination notice period</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Purchase Obligation, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2021</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2022</a></td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the remainder of the fiscal year following the latest fiscal year ended. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreements For Clinical And Marketing Services, Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882551376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average expected volatility</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted average expected term (years)</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">5 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free rate</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">2.51%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>vnda331202010q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:vnda="http://www.vandapharmaceuticals.com/20200331"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vnda-20200331.xsd" xlink:type="simple"/>
    <context id="FD2020Q1YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="I2020Q2Apr30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="FI2020Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_FanaptMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vnda:NoncurrentInventoryAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">vnda:NoncurrentInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="FI2020Q1_srt_ProductOrServiceAxis_vnda_FanaptMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2015Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_vnda_FanaptMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:FanaptMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_SalesMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q1Apr2012March2020_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q1Mar2017Mar2020_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:RegulatoryApprovalMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="vnda:StatementScenarioSecondaryAxis">vnda:ScenarioFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2019Q1March2019_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:FutureRegulatoryApprovalAndSalesMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q1Feb1Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:HetliozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2004-02-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_VQW765Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:VQW765Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vnda:CftrActivatorsAndInhibitorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">vnda:DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q1July2018_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vnda:TradipitantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:ServiceOptionAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001347178</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vnda:StockOptionsAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vnda:TwoThousandSixPlanAndTwoThousandSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="Customer">
        <measure>vnda:Customer</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Segment">
        <measure>vnda:Segment</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>vnda:installment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2020Q1YTD"
      id="Fact-DF94991DB43C9033F5ACA3EA1A386533-wk-Fact-DF94991DB43C9033F5ACA3EA1A386533">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2020Q1YTD"
      id="Fact-310E06BF556A8BC3455CA3EA1A3D7457-wk-Fact-310E06BF556A8BC3455CA3EA1A3D7457">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2020Q1YTD"
      id="Fact-46000437BC781EE856C9A3EA1A3B8CDA-wk-Fact-46000437BC781EE856C9A3EA1A3B8CDA">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2020Q1YTD"
      id="Fact-75CDF076E22FA6CBF858A3EA1A39436A-wk-Fact-75CDF076E22FA6CBF858A3EA1A39436A">2020</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2020Q1YTD"
      id="Fact-0DE4695AC94D1F1BCFCCA3EA1A3A8EE1-wk-Fact-0DE4695AC94D1F1BCFCCA3EA1A3A8EE1">0001347178</dei:EntityCentralIndexKey>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="Fact-3F7B774A03B63EFC9065A3EA1A017354-wk-Fact-3F7B774A03B63EFC9065A3EA1A017354"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-C3E5043AC6CDFABBDAABA3EA1A049BB8-wk-Fact-C3E5043AC6CDFABBDAABA3EA1A049BB8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-41347909997BD91B2CA4A3EA1A07D800-wk-Fact-41347909997BD91B2CA4A3EA1A07D800"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-CD9C74E954D9973C72ADA3EA19FFD442-wk-Fact-CD9C74E954D9973C72ADA3EA19FFD442"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-913BEA859641E55F3E64A3EA1A02D5A1-wk-Fact-913BEA859641E55F3E64A3EA1A02D5A1"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-39545F43F790BBF0B90BA3EA1A031FEB-wk-Fact-39545F43F790BBF0B90BA3EA1A031FEB"
      unitRef="shares">53549612</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-CBFEC17C0432DB9E7C15A3EA1A00D158-wk-Fact-CBFEC17C0432DB9E7C15A3EA1A00D158"
      unitRef="shares">54132336</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-817C990DE84F7E6D9124A3EA1A01709B-wk-Fact-817C990DE84F7E6D9124A3EA1A01709B"
      unitRef="shares">53549612</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-77BDDCF88804655BC0CAA3EA19FE8564-wk-Fact-77BDDCF88804655BC0CAA3EA19FE8564"
      unitRef="shares">54132336</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_FanaptMember"
      decimals="-5"
      id="Fact-6D68E75717AA59D91F09A3EA1A0127B5-wk-Fact-6D68E75717AA59D91F09A3EA1A0127B5"
      unitRef="usd">27900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-E7B487579B20F8B6672DA3EA19FEAB0C-wk-Fact-E7B487579B20F8B6672DA3EA19FEAB0C"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-53C9099F1309DFA9D3DFA3EA1A007F74-wk-Fact-53C9099F1309DFA9D3DFA3EA1A007F74"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-0C87E675D4AEF6F884C0A3EA1A0AB7AD-wk-Fact-0C87E675D4AEF6F884C0A3EA1A0AB7AD"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-434953ECF09358C770EAA3EA1A059D47-wk-Fact-434953ECF09358C770EAA3EA1A059D47"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-D1E1C7747409D3B968D1A3EA1A0928C4-wk-Fact-D1E1C7747409D3B968D1A3EA1A0928C4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-8A16133D9A4B1597F2D3A3EA1A019AFE-wk-Fact-8A16133D9A4B1597F2D3A3EA1A019AFE"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-CF2874BD32DBC1C456C8A3EA19FD5442-wk-Fact-CF2874BD32DBC1C456C8A3EA19FD5442"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2020Q1"
      decimals="INF"
      id="Fact-9115BA664A6B2E0F390BA3EA1A015A99-wk-Fact-9115BA664A6B2E0F390BA3EA1A015A99"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2019Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="INF"
      id="Fact-0BF7CE577C300C268B17A3EA1A185DE9-wk-Fact-0BF7CE577C300C268B17A3EA1A185DE9"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <dei:DocumentType
      contextRef="FD2020Q1YTD"
      id="d6355e368-wk-Fact-48D5B06D341FC0BEE34BA3EA19F408B3">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2020Q1YTD"
      id="d6355e402-wk-Fact-18635621C2F1A8188D4CA3EA1A3D86A9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2020Q1YTD"
      id="d6355e412-wk-Fact-4099032E2E2CAC202B7BA3EA1A372CC1">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2020Q1YTD"
      id="d6355e434-wk-Fact-A2BD001CA71390123FB8A3EA19FBC0C0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2020Q1YTD"
      id="d6355e455-wk-Fact-BA4ABF3F27315C94B6A6A3EA1A3A9C8E">001-34186</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2020Q1YTD"
      id="d6355e476-wk-Fact-831276FEC64142296144A3EA1A366BE9">VANDA PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2020Q1YTD"
      id="d6355e510-wk-Fact-9E82DF2E30A6B2CEBBA2A3EA1A0A8D75">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2020Q1YTD"
      id="d6355e520-wk-Fact-F6BDE2A34EF6AAD47B7FA3EA1A0B0E6A">03-0491827</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2020Q1YTD"
      id="d6355e546-wk-Fact-E851B2F9FAE13D93356BA3EA1A0D4D0E">2200 Pennsylvania Avenue NW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="FD2020Q1YTD"
      id="d6355e551-wk-Fact-DFC49C06A6269ED49AF3A3EA19F20E65">Suite 300 E </dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="FD2020Q1YTD"
      id="d6355e557-wk-Fact-BEDB7135DA29D303BB11A3EA1A38F7E0">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2020Q1YTD"
      id="d6355e562-wk-Fact-D7D6CAF89614D753761BA3EA1A358289">DC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2020Q1YTD"
      id="d6355e567-wk-Fact-99D33C4995F122D563E6A3EA1A293E1D">20037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2020Q1YTD"
      id="d6355e575-wk-Fact-CA13162507809056726DA3EA19EEFDA7">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2020Q1YTD"
      id="d6355e580-wk-Fact-BD8D28238947CFE87B97A3EA1A32B3F9">734-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2020Q1YTD"
      id="d6355e633-wk-Fact-AA83CC2BB5A56A82E82CA3EA1A38CB6C">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2020Q1YTD"
      id="d6355e638-wk-Fact-305C92A940A1769AE245A3EA1A381279">VNDA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2020Q1YTD"
      id="d6355e643-wk-Fact-08F211992DE4F8212625A3EA1A370F7E">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2020Q1YTD"
      id="d6355e650-wk-Fact-DB163F990645DBAD318FA3EA19EFEF55">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2020Q1YTD"
      id="d6355e665-wk-Fact-8F630ADD012022CBD1E3A3EA1A36642A">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2020Q1YTD"
      id="d6355e701-wk-Fact-30C5347BE6EF737C4ACAA3EA1A2C4540">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2020Q1YTD"
      id="d6355e803-wk-Fact-09B582D81522E2E67803A3EA1A2D53C1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2020Q1YTD"
      id="d6355e875-wk-Fact-5AA34741C3D1281B2436A3EA1A364BC0">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2020Q1YTD"
      id="d6355e887-wk-Fact-C40867033B6C1B37660AA3EA1A3FFF4F">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q2Apr30"
      decimals="INF"
      id="d6355e903-wk-Fact-59AC751C306D558085D4A3EA1A19C379"
      unitRef="shares">54550461</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e491-wk-Fact-4228AC9E19BF97A38573A3EA1A2B0B37"
      unitRef="usd">64950000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e510-wk-Fact-8E2D08A95D585801AF2FA3EA1A241F60"
      unitRef="usd">45072000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e525-wk-Fact-F1BA8FAED271957B1943A3EA1A208C5B"
      unitRef="usd">247376000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e544-wk-Fact-9143B7175A0BBCF10587A3EA1A30FCFC"
      unitRef="usd">267057000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e564-wk-Fact-B06BDF39FEDD9D08BA3DA3EA1A267A5B"
      unitRef="usd">29272000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e583-wk-Fact-D62B9F60CC251E01E6A6A3EA1A2F309B"
      unitRef="usd">26367000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e603-wk-Fact-E5FF2D4D3DC41E7CEBFFA3EA1A27D432"
      unitRef="usd">1320000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e622-wk-Fact-7C2C530DB3097BE332E1A3EA1A30AED6"
      unitRef="usd">1140000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e642-wk-Fact-22C497826033D82C7E61A3EA1A1EDB67"
      unitRef="usd">17828000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e661-wk-Fact-21010E0DEC1FA14F5EDDA3EA1A32ADF1"
      unitRef="usd">14500000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e681-wk-Fact-EFDF5F23764CBAC41363A3EA1A27D157"
      unitRef="usd">360746000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e700-wk-Fact-E7E5B8B6EBECFDAFAA6EA3EA1A296F9F"
      unitRef="usd">354136000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e720-wk-Fact-F3B7EA1AFAC40B855332A3EA1A316E0B"
      unitRef="usd">3877000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e739-wk-Fact-7244D41ACE337ABA4D99A3EA1A31916A"
      unitRef="usd">3864000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e759-wk-Fact-7BEDF3B0A4F56400BBF0A3EA1A2FC12A"
      unitRef="usd">10875000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e778-wk-Fact-0A9A2E66C008C0AF7E17A3EA1A3358D9"
      unitRef="usd">11180000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e799-wk-Fact-DFB14DBF6F0A2D953F54A3EA1A33CBEE"
      unitRef="usd">22667000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e818-wk-Fact-956CD90D4D56AEB4918FA3EA1A2A6BB1"
      unitRef="usd">23037000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e838-wk-Fact-02F1F5D4C3B25D741762A3EA1A29BE38"
      unitRef="usd">86641000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e857-wk-Fact-15C40C64874549314A7CA3EA1A1DCE6E"
      unitRef="usd">87680000</us-gaap:DeferredIncomeTaxAssetsNet>
    <vnda:InventoryAndOtherNonCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e877-wk-Fact-76D21FC534D96850055BA3EA1A1DB3B6"
      unitRef="usd">3719000</vnda:InventoryAndOtherNonCurrent>
    <vnda:InventoryAndOtherNonCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e896-wk-Fact-FAFDE562E44A619F3892A3EA1A29E891"
      unitRef="usd">3851000</vnda:InventoryAndOtherNonCurrent>
    <us-gaap:Assets
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e921-wk-Fact-1AF15008BB721FEA9251A3EA1A234BDF"
      unitRef="usd">488525000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e940-wk-Fact-5512FA690C0E994A8EC0A3EA1A2E8A08"
      unitRef="usd">483748000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1042-wk-Fact-1B412832705ADE87477EA3EA1A2FE88C"
      unitRef="usd">26045000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1061-wk-Fact-469A7B7FB4E36FA99A83A3EA1A1EA055"
      unitRef="usd">27590000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <vnda:ProductRevenueAllowancesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1076-wk-Fact-7520C137D0690C03213DA3EA1A1F4F7E"
      unitRef="usd">33177000</vnda:ProductRevenueAllowancesCurrent>
    <vnda:ProductRevenueAllowancesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1095-wk-Fact-11D9EA390DF7FDF1B2D8A3EA1A2F1276"
      unitRef="usd">31915000</vnda:ProductRevenueAllowancesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1115-wk-Fact-511C136BBA26AD45ED19A3EA1A1CEB0D"
      unitRef="usd">59222000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1134-wk-Fact-804644B7A23B7310AD21A3EA1A2C4575"
      unitRef="usd">59505000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1154-wk-Fact-CD30A214B5DF969ABCC3A3EA1A2B16C7"
      unitRef="usd">12139000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1173-wk-Fact-CFF5337B5F2767ED247FA3EA1A259AA2"
      unitRef="usd">12455000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1193-wk-Fact-9533E1F4DB68767201DAA3EA1A21C932"
      unitRef="usd">778000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1212-wk-Fact-ED509968E6AB001E378EA3EA1A2C290B"
      unitRef="usd">843000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1233-wk-Fact-52024AFF9DE5B59642D5A3EA1A260F47"
      unitRef="usd">72139000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1252-wk-Fact-30916798DA94BF8C39FEA3EA1A201C4A"
      unitRef="usd">72803000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2020Q1"
      id="d8383e1272-wk-Fact-9D303604F7526C0D1BD0A3EA1A1CD63C"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d8383e1291-wk-Fact-158B81F43C83C82BD1D8A3EA1A2A34B2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1352-wk-Fact-678960C448803D75E3A2A3EA1A216E98"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1371-wk-Fact-7BCF1BEC7AD593D45608A3EA1A246CC6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1391-wk-Fact-A76805292372A160B447A3EA1A28B218"
      unitRef="usd">54000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1410-wk-Fact-94CAF70212322162D138A3EA1A223DF8"
      unitRef="usd">54000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1430-wk-Fact-23E1637362CFCD0AD710A3EA1A3041DA"
      unitRef="usd">635730000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1449-wk-Fact-C9D5AF3142285B4BCE56A3EA1A22EF37"
      unitRef="usd">631307000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1469-wk-Fact-8CF55ACDEE4088629324A3EA1A265B32"
      unitRef="usd">781000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1488-wk-Fact-3EF41A751627B000C675A3EA1A2413D3"
      unitRef="usd">249000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1508-wk-Fact-5AEA32F2EE5415A827E9A3EA1A2C7766"
      unitRef="usd">-220179000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1528-wk-Fact-88C099E1C13ABE4C944EA3EA1A1FCC8C"
      unitRef="usd">-220665000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1549-wk-Fact-83A230F9E60CB342F6D8A3EA1A2B6CD0"
      unitRef="usd">416386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1568-wk-Fact-4DA19984309DAB17A8CBA3EA1A1DBC32"
      unitRef="usd">410945000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8383e1593-wk-Fact-D200FBF649A8AECDD723A3EA1A242C93"
      unitRef="usd">488525000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8383e1612-wk-Fact-5852E0B8134E94AD2192A3EA1A2DC785"
      unitRef="usd">483748000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e490-wk-Fact-48A15EB70D764791142CA3EA1A1F7848"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e509-wk-Fact-F9383CA5E946C3635BA1A3EA1A17C792"
      unitRef="usd">47713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e524-wk-Fact-C34AD2BD4963A5C3CC5CA3EA1A18651D"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e543-wk-Fact-85D2ADFDDC6EC99D2712A3EA1A177C53"
      unitRef="usd">47713000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e604-wk-Fact-23AFA8996003643C036AA3EA1A16B253"
      unitRef="usd">5207000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e623-wk-Fact-AFA212BEC3B152DAE8F5A3EA1A170383"
      unitRef="usd">5113000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e643-wk-Fact-90119094ECE04BA93F9AA3EA1A1DC275"
      unitRef="usd">15527000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e662-wk-Fact-3E92294BCEB69FF1F6C2A3EA1A1E9A01"
      unitRef="usd">13278000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e682-wk-Fact-4690F2F35C2FF5BD4581A3EA1A223530"
      unitRef="usd">37021000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e701-wk-Fact-55FE6034FDEF2208C2FDA3EA1A22FD76"
      unitRef="usd">31029000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e721-wk-Fact-5ED0E1074A1989F6D77FA3EA1A1D01C7"
      unitRef="usd">370000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e740-wk-Fact-CD02064756DA0ECE870BA3EA1A1FBA68"
      unitRef="usd">380000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e760-wk-Fact-DB8FA31F99890413DFA7A3EA1A1A2B72"
      unitRef="usd">58125000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e779-wk-Fact-0F24100F73D3C42098D7A3EA1A1675BF"
      unitRef="usd">49800000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e800-wk-Fact-B2B07A4302A4A7EF417BA3EA1A1BA612"
      unitRef="usd">-125000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e820-wk-Fact-5FC4797256DEB4A27C20A3EA1A1EE374"
      unitRef="usd">-2087000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherIncome
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e841-wk-Fact-4BA70488227BD7A22592A3EA1A210299"
      unitRef="usd">1366000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e860-wk-Fact-E813B5D43264C166CDFAA3EA1A1A5D4D"
      unitRef="usd">1485000</us-gaap:OtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e880-wk-Fact-51AFD070F52B6443A323A3EA1A1A70B0"
      unitRef="usd">1241000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e899-wk-Fact-22B76CD143EC5C5DA78DA3EA1A18A2ED"
      unitRef="usd">-602000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e920-wk-Fact-C2FD22ABAA83876770D6A3EA1A19A65E"
      unitRef="usd">755000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e939-wk-Fact-5345D17DC7A21A0E6FE1A3EA1A219C43"
      unitRef="usd">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7443e964-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734"
      unitRef="usd">486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7443e983-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8"
      unitRef="usd">-612000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d7443e1045-wk-Fact-DB56EAA2B2E84199C268A3EA1A15480C"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d7443e1064-wk-Fact-69AA522C761FDD2E53F9A3EA1A157FF6"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d7443e1085-wk-Fact-EC58C28E514512EF12DBA3EA1A22D909"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d7443e1104-wk-Fact-4B0A6AF5514CED92404CA3EA1A20F671"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d7443e1161-wk-Fact-B2E6B312D839F80D888CA3EA1A1B571D"
      unitRef="shares">53806317</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d7443e1180-wk-Fact-B7D1F0FAAF7A9D852EC7A3EA1A1EBD64"
      unitRef="shares">52752774</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d7443e1200-wk-Fact-5BB133E9BFC696DB03CEA3EA1A230D7B"
      unitRef="shares">54870146</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d7443e1219-wk-Fact-9276896B58A7C4180CE3A3EA1A1614BE"
      unitRef="shares">52752774</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7266e449-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734"
      unitRef="usd">486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7266e468-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8"
      unitRef="usd">-612000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7266e525-wk-Fact-480E4E9C7B3927674E40A3EA1A0E0646"
      unitRef="usd">-13000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7266e545-wk-Fact-ECF89EE3E5D433F7E098A3EA1A08E194"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7266e566-wk-Fact-3124E2B3AEF18936C522A3EA1A04F203"
      unitRef="usd">705000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7266e585-wk-Fact-0D8F5697B56F0AF1403FA3EA1A0E3791"
      unitRef="usd">138000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7266e605-wk-Fact-B84E7C74A0182EB5F567A3EA1A0CD62D"
      unitRef="usd">160000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7266e625-wk-Fact-905FDD7D49A9CED5BAE6A3EA1A030008"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7266e645-wk-Fact-E633AC2B2373F67CDFFCA3EA1A0B9598"
      unitRef="usd">532000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7266e664-wk-Fact-147629AB8F1E38B7D0D1A3EA1A033657"
      unitRef="usd">134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7266e689-wk-Fact-0D6F80C2769B59FE7E65A3EA1A08A8E4"
      unitRef="usd">1018000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7266e708-wk-Fact-3918AD663CFBFC0B2050A3EA1A04828F"
      unitRef="usd">-478000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8411e626-wk-Fact-04DFD4F90A11833E3999A3EA1A2026DE"
      unitRef="shares">53549612</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8411e645-wk-Fact-42F26B36160364947D85A3EA1A2281AB"
      unitRef="usd">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e664-wk-Fact-B8A5D2868804553E2D6CA3EA1A29E50F"
      unitRef="usd">631307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8411e684-wk-Fact-963206457842DAF7C999A3EA1A285C3C"
      unitRef="usd">249000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8411e703-wk-Fact-BD8C1A85E8389678C737A3EA1A1F9B23"
      unitRef="usd">-220665000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8411e723-wk-Fact-4DA19984309DAB17A8CBA3EA1A1DBC32"
      unitRef="usd">410945000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8411e739-wk-Fact-D14A0AF58BBC7694D150A3EA1A22E30F"
      unitRef="shares">582724</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8411e753-wk-Fact-0A885A368F3A2B4B9A25A3EA1A38AB55"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e772-wk-Fact-E2BBC975AFBED9CC093AA3EA1A1E6EBB"
      unitRef="usd">479000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8411e830-wk-Fact-D727CED6A6B766BCA10FA3EA1A2D6DEC"
      unitRef="usd">479000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e884-wk-Fact-EA3071DC2B7C4BDE1C58A3EA1A21F0B8"
      unitRef="usd">3944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8411e942-wk-Fact-68ADF435A62EB567E288A3EA1A2D4EB0"
      unitRef="usd">3944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8411e1035-wk-Fact-F79CCFE6A973F8703A1BA3EA1A20A220"
      unitRef="usd">486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8411e1054-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734"
      unitRef="usd">486000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8411e1128-wk-Fact-0A5035C0C5A91CF8C46FA3EA1A3330EE"
      unitRef="usd">532000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8411e1166-wk-Fact-E633AC2B2373F67CDFFCA3EA1A0B9598"
      unitRef="usd">532000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8411e1187-wk-Fact-6D26FA1FB0EB9CA761CCA3EA1A26931C"
      unitRef="shares">54132336</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8411e1201-wk-Fact-FBC9588CEBD7C086DA31A3EA1A1CA383"
      unitRef="usd">54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e1220-wk-Fact-1D9ED48F9EE152094E3CA3EA1A26EF08"
      unitRef="usd">635730000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8411e1240-wk-Fact-B3B4618A971E6F3D5797A3EA1A25BC6C"
      unitRef="usd">781000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8411e1259-wk-Fact-52F2B1262C9C7012B1C1A3EA1A273FF5"
      unitRef="usd">-220179000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8411e1279-wk-Fact-83A230F9E60CB342F6D8A3EA1A2B6CD0"
      unitRef="usd">416386000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8411e1567-wk-Fact-2003B9285769ECE55D8DA3EA1A3276E6"
      unitRef="shares">52477593</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8411e1586-wk-Fact-FE3F4731DFEF6F667F4AA3EA1A3B2D2D"
      unitRef="usd">52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e1605-wk-Fact-1372045FCCDCD671305AA3EA1A37CED8"
      unitRef="usd">611587000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8411e1625-wk-Fact-DAADBBC18E747567154EA3EA1A362360"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8411e1644-wk-Fact-9DFD930F605D7A36C7F2A3EA1A3A0CD6"
      unitRef="usd">-336218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d8411e1664-wk-Fact-08DE27984B0477BFEB2CA3EA1A35CB51"
      unitRef="usd">275422000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8411e1680-wk-Fact-B936A3119C67C11A791CA3EA1A30F32F"
      unitRef="shares">485083</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8411e1694-wk-Fact-6BDE0DBEED63DCE26939A3EA1A3BD39C"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e1713-wk-Fact-684D8D13789E2E75BAD6A3EA1A351238"
      unitRef="usd">178000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8411e1771-wk-Fact-523ED0FEAFB084A013ACA3EA1A3DCD45"
      unitRef="usd">179000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e1825-wk-Fact-E9D3C5364E76A69ED36EA3EA1A3B6490"
      unitRef="usd">3282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8411e1883-wk-Fact-F8CE57A009E657123877A3EA1A3CFC04"
      unitRef="usd">3282000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8411e1976-wk-Fact-662AB9936A7975EBB21DA3EA1A39680D"
      unitRef="usd">-612000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8411e1996-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8"
      unitRef="usd">-612000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8411e2071-wk-Fact-826CEBFA7B975790F014A3EA1A39BD79"
      unitRef="usd">134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8411e2109-wk-Fact-147629AB8F1E38B7D0D1A3EA1A033657"
      unitRef="usd">134000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d8411e2130-wk-Fact-D9D5D74A9072D0E582ECA3EA1A3B61C4"
      unitRef="shares">52962676</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d8411e2144-wk-Fact-16C5990928AE9B1491E6A3EA1A36951E"
      unitRef="usd">53000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d8411e2163-wk-Fact-16862802FFD8FF9429AFA3EA1A320989"
      unitRef="usd">615047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d8411e2183-wk-Fact-D13EF8FF234542946B21A3EA1A380AF8"
      unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d8411e2202-wk-Fact-3F61A484462E7A68E229A3EA1A39385C"
      unitRef="usd">-336830000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8411e2222-wk-Fact-E9205C029ABD494CE750A3EA1A37D593"
      unitRef="usd">278405000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e489-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734"
      unitRef="usd">486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e508-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8"
      unitRef="usd">-612000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e565-wk-Fact-F9376F913FD20E2C9167A3EA1A2FB80D"
      unitRef="usd">351000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e584-wk-Fact-CA469E78FC91537D4F6DA3EA1A35892C"
      unitRef="usd">332000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e604-wk-Fact-5274B1A9C69197A6EA20A3EA1A2ECDFF"
      unitRef="usd">3944000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e623-wk-Fact-2E237962A71A6C602A60A3EA1A28F981"
      unitRef="usd">3282000</us-gaap:ShareBasedCompensation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e643-wk-Fact-EC3B34476B945885FC5EA3EA1A3CC9BF"
      unitRef="usd">287000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e663-wk-Fact-C731D879BDA83891EE38A3EA1A2BA78D"
      unitRef="usd">906000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e684-wk-Fact-5ED0E1074A1989F6D77FA3EA1A1D01C7"
      unitRef="usd">370000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e703-wk-Fact-CD02064756DA0ECE870BA3EA1A1FBA68"
      unitRef="usd">380000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e723-wk-Fact-FD9CC5F7095BF1279568A3EA1A2BB0CD"
      unitRef="usd">879000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e742-wk-Fact-67EBDA6B27DC40D156F8A3EA1A33C441"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e762-wk-Fact-EC91F8B7BD3CFFE067EBA3EA1A27DBE0"
      unitRef="usd">-314000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e781-wk-Fact-C0079F83C8240480E980A3EA1A328005"
      unitRef="usd">-317000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e843-wk-Fact-E5D84925FC4E46807BF6A3EA1A2B1040"
      unitRef="usd">2905000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e863-wk-Fact-8AAA0056F323B800AC89A3EA1A2C70E1"
      unitRef="usd">-2434000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e883-wk-Fact-5FE929F5B951F6E1FCBBA3EA1A3017CC"
      unitRef="usd">3524000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e903-wk-Fact-11A1FB0E7B42DC459B96A3EA1A23F4D2"
      unitRef="usd">-247000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e923-wk-Fact-077819D3AD0A968784FDA3EA1A323031"
      unitRef="usd">-76000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e942-wk-Fact-97939A1632999D1B4B1EA3EA1A357BD1"
      unitRef="usd">44000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e963-wk-Fact-AD2C1ACDA36BB310A396A3EA1A2F18F1"
      unitRef="usd">-1795000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e983-wk-Fact-CC988CABC907405719B2A3EA1A312B7F"
      unitRef="usd">3507000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <vnda:IncreaseDecreaseProductRevenueAllowances
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1003-wk-Fact-4D637904F3AAA7C3B633A3EA1A2BAF5E"
      unitRef="usd">1184000</vnda:IncreaseDecreaseProductRevenueAllowances>
    <vnda:IncreaseDecreaseProductRevenueAllowances
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1022-wk-Fact-42F45213130D59B56196A3EA1A325511"
      unitRef="usd">706000</vnda:IncreaseDecreaseProductRevenueAllowances>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1042-wk-Fact-2491660D6B43EE8DA13DA3EA1A2C7016"
      unitRef="usd">-907000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1062-wk-Fact-F6443A1127F73A4CDE69A3EA1A2DC575"
      unitRef="usd">9643000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1123-wk-Fact-DAF2AE0088226C64E3EDA3EA1A2EBD01"
      unitRef="usd">373000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1143-wk-Fact-B00F30E20F1FA743F635A3EA1A2A4038"
      unitRef="usd">393000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1164-wk-Fact-D7FA4EC681A1AB4B420CA3EA1A308EC8"
      unitRef="usd">41400000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1184-wk-Fact-F9D4884444784AD5B820A3EA1A348FB7"
      unitRef="usd">100803000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1205-wk-Fact-06959C19FCF79B376B6BA3EA1A2E3CCC"
      unitRef="usd">62073000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1224-wk-Fact-28B9C34B9CA183F714C1A3EA1A2A9F5D"
      unitRef="usd">64745000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1245-wk-Fact-D8C5C9A00C723D5DA3F1A3EA1A2D1381"
      unitRef="usd">20300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1264-wk-Fact-2F978B7579AE257BE649A3EA1A25E692"
      unitRef="usd">-36451000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1326-wk-Fact-1EF6EF0BB6A1F2BB8110A3EA1A33D833"
      unitRef="usd">479000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1345-wk-Fact-2EFB5B5B7A238D13EAF8A3EA1A31990D"
      unitRef="usd">179000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1365-wk-Fact-6A55CBEAD54B67524815A3EA1A31775F"
      unitRef="usd">479000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1384-wk-Fact-3AC7D5D9AC610B10B6D3A3EA1A314CB4"
      unitRef="usd">179000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1404-wk-Fact-8DA87EFA96297CDF0F6BA3EA1A2BCADF"
      unitRef="usd">5000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1423-wk-Fact-7CFD4686CF584E5DD5F3A3EA1A2EEB8E"
      unitRef="usd">2000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d8387e1443-wk-Fact-EDE38E19A714800EAF2EA3EA1A23330F"
      unitRef="usd">19877000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d8387e1462-wk-Fact-4F548C6B67A01B12480CA3EA1A277093"
      unitRef="usd">-26627000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-3"
      id="d8387e1524-wk-Fact-E4E1780F7B6CD43E418CA3EA1A36009B"
      unitRef="usd">45650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d8387e1543-wk-Fact-25F773D7314E39733EA1A3EA1A23D2CF"
      unitRef="usd">61749000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-3"
      id="d8387e1568-wk-Fact-09920F22E2D171F61078A3EA1A3BB38E"
      unitRef="usd">65527000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q1"
      decimals="-3"
      id="d8387e1587-wk-Fact-3332953422FBE70E7CB7A3EA1A2BC287"
      unitRef="usd">35122000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F93341E4D44A831AE1AFA3EA1A4A014A-0-wk-Fact-4C9021DD594B985F372AA3EA1A3356BC">Business Organization and Presentation&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Business organization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vanda Pharmaceuticals Inc. (the Company) &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; The Company commenced its operations in 2003 and operates in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reporting segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span&gt;The Company&#x2019;s commercial portfolio is currently comprised of two products, HETLIOZ&lt;/span&gt;&lt;span&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span&gt; for the treatment of Non-24 Hour Sleep-Wake Disorder (Non-24) and Fanapt&lt;/span&gt;&lt;span&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span&gt; for the treatment of schizophrenia. HETLIOZ&lt;/span&gt;&lt;span&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span&gt; is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:6pt;"&gt;&lt;span style="font-family:inherit;font-size:6pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span&gt;HETLIOZ&lt;/span&gt;&lt;span&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span&gt;&#160;(tasimelteon) for the treatment of jet lag disorder (JLD), Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span&gt;Fanapt&lt;/span&gt;&lt;span&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span&gt;&#160;(iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, motion sickness and COVID-19 Acute Respiratory Distress Syndrome (ARDS);&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#x2019;s consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (Annual Report) for the fiscal year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The financial information as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt; was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company&#x2019;s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d8394e350-wk-Fact-AC01E1FD07BC209F070FA3EA1A3B1A48"
      unitRef="Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-A2DB99865A4D5F9544EEA3EA1A4A2042-0-wk-Fact-DFB3B7BEAF5B41D7E8C7A3EA1A2935B3">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#x2019;s consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (Annual Report) for the fiscal year ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The financial information as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company&#x2019;s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period. &lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F5040665F35EF2C8E189A3EA1A4A5981-0-wk-Fact-9AB87185374FA7CA85CCA3EA1A04003D">Summary of Significant Accounting Policies&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There have been no material changes to the significant accounting policies previously disclosed in the Annual Report. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#x2019;s evaluation could change. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#x2019;s Washington, D.C. headquarters.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64,950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,379&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-current inventory and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;577&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue from Net Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s net product sales consist of sales of HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Net sales by product for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;product sales, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,957&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;product sales, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,713&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; major customers that each accounted for more than 10% of total revenues and, as a group, represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total revenues for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; major customers that each accounted for more than 10% of accounts receivable and, as a group, represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;94%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total accounts receivable at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12,&#160;Income Taxes (Topic 740), &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;which clarifies and simplifies certain aspects of the accounting for income taxes.&#160;The standard is effective&#160;for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which changes the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#x201c;expected loss&#x201d; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's condensed consolidated financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="FD2020Q1YTD"
      id="TextSelection-EB720926A199D22A5DE8A3EA1A4AB164-0-wk-Fact-15B33A1AF9B956D3BEEFA3EA1A03D19B">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#x2019;s evaluation could change. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="FD2020Q1YTD"
      id="TextSelection-5D9004DE442FBDA3F5BFA3EA1A4A6D89-0-wk-Fact-2109A061E861F5AC01F9A3EA1A06DEB2">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#x2019;s Washington, D.C. headquarters.&#160;&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-3B64B1D65E98FDDFDB05A3EA1A4A6998-0-wk-Fact-9C5341609B9BC66EB825A3EA1A068636">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statement of Cash Flows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;64,950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34,379&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Restricted cash included in: &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-current inventory and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;577&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;65,527&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2020Q1"
      decimals="-3"
      id="d7280e447-wk-Fact-4228AC9E19BF97A38573A3EA1A2B0B37"
      unitRef="usd">64950000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q1"
      decimals="-3"
      id="d7280e466-wk-Fact-68003F3A286586DC2AA0A3EA1A16C36F"
      unitRef="usd">34379000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"
      decimals="-3"
      id="d7280e522-wk-Fact-3065F75DDF9B65DF646CA3EA1A129977"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"
      decimals="-3"
      id="d7280e541-wk-Fact-111B7B703AD56B24D975A3EA1A12883B"
      unitRef="usd">157000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember"
      decimals="-3"
      id="d7280e561-wk-Fact-A69E303F6AF75927EBF4A3EA1A13570C"
      unitRef="usd">577000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="FI2019Q1_us-gaap_BalanceSheetLocationAxis_vnda_NoncurrentInventoryAndOtherMember"
      decimals="-3"
      id="d7280e580-wk-Fact-554D990EAFBCEA0BC9D1A3EA1A12DC32"
      unitRef="usd">586000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2020Q1"
      decimals="-3"
      id="d7280e605-wk-Fact-09920F22E2D171F61078A3EA1A3BB38E"
      unitRef="usd">65527000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q1"
      decimals="-3"
      id="d7280e624-wk-Fact-3332953422FBE70E7CB7A3EA1A2BC287"
      unitRef="usd">35122000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-7FD0252DF79FB2A846ECA3EA1A4A7CB2-0-wk-Fact-94C807D45D8F48DC3979A3EA1A04A4AF">&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s net product sales consist of sales of HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Net sales by product for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;product sales, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;35,336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,957&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;product sales, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18,756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total net product sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;47,713&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d7280e791-wk-Fact-C9C5B09CF31130CF06CAA3EA1A3A7398"
      unitRef="usd">35336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d7280e810-wk-Fact-457217D8F47ACEB74FCAA3EA1A33E3B8"
      unitRef="usd">28957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember"
      decimals="-3"
      id="d7280e829-wk-Fact-B1E33774BE8A2DCEB3B8A3EA1A39F7A5"
      unitRef="usd">22664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_vnda_FanaptMember"
      decimals="-3"
      id="d7280e848-wk-Fact-E6108D3A241ABD58ACC3A3EA1A39C929"
      unitRef="usd">18756000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d7280e873-wk-Fact-48A15EB70D764791142CA3EA1A1F7848"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d7280e892-wk-Fact-F9383CA5E946C3635BA1A3EA1A17C792"
      unitRef="usd">47713000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:MajorCustomersPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-53016270A3A3ADB0A10CA3EA1A4AF5A2-0-wk-Fact-983809A495617CF945E3A3EA1A04C933">&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; major customers that each accounted for more than 10% of total revenues and, as a group, represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;96%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total revenues for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; major customers that each accounted for more than 10% of accounts receivable and, as a group, represented &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;94%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of total accounts receivable at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:MajorCustomersPolicyPolicyTextBlock>
    <vnda:NumberOfMajorCustomersAccountedForRevenue
      contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d7280e924-wk-Fact-DA9DADB073FE6AF7D778A3EA1A0753BE"
      unitRef="Customer">5</vnda:NumberOfMajorCustomersAccountedForRevenue>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d7280e928-wk-Fact-FB67E16B7F3363E7488FA3EA1A029B8D"
      unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
    <vnda:NumberOfMajorCustomersAccountedForTradeAccountsReceivable
      contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="INF"
      id="d7280e941-wk-Fact-F31B8466DF3A14D04E6DA3EA1A0761AF"
      unitRef="Customer">5</vnda:NumberOfMajorCustomersAccountedForTradeAccountsReceivable>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember"
      decimals="2"
      id="d7280e945-wk-Fact-618B68FB70D819C6788EA3EA1A059812"
      unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-E19E13664F3B92D34E08A3EA1A4A7345-0-wk-Fact-A853532356E7569EADD0A3EA1A068025">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12,&#160;Income Taxes (Topic 740), &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;,&#160;which clarifies and simplifies certain aspects of the accounting for income taxes.&#160;The standard is effective&#160;for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#x2019;s condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which changes the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#x201c;expected loss&#x201d; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's condensed consolidated financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-D3702DBD6402A2234BC7A3EA1A4B26A0-0-wk-Fact-A579F2D8328BEC1D0358A3EA1A361B6F">Marketable Securities&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which all have contractual maturities of less than two years:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;246,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;247,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which all have contractual maturities of less than two years:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;266,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;267,057&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F4497B6CBB59184FDC7AA3EA1A4B834A-0-wk-Fact-E0BFB9DAAB1E12FAFA23A3EA1A368970">&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which all have contractual maturities of less than two years:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;122,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;246,364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(174&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;247,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which all have contractual maturities of less than two years:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Market&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;129,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;130,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total marketable securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;266,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;267,057&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e574-wk-Fact-CE62B48256D0409F63D1A3EA19F845B5"
      unitRef="usd">87014000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e593-wk-Fact-FD8E51D42F367B947DB1A3EA19F25485"
      unitRef="usd">558000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e612-wk-Fact-6232FF856B4297755107A3EA19FC9B80"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e632-wk-Fact-87A99025B665A49C7D11A3EA1A00A9E1"
      unitRef="usd">87572000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e647-wk-Fact-1F03C14D2FCDD33EF896A3EA1A02BBC0"
      unitRef="usd">122964000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e666-wk-Fact-7387FA60783F5D35E0BAA3EA19FA7A29"
      unitRef="usd">572000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e685-wk-Fact-B0253641728D94AE84BFA3EA1A2AD73E"
      unitRef="usd">110000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e706-wk-Fact-DF9E0C1F13F77BF53C2BA3EA1A2A43E0"
      unitRef="usd">123426000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e726-wk-Fact-E545CCAEADC047F90BECA3EA19FB2423"
      unitRef="usd">36386000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e745-wk-Fact-B63319798AFE0850217AA3EA19F506B9"
      unitRef="usd">56000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e764-wk-Fact-496EEA0858DED37297D6A3EA19F95D4A"
      unitRef="usd">64000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e785-wk-Fact-E1E662FBE5CBC5D9A89BA3EA19F14E89"
      unitRef="usd">36378000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e810-wk-Fact-FB8938FE7D67F0445F9DA3EA19FF0F14"
      unitRef="usd">246364000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e829-wk-Fact-8650D9AC7DF3740CD964A3EA19F2E2A3"
      unitRef="usd">1186000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e848-wk-Fact-3FBAFFB9F61923006179A3EA19F86079"
      unitRef="usd">174000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e869-wk-Fact-F2CB06C2A492B0CD2BE3A3EA19F44B1A"
      unitRef="usd">247376000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1107-wk-Fact-EB3F02F3EA1239DF37C0A3EA1A087A5A"
      unitRef="usd">88535000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1126-wk-Fact-D59550B3622071F96BC0A3EA1A0DC410"
      unitRef="usd">68000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1145-wk-Fact-D5B6F9420C1F48AD2C2AA3EA1A0C5329"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1166-wk-Fact-CD6161E91438AFE72F43A3EA1A0C150B"
      unitRef="usd">88601000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1181-wk-Fact-D4531A46E77FFD9DED04A3EA1A09C046"
      unitRef="usd">129860000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1200-wk-Fact-59D3DBFB8603AC5CB084A3EA1A0BCA3B"
      unitRef="usd">196000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1219-wk-Fact-DA31774A41C22309812DA3EA1A06CCBC"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1240-wk-Fact-C2EC0DF64DA107C7AA26A3EA1A0B998C"
      unitRef="usd">130055000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1260-wk-Fact-4E59DD8014930ECC017FA3EA1A098E42"
      unitRef="usd">48355000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1279-wk-Fact-DE061EDBA7AEE0CE2893A3EA1A09EF3A"
      unitRef="usd">49000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1298-wk-Fact-5F8E5DE98DE12084F7AEA3EA1A0D6B87"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1319-wk-Fact-487A041F365F435DA99BA3EA1A0A4454"
      unitRef="usd">48401000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1344-wk-Fact-6FFDA3F0A632D6E70B22A3EA1A08EAAA"
      unitRef="usd">266750000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1363-wk-Fact-02DF4B9969339D3D72B0A3EA1A0979D2"
      unitRef="usd">313000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1382-wk-Fact-D67D6832F08F6AEF9653A3EA1A07EE76"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember"
      decimals="-3"
      id="d11895e1403-wk-Fact-ABBEE8CD00D38A85C781A3EA1A0A0C1B"
      unitRef="usd">267057000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-ABB9C3EF695D47E02C9EA3EA1A4B0B8D-0-wk-Fact-7C9AB0A30E77F69F17B1A3EA19EF8B33">Fair Value Measurements&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:6pt;"&gt;&lt;span style="font-family:inherit;font-size:6pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;1 &#x2014; defined as observable inputs such as quoted prices in active markets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;2 &#x2014; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Level&#160;3 &#x2014; defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities classified in Level&#160;1 and Level&#160;2 as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level&#160;2 is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurement as of March 31, 2020 Using&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;247,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;159,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurement as of December 31, 2019 Using&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices in&lt;br/&gt;Active&#160;Markets&#160;for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;137,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;137,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;274,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;185,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; include &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$7.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="FD2020Q1YTD"
      id="TextSelection-08763BB2371190C2BDAAA3EA1A4BD2EC-0-wk-Fact-64D863A8CC15F6845FEDA3EA1A3EB045">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Marketable securities classified in Level&#160;1 and Level&#160;2 as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level&#160;2 is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-40D7DB0FDA52769216B5A3EA1A4BB012-0-wk-Fact-8F227EA233564D3BF70EA3EA19EE9923">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurement as of March 31, 2020 Using&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;123,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36,378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;247,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;87,572&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;159,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurement as of December 31, 2019 Using&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices in&lt;br/&gt;Active&#160;Markets&#160;for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury and government agencies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;137,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;137,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;48,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;274,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;88,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;185,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e691-wk-Fact-0FE3245FE485C65A36B3A3EA1A3EBD70"
      unitRef="usd">87572000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e710-wk-Fact-D5A47B06FCC4EB319F3EA3EA1A3E246E"
      unitRef="usd">87572000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e729-wk-Fact-3B8DE5B8FF87AB6DDD9DA3EA1A3D43C9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e749-wk-Fact-E00EFCBE4612AD4CB450A3EA1A3E7115"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e764-wk-Fact-9D34225DBF5D51F66CC1A3EA1A3A0324"
      unitRef="usd">123426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e783-wk-Fact-2E666820FDA15E1B2E49A3EA1A3CD4B6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e802-wk-Fact-880181D9BFDF00A8ACDCA3EA1A395F49"
      unitRef="usd">123426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e822-wk-Fact-364B77A3CF7E91998FF9A3EA1A3C3484"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e842-wk-Fact-5EE4B9223587838AA3F3A3EA1A3F7425"
      unitRef="usd">36378000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e861-wk-Fact-B273899505907089EB92A3EA1A3D0136"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e880-wk-Fact-3400EDA03BB33B0B71D0A3EA19F119B6"
      unitRef="usd">36378000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e900-wk-Fact-0C1A83EABE0D5EBAB27EA3EA1A3F8523"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1"
      decimals="-3"
      id="d12568e925-wk-Fact-EFB10B5C9D193E1F3591A3EA1A3EE244"
      unitRef="usd">247376000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="d12568e944-wk-Fact-DB2E55C8CF72C03C02A7A3EA1A3BF920"
      unitRef="usd">87572000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d12568e963-wk-Fact-41870874ACF2124C6CE6A3EA1A3EAE0F"
      unitRef="usd">159804000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d12568e983-wk-Fact-CFCF4C0AE4C1E596BF7CA3EA1A3F3E72"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e1279-wk-Fact-8DD181FE0CA09DABDC48A3EA19F6E1BE"
      unitRef="usd">88601000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e1298-wk-Fact-AA4E2C86E5308656211EA3EA19F7F8E4"
      unitRef="usd">88601000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e1317-wk-Fact-045A6AB3511FB0D70FCBA3EA19F510FA"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d12568e1337-wk-Fact-521D8762F68F118E708DA3EA19F354B1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e1352-wk-Fact-AE3DF8464FF942224F25A3EA19F5A171"
      unitRef="usd">137025000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e1371-wk-Fact-FC376CB9ADE0E2F6EC03A3EA19F6B59D"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e1390-wk-Fact-00D083239C0CA66B8041A3EA19F5C773"
      unitRef="usd">137025000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d12568e1410-wk-Fact-B1B0410A137B39EF9DD6A3EA19FC6164"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e1430-wk-Fact-C867A6430CCC9DCA9302A3EA19F05C02"
      unitRef="usd">48401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e1449-wk-Fact-3195E294EE3E6C50430FA3EA19F72A32"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e1468-wk-Fact-0795D298F5C6EDE59791A3EA19F520D3"
      unitRef="usd">48401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember"
      decimals="-3"
      id="d12568e1488-wk-Fact-05EC2745C18F8D39FD51A3EA19F4A8B4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-3"
      id="d12568e1513-wk-Fact-66414FAE6C43F17C7E75A3EA19F3848C"
      unitRef="usd">274027000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="d12568e1532-wk-Fact-7EA3775C8E8BEF24C82DA3EA19F39503"
      unitRef="usd">88601000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-3"
      id="d12568e1551-wk-Fact-0D1727DA2191BCAAA27EA3EA19F3E902"
      unitRef="usd">185426000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="d12568e1571-wk-Fact-1E6B8B3FF0D3832407D1A3EA19F2C69F"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember"
      decimals="-5"
      id="d12568e1590-wk-Fact-E20C4EE358814C6924A1A3EA1A3C1352"
      unitRef="usd">7000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-4FDD5DF00531860FA5E8A3EA1A4B64D0-0-wk-Fact-3614B16B41068EA2F766A3EA1A064F93">Inventory&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory consisted of the following as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Non-Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,824&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-63CC47735B56F708D948A3EA1A4BF621-0-wk-Fact-6B411217EEC58630F4C3A3EA1A0AC4E7">InventoryThe Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current.</us-gaap:InventoryPolicyTextBlock>
    <vnda:ScheduleOfInventoriesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B7768477DDA7BB7376A4A3EA1A4B6A65-0-wk-Fact-C9E12C51E0BC3A964C3CA3EA1A06D46E">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Inventory consisted of the following as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory, current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,320&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Non-Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Work-in-process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;934&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,056&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory, non-current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,824&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</vnda:ScheduleOfInventoriesTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2020Q1"
      decimals="-3"
      id="d11872e477-wk-Fact-932C3FA73DC1E5530381A3EA1A17DE01"
      unitRef="usd">1320000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11872e496-wk-Fact-5DF31B92F4FA59E5A1BFA3EA1A12A2F9"
      unitRef="usd">1140000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2020Q1"
      decimals="-3"
      id="d11872e516-wk-Fact-E5FF2D4D3DC41E7CEBFFA3EA1A27D432"
      unitRef="usd">1320000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11872e535-wk-Fact-7C2C530DB3097BE332E1A3EA1A30AED6"
      unitRef="usd">1140000</us-gaap:InventoryNet>
    <vnda:InventoryRawMaterialsNetOfReservesNonCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d11872e596-wk-Fact-3C7671938F982C531BEFA3EA1A128811"
      unitRef="usd">659000</vnda:InventoryRawMaterialsNetOfReservesNonCurrent>
    <vnda:InventoryRawMaterialsNetOfReservesNonCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11872e615-wk-Fact-B991349C1AD070367ACEA3EA1A17E6FA"
      unitRef="usd">659000</vnda:InventoryRawMaterialsNetOfReservesNonCurrent>
    <vnda:InventoryWorkInProcessNetOfReservesNonCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d11872e630-wk-Fact-AD4428E18D5829185759A3EA1A151B0A"
      unitRef="usd">949000</vnda:InventoryWorkInProcessNetOfReservesNonCurrent>
    <vnda:InventoryWorkInProcessNetOfReservesNonCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11872e649-wk-Fact-4D039A5B188244985EF3A3EA1A12F96C"
      unitRef="usd">1109000</vnda:InventoryWorkInProcessNetOfReservesNonCurrent>
    <vnda:InventoryFinishedGoodsNetOfReservesNonCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d11872e669-wk-Fact-528D9CCE5152D728F7B8A3EA1A187E1E"
      unitRef="usd">934000</vnda:InventoryFinishedGoodsNetOfReservesNonCurrent>
    <vnda:InventoryFinishedGoodsNetOfReservesNonCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11872e688-wk-Fact-3F1C8BBA56A61479B458A3EA1A11BAE7"
      unitRef="usd">1056000</vnda:InventoryFinishedGoodsNetOfReservesNonCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d11872e708-wk-Fact-FECA35EB310F422DDFD7A3EA1A165F02"
      unitRef="usd">2542000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11872e727-wk-Fact-E1F7F702284BBF89F672A3EA1A15740D"
      unitRef="usd">2824000</us-gaap:InventoryNoncurrent>
    <vnda:Inventory
      contextRef="FI2020Q1"
      decimals="-3"
      id="d11872e752-wk-Fact-B1D173A4133E6BE5AB67A3EA1A14FA00"
      unitRef="usd">3862000</vnda:Inventory>
    <vnda:Inventory
      contextRef="FI2019Q4"
      decimals="-3"
      id="d11872e771-wk-Fact-8D385B253AB3B5BC1445A3EA1A19AF48"
      unitRef="usd">3964000</vnda:Inventory>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-4B02119E4B1541662E1FA3EA1A4CCDB6-0-wk-Fact-439F1585F4A7BC015BECA3EA1A3FE809">Intangible Assets&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to BMS. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July 2035&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In April 2018, the Company met its final milestone under its license agreement when cumulative worldwide sales of HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;reached &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$250.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As a result of the achievement of this milestone, the Company made a payment to BMS of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in 2018. The &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July 2035&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The estimated economic useful life of both the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; intangible assets were changed from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;February 2035&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July 2035&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; based on the July 2035 expiration date of U.S. patent number 10,376,487&#160;('487 Patent) issued by the U.S. Patent and Trademark Office in August 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s intangible assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Useful Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July 2035&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s intangible assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Useful Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July 2035&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,963&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company also had &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$27.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of fully amortized intangible assets related to Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for each of the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The following is a summary of the future intangible asset amortization schedule as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d11954e353-wk-Fact-79BFE1C1AC66F55A6B10A3EA19FA985B"
      unitRef="usd">8000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d11954e357-wk-Fact-79BFE1C1AC66F55A6B10A3EA19FA985B"
      unitRef="usd">8000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <vnda:CumulativeNetSalesToAchieveMilestone
      contextRef="D2018Q2Apr_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d11954e373-wk-Fact-8E74A75D34F96D01C0D3A3EA19F9D570"
      unitRef="usd">250000000.0</vnda:CumulativeNetSalesToAchieveMilestone>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d11954e377-wk-Fact-D9A2DAFB58F524C83BB0A3EA19F63388"
      unitRef="usd">25000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2015Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d11954e381-wk-Fact-27747297C12960A5D536A3EA1A3FA85F"
      unitRef="usd">25000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D2014Q1Jan1-Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d11954e397-wk-Fact-79BFE1C1AC66F55A6B10A3EA19FA985B"
      unitRef="usd">8000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="FD2015Q1YTD_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d11954e401-wk-Fact-27747297C12960A5D536A3EA1A3FA85F"
      unitRef="usd">25000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-506C63AD3F43394EE1FAA3EA1A4C41F3-0-wk-Fact-A988F74BCCC74A284593A3EA19F16767">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s intangible assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Useful Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July 2035&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s intangible assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Useful Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July 2035&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;33,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;9,963&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e639-wk-Fact-A437D35C3D9CB62078AAA3EA19FC4220"
      unitRef="usd">33000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e658-wk-Fact-12CD91D091205299C64BA3EA19F87713"
      unitRef="usd">10333000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e678-wk-Fact-D09B8602B8D736A8FBE4A3EA1A0B5090"
      unitRef="usd">22667000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e906-wk-Fact-DD72DF9586CC085E6167A3EA19FDA635"
      unitRef="usd">33000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e925-wk-Fact-EA06810B0E9EA89C2572A3EA19FFC57C"
      unitRef="usd">9963000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e945-wk-Fact-E76842ECBD2FAE6D5572A3EA19F40461"
      unitRef="usd">23037000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_FanaptMember"
      decimals="-5"
      id="d11954e967-wk-Fact-E5D5F23DE823AAFB1D0CA3EA19F00741"
      unitRef="usd">27900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d11954e979-wk-Fact-339E7158F42412018E7DA3EA19EFD4F5"
      unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-9CD8A87DEB6F129E5CF8A3EA1A4CDF75-0-wk-Fact-3F1BF73C8EC52CD373C8A3EA19F2C1DF">The following is a summary of the future intangible asset amortization schedule as of &lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e1199-wk-Fact-D09B8602B8D736A8FBE4A3EA1A0B5090"
      unitRef="usd">22667000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e1218-wk-Fact-A3337D1C4C0257C58627A3EA1A0B3283"
      unitRef="usd">1108000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e1237-wk-Fact-EE48B5819DEB31531846A3EA1A0E673D"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e1257-wk-Fact-460A8942C168AB7B2DE3A3EA1A0AFB57"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e1276-wk-Fact-6684C915F356BC5370FFA3EA1A0A518A"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e1296-wk-Fact-7FDD208B5872A70C0473A3EA1A0E25DE"
      unitRef="usd">1478000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-3"
      id="d11954e1315-wk-Fact-C8EB95BD2343248A1274A3EA1A0ABF85"
      unitRef="usd">15647000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-1AE3F5437A534E205B73A3EA1A4CB77B-0-wk-Fact-BCEA013EE0A9E892275CA3EA19FAD436">Accounts Payable and Accrued Liabilities&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s accounts payable and accrued liabilities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Consulting and other professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,893&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Royalties payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,590&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-7A4803B3EC1358240568A3EA1A4CD39C-0-wk-Fact-37EE8764A4BDDEBDEB3DA3EA19FBFA1E">&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the Company&#x2019;s accounts payable and accrued liabilities as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Consulting and other professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,376&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,893&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Royalties payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,912&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Compensation and employee benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;27,590&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d13731e426-wk-Fact-D98076011D4017863161A3EA19FC8C7F"
      unitRef="usd">7636000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d13731e445-wk-Fact-D2A212B09A5D30E7350BA3EA1A0D15C8"
      unitRef="usd">5376000</us-gaap:AccruedProfessionalFeesCurrent>
    <vnda:AccruedResearchAndDevelopmentExpense
      contextRef="FI2020Q1"
      decimals="-3"
      id="d13731e460-wk-Fact-88B5280E7B109CE1E26CA3EA19FBB68A"
      unitRef="usd">5839000</vnda:AccruedResearchAndDevelopmentExpense>
    <vnda:AccruedResearchAndDevelopmentExpense
      contextRef="FI2019Q4"
      decimals="-3"
      id="d13731e479-wk-Fact-FE1C5AD34AA5C748B437A3EA19FAAA6E"
      unitRef="usd">5893000</vnda:AccruedResearchAndDevelopmentExpense>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d13731e499-wk-Fact-7A94713F87B975CA2593A3EA1A002199"
      unitRef="usd">4912000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d13731e518-wk-Fact-B068C552D03CB995CB11A3EA19FC4511"
      unitRef="usd">5904000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d13731e538-wk-Fact-9158E8862BA0FD22113BA3EA19FED5CA"
      unitRef="usd">3762000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d13731e556-wk-Fact-6CF173876FA2635D0EE2A3EA1A03C83C"
      unitRef="usd">6597000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d13731e576-wk-Fact-30F2AD8BCFC172D8F21AA3EA19FFFEE6"
      unitRef="usd">2101000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d13731e595-wk-Fact-DA8EDE01449B61B2F289A3EA19FFB717"
      unitRef="usd">2147000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d13731e615-wk-Fact-138D7D3EAE7F42188A17A3EA19FD48AA"
      unitRef="usd">1795000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d13731e634-wk-Fact-7B6F36E8FE35B79EA9C7A3EA1A009295"
      unitRef="usd">1673000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2020Q1"
      decimals="-3"
      id="d13731e659-wk-Fact-1B412832705ADE87477EA3EA1A2FE88C"
      unitRef="usd">26045000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-3"
      id="d13731e678-wk-Fact-469A7B7FB4E36FA99A83A3EA1A1EA055"
      unitRef="usd">27590000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B3FB0EECFD47C4D239CCA3EA1A4C0044-0-wk-Fact-BAF8BB956AEE5A1CD7A4A3EA19F7505B">Commitments and Contingencies&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#x2019;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#x2019;s products. The term of these indemnification agreements is generally perpetual from the date of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has paid BMS &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$37.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in upfront fees and milestone obligations, including &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$33.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of regulatory approval and commercial milestones capitalized as intangible assets (see Note &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;6&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;net sales to BMS in any territory where the Company commercializes HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;for a period equal to the greater of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; royalty on net sales in that territory.&#160;The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;mid-twenties&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&#160;The Company has agreed with BMS in the license agreement for HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;to use its commercially reasonable efforts to develop and commercialize HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; franchise to the Company on December&#160;31, 2014. The Company paid directly to Sanofi S.A (Sanofi) a fixed royalty of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net sales through December&#160;2019 related to manufacturing&#160;know-how.&#160;The Company is also obligated to pay Sanofi a fixed royalty on Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;net sales equal to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on Sanofi&#160;know-how&#160;not related to manufacturing under certain conditions for a period of up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Tradipitant.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an&#160;NK-1R&#160;antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;low double digits&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has paid Lilly &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in upfront fees and development milestones, including a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone payment in July 2018 as a result of enrolling the first subject into a Phase III study for tradipitant. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, remaining milestone obligations include a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or European Union (E.U.), &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$80.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;VQW-765.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;In connection with a settlement agreement with Novartis relating to Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765,&#160;a Phase II&#160;alpha-7&#160;nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize&#160;VQW-765&#160;and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;mid-teens&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Portfolio of CFTR activators and inhibitors&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;single-digit&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;royalties on net sales. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has paid UCSF &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in upfront fees and development milestones, including an upfront license fee payment of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in 2017 and a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; development milestone payment in March 2019. As of &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, remaining milestone obligations include &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;for development milestones and&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$33.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;for future regulatory approval and sales milestones. Included in the&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$12.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160; in development milestones is a &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$350,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;in total for the CFTR portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company&#x2019;s current agreements for clinical, marketing, and other services may be terminated on generally &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; days&#x2019; notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company&#x2019;s contractors in closing out work in progress as of the effective date of termination. Noncancellable long-term contractual cash obligations include noncancellable purchase commitments longer than one year and primarily relate to commitments for media and data services, of which &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; are expected to be paid in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/span&gt;, respectively.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D2020Q1Feb1Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d13962e378-wk-Fact-EB718DB0B78F73118A0AA3EA1A0C86BA"
      unitRef="usd">37500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="D2020Q1Feb1Mar31_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="-5"
      id="d13962e382-wk-Fact-3C0783136302E9C5C9B9A3EA1A03AFD2"
      unitRef="usd">33000000.0</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <vnda:RoyaltyPeriod
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember"
      id="d13962e399-wk-Fact-4AD83537EAC605D351FDA3EA19FC8818">P10Y</vnda:RoyaltyPeriod>
    <vnda:RoyaltyPayableOnNetSalesPercentage
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember"
      decimals="2"
      id="d13962e403-wk-Fact-B82C56913CEDB0556C2EA3EA1A03B54E"
      unitRef="number">0.10</vnda:RoyaltyPayableOnNetSalesPercentage>
    <vnda:PercentageOfFutureSublicenseFeesPayable
      contextRef="FD2020Q1YTD"
      id="d13962e408-wk-Fact-D4914691762A38B18643A3EA19FF7931">mid-twenties</vnda:PercentageOfFutureSublicenseFeesPayable>
    <vnda:RoyaltyPayableOnNetSalesPercentage
      contextRef="FD2020Q1YTD_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember"
      decimals="2"
      id="d13962e433-wk-Fact-6FB9A7B43BB989A7FB68A3EA1A0091D9"
      unitRef="number">0.03</vnda:RoyaltyPayableOnNetSalesPercentage>
    <vnda:RoyaltyPayableOnNetSalesPercentage
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember"
      decimals="2"
      id="d13962e441-wk-Fact-33767FEAA726E08A2A77A3EA19FEDB2D"
      unitRef="number">0.06</vnda:RoyaltyPayableOnNetSalesPercentage>
    <vnda:RoyaltyPeriod
      contextRef="FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_FanaptMember"
      id="d13962e446-wk-Fact-FCE8D53BDFDCECD07541A3EA1A04D80B">P10Y</vnda:RoyaltyPeriod>
    <vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember"
      id="d13962e455-wk-Fact-0DCAF0CAAE2AB4EBA5B4A3EA19F8F33D">low double digits</vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="D2020Q1Apr2012March2020_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember"
      decimals="-5"
      id="d13962e463-wk-Fact-9D21DA85EBD08118EFBEA3EA1A1C61E6"
      unitRef="usd">3000000.0</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="D2018Q1July2018_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember"
      decimals="-5"
      id="d13962e467-wk-Fact-F350827016BBEEBB3200A3EA1A05C1A5"
      unitRef="usd">2000000.0</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember"
      decimals="-5"
      id="d13962e476-wk-Fact-8DF6CE7403B589FC7C22A3EA19FFDFAC"
      unitRef="usd">2000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember"
      decimals="-5"
      id="d13962e480-wk-Fact-D3C97DAEE594DDB70D44A3EA1A1924BF"
      unitRef="usd">10000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember"
      decimals="-5"
      id="d13962e484-wk-Fact-00E282CB3725C7A98F71A3EA1A05F675"
      unitRef="usd">5000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_SalesMilestoneMember_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember"
      decimals="-5"
      id="d13962e488-wk-Fact-9AA9EA80DA32C2E45EB9A3EA1A1BFE86"
      unitRef="usd">80000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
      contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_VQW765Member"
      id="d13962e501-wk-Fact-C0A09342388FA8B988A2A3EA19FAE827">mid-teens</vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales>
    <vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember"
      id="d13962e510-wk-Fact-C40DCC669FB05F6CAD4BA3EA1A0A19AD">single-digit</vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="D2020Q1Mar2017Mar2020_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember"
      decimals="-5"
      id="d13962e518-wk-Fact-34D9E9210367FE900861A3EA1A036A22"
      unitRef="usd">1200000</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember"
      decimals="-5"
      id="d13962e522-wk-Fact-1C210AF15FEB664A83CAA3EA1A04BE53"
      unitRef="usd">1000000.0</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty
      contextRef="D2019Q1March2019_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember"
      decimals="-5"
      id="d13962e526-wk-Fact-0258CF357D9886AEA06EA3EA19F80498"
      unitRef="usd">200000</vnda:DevelopmentAndMilestoneObligationsPaidToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember"
      decimals="-5"
      id="d13962e537-wk-Fact-45B670E390105C49CF94A3EA1A1BDE3C"
      unitRef="usd">12200000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_FutureRegulatoryApprovalAndSalesMilestonesMember"
      decimals="-5"
      id="d13962e541-wk-Fact-D558C4B57EAE40140956A3EA1A0237A7"
      unitRef="usd">33000000.0</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_RegulatoryApprovalMilestoneMember"
      decimals="-5"
      id="d13962e545-wk-Fact-45B670E390105C49CF94A3EA1A1BDE3C"
      unitRef="usd">12200000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember"
      decimals="-3"
      id="d13962e549-wk-Fact-AC31A5FF4D2F05C4F6E1A3EA1A1B6AB6"
      unitRef="usd">350000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
      contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember"
      decimals="-5"
      id="d13962e553-wk-Fact-E21D825051C1B2C76F88A3EA19F7C964"
      unitRef="usd">1100000</vnda:DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty>
    <vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod
      contextRef="FD2020Q1YTD"
      id="d13962e564-wk-Fact-F58900D6143D39B1F64BA3EA1A1D6849">P90D</vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod>
    <us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
      contextRef="FI2020Q1"
      decimals="-5"
      id="d13962e568-wk-Fact-6D39440C871C17090DACA3EA19FE0BE9"
      unitRef="usd">3200000</us-gaap:PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="FI2020Q1"
      decimals="-5"
      id="d13962e572-wk-Fact-B406185421B67347F532A3EA19FBE725"
      unitRef="usd">1000000.0</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="FI2020Q1"
      decimals="-5"
      id="d13962e576-wk-Fact-3068F12CEE55B51EEDAFA3EA1A0E1A86"
      unitRef="usd">500000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-CE5E0E3F11DABF2D2600A3EA1A4DC87C-0-wk-Fact-9295E86A75EFE631AEA6A3EA19F18E0D">Accumulated Other Comprehensive Income &lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain on marketable securities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; reclassifications out of accumulated other comprehensive income for either of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-5A9912C8287A7F0FA9E6A3EA1A4D1E99-0-wk-Fact-02EDED3F1C98811979E7A3EA19F14948">&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrealized gain on marketable securities &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accumulated other comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d14227e425-wk-Fact-BE1E6BE7B8F972904A40A3EA1A0AE1C2"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d14227e444-wk-Fact-DBE68530CA77D018A123A3EA1A09A51E"
      unitRef="usd">13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d14227e459-wk-Fact-6E0EAA942997FA991F77A3EA1A0B2591"
      unitRef="usd">781000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d14227e478-wk-Fact-8C101476E8AB660FCA0FA3EA1A14FA6A"
      unitRef="usd">236000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2020Q1"
      decimals="-3"
      id="d14227e503-wk-Fact-8CF55ACDEE4088629324A3EA1A265B32"
      unitRef="usd">781000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-3"
      id="d14227e522-wk-Fact-3EF41A751627B000C675A3EA1A2413D3"
      unitRef="usd">249000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2020Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"
      decimals="INF"
      id="d14227e536-wk-Fact-52A2E2D722F0312A982FA3EA19F0D86B"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-FCF9CD9C9E966C217BA8A3EA1A4DA608-0-wk-Fact-A4FAE4A06B8764B6CDB0A3EA1A11DA27">Stock-Based Compensation&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,335,548&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares that were subject to outstanding options and restricted stock units (RSUs) under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April 2016, and the Company adopted the 2016 Plan. Outstanding options and RSUs under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company&#x2019;s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated twice to increase the number of shares reserved for issuance, among other administrative changes. Both amendments and restatements of the 2016 Plan were approved by the Company's stockholders. There are a total of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;7,100,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of common stock reserved for issuance under the 2016 Plan, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,153,920&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of which remained available for future grant as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; with the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the shares subject to service option awards vesting on the first anniversary of the grant date and remaining &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the shares subject to the service option awards in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards to executives and directors provide for accelerated vesting if there is a change in control of the Company. Certain service option awards to employees and executives provide for accelerated vesting if the respective employee&#x2019;s or executive&#x2019;s service is terminated by the Company for any reason other than cause or permanent disability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$9.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years. No option awards are classified as a liability as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of option activity under the Plans for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2006 and 2016 Plans&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands, except for share and per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&#160;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&#160;Price&#160;at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&#160;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&#160;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,495,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(225,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(172,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,575,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,379,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,340,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The weighted average grant-date fair value of options granted was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$5.73&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$11.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; per share for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. Proceeds from the exercise of stock options amounted to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;An RSU is a stock award that entitles the holder to receive shares of the Company&#x2019;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#x2019;s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that vest in &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; equal annual installments provided that the employee remains employed with the Company. Annual service RSUs granted to directors vest on the first anniversary of the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$25.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years. No RSUs are classified as a liability as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of RSU activity under the Plans for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2006 and 2016 Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Underlying &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,649,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;745,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(136,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(498,505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unvested at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,760,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The grant date fair value for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;498,505&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares underlying RSUs that vested during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense recognized for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company&#x2019;s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e345-wk-Fact-CD234F84CC6BCE10FD34A3EA1A0F91DB"
      unitRef="shares">6335548</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e349-wk-Fact-0D92A6FC4BB9BB43F1DBA3EA1A0F2361"
      unitRef="shares">7100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e353-wk-Fact-2062CE26BA4D7DAA04A3A3EA1A14C2DC"
      unitRef="shares">2153920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vnda:ShareBasedCompensationOptionAwardsContractualTerm
      contextRef="FD2020Q1YTD"
      id="d16557e367-wk-Fact-27EF5E16BFA63A26005EA3EA1A0C3CA4">P10Y</vnda:ShareBasedCompensationOptionAwardsContractualTerm>
    <vnda:ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors
      contextRef="FD2020Q1YTD"
      id="d16557e371-wk-Fact-4DF931DFD9FAD025CC87A3EA1A09FCC1">P4Y</vnda:ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16557e375-wk-Fact-1BBB18C25A15D04392EBA3EA1A1D57CB"
      unitRef="number">0.25</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards>
    <vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16557e379-wk-Fact-5483345DE8C4A673BB17A3EA1A0F27CD"
      unitRef="number">0.75</vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards>
    <vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d16557e383-wk-Fact-6799757D6A22677EF722A3EA1A0E0DA5"
      unitRef="installment">36</vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="FI2020Q1_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember"
      decimals="-5"
      id="d16557e394-wk-Fact-C06E4F29C50920A6989AA3EA1A0E8375"
      unitRef="usd">9100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_ServiceOptionAwardsMember"
      id="d16557e398-wk-Fact-CFCA98D5AE922FF82631A3EA1A0DFDAF">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-6FE943D39AB48D4F5779A3EA1A4DD7BB-0-wk-Fact-B3CA5B01FE8E139CF21AA3EA1A0F1F2A">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of option activity under the Plans for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2006 and 2016 Plans&lt;/span&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands, except for share and per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&#160;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&#160;Price&#160;at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&#160;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&#160;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,495,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;21,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;487,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(225,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,104&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(172,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,575,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,379,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,340,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;4,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e547-wk-Fact-361D49F66DE59CC2F4D8A3EA1A198A72"
      unitRef="shares">4495145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="2"
      id="d16557e566-wk-Fact-5CECC0471943F7CADDF1A3EA1A1EB5ED"
      unitRef="usdPerShare">12.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      id="d16557e580-wk-Fact-361FF7F5427DADB82F3DA3EA1A1201BC">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="-3"
      id="d16557e596-wk-Fact-ED3415767ECB190AE39DA3EA19FDBE6E"
      unitRef="usd">21148000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e611-wk-Fact-2F39DF841E57DCA01107A3EA1A10E7CE"
      unitRef="shares">487500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="2"
      id="d16557e625-wk-Fact-173657467AD9C8CFF05FA3EA1A214950"
      unitRef="usdPerShare">11.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e676-wk-Fact-23A4635C50D39C82AC97A3EA1A11DC1B"
      unitRef="shares">225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="2"
      id="d16557e691-wk-Fact-C90C6BFE021D65E7CF53A3EA1A1C8422"
      unitRef="usdPerShare">18.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="FD2020Q1YTD"
      decimals="INF"
      id="d16557e742-wk-Fact-F9DB220FE2157E69D12DA3EA1A22653A"
      unitRef="shares">10104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16557e757-wk-Fact-5F08A3063C01CC66EB90A3EA1A297705"
      unitRef="usdPerShare">11.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e808-wk-Fact-B2D1DB51FA8D82D7AB4BA3EA1A221603"
      unitRef="shares">172500</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="2"
      id="d16557e823-wk-Fact-512E55984242FC802A2AA3EA19FFD6BD"
      unitRef="usdPerShare">4.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="-3"
      id="d16557e852-wk-Fact-9B098A9D656E186CDBE9A3EA1A266C28"
      unitRef="usd">890000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e873-wk-Fact-4AC2F3511B9690C0896AA3EA1A203B9D"
      unitRef="shares">4575041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="2"
      id="d16557e887-wk-Fact-1D7D7ED1753A611DEE9FA3EA1A1A82E5"
      unitRef="usdPerShare">12.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      id="d16557e906-wk-Fact-5F25E0980709EC1E39F4A3EA19FE1303">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="-3"
      id="d16557e916-wk-Fact-5BE28605A9F0E00716D5A3EA1A134C14"
      unitRef="usd">4818000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e937-wk-Fact-CDC9337BE98C461B144AA3EA1A1D91E5"
      unitRef="shares">3379139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="2"
      id="d16557e951-wk-Fact-09C2144C4EB69D79FD81A3EA1A035825"
      unitRef="usdPerShare">11.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      id="d16557e970-wk-Fact-7B4A643555063CE8C553A3EA1A02DDB8">P4Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="-3"
      id="d16557e980-wk-Fact-D6A68F5B3AAEED8BB399A3EA1A019DAF"
      unitRef="usd">4818000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="INF"
      id="d16557e1001-wk-Fact-8E56055439B670EB37B7A3EA1A19711F"
      unitRef="shares">4340916</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="2"
      id="d16557e1015-wk-Fact-3834981E4D3F0EBF2204A3EA1A0255E8"
      unitRef="usdPerShare">11.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="FD2020Q1YTD_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      id="d16557e1034-wk-Fact-9BF8C28F0D90C9806401A3EA1A02C4F5">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2020Q1_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember"
      decimals="-3"
      id="d16557e1044-wk-Fact-B52EE424B012A1723B63A3EA1A256A5C"
      unitRef="usd">4818000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16557e1064-wk-Fact-DD2C02F171AB39156598A3EA1A11B79E"
      unitRef="usdPerShare">5.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d16557e1068-wk-Fact-D967D5765FA33F31BD8BA3EA1A07413B"
      unitRef="usdPerShare">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d16557e1085-wk-Fact-C9BF1D7A580CBC4EDC3FA3EA1A108E26"
      unitRef="usd">500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q1QTD"
      decimals="-5"
      id="d16557e1089-wk-Fact-4206E4AC7437B351A7C9A3EA1A10C579"
      unitRef="usd">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d16557e1111-wk-Fact-31D4059084A2761C9B70A3EA1A109293"
      unitRef="installment">4</vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d16557e1123-wk-Fact-C06E8D41DEAB3CCA1BEBA3EA1A0F47EC"
      unitRef="usd">25900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d16557e1127-wk-Fact-2008D04AC76572F72DD1A3EA1A0807F5">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-B70BC66B42DA1E202866A3EA1A4DC240-0-wk-Fact-1DE01A8159B4A5D4E551A3EA1A07DA43">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;A summary of RSU activity under the Plans for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2006 and 2016 Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Underlying &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Grant&#160;Date &lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;Fair&#160;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unvested at December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,649,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;745,818&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(136,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;18.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(498,505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unvested at March 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,760,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;15.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d16557e1227-wk-Fact-BC50ED6B2EC4821183AAA3EA1A009369"
      unitRef="shares">1649285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d16557e1246-wk-Fact-98A399BB92FD43B9CDC2A3EA19FAF847"
      unitRef="usdPerShare">18.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d16557e1261-wk-Fact-7AE9F648C3BC5D8523DFA3EA1A11C8DE"
      unitRef="shares">745818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d16557e1275-wk-Fact-EFBEAB58A0561C078D0AA3EA1A06567E"
      unitRef="usdPerShare">11.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d16557e1295-wk-Fact-15660B5EE049ED3060FDA3EA1A104DA7"
      unitRef="shares">136091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d16557e1310-wk-Fact-58B0C293CCF86A9AC779A3EA1A0CAB1D"
      unitRef="usdPerShare">18.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d16557e1330-wk-Fact-C0EBA581C4AC021A46AAA3EA1A014FEB"
      unitRef="shares">498505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d16557e1345-wk-Fact-48FDA469E2CE5DF87BFAA3EA19EE39A8"
      unitRef="usdPerShare">16.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d16557e1365-wk-Fact-390AC642C8F7C5471A95A3EA1A07915B"
      unitRef="shares">1760507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d16557e1379-wk-Fact-29BC832BC6B41BB7FD42A3EA1A080A14"
      unitRef="usdPerShare">15.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d16557e1398-wk-Fact-C0EBA581C4AC021A46AAA3EA1A014FEB"
      unitRef="shares">498505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d16557e1410-wk-Fact-EB96F3CC6F697B190473A3EA1A12A179"
      unitRef="usd">8300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-436F11950DFA591E490BA3EA1A4DD6C3-0-wk-Fact-B2C68A26EE2B5EF2C8A6A3EA1A115F69">&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense recognized for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,833&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d16557e1549-wk-Fact-90CBADDEB4D9D6365DCDA3EA1A2361C7"
      unitRef="usd">1111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d16557e1568-wk-Fact-A0A864113EE2CD01EFC3A3EA1A2A6590"
      unitRef="usd">728000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d16557e1583-wk-Fact-EDD12BE0253524C42EC1A3EA1A2A449B"
      unitRef="usd">2833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d16557e1602-wk-Fact-4467A92BD34C6CD228B2A3EA1A1B197D"
      unitRef="usd">2554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d16557e1627-wk-Fact-459243CD666622B7A209A3EA1A21FC65"
      unitRef="usd">3944000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d16557e1646-wk-Fact-5672F5EC537FB68CC8D4A3EA1A2E57BA"
      unitRef="usd">3282000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-6F1E83B2E0E2D41A9949A3EA1A4DB6B8-0-wk-Fact-072007C3A878D46CB6A2A3EA1A0CB6F3">Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the &lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were as follows:&lt;/span&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average expected term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;5.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16557e1764-wk-Fact-93BE1C4849296BED442BA3EA1A1709F8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d16557e1779-wk-Fact-F08DF8632407B27B4A16A3EA1A163452"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16557e1795-wk-Fact-17587E8F2A743FB6E098A3EA1A1E3826"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d16557e1810-wk-Fact-9B3D75E3F96540C14A0EA3EA1A17FCB8"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2020Q1YTD"
      id="d16557e1826-wk-Fact-86729A36E982150DF201A3EA1A1CCB98">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q1QTD"
      id="d16557e1840-wk-Fact-BA327367B04560C830B7A3EA1A169004">P5Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2020Q1YTD"
      decimals="4"
      id="d16557e1855-wk-Fact-CB535B604682965A1708A3EA1A182E46"
      unitRef="number">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q1QTD"
      decimals="4"
      id="d16557e1870-wk-Fact-F61B9B6DEB3982EC6D3DA3EA1A182747"
      unitRef="number">0.0251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-F4365D153DCF27A3DE6BA3EA1A4D63F2-0-wk-Fact-B2B4A7E8586C06C5327EA3EA1A24BD63">Income Taxes&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded income tax expense of&#160;$&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; million&#160;and less than &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. The income tax expense for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; was primarily driven by the estimated effective tax rate for the year and the discrete impact of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of net shortfall tax expense related to stock-based compensation activity during the quarter. As a result of the tax valuation allowance against deferred tax assets in the U.S., there was no benefit for federal income taxes associated with the loss before taxes for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Income taxes were recorded related to certain U.S. state and foreign jurisdictions for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During the third quarter of 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance was retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2019&lt;/span&gt;.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d14337e349-wk-Fact-B18784F3BB5F8E4E89D2A3EA1A1B790B"
      unitRef="usd">800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="FD2020Q1YTD"
      decimals="-5"
      id="d14337e362-wk-Fact-BC3D5F8F533A50463E05A3EA1A1CCBC7"
      unitRef="usd">400000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-4379DF582D9681878027A3EA1A4E61DB-0-wk-Fact-3311852334FD3B74208BA3EA1A1BB083">Earnings per Share&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands, except for share and per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;486&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,806,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,752,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,063,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,870,146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,752,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic and diluted:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Antidilutive securities excluded from calculations of diluted net income (loss) per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,095,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,068,806&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company incurred a net loss for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-585130E19FBDBE8CE266A3EA1A4E428E-0-wk-Fact-F1981BA49CC0ABDA9AF1A3EA1A199109">Earnings per Share&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-3C4B65E6AE7D6F37E524A3EA1A4D8719-0-wk-Fact-A46776D483C5956EBD3BA3EA1A1A5AD5">&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;31, 2020&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:12pt;"&gt;&lt;span style="font-family:inherit;font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;"&gt;(in thousands, except for share and per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;486&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;53,806,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,752,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,063,829&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;54,870,146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,752,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic and diluted:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(0.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Antidilutive securities excluded from calculations of diluted net income (loss) per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,095,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,068,806&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2020Q1YTD"
      decimals="-3"
      id="d16548e520-wk-Fact-247B6C484CE7280EFC67A3EA1A20A734"
      unitRef="usd">486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q1QTD"
      decimals="-3"
      id="d16548e539-wk-Fact-8F352CCC896EFA2F8641A3EA1A194FF8"
      unitRef="usd">-612000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d16548e596-wk-Fact-B2E6B312D839F80D888CA3EA1A1B571D"
      unitRef="shares">53806317</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d16548e615-wk-Fact-B7D1F0FAAF7A9D852EC7A3EA1A1EBD64"
      unitRef="shares">52752774</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d16548e635-wk-Fact-8114E0E04FE5A1164832A3EA1A11BA9F"
      unitRef="shares">1063829</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d16548e654-wk-Fact-EE28F486D7A27761E8D2A3EA1A0CD9E0"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d16548e674-wk-Fact-5BB133E9BFC696DB03CEA3EA1A230D7B"
      unitRef="shares">54870146</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d16548e693-wk-Fact-9276896B58A7C4180CE3A3EA1A1614BE"
      unitRef="shares">52752774</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16548e759-wk-Fact-DB56EAA2B2E84199C268A3EA1A15480C"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d16548e778-wk-Fact-69AA522C761FDD2E53F9A3EA1A157FF6"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2020Q1YTD"
      decimals="2"
      id="d16548e799-wk-Fact-EC58C28E514512EF12DBA3EA1A22D909"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q1QTD"
      decimals="2"
      id="d16548e818-wk-Fact-4B0A6AF5514CED92404CA3EA1A20F671"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2020Q1YTD"
      decimals="0"
      id="d16548e835-wk-Fact-5E25431A2FC241605019A3EA1A1504D2"
      unitRef="shares">3095224</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q1QTD"
      decimals="0"
      id="d16548e854-wk-Fact-94D67636037F9325C55EA3EA1A0D2D24"
      unitRef="shares">3068806</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="FD2020Q1YTD"
      id="TextSelection-2C1F7166627862679F8BA3EA1A4E4B1A-0-wk-Fact-4CDBB935AB62B9633605A3EA1A214A92">Legal Matters&lt;div style="line-height:120%;padding-top:8px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The Company has been involved in litigation with Roxane Laboratories, Inc. (Roxane) and its affiliates, West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp (West-Ward), since the Company filed a lawsuit against Roxane in the U.S. District Court for the District of Delaware (Delaware District Court) for patent infringement in June 2014.  The lawsuit was filed in response to Roxane&#x2019;s submission to the U.S. Food and Drug Administration (FDA) of an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;prior to the expiration of certain of the Company&#x2019;s patents covering Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, including U.S. Patent No. 8,586,610 (&#x2018;610 Patent). In August 2016, the Delaware District Court ruled in the Company&#x2019;s favor, permanently enjoining Roxane from manufacturing, using, selling, offering to sell, distributing or importing any generic iloperidone product described in Roxane&#x2019;s ANDA until the expiration of the &#x2018;610 Patent in November 2027, or May 2028 if the Company obtains pediatric exclusivity. In April 2018, following an appeal by Roxane of the Delaware District Court&#x2019;s decision to the Federal Circuit Court of Appeals (Federal Circuit), the Federal Circuit affirmed the&#160;Delaware District Court&#x2019;s&#160;ruling. In June 2018, West-Ward, having replaced Roxane as defendants following the acquisition of Roxane by West-Ward&#x2019;s parent company, Hikma Pharmaceuticals PLC, petitioned the Federal Circuit for a rehearing en banc. In August 2018, the Federal Circuit denied West-Ward's petition. In January 2019, West-Ward filed a petition in the U.S. Supreme Court for a writ of certiorari seeking reversal of the Federal Circuit&#x2019;s decision. In March 2019, the U.S. Supreme Court invited the Solicitor General of the U.S. to file a brief in the matter expressing the views of the U.S. In January 2020, the U.S. Supreme Court denied West-Ward's petition for writ of certiorari.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In 2015, the Company filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp. (Apotex, and collectively with Roxane, Inventia, Lupin and Taro, the Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants). These lawsuits were filed in response to the submission to the FDA by each of the Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae; &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Defendants of ANDAs for generic versions of Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;prior to the expiration of the &#x2018;610 Patent in November 2027 or the U.S. Patent No. 9,138,432 in September 2025.  The Company entered into separate confidential stipulations with each of Inventia and Lupin regarding any potential launch of their generic versions of Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The parties are scheduled to provide the court with a status report on May 28, 2020 with respect to the remaining lawsuits against the other Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae; &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;font-style:italic;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In April and May 2018, the Company filed three separate patent infringement lawsuits in the Delaware District Court against Teva Pharmaceuticals USA, Inc. (Teva), MSN Pharmaceuticals Inc. and MSN Laboratories Private Limited (MSN) and Apotex (collectively with Teva and MSN, the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants) after having received Paragraph IV certification notice letters (Paragraph IV Letters) from each of the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants alleging that certain of the Company's patents covering HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (collectively, the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Patents) were invalid, unenforceable and/or would not be infringed by the manufacture, use or sale of their generic versions of HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, as described in the ANDAs submitted to &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;the FDA by each of the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants, prior to the expiration of the latest to expire of the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Patents in 2034. Each of the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Patents are listed in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Approved Drug Products with Therapeutic Equivalence Evaluations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (Orange Book). In December 2018, the Company filed amended complaints against each of the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants following the receipt of additional Paragraph IV Letters from Teva and Apotex concerning its Orange Book listed '977 Patent, which expires in 2035. These lawsuits are scheduled for trial in July 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2019, April 2019, and May 2019, the Company filed three additional patent infringement lawsuits in the Delaware District Court against the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants following the receipt of additional Paragraph IV Letters from each concerning its Orange Book listed U.S. Patent No. 10,149,829, which expires in 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants and are also scheduled for trial in July 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November and December 2019, the Company filed additional patent infringement lawsuits in the Delaware District Court against Apotex and Teva, respectively, for infringement of its Orange Book listed U.S. Patent No. 10,376,487 (&#x2018;487 Patent) following the receipt of additional Paragraph IV Letters from Apotex and Teva regarding the '487 Patent, which expires in July 2035. Teva asserted a counterclaim for a declaratory judgment that the &#x2018;487 Patent is invalid. The Company answered Teva&#x2019;s counterclaim by denying their allegation that the &#x2018;487 Patent is invalid. In January 2020, the Company filed two additional patent infringement lawsuits in the Delaware District Court against Teva and Apotex for infringement of its Orange Book-listed U.S. Patent No. 10,449,176 (&#x2018;176 Patent) following the receipt of additional Paragraph IV Letters from Teva and Apotex regarding the &#x2018;176 Patent, which expires in January 2033. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae; &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Defendants and are also scheduled for trial in July 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2020 and February 2020, the Company received additional Paragraph IV Letters from MSN concerning the '487 patent and the '176 Patent, respectively, in which MSN alleges that the &#x2018;487 and the '176 Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of MSN's generic version of HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; as described in MSN's ANDA. In February and March 2020 the Company filed two additional lawsuits in the Delaware District Court against MSN for infringement of its &#x2018;487 Patent and &#x2018;176 Patent. These lawsuits have been consolidated with the other lawsuits against the HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Defendants and are also scheduled for trial in July 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Other Matters&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.  In April 2018, the Company submitted a protocol amendment to the FDA, proposing a 52-week open-label extension (OLE) period for patients who had completed the tradipitant Phase II clinical study (2301) in gastroparesis. In May 2018, based on feedback from the FDA, the Company amended the protocol limiting the duration of treatment in the 2301 study to a total of three months, while continuing to seek further dialogue with the FDA on extending the study duration to 52-weeks. As a part of this negotiation process, in September 2018, the Company submitted a new follow-on 52-week OLE protocol to the FDA (2302) for patients who had completed the 2301 study. While waiting for further feedback, the Company did not enroll any patients in any study beyond 12 weeks. In December 2018, the FDA imposed a partial clinical hold (PCH) on the two proposed studies, stating that the Company is required first to conduct additional chronic toxicity studies in canines, monkeys or minipigs before allowing patients access in any clinical protocol beyond 12 weeks. At that time, the FDA informed the Company that the original PCH was not based on any safety or efficacy data related to tradipitant, but, rather that these additional toxicity studies were required by a guidance document. Subsequently, the FDA has taken the position that an additional study was required in order for the FDA to have adequate toxicology data to undertake a risk analysis of tradipitant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On February 5, 2019, the Company filed a lawsuit against the FDA in the U.S. District Court for the District of Columbia (DC District Court), challenging the FDA&#x2019;s legal authority to issue the PCH, and seeking an order to set it aside. In February 2019, the FDA filed a Motion for Voluntary Remand to the Agency and for a Stay of the Case. In March 2019, the DC District Court granted the FDA&#x2019;s request for voluntary remand and returned the matter to the FDA for further consideration. In April 2019, the FDA provided its remand response, in which it indicated that, upon review of scientific literature and tradipitant data, it believes that a PCH continues to be appropriate until the Company has adequate safety data from a nine-month non-rodent toxicity study. In May 2019, the Company filed an amended complaint, and in July 2019, the Company filed a Motion for Summary Judgment based on its continuing belief after review of the FDA&#x2019;s remand response that additional chronic toxicity studies are unjustified, and that it has provided the FDA with sufficient information regarding the safety of tradipitant to justify the continued study of tradipitant in patients beyond 12 weeks, in accordance with applicable law and FDA regulations. The FDA filed a reply and cross-motion for summary judgment in October 2019 and an oral hearing was held in December 2019. In January 2020, the Court granted the FDA's cross-motion for summary judgment and granted judgment in favor of the FDA on the Company's claims. The Company has elected not to appeal the Court's ruling.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2019, a qui tam action filed against the Company was unsealed by order of the DC District Court. The qui tam action, which was filed under seal in March 2017, was brought by a former Company employee on behalf of the U.S., 28 states and the District of Columbia (collectively, the Plaintiff States) and the policyholders of certain insurance companies under the Federal False Claims Act and state law equivalents to the Federal False Claims Act and related state laws. The complaint &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;alleged that the Company violated these laws through the promotion and marketing of its products Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and sought, among other things, treble damages, civil penalties for each alleged false claim, and attorneys&#x2019; fees and costs. By virtue of the DC District Court having unsealed the original complaint, the Company learned that in January 2019, the U.S. Department of Justice (the DOJ), as well as the Plaintiff States, elected not to intervene in the qui tam action at that time. In May 2019, the plaintiff filed an amended complaint under seal repeating the same allegations and seeking the same relief. According to a filing unsealed in June 2019, the DOJ reaffirmed its decision not to intervene and incorporated its prior filing, indicating that neither the DOJ nor the Plaintiff States were intervening regarding the original complaint. Although the DOJ and the Plaintiff States have elected not to intervene, the plaintiff may litigate this action and the DOJ and the Plaintiff States may later seek to intervene in the action. In August 2019, the Company filed a motion to dismiss, and in October 2019 the plaintiff filed a reply. In March 2020, the DC District Court vacated the scheduled hearing on the Company's motion to dismiss and will notify the parties of a new hearing date if one is deemed necessary by the DC District Court. The Company intends to vigorously defend itself in the case. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2019, a securities class action, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Gordon v. Vanda Pharmaceuticals Inc.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, was filed in the U.S. District Court for the Eastern District of New York naming the Company and certain of its officers as defendants. An amended complaint was filed in July 2019. The amended complaint, filed on behalf of a purported stockholder, asserts claims on behalf of a putative class of all persons who purchased the Company&#x2019;s publicly traded securities between November 4, 2015 and February 11, 2019, for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The amended complaint alleges that the defendants made false and misleading statements and/or omissions regarding Fanapt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, HETLIOZ&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&#xae; &lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and the Company&#x2019;s interactions with the FDA regarding tradipitant between November 3, 2015 and February 11, 2019. On March 23, 2020, the Company filed a motion to dismiss the complaint. The plaintiff is expected to file its reply by May 7, 2020. The Company believes that it has meritorious defenses and intends to vigorously defend this lawsuit. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, this lawsuit is subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2019, a shareholder derivative complaint, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Samuel Williams vs. Mihael Polymeropoulos, et al.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, was filed in the U.S. District Court for the Eastern District of New York naming certain current and former Company directors and officers as defendants. In September 2019, a shareholder derivative complaint, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Michael Bavaro v. Mihael Polymeropoulos, et al.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, was filed in the Delaware District Court naming certain current and former Company directors and officers as defendants. In October 2019, the Company filed a motion to transfer the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Bavaro &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;case to the Eastern District of New York, where the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Gordon &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Williams&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; cases are pending. In March 2020, the Delaware District Court transferred the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Bavaro&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; case to the Eastern District of New York, consolidating the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Williams&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Bavaro&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; cases, and the plaintiffs filed a consolidated complaint on April 24, 2020. These complaints, filed on behalf of purported stockholders, derivatively on behalf of the Company, assert claims for alleged breach of fiduciary duties by certain of the Company&#x2019;s current and former directors and officers. The Company believes that it has meritorious defenses and intends to vigorously defend these lawsuits. The Company does not anticipate that this litigation will have a material adverse effect on its business, results of operations or financial condition. However, these lawsuits are subject to inherent uncertainties, the actual cost may be significant, and the Company may not prevail. The Company believes it is entitled to coverage under its relevant insurance policies, subject to a retention, but coverage could be denied or prove to be insufficient.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2017, the CHMP issued a negative opinion recommending against approval of Fanaptum&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the E.U. The CHMP was of the opinion that the benefits of Fanaptum&lt;/span&gt;&lt;span style="font-family:inherit;font-size:9pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:6pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; did not outweigh its risks and recommended against marketing authorization. In March 2018, the Company filed an application seeking annulment of the EMA&#x2019;s negative opinion and the subsequent European Commission decision refusing marketing authorization of Fanaptum in the European General Court. In December 2019, the General Court issued its judgment dismissing the action, leaving the EMA opinion and Commission decision intact. In February 2020, the Company filed an appeal of this judgment with the Court of Justice of the E.U.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885182272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">$ 249<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=116690757&amp;loc=SL116692626-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882652464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - (RSU) - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>installment </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments', window );">Number of vesting equal installments | installment</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSU)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments', window );">Number of vesting equal installments | installment</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expenses related to unvested RSUs | $</a></td>
<td class="nump">$ 25.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expenses, weighted average period</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Grant date fair value of common stock granted (in shares) | shares</a></td>
<td class="nump">498,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Grant date fair value of common stock vested | $</a></td>
<td class="nump">$ 8.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796667936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,542</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,824</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796688288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">Accumulated Other Comprehensive Income <div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accumulated balances related to each component of other comprehensive income (loss), net of taxes, were as follows as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gain on marketable securities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>781</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> reclassifications out of accumulated other comprehensive income for either of the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893466224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities Available-For-Sale Marketable Securities (Detail) - Noncurrent Investments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 246,364<span></span>
</td>
<td class="nump">$ 266,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">247,376<span></span>
</td>
<td class="nump">267,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=vnda_NoncurrentInvestmentsMember', window );">U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">87,014<span></span>
</td>
<td class="nump">88,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">87,572<span></span>
</td>
<td class="nump">88,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=vnda_NoncurrentInvestmentsMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">122,964<span></span>
</td>
<td class="nump">129,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">123,426<span></span>
</td>
<td class="nump">130,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=vnda_NoncurrentInvestmentsMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">36,386<span></span>
</td>
<td class="nump">48,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 36,378<span></span>
</td>
<td class="nump">$ 48,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=vnda_NoncurrentInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=vnda_NoncurrentInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883595664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Presentation (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796677392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - (Fanapt) - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_FanaptMember', window );">Fanapt&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Fully amortized intangible assets</a></td>
<td class="nump">$ 27.9<span></span>
</td>
<td class="nump">$ 27.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_FanaptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_FanaptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882018912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification Out of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassifications out of accumulated other comprehensive income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893711792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(10,104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price at Grant Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">$ 11.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember', window );">2006 Plan and 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">4,495,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(225,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(172,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,575,041<span></span>
</td>
<td class="nump">4,495,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">3,379,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at end of period (in shares)</a></td>
<td class="nump">4,340,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price at Grant Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 12.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">11.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">18.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">4.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">12.07<span></span>
</td>
<td class="nump">$ 12.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">11.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at end of period (in dollars per share)</a></td>
<td class="nump">$ 11.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Term</a></td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
<td class="text">5 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">4 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at end of period</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 21,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">4,818<span></span>
</td>
<td class="nump">$ 21,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at end of period</a></td>
<td class="nump">$ 4,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796557936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 755<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Discrete impact of net shortfall tax expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117330312&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796754928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;">&#160;In January 2014, the Company announced that the FDA had approved the New Drug Application (NDA) for HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required the Company to make a license payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to BMS. The </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, the Company met its final milestone under its license agreement when cumulative worldwide sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;reached </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. As a result of the achievement of this milestone, the Company made a payment to BMS of </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2018. The </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was capitalized as an intangible asset in the first quarter of 2015, was determined to be additional consideration for the acquisition of the HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;intangible asset and is being amortized on a straight-line basis over the estimated economic useful life of the related product patents, the latest of which expires in </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated economic useful life of both the </span><span style="font-family:inherit;font-size:10pt;"><span>$8.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> intangible assets were changed from </span><span style="font-family:inherit;font-size:10pt;">February 2035</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">July 2035</span><span style="font-family:inherit;font-size:10pt;"> based on the July 2035 expiration date of U.S. patent number 10,376,487&#160;('487 Patent) issued by the U.S. Patent and Trademark Office in August 2019.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company also had </span><span style="font-family:inherit;font-size:10pt;"><span>$27.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of fully amortized intangible assets related to Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful economic life using the straight-line method. Amortization expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for each of the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. The following is a summary of the future intangible asset amortization schedule as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WY781>,W=M_;'P1E!W\N@OY!5!+ P04    "  D.*=0F5R<(Q &  "<)P
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MLR'>2:F$!F5W&O&@STACHQ0[U=UR?=_T!X6^H>1Q. 0%XTEL]1]02P,$%
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MR#$;6_TX$;2?KC%OODOS?U!+ P04    "  D.*=0Y_!%@IX#   3$   &
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MBR\0L87HHQD,00(0M#\X=N32#9AQ17XSF( $OAN5361RX6;3&$@\WXR$Z4>
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M:&5E=#$U+GAM;'U386_;(!#]*X@?4!*2MEED6VHZ39NT25&G=9^)?;91@?,
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M=/YE8_\;1 =>2G+C1ZCS'VPQ)#0N'#_XLYG&;#(<]O,/8LLW+O\"4$L#!!0
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M^]\@.O!2DAL_0IW_8*NAH''A^-Z?S3QFL^%P6'X06[]Q^1M02P,$%     @
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MK^>W/!M6#<N8DO5?4?X#4$L#!!0    ( "0XIU"%.GP'N $  -(#   9
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MV8QC-AH.N^D'L?D;YW\!4$L#!!0    ( "0XIU#Q3+CFL@$  -(#   9
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MY^6=UD;9E.3>EG:P5ZA+HU([T[]F]KT=[Q%CP^CC=$=*+A>UU3]02P,$%
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MW YG&#L&&K*5L)#+W4WA&#LN'&P91..!*:(XF7\%F#*92-M]PC'&''&\L93
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M2CU<J#$?.OTPD:P;3S$T':7E/U!+ P04    "  D.*=03'"@@C8"  "X!@
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MK*Y"AT \LN'")$/,QH5)AYBM"S,;%?2("=WE1,[.1X8>#5+,W0*Q4R V O%
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MAU<R)D$Q>D_*6*5&\110**7>1FK/AX$T!))UXZQ%T\#/_@!02P,$%     @
M)#BG4 59H](N @  40<  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
ME579CILP%/T5Q >,L=F2$4%J4E6MU$K15&V?G>0FH#&8VDZ8_GUM0Q #3IN\
M@&W./8OQDK5<O,H"0'EO%:OERB^4:IX1DOL"*BJ?> .U_G+DHJ)*=\4)R48
M/=BBBB$2! FJ:%G[>6;'MB+/^%FQLH:M\.2YJJCXLP;&VY6/_>O 2WDJE!E
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M4]^I@1AOZK&C>#\]0F!^"7?_ %!+ P04    "  D.*=0+1<9C6,"  #B!P
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MNQ.)J>>G@^+]/,[P,E/SOU!+ P04    "  D.*=0O=QH\5\"  !J"   &0
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M^WD>G1]&=;*S=G(=^->_ 5!+ P04    "  D.*=04*RUS6\"  #2!P  &0
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MV@XS,Y9=E^DF6K1]!PV'-K[Z!U!+ P04    "  D.*=0LT'N="T"  "#!@
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M?XF?@B0*O/E3F.P O+^>-/3M<UIY'B_A=_DV6(;_\1>X97F8/85_^?MB%P&
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M[FN)8YR7>*I@0C//N&YDQ')\M?<<$2IZ2$067;YX:+K+8[:-X6L.7-C> +L
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MT3:-@\R,2$8RT/J%F,,_4?(;4&[B9*WW\RL:B-1"A#F<T4,6;(Y  ;-(BG5
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M,DSE]==NV%OM0D8,7F8L&9=FT4QL"![2L\/RVEEEXU"#Y&AP32+@B<L=W@5
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M51A@<&6UD8C:+FY%;?5#JITEO\!RDP(?_<0-I84@S1^H-I&$%,,[BR(P"2>
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MDYM"1FJF[^P2VV"$1_NC%1XLAUFK@2+"H_T)4EKSJ[;@^.*.OP-02P,$%
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MW?V6Y,7:U>=\-ORUY^8=4$L! A0#%     @ )#BG4!\CSP/     $P(   L
M             ( !     %]R96QS+RYR96QS4$L! A0#%     @ )#BG4"?H
MAPZ"    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    "  D.*=0^J%S ^X    K @  $0              @ &9 0
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  D.*=0F5R<(Q &  "<)P
M$P              @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( "0XIU 98LO700,  * /   8              "  ?<(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  D.*=0;#XWZN0#   \$@
M&               @ %N#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ )#BG4%)J+%!! @  M0<  !@              ( !B!   'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "0XIU#\JYIL1 ,
M )4-   8              "  ?\2  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  D.*=0A-3R[U<"  !7!P  &               @ %Y
M%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ )#BG4.?P
M18*> P  $Q   !@              ( !!AD  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( "0XIU!<T):T[0,  .41   8
M  "  =H<  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  D
M.*=0K]43&[$!  #2 P  &               @ '](   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ )#BG4 2[@ >U 0  T@,  !@
M         ( !Y"(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( "0XIU"0++!;M $  -(#   9              "  <\D  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ )#BG4 %4MH&U 0  T@,
M !D              ( !NB8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  D.*=0V[4I];8!  #0 P  &0              @ &F*
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "0XIU#%=XK-
MLP$  -(#   9              "  9,J  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ )#BG4-3)-$.T 0  T@,  !D
M ( !?2P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  D
M.*=0/D5TUK0!  #2 P  &0              @ %H+@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "0XIU!H[$;TM@$  -(#   9
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M970R,"YX;6Q02P$"% ,4    "  D.*=0I$+P%1L"  ":!@  &0
M    @ 'N.0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M "0XIU#QLO DQ0$  #<$   9              "  4 \  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ )#BG4'^BFYFW 0  T@,  !D
M             ( !/#X  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  D.*=0FKA@?;@!  #2 P  &0              @ $J0   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "0XIU#%@D$SN0$
M -$#   9              "  1E"  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ )#BG4" $WP7% 0  -P0  !D              ( !
M"40  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  D.*=0
MA3I\![@!  #2 P  &0              @ $%1@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( "0XIU#Q3+CFL@$  -(#   9
M      "  ?1'  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ )#BG4&-FFEC< 0   04  !D              ( !W4D  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  D.*=0^;6(2+8!  #2 P
M&0              @ 'P2P  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( "0XIU"4FV/ON0$  -(#   9              "  =U-  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ )#BG4+H4HJ%2
M @  U@<  !D              ( !S4\  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  D.*=0+7#3LC4"  "*!@  &0
M@ %64@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "0X
MIU"QT-2/_P$  ,8%   9              "  <)4  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ )#BG4"SL#<8D P  M T  !D
M         ( !^%8  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    "  D.*=0'>!!U<0#  #=%   &0              @ %36@  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "0XIU U"I+7/ (  %8'
M   9              "  4Y>  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ )#BG4$QPH((V @  N 8  !D              ( !P6
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  D.*=0/*:0
MH;D!   3!   &0              @ $N8P  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( "0XIU"/1]F!W0$  &,$   9
M  "  1YE  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M)#BG4"-)][<% @  _ 4  !D              ( !,F<  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    "  D.*=0!5FCTBX"  !1!P  &0
M            @ %N:0  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( "0XIU =]SDC0 (  !4'   9              "  =-K  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ )#BG4"T7&8UC @
MX@<  !D              ( !2FX  'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    "  D.*=0"<B9<>L!  !?!0  &0              @ 'D
M<   >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "0XIU"]
MW&CQ7P(  &H(   9              "  09S  !X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ )#BG4/?.9DO! 0  $P0  !D
M     ( !G'4  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "0XIU!8&3)[_P$  &T%   9              "
M <6   !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ )#BG
M4'<OT*9O @  1 @  !D              ( !^X(  'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    "  D.*=0;JZNM2,"  !E!@  &0
M        @ &AA0  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( "0XIU -6Q,%G0,  /P/   9              "  ?N'  !X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ )#BG4%"LM<UO @  T@<
M !D              ( !SXL  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    "  D.*=0LT'N="T"  "#!@  &0              @ %UC@
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( "0XIU#RT5--
M#0(  /X%   9              "  =F0  !X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ )#BG4/5YK*SM 0  QP0  !D
M ( !'9,  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  D
M.*=0^E0(2HD"  !-"   &0              @ %!E0  >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( "0XIU QPS'9]%@  .5= 0 4
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K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !% $4 U1(  -7\      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883603008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span>6,335,548</span></span><span style="font-family:inherit;font-size:10pt;"> shares that were subject to outstanding options and restricted stock units (RSUs) under the 2006 Equity Incentive Plan (2006 Plan) and the Amended and Restated 2016 Equity Incentive Plan (2016 Plan, and together with the 2006 Plan, Plans). The 2006 Plan expired by its terms in April 2016, and the Company adopted the 2016 Plan. Outstanding options and RSUs under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. In June 2016, the Company&#8217;s stockholders approved the 2016 Plan. The 2016 Plan has been amended and restated twice to increase the number of shares reserved for issuance, among other administrative changes. Both amendments and restatements of the 2016 Plan were approved by the Company's stockholders. There are a total of </span><span style="font-family:inherit;font-size:10pt;"><span>7,100,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock reserved for issuance under the 2016 Plan, </span><span style="font-family:inherit;font-size:10pt;"><span>2,153,920</span></span><span style="font-family:inherit;font-size:10pt;"> shares of which remained available for future grant as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> year contractual terms. Service option awards granted to employees and new directors upon their election vest and become exercisable over </span><span style="font-family:inherit;font-size:10pt;"><span>four years</span></span><span style="font-family:inherit;font-size:10pt;"> with the first </span><span style="font-family:inherit;font-size:10pt;"><span>25%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares subject to service option awards vesting on the first anniversary of the grant date and remaining </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> of the shares subject to the service option awards in </span><span style="font-family:inherit;font-size:10pt;"><span>36</span></span><span style="font-family:inherit;font-size:10pt;"> equal monthly installments thereafter. Subsequent annual service option awards granted to directors vest and become exercisable in full on the first anniversary of the grant date. Certain service option awards to executives and directors provide for accelerated vesting if there is a change in control of the Company. Certain service option awards to employees and executives provide for accelerated vesting if the respective employee&#8217;s or executive&#8217;s service is terminated by the Company for any reason other than cause or permanent disability.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$9.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation costs related to unvested service option awards are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span><span style="font-family:inherit;font-size:10pt;"> years. No option awards are classified as a liability as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of option activity under the Plans for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2006 and 2016 Plans</span><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price&#160;at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining&#160;Term</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,495,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(225,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,104</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,575,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.81</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,379,139</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,818</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,340,916</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.60</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant-date fair value of options granted was </span><span style="font-family:inherit;font-size:10pt;"><span>$5.73</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$11.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Proceeds from the exercise of stock options amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An RSU is a stock award that entitles the holder to receive shares of the Company&#8217;s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company&#8217;s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that vest in </span><span style="font-family:inherit;font-size:10pt;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> equal annual installments provided that the employee remains employed with the Company. Annual service RSUs granted to directors vest on the first anniversary of the grant date. </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$25.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span><span style="font-family:inherit;font-size:10pt;"> years. No RSUs are classified as a liability as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of RSU activity under the Plans for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2006 and 2016 Plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(136,091</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498,505</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,760,507</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant date fair value for the </span><span style="font-family:inherit;font-size:10pt;"><span>498,505</span></span><span style="font-family:inherit;font-size:10pt;"> shares underlying RSUs that vested during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$8.3 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense recognized for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was comprised of the following:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company&#8217;s publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has never paid cash dividends to its stockholders and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average risk-free rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796838384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - (HETLIOZ) - Additional Information (Detail) - HETLIOZ&#174; - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">194 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CumulativeNetSalesToAchieveMilestone', window );">Cumulative worldwide sales milestone</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Intangible assets capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CumulativeNetSalesToAchieveMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CumulativeNetSalesToAchieveMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882129936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Major Customers (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>Customer</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_NumberOfMajorCustomersAccountedForRevenue', window );">Number of major customers that each accounted for more than 10% of total revenues</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable', window );">Number of major customers that each accounted for more than 10% of total accounts receivable</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_NumberOfMajorCustomersAccountedForRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers that each accounted for more than 10% of total revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_NumberOfMajorCustomersAccountedForRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of major customers that each accounted for more than 10% of total accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883488736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Loss Per Share of Common Stock</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(612</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,806,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,752,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,063,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,870,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,752,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic and diluted:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Antidilutive securities excluded from calculations of diluted net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,095,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,068,806</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894476944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">54,132,336<span></span>
</td>
<td class="nump">53,549,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">54,132,336<span></span>
</td>
<td class="nump">53,549,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6880826992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="num">$ (612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,944<span></span>
</td>
<td class="nump">3,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of discounts and premiums on marketable securities</a></td>
<td class="num">(287)<span></span>
</td>
<td class="num">(906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash adjustments, net</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,905)<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(3,524)<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">76<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other liabilities</a></td>
<td class="num">(1,795)<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_IncreaseDecreaseProductRevenueAllowances', window );">Product revenue allowances</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(907)<span></span>
</td>
<td class="nump">9,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(373)<span></span>
</td>
<td class="num">(393)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(41,400)<span></span>
</td>
<td class="num">(100,803)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">62,073<span></span>
</td>
<td class="nump">64,745<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">20,300<span></span>
</td>
<td class="num">(36,451)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">19,877<span></span>
</td>
<td class="num">(26,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning of period</a></td>
<td class="nump">45,650<span></span>
</td>
<td class="nump">61,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">End of period</a></td>
<td class="nump">$ 65,527<span></span>
</td>
<td class="nump">$ 35,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_IncreaseDecreaseProductRevenueAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_IncreaseDecreaseProductRevenueAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6880674064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (Annual Report) for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The financial information as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company&#8217;s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period. </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#8217;s evaluation could change. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#8217;s Washington, D.C. headquarters.&#160;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Major Customers</a></td>
<td class="text"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Major Customers</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. There were </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of total revenues and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;"><span>96%</span></span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. There were </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of accounts receivable and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;"><span>94%</span></span><span style="font-family:inherit;font-size:10pt;"> of total accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12,&#160;Income Taxes (Topic 740), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">,&#160;which clarifies and simplifies certain aspects of the accounting for income taxes.&#160;The standard is effective&#160;for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments &#8211; Credit Losses</span><span style="font-family:inherit;font-size:10pt;">, which changes the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#8220;expected loss&#8221; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's condensed consolidated financial results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities classified in Level&#160;1 and Level&#160;2 as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level&#160;2 is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">InventoryThe Company evaluates expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory can exceed the forecasted level of cost of goods sold for the next twelve months. The Company classifies the estimate of such inventory as non-current.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9054-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883532592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ScheduleOfInventoriesTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory consisted of the following as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, current</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Non-Current assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>949</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>934</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,056</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory, non-current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,542</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,824</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total inventory</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,862</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ScheduleOfInventoriesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of inventories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ScheduleOfInventoriesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6880630608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity Plan</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of option activity under the Plans for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:41%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2006 and 2016 Plans</span><span style="font-family:inherit;font-size:8pt;">&#160;</span></div><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price&#160;at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted&#160;Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining&#160;Term</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,495,145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21,148</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(225,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,104</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(172,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>890</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Outstanding at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,575,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.81</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,379,139</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,818</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested and expected to vest at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,340,916</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.60</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity for 2006 Plan and 2016 Plan</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of RSU activity under the Plans for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2006 and 2016 Plans</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Underlying </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant&#160;Date </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair&#160;Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745,818</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(136,091</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498,505</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.73</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unvested at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,760,507</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense recognized for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> was comprised of the following:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,282</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted</a></td>
<td class="text">Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the <span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:71%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average expected term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average risk-free rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882190896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - (CFTR Activators and Inhibitors) - Additional Information (Detail) - CFTR Activators and Inhibitors - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales', window );">Future percentage of royalty payments based net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">single-digit<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty', window );">Development and milestone obligations paid to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember', window );">Regulatory Approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember', window );">Future Regulatory Approval And Sales Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember', window );">Development And Milestone Payment, Conclusion Of Phase I Study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty', window );">Development and milestone obligations paid to third party</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Development And Milestone Payment, Conclusion Of Phase I Study</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CftrActivatorsAndInhibitorsAbstract', window );"><strong>CFTR activators and inhibitors</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CftrActivatorsAndInhibitorsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CFTR activators and inhibitors [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CftrActivatorsAndInhibitorsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Milestone Obligations Paid To Third Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Percentage Of Royalty Payments Based On Net Sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_CftrActivatorsAndInhibitorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_FutureRegulatoryApprovalAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885406912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - (HETLIOZ) - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">194 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_HetliozAbstract', window );"><strong>HETLIOZ</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_PercentageOfFutureSublicenseFeesPayable', window );">Percentage of future sublicense fees payable to third-party</a></td>
<td class="text">mid-twenties<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_HetliozAbstract', window );"><strong>HETLIOZ</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 37.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Intangible assets capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPeriod', window );">Royalty payment period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_RoyaltyPayableOnNetSalesPercentage', window );">Royalty payable percentage on net sales</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_HetliozAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Hetlioz [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_HetliozAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_PercentageOfFutureSublicenseFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_PercentageOfFutureSublicenseFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPayableOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPayableOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_RoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_RoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796794592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882327008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - (Stock Option) - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationOptionAwardsContractualTerm', window );">Share based compensation option awards contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards', window );">Portion of initial stock options granted to employees that vests on employee's first anniversary</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards', window );">Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments', window );">Number of vesting equal installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors', window );">Vesting period for subsequent stock options granted to directors</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted, weighted average fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.73<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of employee stock options</a></td>
<td class="nump">$ 479<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vnda_ServiceOptionAwardsMember', window );">Service option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expenses</a></td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expenses, weighted average period</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of new hire stock option award that vests after one year of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of new hire stock option award that vests monthly after one year of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationOptionAwardsContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual term of stock option awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationOptionAwardsContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnda_ServiceOptionAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnda_ServiceOptionAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6698983152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,944<span></span>
</td>
<td class="nump">$ 3,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,833<span></span>
</td>
<td class="nump">$ 2,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894763536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 247,376<span></span>
</td>
<td class="nump">$ 274,027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">87,572<span></span>
</td>
<td class="nump">88,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">123,426<span></span>
</td>
<td class="nump">137,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">36,378<span></span>
</td>
<td class="nump">48,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">87,572<span></span>
</td>
<td class="nump">88,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">87,572<span></span>
</td>
<td class="nump">88,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">159,804<span></span>
</td>
<td class="nump">185,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">123,426<span></span>
</td>
<td class="nump">137,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">36,378<span></span>
</td>
<td class="nump">48,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | U.S. Treasury and government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Corporate debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893631744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 64,950<span></span>
</td>
<td class="nump">$ 45,072<span></span>
</td>
<td class="nump">$ 34,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted cash included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">65,527<span></span>
</td>
<td class="nump">$ 45,650<span></span>
</td>
<td class="nump">35,122<span></span>
</td>
<td class="nump">$ 61,749<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted cash included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=vnda_NoncurrentInventoryAndOtherMember', window );">Non-current inventory and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract', window );"><strong>Restricted cash included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vnda_NoncurrentInventoryAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vnda_NoncurrentInventoryAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6701167712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text">Earnings per Share<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the calculation of basic and diluted net income (loss) per share of common stock for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands, except for share and per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(612</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,806,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,752,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,063,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,870,146</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,752,774</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic and diluted:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Antidilutive securities excluded from calculations of diluted net income (loss) per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,095,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,068,806</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurred a net loss for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> causing inclusion of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883518144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;1 &#8212; defined as observable inputs such as quoted prices in active markets</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;2 &#8212; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level&#160;3 &#8212; defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions</span></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities classified in Level&#160;1 and Level&#160;2 as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> consist of cash equivalents and available-for-sale marketable securities. The valuation of Level&#160;1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level&#160;2 is also determined using a market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level&#160;2 securities include certificates of deposit, commercial paper, corporate notes and asset-backed securities that use as their basis readily observable market parameters.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of March 31, 2020 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active&#160;Markets&#160;for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable&#160;Inputs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,804</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company held certain assets that are required to be measured at fair value on a recurring basis, as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurement as of December 31, 2019 Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in<br/>Active&#160;Markets&#160;for<br/>Identical Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant&#160;Other<br/>Observable&#160;Inputs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant<br/>Unobservable<br/>Inputs</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,025</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274,027</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;"> include </span><span style="font-family:inherit;font-size:10pt;"><span>$7.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash equivalents.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also has financial assets and liabilities, not required to be measured at fair value on a recurring basis, which primarily consist of cash, accounts receivable, restricted cash, accounts payable and accrued liabilities, product revenue allowances and milestone obligations under license agreements, the carrying values of which materially approximate their fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883627184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business. Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#8217;s business partners or customers, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#8217;s products. The term of these indemnification agreements is generally perpetual from the date of </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company by other pharmaceutical companies.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;">&#160;In February 2004, the Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.  As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has paid BMS </span><span style="font-family:inherit;font-size:10pt;"><span>$37.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and milestone obligations, including </span><span style="font-family:inherit;font-size:10pt;"><span>$33.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of regulatory approval and commercial milestones capitalized as intangible assets (see Note </span><span style="font-family:inherit;font-size:10pt;">6</span><span style="font-family:inherit;font-size:10pt;">). The Company has no remaining milestone obligations to BMS. Additionally, the Company is obligated to make royalty payments on HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;net sales to BMS in any territory where the Company commercializes HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;for a period equal to the greater of </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;"> following the first commercial sale in the territory or the expiry of the new chemical entity (NCE) patent in that territory. During the period prior to the expiry of the NCE patent in a territory, the Company is obligated to pay a </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> royalty on net sales in that territory.&#160;The royalty rate is decreased by half for countries in which no NCE patent existed or for the remainder of the 10 years after the expiry of the NCE patent. The Company is also obligated under the license agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>mid-twenties</span></span><span style="font-family:inherit;font-size:10pt;">.&#160;The Company has agreed with BMS in the license agreement for HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;to use its commercially reasonable efforts to develop and commercialize HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span><span style="font-family:inherit;font-size:10pt;">&#160;Pursuant to the terms of a settlement agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> franchise to the Company on December&#160;31, 2014. The Company paid directly to Sanofi S.A (Sanofi) a fixed royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of net sales through December&#160;2019 related to manufacturing&#160;know-how.&#160;The Company is also obligated to pay Sanofi a fixed royalty on Fanapt</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;net sales equal to </span><span style="font-family:inherit;font-size:10pt;"><span>6%</span></span><span style="font-family:inherit;font-size:10pt;"> on Sanofi&#160;know-how&#160;not related to manufacturing under certain conditions for a period of up to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;"> in markets where the NCE patent has expired or was not issued. The Company is obligated to pay this 6% royalty on net sales in the U.S. through November 2026. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Tradipitant.</span><span style="font-family:inherit;font-size:10pt;">&#160;In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an&#160;NK-1R&#160;antagonist, tradipitant, for all human indications. Lilly is eligible to receive future payments based upon achievement of specified development, regulatory approval and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the </span><span style="font-family:inherit;font-size:10pt;"><span>low double digits</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has paid Lilly </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and development milestones, including a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment in July 2018 as a result of enrolling the first subject into a Phase III study for tradipitant. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, remaining milestone obligations include a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone due upon the filing of the first marketing authorization for tradipitant in either the U.S. or European Union (E.U.), </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the first approval of a marketing authorization for tradipitant in the U.S. and E.U., respectively, and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$80.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for sales milestones. The Company is obligated to use its commercially reasonable efforts to develop and commercialize tradipitant.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">VQW-765.</span><span style="font-family:inherit;font-size:10pt;">&#160;In connection with a settlement agreement with Novartis relating to Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize VQW-765,&#160;a Phase II&#160;alpha-7&#160;nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize&#160;VQW-765&#160;and is responsible for all development costs. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>mid-teens</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Portfolio of CFTR activators and inhibitors</span><span style="font-family:inherit;font-size:10pt;">. In March 2017, the Company entered into a license agreement with the University of California San Francisco (UCSF), under which the Company acquired an exclusive worldwide license to develop and commercialize a portfolio of CFTR activators and inhibitors. Pursuant to the license agreement, the Company will develop and commercialize the CFTR activators and inhibitors and is responsible for all development costs under the license agreement, including current pre-investigational new drug development work. UCSF is eligible to receive future payments based upon achievement of specified development and commercialization milestones as well as&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>single-digit</span></span><span style="font-family:inherit;font-size:10pt;">&#160;royalties on net sales. As of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company has paid UCSF </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in upfront fees and development milestones, including an upfront license fee payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2017 and a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> development milestone payment in March 2019. As of </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, remaining milestone obligations include </span><span style="font-family:inherit;font-size:10pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;for development milestones and&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$33.0 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;for future regulatory approval and sales milestones. Included in the&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$12.2 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160; in development milestones is a </span><span style="font-family:inherit;font-size:10pt;"><span>$350,000</span></span><span style="font-family:inherit;font-size:10pt;"> milestone due upon the conclusion of a Phase I study for each licensed product but not to exceed&#160;</span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">&#160;in total for the CFTR portfolio. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</span></div><span style="font-family:inherit;font-size:10pt;">In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to clinical development and clinical manufacturing activities under fee service arrangements. The Company&#8217;s current agreements for clinical, marketing, and other services may be terminated on generally </span><span style="font-family:inherit;font-size:10pt;"><span>90</span></span><span style="font-family:inherit;font-size:10pt;"> days&#8217; notice without incurring additional charges, other than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company&#8217;s contractors in closing out work in progress as of the effective date of termination. Noncancellable long-term contractual cash obligations include noncancellable purchase commitments longer than one year and primarily relate to commitments for media and data services, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> are expected to be paid in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2022</span>, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883532592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Marketable Securities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than two years:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,014</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(110</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than two years:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,055</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883635584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s accounts payable and accrued liabilities as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and other professional fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,893</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,912</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893236496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VANDA PHARMACEUTICALS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">03-0491827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2200 Pennsylvania Avenue NW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300 E <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">734-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,550,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001347178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6880627584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="num">$ (612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Net foreign currency translation loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Change in net unrealized gain on marketable securities</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision on other comprehensive income (loss)</a></td>
<td class="num">(160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 1,018<span></span>
</td>
<td class="num">$ (478)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118948100&amp;loc=d3e30304-110892<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796583328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There have been no material changes to the significant accounting policies previously disclosed in the Annual Report. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Management continually re-evaluates its estimates, judgments and assumptions, and management&#8217;s evaluation could change. Actual results could differ from those estimates.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For purposes of the Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows, cash equivalents represent highly-liquid investments with a maturity date of three months or less at the date of purchase. Cash and </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">cash equivalents include investments in money market funds with commercial banks and financial institutions, and commercial paper of high-quality corporate issuers.&#160;Restricted cash relates primarily to amounts held as collateral for letters of credit for leases for office space at the Company&#8217;s Washington, D.C. headquarters.&#160;</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statement of Cash Flows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,950</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,379</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current inventory and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>577</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,527</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,122</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue from Net Product Sales</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. Net sales by product for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,756</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,713</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Major Customers</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of specialty pharmacies, and is not available in retail pharmacies. Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> is available in the U.S. for distribution through a limited number of wholesalers and is available in retail pharmacies. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse which is the point at which control is transferred to the customer. There were </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of total revenues and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;"><span>96%</span></span><span style="font-family:inherit;font-size:10pt;"> of total revenues for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. There were </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> major customers that each accounted for more than 10% of accounts receivable and, as a group, represented </span><span style="font-family:inherit;font-size:10pt;"><span>94%</span></span><span style="font-family:inherit;font-size:10pt;"> of total accounts receivable at </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Receivables are carried at transaction price net of allowance for credit losses. Allowance for credit losses is measured using historical loss rates based on the aging of receivables and incorporating current conditions and forward-looking estimates.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2019-12,&#160;Income Taxes (Topic 740), </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Accounting for Income Taxes</span><span style="font-family:inherit;font-size:10pt;">,&#160;which clarifies and simplifies certain aspects of the accounting for income taxes.&#160;The standard is effective&#160;for years beginning after December&#160;15, 2020, and interim periods within annual periods beginning after December&#160;15, 2020. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#8217;s condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments &#8211; Credit Losses</span><span style="font-family:inherit;font-size:10pt;">, which changes the impairment model for most financial assets and certain other financial instruments. The standard requires the use of a forward-looking &#8220;expected loss&#8221; model for instruments measured at amortized cost that generally will result in the earlier recognition of allowances for losses. The standard is effective for years beginning after December&#160;15, 2019, and interim periods within annual periods beginning after December&#160;15, 2019. The adoption of this standard on January 1, 2020 did not have a material impact on the Company's condensed consolidated financial results.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>122</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>39</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Business Organization and Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation</Role>
      <ShortName>Business Organization and Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Legal Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/LegalMatters</Role>
      <ShortName>Legal Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/MarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/Tables</Role>
      <ShortName>(Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/IntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/EarningsPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Business Organization and Presentation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail</Role>
      <ShortName>Business Organization and Presentation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Sales by Product (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Major Customers (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Major Customers (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Marketable Securities Available-For-Sale Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail</Role>
      <ShortName>Marketable Securities Available-For-Sale Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Inventory (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/InventoryDetail</Role>
      <ShortName>Inventory (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/InventoryTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Intangible Assets - (HETLIOZ) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - (HETLIOZ) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Intangible Assets - (Fanapt) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - (Fanapt) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Summary of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail</Role>
      <ShortName>Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Commitments and Contingencies - (HETLIOZ) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - (HETLIOZ) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Commitments and Contingencies - (Fanapt) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - (Fanapt) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Commitments and Contingencies - (Tradipitant) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - (Tradipitant) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Commitments and Contingencies - (VQW-765) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - (VQW-765) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Commitments and Contingencies - (CFTR Activators and Inhibitors) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - (CFTR Activators and Inhibitors) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Purchase Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Accumulated Other Comprehensive Income - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail</Role>
      <ShortName>Accumulated Other Comprehensive Income - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Stock-Based Compensation - (Stock-Based Compensation) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - (Stock-Based Compensation) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Stock-Based Compensation - (Stock Option) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - (Stock Option) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Stock-Based Compensation - (RSU) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - (RSU) - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity Plan (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail</Role>
      <ShortName>Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/IncomeTaxes</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="vnda331202010q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Earnings per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail</Role>
      <ShortName>Earnings per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vandapharmaceuticals.com/role/EarningsPerShareTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vnda331202010q.htm">vnda331202010q.htm</File>
    <File>vnda-20200331.xsd</File>
    <File>vnda-20200331_cal.xml</File>
    <File>vnda-20200331_def.xml</File>
    <File>vnda-20200331_lab.xml</File>
    <File>vnda-20200331_pre.xml</File>
    <File>vndaex1042331202010q.htm</File>
    <File>vndaex311331202010q.htm</File>
    <File>vndaex312331202010q.htm</File>
    <File>vndaex321331202010q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vnda331202010q.htm": {
   "axisCustom": 1,
   "axisStandard": 16,
   "contextCount": 122,
   "dts": {
    "calculationLink": {
     "local": [
      "vnda-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vnda-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "vnda331202010q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vnda-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnda-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vnda-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 386,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 19,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 24
   },
   "keyCustom": 25,
   "keyStandard": 279,
   "memberCustom": 16,
   "memberStandard": 23,
   "nsprefix": "vnda",
   "nsuri": "http://www.vandapharmaceuticals.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.vandapharmaceuticals.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Marketable Securities",
     "role": "http://www.vandapharmaceuticals.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Fair Value Measurements",
     "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Inventory",
     "role": "http://www.vandapharmaceuticals.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Intangible Assets",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Accounts Payable and Accrued Liabilities",
     "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Commitments and Contingencies",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Accumulated Other Comprehensive Income",
     "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124100 - Disclosure - Income Taxes",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125100 - Disclosure - Earnings per Share",
     "role": "http://www.vandapharmaceuticals.com/role/EarningsPerShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126100 - Disclosure - Legal Matters",
     "role": "http://www.vandapharmaceuticals.com/role/LegalMatters",
     "shortName": "Legal Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/Tables",
     "shortName": "(Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ScheduleOfInventoriesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Inventory (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ScheduleOfInventoriesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316301 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325301 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.vandapharmaceuticals.com/role/EarningsPerShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401401 - Disclosure - Business Organization and Presentation (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail",
     "shortName": "Business Organization and Presentation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Segment",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2019Q1",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Summary of Significant Accounting Policies - Net Sales by Product (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail",
     "shortName": "Summary of Significant Accounting Policies - Net Sales by Product (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1QTD_srt_ProductOrServiceAxis_vnda_HetliozMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vnda:NumberOfMajorCustomersAccountedForRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Customer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Summary of Significant Accounting Policies - Major Customers (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail",
     "shortName": "Summary of Significant Accounting Policies - Major Customers (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:MajorCustomersPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vnda:NumberOfMajorCustomersAccountedForRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Customer",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Marketable Securities Available-For-Sale Marketable Securities (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail",
     "shortName": "Marketable Securities Available-For-Sale Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1_us-gaap_InvestmentTypeAxis_vnda_NoncurrentInvestmentsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "vnda:ScheduleOfInventoriesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Inventory (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/InventoryDetail",
     "shortName": "Inventory (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "vnda:ScheduleOfInventoriesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2018Q2QTD_srt_ProductOrServiceAxis_vnda_HetliozMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Intangible Assets - (HETLIOZ) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail",
     "shortName": "Intangible Assets - (HETLIOZ) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "D2018Q2Apr_srt_ProductOrServiceAxis_vnda_HetliozMember",
      "decimals": "-5",
      "lang": null,
      "name": "vnda:CumulativeNetSalesToAchieveMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1_srt_ProductOrServiceAxis_vnda_FanaptMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Intangible Assets - (Fanapt) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
     "shortName": "Intangible Assets - (Fanapt) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1_srt_ProductOrServiceAxis_vnda_FanaptMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Intangible Assets - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail",
     "shortName": "Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Intangible Assets - Summary of Intangible Assets (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Summary of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail",
     "shortName": "Intangible Assets - Summary of Future Intangible Asset Amortization (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1_srt_ProductOrServiceAxis_vnda_HetliozMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Accounts Payable and Accrued Liabilities (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail",
     "shortName": "Accounts Payable and Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:PercentageOfFutureSublicenseFeesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - Commitments and Contingencies - (HETLIOZ) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - (HETLIOZ) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:PercentageOfFutureSublicenseFeesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "vnda:RoyaltyPayableOnNetSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Commitments and Contingencies - (Fanapt) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - (Fanapt) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_vnda_StatementScenarioSecondaryAxis_vnda_ScenarioFourMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "vnda:RoyaltyPayableOnNetSalesPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414403 - Disclosure - Commitments and Contingencies - (Tradipitant) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - (Tradipitant) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_TradipitantMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_VQW765Member",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - Commitments and Contingencies - (VQW-765) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - (VQW-765) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_vnda_VQW765Member",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Commitments and Contingencies - (CFTR Activators and Inhibitors) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - (CFTR Activators and Inhibitors) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_srt_ProductOrServiceAxis_vnda_CftrActivatorsAndInhibitorsMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails",
     "shortName": "Commitments and Contingencies - Purchase Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)",
     "role": "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416402 - Disclosure - Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail",
     "shortName": "Accumulated Other Comprehensive Income - Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2020Q1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416403 - Disclosure - Accumulated Other Comprehensive Income - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail",
     "shortName": "Accumulated Other Comprehensive Income - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419402 - Disclosure - Stock-Based Compensation - (Stock-Based Compensation) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - (Stock-Based Compensation) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_vnda_StockOptionsAndRestrictedStockUnitsRSUsMember_us-gaap_PlanNameAxis_vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vnda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ShareBasedCompensationOptionAwardsContractualTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419403 - Disclosure - Stock-Based Compensation - (Stock Option) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - (Stock Option) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vnda:ShareBasedCompensationOptionAwardsContractualTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments",
      "reportCount": 1,
      "unitRef": "installment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419404 - Disclosure - Stock-Based Compensation - (RSU) - Additional Information (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - (RSU) - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "lang": null,
      "name": "vnda:SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "installment",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419405 - Disclosure - Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail",
     "shortName": "Stock-Based Compensation - Summary of Option Activity for 2006 Plan and the 2016 Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419406 - Disclosure - Stock-Based Compensation - Summary of RSU Activity Plan (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity Plan (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419407 - Disclosure - Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Total Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail",
     "shortName": "Stock-Based Compensation - Black-Scholes-Merton Option Pricing Model for Stock Options Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424401 - Disclosure - Income Taxes (Details)",
     "role": "http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425402 - Disclosure - Earnings per Share (Detail)",
     "role": "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail",
     "shortName": "Earnings per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Business Organization and Presentation",
     "role": "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation",
     "shortName": "Business Organization and Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vnda331202010q.htm",
      "contextRef": "FD2020Q1YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 39,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r111",
      "r164",
      "r166",
      "r267",
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r112",
      "r164",
      "r167",
      "r269",
      "r277",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r15",
      "r114",
      "r115",
      "r165"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r28"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Consulting and other professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r28"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized gain on marketable securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r38",
      "r42",
      "r44",
      "r45",
      "r229",
      "r235",
      "r237"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "totalLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeSummaryOfAccumulatedBalancesRelatedToEachComponentOfOtherComprehensiveIncomeLossDetail",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r45",
      "r46",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r171",
      "r173",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r173",
      "r199",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r72",
      "r148",
      "r152"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible asset amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from calculations of diluted net income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r126",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r109",
      "r248",
      "r258"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r37"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r120",
      "r137"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r117",
      "r121",
      "r137"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r119",
      "r137"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r175",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r222",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r80",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Business Organization and Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r24",
      "r74"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r75",
      "r77",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r69",
      "r74",
      "r76"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r69",
      "r234"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r159",
      "r251",
      "r263"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Notes 8 and 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 150,000,000 shares authorized; 54,132,336 and 53,549,612 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r230",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r100",
      "r101",
      "r230",
      "r231",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r100",
      "r101",
      "r230",
      "r231",
      "r271"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r100",
      "r101",
      "r230",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r230",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r168",
      "r170",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r55",
      "r56"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of goods sold excluding amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r72",
      "r78",
      "r214",
      "r215"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r72",
      "r155"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r58",
      "r81",
      "r84",
      "r85",
      "r86",
      "r87",
      "r91",
      "r253",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income (loss) per share, basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r58",
      "r81",
      "r84",
      "r85",
      "r86",
      "r87",
      "r91",
      "r253",
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r207",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Discrete impact of net shortfall tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expenses, weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expenses related to unvested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expenses"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r224",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r225",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r225",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r225",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r225",
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r151",
      "r245"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount",
        "verboseLabel": "Fully amortized intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "terseLabel": "Intangible assets capitalized"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r108",
      "r217"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r21",
      "r146"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r34",
      "r143"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 2.0,
       "parentTag": "vnda_Inventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory, current"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 1.0,
       "parentTag": "vnda_Inventory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "totalLabel": "Total inventory, non-current"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Noncurrent [Abstract]",
        "terseLabel": "Non-Current assets"
       }
      }
     },
     "localname": "InventoryNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r35",
      "r77",
      "r93",
      "r144",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Amortization of discounts and premiums on marketable securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r131",
      "r246",
      "r257",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Matters"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/LegalMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r249",
      "r261"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MajorCustomersPolicyPolicyTextBlock": {
     "auth_ref": [
      "r98",
      "r100",
      "r101",
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.",
        "label": "Major Customers, Policy [Policy Text Block]",
        "terseLabel": "Major Customers"
       }
      }
     },
     "localname": "MajorCustomersPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r47",
      "r50",
      "r57",
      "r73",
      "r89",
      "r252",
      "r264"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/BusinessOrganizationAndPresentationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "netLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease non-current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r28"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r39",
      "r40",
      "r42"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax",
        "terseLabel": "Change in net unrealized gain on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), before Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r38",
      "r42",
      "r233",
      "r236"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Net foreign currency translation loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r51",
      "r53",
      "r161"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r43",
      "r216",
      "r218"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "negatedTerseLabel": "Tax provision on other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r64",
      "r66",
      "r118"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of intangible asset",
        "terseLabel": "Acquisition of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r175",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or outstanding at March 31, 2020 and December 31, 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r64",
      "r65",
      "r118"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r202"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of employee stock options",
        "verboseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r156",
      "r262"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Second Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Due in Third Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Purchase Obligation, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "PurchaseObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement maturing in the remainder of the fiscal year following the latest fiscal year ended. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.",
        "label": "Purchase Obligation, Future Minimum Payments, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r45",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "terseLabel": "Reclassifications out of accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r209",
      "r279"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r10",
      "r74",
      "r76",
      "r247",
      "r259"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Restricted cash included in:"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSU)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r162",
      "r260"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r54",
      "r106",
      "r107",
      "r110"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of Accumulated Balances Related to Each Component of Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r254",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r173",
      "r198",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r173",
      "r198",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Net Sales by Product"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r175",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity for 2006 Plan and 2016 Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r177",
      "r188",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Option Activity Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Black-Scholes-Merton Option Pricing Model for Employee and Director Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Future Intangible Asset Amortization"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r60",
      "r142"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationTotalStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "verboseLabel": "Grant date fair value of common stock granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Grant date fair value of common stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted average risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted average expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares of common stock available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted, weighted average fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r179",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price at Grant Date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r172",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r194",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Weighted average expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationBlackScholesMertonOptionPricingModelForStockOptionsGrantedDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r33",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r161",
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock form the exercise of stock options and settlement of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r161",
      "r162",
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r162",
      "r174",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock from the exercise of stock options and settlement of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r116"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r168",
      "r250",
      "r270"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government agencies"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/FairValueMeasurementsAssetsMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r97",
      "r102",
      "r103",
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r83",
      "r87"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r82",
      "r87"
     ],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted average shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vandapharmaceuticals.com/role/EarningsPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnda_AccruedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpense",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/AccountsPayableAndAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreements For Clinical And Marketing Services, Termination Notice Period",
        "label": "Agreements For Clinical And Marketing Services, Termination Notice Period",
        "terseLabel": "Agreements for clinical and marketing services, termination notice period"
       }
      }
     },
     "localname": "AgreementsForClinicalAndMarketingServicesTerminationNoticePeriod",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_CftrActivatorsAndInhibitorsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CFTR activators and inhibitors [Abstract]",
        "label": "CFTR activators and inhibitors [Abstract]",
        "terseLabel": "CFTR activators and inhibitors"
       }
      }
     },
     "localname": "CftrActivatorsAndInhibitorsAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_CftrActivatorsAndInhibitorsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CFTR activators and inhibitors [Member]",
        "label": "CFTR activators and inhibitors [Member]",
        "terseLabel": "CFTR Activators and Inhibitors"
       }
      }
     },
     "localname": "CftrActivatorsAndInhibitorsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments and Contingencies [Line Items]",
        "terseLabel": "Commitments and Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments and Contingencies [Table]",
        "terseLabel": "Commitments and Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_CumulativeNetSalesToAchieveMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net cumulative worldwide sales to achieve milestone and trigger payment of milestone obligation.",
        "label": "Cumulative Net Sales To Achieve Milestone",
        "terseLabel": "Cumulative worldwide sales milestone"
       }
      }
     },
     "localname": "CumulativeNetSalesToAchieveMilestone",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Milestone Obligations Paid To Third Party",
        "label": "Development And Milestone Obligations Paid To Third Party",
        "terseLabel": "Development and milestone obligations paid to third party"
       }
      }
     },
     "localname": "DevelopmentAndMilestoneObligationsPaidToThirdParty",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Milestone Payment, Conclusion Of Phase I Study [Member]",
        "label": "Development And Milestone Payment, Conclusion Of Phase I Study [Member]",
        "terseLabel": "Development And Milestone Payment, Conclusion Of Phase I Study"
       }
      }
     },
     "localname": "DevelopmentAndMilestonePaymentConclusionOfPhaseIStudyMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.",
        "label": "Development And Milestone Payments Potentially Due To Third Party",
        "terseLabel": "Possible future milestone payment",
        "verboseLabel": "Possible future milestone payments"
       }
      }
     },
     "localname": "DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_FanaptAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fanapt [Abstract]",
        "label": "Fanapt [Abstract]",
        "terseLabel": "Fanapt"
       }
      }
     },
     "localname": "FanaptAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_FanaptMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fanapt.",
        "label": "Fanapt [Member]",
        "terseLabel": "Fanapt\u00ae",
        "verboseLabel": "Fanapt\u00ae product sales, net"
       }
      }
     },
     "localname": "FanaptMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Percentage Of Royalty Payments Based On Net Sales.",
        "label": "Future Percentage Of Royalty Payments Based On Net Sales",
        "terseLabel": "Future percentage of royalty payments based net sales"
       }
      }
     },
     "localname": "FuturePercentageOfRoyaltyPaymentsBasedOnNetSales",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_FutureRegulatoryApprovalAndSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future Regulatory Approval And Sales Milestones [Member]",
        "label": "Future Regulatory Approval And Sales Milestones [Member]",
        "terseLabel": "Future Regulatory Approval And Sales Milestones"
       }
      }
     },
     "localname": "FutureRegulatoryApprovalAndSalesMilestonesMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_HetliozAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hetlioz [Abstract]",
        "label": "Hetlioz [Abstract]",
        "terseLabel": "HETLIOZ"
       }
      }
     },
     "localname": "HetliozAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_HetliozMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hetlioz [Member]",
        "label": "Hetlioz [Member]",
        "terseLabel": "HETLIOZ\u00ae product sales, net",
        "verboseLabel": "HETLIOZ\u00ae"
       }
      }
     },
     "localname": "HetliozMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsHetliozAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfFutureIntangibleAssetAmortizationDetail",
      "http://www.vandapharmaceuticals.com/role/IntangibleAssetsSummaryOfIntangibleAssetsDetail",
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesNetSalesByProductDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_IncreaseDecreaseProductRevenueAllowances": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of obligations and expenses incurred but not paid for product revenue allowances.",
        "label": "Increase (Decrease) Product Revenue Allowances",
        "terseLabel": "Product revenue allowances"
       }
      }
     },
     "localname": "IncreaseDecreaseProductRevenueAllowances",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_Inventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "inventory",
        "label": "inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventory",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryAndOtherNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle and other non current assets.",
        "label": "Inventory and Other Non Current",
        "terseLabel": "Non-current inventory and other"
       }
      }
     },
     "localname": "InventoryAndOtherNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryFinishedGoodsNetOfReservesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Finished Goods, Net of Reserves, Non Current",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryRawMaterialsNetOfReservesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Raw Materials, Net of Reserves, Non Current",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReservesNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_InventoryWorkInProcessNetOfReservesNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/InventoryDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Work in Process, Net of Reserves, Non Current",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReservesNonCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_NoncurrentInventoryAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncurrent Inventory and Other [Member]",
        "label": "Noncurrent Inventory and Other [Member]",
        "terseLabel": "Non-current inventory and other"
       }
      }
     },
     "localname": "NoncurrentInventoryAndOtherMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_NoncurrentInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncurrent Investments [Member]",
        "label": "Noncurrent Investments [Member]",
        "terseLabel": "Noncurrent Investments"
       }
      }
     },
     "localname": "NoncurrentInvestmentsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/MarketableSecuritiesAvailableForSaleMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_NumberOfMajorCustomersAccountedForRevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of major customers that each accounted for more than 10% of total revenues.",
        "label": "Number Of Major Customers Accounted For Revenue",
        "terseLabel": "Number of major customers that each accounted for more than 10% of total revenues"
       }
      }
     },
     "localname": "NumberOfMajorCustomersAccountedForRevenue",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "vnda_NumberOfMajorCustomersAccountedForTradeAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of major customers that each accounted for more than 10% of total accounts receivable.",
        "label": "Number Of Major Customers Accounted For Trade Accounts Receivable",
        "terseLabel": "Number of major customers that each accounted for more than 10% of total accounts receivable"
       }
      }
     },
     "localname": "NumberOfMajorCustomersAccountedForTradeAccountsReceivable",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "vnda_PercentageOfFutureSublicenseFeesPayable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of sublicense fees payable to third party under a contractual arrangement for use of technology or intellectual property.",
        "label": "Percentage Of Future Sublicense Fees Payable",
        "terseLabel": "Percentage of future sublicense fees payable to third-party"
       }
      }
     },
     "localname": "PercentageOfFutureSublicenseFeesPayable",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ProductRevenueAllowancesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product Revenue Allowances, Current",
        "label": "Product Revenue Allowances, Current",
        "terseLabel": "Product revenue allowances"
       }
      }
     },
     "localname": "ProductRevenueAllowancesCurrent",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vnda_RegulatoryApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Regulatory Approval Milestone [Member]",
        "label": "Regulatory Approval Milestone [Member]",
        "terseLabel": "Regulatory Approval Milestone"
       }
      }
     },
     "localname": "RegulatoryApprovalMilestoneMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesCftrActivatorsAndInhibitorsAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_RoyaltyPayableOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty payable percentage under a contractual arrangement for use of technology or intellectual property.",
        "label": "Royalty Payable On Net Sales Percentage",
        "terseLabel": "Royalty payable percentage on net sales"
       }
      }
     },
     "localname": "RoyaltyPayableOnNetSalesPercentage",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_RoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Period",
        "label": "Royalty Period",
        "terseLabel": "Royalty payment period"
       }
      }
     },
     "localname": "RoyaltyPeriod",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesHetliozAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Milestone [Member]",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ScenarioFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Scenario 4 [Member]",
        "label": "Scenario 4 [Member]",
        "terseLabel": "November 16,2016 through December 31,2019"
       }
      }
     },
     "localname": "ScenarioFourMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ScheduleOfInventoriesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of inventories.",
        "label": "Schedule Of Inventories [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoriesTableTextBlock",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]",
        "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]",
        "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsLineItems",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]",
        "label": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]",
        "terseLabel": "Schedule of Share based Compensation Arrangements by Share based Payment Award, Equity Instruments, Other Than Options, Restricted Stock Units [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRestrictedStockUnitsTable",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ServiceOptionAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service Option Awards [Member]",
        "label": "Service Option Awards [Member]",
        "terseLabel": "Service option awards"
       }
      }
     },
     "localname": "ServiceOptionAwardsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract]",
        "label": "Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Price/Share Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfRsuActivityPlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options and Restricted Stock Units (RSUs) Outstanding Number",
        "terseLabel": "Shares subject to outstanding options and RSUs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of new hire stock option award that vests after one year of service.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Share Subject To Option Awards",
        "terseLabel": "Portion of initial stock options granted to employees that vests on employee's first anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfShareSubjectToOptionAwards",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of new hire stock option award that vests monthly after one year of service.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Remaining Percentage Of Share Subject To Option Awards",
        "terseLabel": "Portion of initial stock options granted to employees that vests ratably over three years after completion of first year of service"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRemainingPercentageOfShareSubjectToOptionAwards",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "vnda_ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee and new director's right to exercise an annual option award is no longer contingent on satisfaction of either a service, market or a performance condition.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Annual Award Vesting Period Employees and New Directors",
        "terseLabel": "Vesting period for subsequent stock options granted to directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAnnualAwardVestingPeriodEmployeesandNewDirectors",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_ShareBasedCompensationOptionAwardsContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual term of stock option awards.",
        "label": "Share Based Compensation Option Awards Contractual Term",
        "terseLabel": "Share based compensation option awards contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAwardsContractualTerm",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "vnda_SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments",
        "label": "Share-based Compensation Arrangement by Share-Based Payment Award, Options, Vesting Period, Number Of Equal Monthly Installments",
        "terseLabel": "Number of vesting equal installments"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbyShareBasedPaymentAwardOptionsVestingPeriodNumberOfEqualMonthlyInstallments",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationRsuAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockOptionAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "vnda_StatementScenarioSecondaryAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statement, Scenario Secondary [Axis]",
        "label": "Statement, Scenario Secondary [Axis]",
        "terseLabel": "Statement, Scenario Secondary [Axis]"
       }
      }
     },
     "localname": "StatementScenarioSecondaryAxis",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_StatementScenarioSecondaryDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statement, Scenario Secondary [Domain]",
        "label": "Statement, Scenario Secondary [Domain]",
        "terseLabel": "Statement, Scenario Secondary [Domain]"
       }
      }
     },
     "localname": "StatementScenarioSecondaryDomain",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesFanaptAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_StockOptionsAndRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Options and Restricted Stock Units (RSUs) [Member]",
        "label": "Stock Options and Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Outstanding options and RSUs granted (RSUs)"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/SummaryOfSignificantAccountingPoliciesMajorCustomersDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "vnda_TradipitantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tradipitant [Member]",
        "label": "Tradipitant [Member]",
        "terseLabel": "Tradipitant"
       }
      }
     },
     "localname": "TradipitantMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesTradipitantAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]",
        "label": "Two Thousand Six Plan and Two Thousand Sixteen Plan [Member]",
        "terseLabel": "2006 Plan and 2016 Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanAndTwoThousandSixteenPlanMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail",
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationSummaryOfOptionActivityFor2006PlanAnd2016PlanDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_TwoThousandSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two Thousand Sixteen Plan [Member]",
        "label": "Two Thousand Sixteen Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenPlanMember",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/StockBasedCompensationStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vnda_VQW765Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VQW-765 [Member]",
        "label": "VQW-765 [Member]",
        "terseLabel": "VQW-765"
       }
      }
     },
     "localname": "VQW765Member",
     "nsuri": "http://www.vandapharmaceuticals.com/20200331",
     "presentation": [
      "http://www.vandapharmaceuticals.com/role/CommitmentsAndContingenciesVqw765AdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r281": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r282": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r283": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r284": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r285": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882118032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - (Tradipitant) - Additional Information (Detail) - Tradipitant - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">96 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales', window );">Future percentage of royalty payments based net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low double digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty', window );">Development and milestone obligations paid to third party</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember', window );">Sales Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Regulatory Approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe | Regulatory Approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty', window );">Possible future milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Milestone Obligations Paid To Third Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Percentage Of Royalty Payments Based On Net Sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893854992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Summary of Future Intangible Asset Amortization (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 22,667<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">22,667<span></span>
</td>
<td class="nump">$ 23,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">1,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 15,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796671008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the total end of period cash, cash equivalents and restricted cash reported within the Condensed Consolidated Statement of Cash Flows:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,950</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,379</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash included in: </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-current inventory and other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>577</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65,527</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,122</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#bfe4ff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Net Sales by Product</a></td>
<td class="text"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s net product sales consist of sales of HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;"> and Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">. Net sales by product for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,336</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fanapt</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:inherit;font-size:10pt;">&#160;product sales, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,756</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net product sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,713</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6880854144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:41%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Useful Life</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 2035</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,963</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,037</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Summary of Future Intangible Asset Amortization</a></td>
<td class="text">The following is a summary of the future intangible asset amortization schedule as of <span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Thereafter</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HETLIOZ</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,647</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883640656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Organization and Presentation</a></td>
<td class="text">Business Organization and Presentation<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business organization</span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vanda Pharmaceuticals Inc. (the Company) </span><span style="font-family:inherit;font-size:10pt;">is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.</span><span style="font-family:inherit;font-size:10pt;"> The Company commenced its operations in 2003 and operates in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> reporting segment. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span>The Company&#8217;s commercial portfolio is currently comprised of two products, HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span> for the treatment of Non-24 Hour Sleep-Wake Disorder (Non-24) and Fanapt</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span> for the treatment of schizophrenia. HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span> is the first treatment for Non-24 approved by the U.S. Food and Drug Administration (FDA). In addition, the Company has a number of drugs in development, including:</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;">&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>HETLIOZ</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span>&#160;(tasimelteon) for the treatment of jet lag disorder (JLD), Smith-Magenis Syndrome (SMS), pediatric Non-24 and delayed sleep phase disorder (DSPD);</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span>Fanapt</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></span><span>&#160;(iloperidone) for the treatment of bipolar disorder and a long acting injectable (LAI) formulation program for the treatment of schizophrenia;</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, motion sickness and COVID-19 Acute Respiratory Distress Syndrome (ARDS);</span><span style="font-family:inherit;font-size:10pt;">  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VTR-297, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for several oncology indications;</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist, with potential use for the treatment of psychiatric disorders; and</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Portfolio of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activators and inhibitors for the treatment of dry eye and ocular inflammation and for the treatment of secretory diarrhea disorders, including cholera.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company&#8217;s consolidated financial statements and accompanying notes included in the Company's annual report on Form 10-K (Annual Report) for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The financial information as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> is unaudited, but in the opinion of management, all adjustments considered necessary for a fair statement of the results for these interim periods have been included. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated balance sheet data as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span> was derived from audited financial statements but does not include all disclosures required by GAAP. The results of the Company&#8217;s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or any future year or period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893100400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 47,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">47,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of goods sold excluding amortization</a></td>
<td class="nump">5,207<span></span>
</td>
<td class="nump">5,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,527<span></span>
</td>
<td class="nump">13,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">37,021<span></span>
</td>
<td class="nump">31,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">58,125<span></span>
</td>
<td class="nump">49,800<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(2,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">1,485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="num">(602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">755<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="num">$ (612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">53,806,317<span></span>
</td>
<td class="nump">52,752,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">54,870,146<span></span>
</td>
<td class="nump">52,752,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6893347072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 486<span></span>
</td>
<td class="num">$ (612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">53,806,317<span></span>
</td>
<td class="nump">52,752,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">1,063,829<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">54,870,146<span></span>
</td>
<td class="nump">52,752,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income (loss) per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from calculations of diluted net income per share (in shares)</a></td>
<td class="nump">3,095,224<span></span>
</td>
<td class="nump">3,068,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882049328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - (VQW-765) - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vnda_VQW765Member', window );">VQW-765</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales', window );">Future percentage of royalty payments based net sales</a></td>
<td class="text">mid-teens<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Percentage Of Royalty Payments Based On Net Sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vnda_VQW765Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vnda_VQW765Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6885483424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and other professional fees</a></td>
<td class="nump">$ 7,636<span></span>
</td>
<td class="nump">$ 5,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_AccruedResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">5,839<span></span>
</td>
<td class="nump">5,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">4,912<span></span>
</td>
<td class="nump">5,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and employee benefits</a></td>
<td class="nump">3,762<span></span>
</td>
<td class="nump">6,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,101<span></span>
</td>
<td class="nump">2,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 26,045<span></span>
</td>
<td class="nump">$ 27,590<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for research and development expenses (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>72
<FILENAME>0001347178-20-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001347178-20-000013-xbrl.zip
M4$L#!!0    ( "0XIU!O/[^3>A   '6W   1    =FYD82TR,#(P,#,S,2YX
M<V3M75MSXD86?L^OZ.5E)U7+ !Y[$D_%D\(VSE!K&P>8F>R^I!JI@<X(->EN
M89-?OZ=;%R0D= 5#%JHFL9#ZW#^=/GV1]-//+S,++0@7E-E7M=;;9@T1VV F
MM2=7M<^#>GMPT^W6?O[XW4__J-=_N^[?HUMF.#-B2W3#"9;$1,]43M%7DXAO
M:,S9#'UE_!M=X'K=)4+ZX$68'X0Q)3.,L)2<CAQ)[AB?W9(Q=BQY57/L/QUL
MT3$E)JA@$24BTB!T66(^(?(1SXB88X-<U:92SC\T&L_/SV\7V#;Q?(KY#*XX
MDAK8$F\--FN<-<^:S7?O6C4$)MOB@T7M;Q'*EQ&WWC(^::AV#75YA 7QF]O,
MMIU9,H$I>4,NYZ0!C>K0BG!J!'391%&"!>A?SB+%VI0!;=B>BX9[,=R4IEA/
M;2&Q;036O\2\]?Q.MVY=7EXV]-6@J3"3&@+;5N.WA_N!!D'MXW<(:5#0V9QQ
MB>Q8,,=8C#2EX+*N'"6 1^NRWFS5E<DNF.Z9@:6&;MCH,*DF:A!+BA6C^HK1
M6]"AAAK%U-F&(E54<$1]@O&\N!IA0E<5[TQ5=3BSRL0G41_-JZI")0&3J%!I
MS*3=5QO4B9.H7W6?KJY.U5MGU;18Y;9B6OATV]#BLH&YH4(-83-DG;S,+6QC
MR?CR#G[GT\SB/,*ELV*B5+Q4*K;>5U!1<[;)1/5S^54*4VU5CP)N\2DJRT_N
MV_*H$:9\= FWJ$TY3<JKD=R;YKQ_? (E^**82$&,MQ.V:!C,L25?JLST0UI*
M$VF$_H_ZBDM);1S.H4Y<9F;8N#IARN!7F>P:86L26EP7GT@=5-: O!C3XBH$
M5/JHLA(VIH;(Q,AF*O>P,CP$-12[5A$E?!IU4%\1EU1 SKGB]F.A8 14^JB^
MHE]7 MLVDYJ3.N6?G,^I/6;N&3BG>LL/?I?9)V.DR^0/7H>57DPWYIS-"9<4
MBIC02$0SF'(ROJJI84+='P'\#F."MU!^^TUB J*=N>X<@,1P+&W$_4I)GX-*
MEU<U =ZVB&?YJQMEDG%1HX"$VO2 ;;+PJ*A-0$*L S5GSDE1<X!$P-B^%/ 4
M@R$T0!3&F&U#]V;B"2_QR")MVX0SW"'F/<4C:E%E1 TIDL_];KX1M58P%U]?
M+U^S%? ^GK5:S5:SB>KHE@K#8L+A!'[X;)''%X$2R..,0JQ_:JPS7!/E"&+V
M[(_Z>-V9'K'7)(5P[>[/31>]P1+)O)-^K"I&\)9(3*U=Q='CGA;-\U;SO'E6
M-IKHC2OB^U-8(XX?JBL[NST][FEA?==JOFNVRH?5%7%D875F2@L@EU/";]@,
M#)H26] %Z=H0(%(RGIELT[/M^^1LZW-%FBV*\$4NXU/TPFYNFZ:6AJTNU+$0
M+?6C4OZM(C$])[\_;[XK%W/5,!"+0G*/-%5GQ6C@S&:8+WOC4-MK;*G92-$G
M^N>0=; Q5;3,!E_TQIMXW3-1K4/?D[*96$RJ#_)AT=,8L7&$QE<:>5HCR9#2
M&P6**XH4SF^4^M^?,)T8VDK51T[FZ<7'^^3B(P]FCK#TN'8$M8D0/3[!-OU+
M:P.%WU/(J#+!S,,VM?1HMA)*#Y\K"K/5A628\2EZ86^4[Q3R,T]-XLW6>?R&
MS!?)8\RQD)AF5*H]&@*<?<-L2>T)L8V24RYI[-)K__.$&S#$30<KPN\4).6%
MF['D;4/2A5HL55>[]I2.J/ZQW5' ]I5(+\;.SYL7A0 !U]_<W W[:*6*;K12
MYOO3D"$?JNZPC>?R]0"4+2\3*['"/1,KKM 3)G)BXA.1%F5_O1XH<@C,1$6L
M$LA$Q:?.\+[;^^\)%CEA\>1P8XH%"35Q_;/M^B%%4"8,WA>%@2\LTM +_%$-
MV%(",N38I',JL?V*/45.H9F(B,TY9B:&D.13<L@)D2]_/O_P_N+UT)$M+Q,8
MYX6!\>77KW60>@)%%!2V26P@A@/!+&J&)G '4T*D^&QC![RE]F.6P4!^]BDA
MAS$G_%/CS@$X6C^JH"+>>[SM/ XZM^IHT+OOWK:'\..Z?=]^O.F@P:=.9SA
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MX:&;G\?2OX%17W[]^L/[BZ@1:^=>3VGWH3%A3&$(\?&[_P%02P,$%     @
M)#BG4+^+T<?.&P  \S$! !4   !V;F1A+3(P,C P,S,Q7V-A;"YX;6SM7>N3
M$SF2_[Y_!<=]UJ#W8V-G+WC.$0%#!S W=Y\J]*2]N%U<E0WT_O67LMW0#[==
M=E7)AMN(F:;;EE29J9^DS*S,U-_^X^O%],'GV+23>O;K0_(+?O@@SGP=)K,/
MOS[\XQUZ_.[IRY</_^/O?_G;OR'TWT_>OGKPK/:+BSB;/WC:1#N/X<&7R?S\
MP9\AMA\?I*:^>/!GW7R<?+8(K3H]6/XRG<P^_C7_<+:-#[ZVD[^V_CQ>V%>U
MM_/EL\_G\T]_??3HRY<OOWQUS?27NOGPB&+,'GWK=6^+_!>Z:H;R1XA0Q,@O
M7]OP\ %P.&N7S^[PD*OF7^^T_\*6K8DQYM'RVV]-V\FFAC L>?3?KU^]6_*)
M)K-V;F<^/OS[7QX\6(FCJ:?Q;4P/\K]_O'UY8Y#/=A;LIW/;7%@?%_.)M]/V
M%U]?/,J-'SWVOE[,YNV9O;1N&A_/ GS2+&)X-;%N,IW,)[$%\I9/.6]B^O7A
M9Q@.))-Y7<GEW_<98W[Y*?[ZL)U<?)J"A!Z58N%9G-O)= A&;HYT)';>YV\&
MF9>;(XW#SN)B,<WK^\W\/#9/ZXM/33R/LW;R.;Z$#>(B=N"CZQ#'8>!Q").\
M]=CIRUFJ89C\1V?(#3#Z<=A^M[BXL,WEFW2M[1,[S7M3^S8N_WQ?/[?^//>M
M9[#3OTGWC?6J;KLOTN,2=AQA=U[R^PTT C-/%NUD%MOV3?/!SB;_7,(5]IZS
M)K8@Z>6?N]C88XCC,- -JGL/- (S@("+R3RK62T\^FD]FX-"!HI9AW.]0]>R
M!#]-\^:QGX-*.*^;_.W+V?G$399_'+X%C_; LL)Y86?VTWP<.70>NRS+_QGG
MTTG]SW%X[CYX6:;/%HT_!_OB6I,5.7W6\^Y!RS+YOK%A\FD"=LY(B-[O 669
M_Z___:*D&(?OSF./PO(L@"82,T5M/9V$:WK9N_,8Y^T?,[L RF+8S>'>0QV7
MH3/;P'2<Q^40 W*W<=Q2K+X#'28N8?8F/;7M^8MI_:7G''8;\B@,GEM81.W+
MV;MY[3^>U],0F_;Y_RXF\\L!6=[C(4<1PF8#:4 !='S ,9A_\RDVRYUR0'ZW
MC#D*BY]C<V8_['2YW&DX C'/;3.#<ZD]B\T[:+.3IOO:%R"MV[&[O5<!,KOY
M"+;W&H',%W;2_)>=+N+K:-M%LX+^+BJW=BI%Y..VA<-V_4EX//_6Z,WL;?2+
MI@$Y/K'MI*/K:LAGC"""*__0U]T8VM!T7((ZFCCW]QB%/# ?/DRR:WTYA[N)
MV]R^ &D]C(D#ABK 4&]OQ\$#%F"NOU_C\!$+L/?-/?]B,8<][];7CR_J9KYV
MEA[&[*'CEV3]]A<].=T^7 '&NJD>VWN-0N9G.&/KYG(W9;<:CDE,U\G>V'Q,
MPKK.XL;F(Q#V*GZPT]=V/@<K>!=5F]J.0-)KVWR$^0#&WV7MK%. Q+8^A4A\
M_!D@E#]Z43?O[#1N:M,-EL.,7HCM;H#>W7,$<I<>'E#LLV_@XE.<M9W>C&[O
M58S,)U/K/[[SY] "3)=F7L_>?,J?GS43#_;*ZSK$:<9"[KSZIOVML;-Y#-U
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MZT<#VD.PU[SC X/IQ(+04:=58DXA\0)QA"#UR L0[,B5!*B$6-?*1!LZK5)
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M5R#<Z.8QXLZ2_(;3C6:8]:8;DUEP+R=E&<CYHEC6*$JWIT7"*73*446=Q%H
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M-_?%NML?&RX&<"EBNOBAM)Y@?%YL/BJ?@T.,GYV$),1:H2FPG#/G@98"D<I
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M%?/6RZO7HN%0J+Q)-XD%C!AGJ=#8(4])F!/X9@\&$8-8'>UNE</#5<;K=Y$
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ML[MLMLQ^SA;'CT_L>CXAQ O$E-%&6X2<!=JI*KP$N*P5#1S8(&TLKJ<)I2T
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M?-UD7VO$2/QMX<8@LC&- /4"$F,_B':+K5Y"W5AMUZH9+*:WLFX?'M+RF>O
MH7J@=,V/2U76IZS]0EU8)%W>-X)2;/@!-/8;%S5&==NKH;"*Z?Z<(BJG_X<;
M9*5R0;=?UN).6(T7DVV=5>)<:#^MV6C.(R^,YNW)G;=CL'PI3ZRR?(&+IZS<
MY2';HYX=VPFQ;<@R$:]7/6*[08)]0!T'7I &^0\TU\D;'(H%6]7WU"I;?G]7
M//W '&L[*?O+<=]\Y?0;O4R=F&G[RP#<Q= F(=Z&^\/>-^PW%I%'0PI=' %
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M#6P4P4L3>AHL&&SC.U!6C\KZM<?U?V3:?-_D;]/J2P.I\[MM]]FZKOJO''>
MRP2]T2,TLCIM%]'I2*&]Q8EUHJ?-*EU\WCX\I.7S]>WG_&[3/&FPJ5\CN$F_
MK+.%#6@<L/\Z-G(H1$X<P: WCT-?Z/X*[48-Y]<.JG5]:QV M=[L@0W@T]W/
M,/GG]6Q2WN74[=NA?-75LLTS(/.D_@7$*4)PE'0X&2R5<(!=(I&EYXVT8HSA
M:9.,.;<*PRU3KHK#G :^]-6\6YQ7OZ'G&_8!\&M>+3P7 ^03XB38<7SLNV%D
M]Q;MQ!9ZB$*''=/K4X?0+([-XM!85<? ">J;%CK%JN*QF)1<KU(CT4A9?(:A
M,W6Q#E[G41AK\:30W^H&*A.WEQ0/:;Y9)#'! 78P3BAT X=X-"2]13]VA2YN
MT&%G*F5JX0W5)AE"%;7)$)>:M.D2C>.HTYXC&7528':FZJ3BR25U4F9'6)VV
M55T\9.4KRS]ES966Q,%1")(@(1&&,8!^ &EGU>''M*04:J MX_M[6GC6ZWXF
M*5!#.144J1'IE!2JTTQ:O[;HQA:K\UR=$RQ-+,]$M'1Y<RQ<6ED2%J\R6^7U
M*9MNY% VNHQLX,8!#%S'P<G.)J%"KROKL61:N!IPPV5K&)N"HC4:D9*2=8K#
MJ03K'$_GY$H+OS,1*SV^'$N51H8&S$ZA;+.\?TC+WYJA)TF80&+7#6,W\:EO
M)Y!&O5D_)$.GJ.2,C3\:W.'3-5DER:[RC)4Y8@</#84Y'6ONZ@57<A-8:C3/
M1,6TN7-Y*FL(3^I:UAOM!JJ(.('C>0#$$824N(3X_4#5B;#8ADMMQB;5,CW3
M6]+\JJJ906IUJMD\9KN.V)+2,T6BYZIGJNY<U+-!/(GJV>=TG56?LJ=LL\U^
MSNJN#O1]&KDAQ BCQ'5)8B,".UNN#<1N&QQFP?2F% [*ZE!=60R7G$PITB:F
M3>89DQ.D#LJA"DTR*GR3ES/2,XS'>>C-0!\*G2U+:6<I,[?,\B>^^:$?9"9N
MA(C/ZC+B 2]VPR1$O;DH<*1&>\I&#.M+C\O: Y,3&'7VQ#1F%.+D9.8-SB82
MFE/DG-&:P7S.0VZ&N_'V7MRAO&C<B?LAWV3OZ^RA6B1VZ&.2!!'RB$L#'P($
M>@@^=H6J'".&31<_$GL3.6BK0:U_CZA$),Z+VN1!D!.Z;Y!_[?MTS<3!_%Y=
MD7CHW+"[X^F-W&.4[F]FXZZ":_*;=U7Y$\I;[?NIU[<_I?]9E/U:<M6!R%:T
M*+N2?9%X/@X=%Q'7CZD3AYZ'O=YX@'$LG+'TF32<JUJ@_.G/!P[56O98K?H^
MK:TL7=Y;:0_;NF4_\5"4&?_FQG+L_Y?_8EW4Z=HJ6W\$SX3KCHM _IHF)'*9
MJXL&$\H&I;6#:>UP6@QH/[$R#=<2N6H:SM6RE/:>\/W !"9,WJG4I9_]&20M
M TX51EOLP/6OCUG)OY#>9<Z"!LCV$I2@, '$21PVP L[DYX=X6'K^#*&1EWW
M*AFX*^MQ!V_@@I<4H8J+7::X'+K0=65]O$SC."M<!Q3)K&ZI,#N/J1\]KEQ:
MU5+G1U,IS=\SSE[/2BV@$R38PPE&#ON/C8CM],=?O!@BH?L;#4/X5DKMM)_(
M+24GOTV'4$L5/D;TS%3E#?+^:_)+$Z:CH[5N'R-*$]?Q;W0S\R7]"5[52_RA
M@?HF2O[!3LH- ?1P*CHD>+]A PY&_G.25\MU46W+;'??"G"\"#FQRX^V!PX-
MG9B$F-FU Q)% ;YT+98.$^9T=X?*VL.:[!:A,Q2=J5]U$#N/\E6+)X7^9J?8
MEW[.ZIVI!&/(SPP!#T1!@$  ;;\W16);:C>6D@'3P^GNENRTJK):<()V&&&2
MJF.**T6Y:?:K32\T!ZR(*(P*B3.3%B473FF*.A_28D+S35[=9ZL?BV)5,;O7
MMY^R*BN?LFH1QQX$#AMZ>Q&)@ U#ST:]911$5$E;!M@S+#4],NN.0U.4FB%T
M2BK/2$PJ"]&.SP9@*TQL@-*#G$B93K,F(E0:.)^9;NGPZ)2,:6-+I41:\+N.
MW1A'Q",T@"YP0SOI3,2(N$R^^%!9OC2Z^,%2.K7#(-S%;IH1?K[O:,NV1E(O
MCBY3)5\4:65I2#$T704D6/D(,S4SY9""?J;2D?1?7@N87VT/V=54812%-DBP
MFZ 0.Q3'L1WW%GT66;51D[P=T[/VQ>:=G@&4 H6RDF&6/74%V>&:P:CJ%4="
M$J/.[-P49X G)P5H*#M":X\[<Y_2WW]*65?.T_7+BHCAZ+KJ(J& )($+DM@'
M$$4. ]./^.($>T+7L^BW:EBK&$3KH<<HL>BDEUF!5<#)2%66,$[M#NFK<5@C
M<1:6J2$-$"^QP#=9 -36]%XT[%W9SC>,;XK:RKX^9DN^F%<7UI?,8HKXE)7=
MOY=I=7]E5<5ZQ326_>3RGGTN^];O>7V?;ZSZ/F,?43ZPP4#QF/%M%)L[:_F\
M'+[4)\/PJ=4](U&:P8*>&;\*T^U;)5?]K2A_>[_Y6!;+K#H)@(8D2B(G26(;
MX,"&+L)P5[R#0.A."P-F#6<KCO%=OGGWV*)4D4T][,HDK-&)5<Y8'"F32JO#
MJC]GZ2%?)6F-'@2UK-5'H&O@WUC>$B'Y8N+2&JDY92Z]CKV9N@QP)Y>[3D\]
M'P" +O"!1U#H^,@)$R]*@J@'X$%?:$^Z ;,S7.<R0:Y,ZAJ=5U.K7H,SEQ[N
M53+7Z#%0RUPOF_<WEKA$.+Z8N+0&:DZ)2Z]C;R8N ]P-6+!8D #:;$SGVW[@
MXQ#"( YV*1)"SU5;PQ3__+&7,C?%YMW Y4P)\I27*+3RIF%I8O+U"+EU"&'Z
M9KO^(.[!Y74'23;DZN!%$@0XM@,,;/:AL>\D(>D7,V"(L2>B()(?.:YHJ!11
MEUF1*4ZU$B*G!H994"D3M;*A5@)>9D6R++M8<@D[/:=R2ASTFZ62I,]BUW0M
M6>VU76?7M^_W=7OS.N)-]K5&S(??%H%'8LKJK<A)"(IH$E'JMR=5/,KAB%_-
MI<&8X;'Z>X7^K85# ?T;FSXY9>S1\:./!_BZ%U4M#M%J,$K=G:6#6IG[LD:F
M6/&.K)[JXO9PN#UT4"S@_"E=ULG;#!1;JSN%H?8E-]A%:957U[='MVD]M_^[
M-^Z Q,:NX[H.\"(:QFS8'3?&$TIQDD@=;])DTK#B-RAY3_K(?JCOBG)C85W<
MB@V/)Z!5+A/L&-U#O&IO[7NV?NW^%$D'1L;28NR=&5YKIG\>(V[=3A5&FZR<
M\OU2,;DE59WS34'5 A'BA23T(A)0#X3L'S#JC;C$CV043O*C#2L90\-[W0Z/
MG(C)TB0F5@89DA.E8W+FHT@O*3JC/(I<SD-A5,$76MJ3Y+UJ:74/-RO^!_FO
M;?Z4KK/F[H:J+G.^E/7V]]MVM C]@  ((/%\3"@([2!JGVUCXW3B>5#JWC63
M0 RK$6[6]OC_6@?8K'2SLO8.--^7O*/-:'#$5&TV<9'3P"88/ #'4;DZ#LF)
MGYJ+9 [A_XS CA+6><CQ.*X>7T W'K^B4O_RWIZWRU(_<8#O0QBSD7CDA8'K
M=@-R9CFBL2^CZ#KL&1;NHWO+Y-19"Y]B(CPVE7):>\3B?+13@+8S$JF3]'DH
MH5:/"G--5$[7?LY^/QAME\6&_769/>SU]!@&#B@KG9EY2 (0!7:$7-3# *'K
MR8B<=N.&%8_?RG;TQL0+T'(2J)]Z,3V<E'4Y<6103[,]'ZF49?2,;AH+SCQ$
MU)Q[Q4B-7+9L+'_+:KYN\SE;;LN\SK.^3@WB$,+("0%U$"%V%">VTQNTF<[+
M58O*9HP7B3TRJ]I!DRT5U3D4K1!'H4^V,-PQMT<U'\T[S=G9JG PT?/0,1V.
MO*H!-7$CO:WY6 J1#["?A,"#D>>YCAWYU.O-><17NX1%ULB\]N\,YTQ,B4:A
M2TZ'#O8UST5[3K%T1GD&$SL/W1GNQJEMS\-X$=4<DI8;5I!5'[/R\WU:9J\&
MN3[U/4(C.\2Q1Y";@"CLK<9^('6SY5!;AA6HA\<?H;$:@')2-)A*,44:DT4Y
M8=H1^+$G<#X*=8&U,T*EB^]YZ)4V;PHSK5+V':V'A[QN!I%\^:%H!I?9AK\U
M^<9EXTX"89 X;L@&E 1C+Z();??G@<!GHTSA=Z!T&C6X:+C'V:X*'B*=PV7[
M4D2>6_TS$I!Y]%=#OKUZ8,H<@T*G&<X :#;9+ES'1P3[KL?L)3"DM@MQ;S,.
M8Z$AD!Y+IG=?G.VU[9Y\F8WXPYD]KXKCDZI3!:?@4^)4PZB\JAUI..9W>0AR
MZ,&&2_Z_D13T\C:#(PWZ?"E,M"RY@NV&_?3U+2Q+?ET$MPZ_YM4BB!,<A0X-
M0@P02RV)FWB]K83(/9^@9L&XJ*\9QH)?A/&460?@FBYS^._K^IX-GIIGRE[^
MTJ_<#T&A&LBV6!ELGFA9H3?-L9$B^$T:SQ2[PVB?1U$[T(="9T.4TZ\#*UPW
M?RXVZ?XK-^QO%2N06?JL?LKX\W(+0&P:$0CB*$9A"$CD)'&/ KAR;SGKMOT-
M:%Y2/*3Y1E+UM,=(3 ^G#,_X2GDI,D:T4I+B,RIJ*ECST%=CWA7C-'F)B8._
M_J^_@3#H/C]&D0=L!\08 @*0G7BD__S0HS06GB20^E3#.LJPO&-@)(:H<IP(
M#.^-T2&G6QT3UJ\M$IE1NQPE$B-T8]2HC<:%*1(;?Q]Z=VJLK<3 #,;5:KB+
MH;'7,RGZ(=]D[^OLH5J$282@31T2X21@_X?]N*]S^0(+T#$Q*FYMVLE1CM-J
M@&J:T9.@>=@LJ1F&M<Z43DFNGBE3,R1_6].F.PX4ID[E^9N!S.OU1W *594I
MH;1 M_6VS#YF)3_[D-YEU[>?BN=T73]_3)\;-"BMLM7UYN>L_IRNLVIA0S>V
M;002[( $1B2R$>HQ(,]&PBE"NV7#Z:+%R_?S=(#Y10)E"]EZ[#!;7SAH:Y/5
M5L5!2XB;_D@(9)%)@R"743K^]UCY%6,=6JN':S5XK>M-<P'XY\E#()%K)@V%
MXIW?BB$9FI)DJ3J5GHQ1/H-49<ZW8HQ&*S>3OK]0C9\:I^OB]\_;Q\=U,W64
MKO>[3HXO6?.2T DALH,H"" FP/?"[C0Y0&$4N3(SZJ8P&$YKA[<(-E<]<.17
MUB'V@^U=DH=[C,5%;!9]#B&12W*2T9"Y5M/()+HBPV<FTTW';!Z3ZL:]+,;M
M":IR3=@XIW[^6[[*WF]N^1L?O/[XE#UEFVU&&6OD*Y.T3;K>G9Y'SQ_+8K5=
M-L.DSUGYE"\9Z!W>",0T@0&PXX 2WTL<!'=X^6U0:H(^-DK#DK^KPZPOSU8'
M5%771P^@K/+/.79RN:$#;7$UL7K8^[M%#H+9S@+UV&>4)#0'0RB-3-4 YI9H
M)N/A9"J:-C*BR6J?'%GR+!X>LTW5 5VG_+:JHJJKYI1*,_73CWMV^]N3""1A
MQ#H&!C!!/B0^M=L!3X!CX(@>8C>,PF!%RT&]:Z?%.E@O=H5,=5YD&*%GE&>D
M2,U#7L9RMIBD-RA7M0^/Z^(YRSJ):I T$R&'6.&Z"1[[&W_L;%G<;?(_&-:L
MS(O6@7;K=$AC[#FQXX8 0#>);=1/F 081"Y1K&A'1&AZ N.\P%RQ4HE[Q+[;
MWF;YF+,1#W?DRH(/_ H9N7,;$T=;NOR=::"U)A$-,39=^.H+@UC1.T'8YY&1
M)N;@=+$[643$;XQ9LBK[<\TR*.]4'SHDS0;X),3(B0/;9R$)$M<GT$XZBPEV
M'*FMYT/L&,XE+31KA\WJP2F=F!E$J)C0C\6EG%PKTVCH/IF3')W14AW,SD,1
MM7CRZF(97>P,5*?VZ, "X2CT2.1Z'D@<'T,7V%YO$X2REUH-L32=0BF=;QE(
MZR"5,L"H-IV:Y$C*69[DM4J2WUFKE:PO8GJEQ)"H8O$7S-G/\KOLD^PI6Q>/
MW'0W4NDV>B?(CB)*L$M]2MTH@C$*>\N^@Z5&]SKL&5:O'F(S3%OM0<IIEA9B
MQ91K;$YE5X0.Z#S UP^'I4]NZ)$Q =+.B)E.RN<A:5H]*LPU4,GISFS-OGOW
M8[;)RG3-[,/50[[)^10K/]790>A/ZP4A] &)2!@CGSIQ3'#WJ!O#$-F1U'W(
M>BV;GIYLP5Y9=RW<IJ^F+P!+3CSJY5UP0G$RRB4G"GNV?SQ@^R767ARKB=11
MBLISDWU&0C(/Q33DV_'DG$$&A:],U3(M^&%W1"3Q/,>/$+!!1"F%(,+Q#F48
M)5([6L?&-O^%H@^RQ]8F"[.8K,\YPJ.O$(D$U\QULGJC<"9G3!7O>625R;P_
MOMYVTB@(WT[4 LA6;^/K^M/"]Y&'$Y DH1>$-*(VA;UQ$B6Q+74ID1Z3IO-(
M72Q_ZZ1F>0#/REI\DA<,::)93/ G8-B,CH]\5Y 0;6>$5S/O\]!3W4X=7PAD
M@C/QY:::M;G\RSJ#5975!S<7'QR.B&$810 E211CB#W?)^V;?=1GHP,D==A
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M)XY!H60UJ,2>F7KO!#OGJKJAA,Y#F8:[<5RAZ>%EB/YT5SA'B-5X(+9=$I'
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M'3$G+7*JS,]9ZI1]$A*\88R)RMZGK*K+G-\M< )%O^\1>0EQ +)CZ$?$]I*
M-CBX>>"31.KLC#:CADNZ/<Y6^O+-<KU=L7_EFW^6TSY]-(O)WR0,RRG@ ;EG
MJKR)=G^+\G=&![6'8!Y2J-^MPG#3U2N("P_:'D60&<:QCV$4 KL?2 ,WQDBG
M$%XT-JX ZM6\RTSJT3JM).K7N'D)VP!!$^;YVQ R<7<D!4R2)YD![)&E5TA>
M?N$0D^-Y;NP #&U"09#$"0Z2'28O(HNZJ-.U^+#6'!(IR=N!%NZR-_Q7&K6[
M>C7>;?IO.403#0=)?&P\C_C(CYFOWA@POZ6RQU^;3' 'D7UAF&T^B/.0ZI%\
M?6-8/A;#\@=6+MZC5)VZ2*G=2 X3)P$^\&/7#9PP26B,HO9 3>1ZDF7L>*@,
MU[N'!S)$KFNKSM[7-O2$C/$0BZ6+>497+G6,'%C#1W(&QN%,5AD_UO/(,!/X
M??+XS[C,"V^'9?WIY_0A:TX!>#;Q?9;3/ \[R$?4#ZC7F?#L))*:#);Z8--;
M6MF_+ Y&Z?2/'$5BXFN,'3G]%";&S-[2 Q+.[1Y5X6H>^J,&_7@'J+K_LBK0
M[;PG04 I<GP;^XC$A%(O='LC$$.I&YTE/WH\)5 Z@R-+E)P:&.!(60\F.5[S
MD@@!39!D;%ZJ( O^A"XH<2"T^_OF]^+FOMA6Z6;U.?_*[;&Q\<LOUEFVX=_H
MMB,Z+G$!BVWD4D"!%R9NC'H0@+CBN\'UFS:L+.R70ZOI/WR>BK7O]E\2.Y@-
ML'U>?F9 M)P\,5A6C\MBP/9\'W^'0VZ_J["5W$ @)+:63QL0M:WF1@(CMO]<
MFJXWLHIAWF>P/]V@<\4H;5<Y:QW9(Q!%.(Y]UHA<VW<B%P':V?,=F A=KS;<
MBO%<-#3[R+(FG6@,$C8LIVC,'+(D*B<)@V3JR0>&55]%X!4YFYV6J_IQ6K8'
M,2,ZX]!.;+)?:68UDL F0>(C/W8BZH=)$OG]K(8?$@)E)ASD/MFP$K?K"AR-
MTM2C)$MBLPWF"))37G%NC,PUO*#AS%2#&EWSF&E0Q%[H:#":GZD[N3JR1[=9
M'4V)!-1&B 9!; / 9,NE..Z73'PWEI.520".J$Y*TZ'31$UP?7ON 5-7RTGF
M9DWP>6[)>LKPS4.]IZ5 ]H$W\_$0&OU_KHOE;]?M.W(O=G(UW_AED]?5I\^_
M]%>F0(Q XKB1;]M)X'E)2$ __>"C$(G/5^LU:UCWK[=U5;-BGQ]%+%K,[>Y*
MAM"Z8Q'E^RN_X_\2?'O;!/,"4PK3D2ZGW0T<Z_J0Z?T^UO:;#=B.<Y69!\WD
M2TQ%3!<$M;D)[<$0F[&0HNG4%(89KF<PIV'(L<)X.QWI,>X/^VL2, U0%"(7
ML<$60 FF3M@#"Q)7;H.O>3B&,]G@QY<'W.(R1C U#77&C:-D<APGA/-Z&_N#
MP+4R(T;U&QGO:'18U_/5JER+C65445U,<P<C@)^W3<*+L>T39-LN0AYR*+_U
M.^CA8XAL\9'0C$"/D7TJJ]I^^<]L65MU817G1E;?Y1NK:GY%:E@U(SZ%!F4S
MPFLX:UE(+&MU/_<R:XF/0 Z'ZZWCWVKSD1E6S@BW^4%I"X0?8^I5XT!)KKH;
M:GC\GYA/K)7P1K,I-N^Z?W:_=&6ES4-M]7UF?>FNS:_XS>I7UN-Z6S5?W^PL
M'?S^P>'GJFE_VZ;]':K9B4^V5FF=?3]T;#Q>K$^.K&?8W.8P+I\C+<7,94+R
M@H?BX:'8-*9Q^IC7Z;HM*QBLK'S*5K0HV\>3WU?5EG>\A1/X2>QZH<O*S<!V
M0APE_0IL$+N!U.M-^JT;KKGV2MF64OQOR\:)3KK*#KEU6Y16WJ&6K[T,AD=L
M4#]M9.2JH19K6[OPJQP:N%97'G\Z#$CW7GV/>>1+&V0I/3,Z-Q>>>0S&#?IW
M?"&#82:-3\ZVDM2=\*W@4YJO^8E=AOM'OI:V"% 4>#ARL.- F/@!0+L=,P'V
M<#C*E.U0D%/+>MHC;F3DMI619JU27=NGB[CA>=TQ@SWR;.^5M6\J78*!+YI&
MX^$W,@U\(4XF)H=U-8UY9*GI:= UD:PW+L+;L)?+[<-VS<;PW;-"#'29W3/<
M^5/V?L,4./M05!5#D>5WF_;1H>7S#4-4K5O/5O^YK6KNQ<]9?7U[DWY=)-AF
M.9DZT,%L8)00)[1;I D)HL"E4INY)\!G.--U6+O'U);/5KU'*[D[?(K@B66N
MN<=-<N_EWIO^;;9#?ZS6(>L[[M*?KZP^PKU;UH%?UMXQELFRFJ<QYMS(6]_U
M1^?<!OH)V\(\LM2D#!QOYI\\&IISTV&J_)RNL\\94]:\SED2?8V4Q&Z,8A"'
M+)UBUR:V;]L]TMCQI9[TG *?X=STRZ;,TG7^!].YNY2-JIA>/:3E;UG=5-?5
M#KF1/*4WD%KSU&0QE,Q3U_C]E95D7VIKC_!J/SYZQ\9'[RJ&_^I%&DIO65.9
M;1:2X7YX%C(2Z6\J"YEA0"T+&8R&YBRT0^'YV'=]#S##0>@"-XJAWZ, G@=E
M;MS6;5LJ>\C?L7U8)G</1K\HD_,&L9'<(4Z_UKQ@A'FC8Y.9#SGT";ET:+XI
MD9;W3DV %5D4VMT([\JL/3G&U!VSG\J7Z1IN5C\U%6>^N?N<E4_Y,JMNLO(A
MWS2#CY^+FGWE8U;FQ6H!J>OYD0M $L"$4!<EMM-@H@[&'A*ZIG <)(;+]CW^
M9@9\V7G0[!)ZZ'VPJLZ)*ZO>NV%M&C^LQ\81B7UEYJ-W7JGG%SA)W=['C&&W
M>O 60V_MX%N?=S$[\,!J7; ^SB]F$AO\9A4[M5U[YF,HMG]N*)6G-L6-%J(9
M['0;S]=BBDX@>1\P:_#W:95=?UGG=XU1FE<,V;]G:?E36O,QV//NP39LQ_SA
M2M]SW8@2+T!!0GH(<1@#J=N"=1HVG'5[K-8>[)75PK4X7JL'+/+<X0AA$!OY
M3!8!N?2IE7PS=QE+$'EFN&,D'O,8ZYAQ[?B69'/\#5#39OO23TSN'[8/W2Z
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M^X-?WPD?BNW8]_R,$J8SYPSGU4SF<69Q9IP4<^[8,TF4;=JG17EP;YRS0$X
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M622 C>M!1$+J)-2G(82P/WAL(P^&,MHTQ(YA96J@O?O28+.J'3@YB1K$HYA
MC46AG#R]8&]R<3K#T1EITL'L/(1)BR>%_G:G?S?QA]VA+QK%*/'L.'0Q0"!V
M8Q+U1Q%L8#M2<WUZ+1L6KJ-ZX.JM;:[J)V U!T%,XZ;C7T[UM%$_V=[B#P)'
M7,U$8QY*:<@WA7W&J@P*EWA'EE]6E_"A*&O^Y Q_A@:E55XM((RIC1WL0H!<
M:GO0[X^(A ZU$5G4_)I<P;I/MW$I3=WA%"]G>D3-LU:2-:!VH@4+PRDYUJZ;
MS;MA(C$P4T!*<GFNJC05EGD(J#GWCNM/LSQJDM'E<ONP;=Y1_+$LJHH_NYBN
M.:X?TWR#,M:Z^3/#"\<.0^S$"46>AX'G8.KX/3874:D=-.,@,ES$-MBL/3B+
MHY,=?(\3&BUJ/$%43$CTW@WKS0A>65\:7\:_:4 +_^JRKCF^WX36Z_99+@$8
M8=QT5OC _K7'%ONVFT0!@#A.O,@+:&2'/;;(\9W%)KOC'V(V+\AA$E*@N%6@
M0_CJF8'CDYZ7'2<^9E.#@<!,E!JX)]]>:GC!OX'4H!;?;SLU*/JL*34,85PU
M->QQO42Y2&CB)4D0)G[L1T[BVM3?92881'+K;+J,FMZ(RI\K^RDM?\OJ"Z^6
M&>963;E'H56[.$^KMJ<XDQ#4P;3/4S.'NW5!%C7QIG"-U_M-=R%1V]<YIE=7
M$VU6."MK5JS?E&E_SUC]YD-"KDL B&"" ,8>2HCC..W,#O4 P9'B'1DC@S2L
MK'L?#M1 ]2#\V/$34^-O(G1RZGUX C/?["]Y.XCFZ_O>OFO>:FM]LSKGK-:[
M/\_G=2,3D3J3,R9O'//(,=/3</J.NBGC(KP'I6;#!H[V^A:GU3U=%[_O+]%+
M$MNC( %.0+P(.7%H P\C8MNA2S -A=_K&6+#G!;M8/&KTS@PJT$VV?62YV@Z
MMWM!![OSZ,QZ7#G>FZ"/']%.]7-6<U,?R^(I7V4K]/Q+Q1_?O7[,RI0_(0F7
M=?[4]/_V3<DM/X/4?K/8[,&!,$*$C=AC_HH(CMS !W$/SH>1(U,&C@3)].YZ
MWDMOFU[:7 5=]/"M=(=?K@8<*U1B2CG#*,EI*K\0O0E2[P)_O.P[[@4K]_YL
M[1RQ]IY<67M?K+TSD\FPGAB<$>R1@SP/:1_;Z6+2CB6=+MYOEL5#QJ=K%QB'
M7I38-(ZC)/%"DC@$]#82BI'8$T]JGRTC#$K//'%]R!L\UG>LP*W^/'K?WK-Q
MOHLJL#:;GJ:"_76'469 >.5@]9_;;JAT4WS*N'_Y.GMA^:80[+:[+HI<2G%,
M,/'#P$T<:F,[Z*!2'\=2YZ,G 6BXA#KPR:H+J^R]XJ^LO>R:_-O\BTN>SQ\/
M\_FVS^=OU5__++G$,4DC$%P.F7O\Y8JSH]#O'+*X*K_O0O^A#[UD&3=9O68B
M2.?6:J9L$_/(,--2<+P&-'T\1/-=DCTRN<W;&Q43-TZ")$ NA)35E "&#NU-
MV#"2.A$O]<&&\\LA%CZQQA('([IN[YS(_FN;/_)8R>4(.>+$M-T89[++V7L8
MX^KFH>4S>J?$TSQT2@UZH:&=2,[!WZ=EAM**;^Y_>,PV56LLHB@&[$.)BR+J
MV:[O4K<W!A-'2B$431C6BL]UL?SMW1<.RUH>X)(\P:E(G^#BA7GF))<M.*".
MM(_I<[.  <N2_4@SRWUE\7M4>>U&OG*X(^^&>9NN<\L7P_B=A](,=>)XR4('
M)_*[6-J*B95.W6&CQNKU+5^,++8;OI#YL<P>\NW#PO<33&@(0H0"$@20U4G>
M3@<)MN4V<IM 8'S;]B%"7N>L.HQ54^@\MC KBWWS8;^W0?7:#2,QDMV$,G)P
MACXJT\*]XH/;W5G+7;1ZT$VP.MA3;1D1YE5H-XC^*,U#8HUZ>'(/ARDVA:=(
M7YA]OZE98\^9DK3;1!8>M5T<AZ&#/9MX@/B>MQNG(B^4*A$'FC)<*N[Q6"D'
M9*4'<"5G' =R*CAW.!Z=DK. 1U)XP&R+;>3IN[,\G9N(TT/P/-1-ES/'DV,Z
M.1*?YKK-RI)/L7'MO$F_=@,1E&VRV[Q> #^*D.M XD9>Y(34=8.=51BX4A<9
M#;5E?#*LA=<OK-3I5]G2;S";HM-AXQ$I.T/6<=BM4#!L_=#6^JZ#-_(R\@6R
MSLZFZ:%Y'JJES9M7<VXZ61+5K>OZ/BN[R9/6<F=V 0+LQ2&-HS &;F!'OI?
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M+^M\R1]VH%G6/TBS\%""$$FPY[!J-7 H@&Y?6@& Q18(M1HT+*5[F+S(N6V
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MI)3&01!W,(,(<IW#D9.#L[T34FQ75;[+O>+V;MF\#K_)=][V>UGM;D2T.59
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M#T"W0\A#&'&=$J,!'S])I='VQ>VZN;>4M+:2E,ET8P"-,>#5K2--+DQ=Z;1
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M>7V6Y.BZUU_SY79?Y=?GFR_Y:E]5,A'>7'\N-U7WI53X[:5\\G81R0>WXI
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M&%&(' 1OM_ENBV_+:E?\O390HMULVW)8T2G.;[)BNUJNY259"TJ#. :( P0
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MST@9UAMR$ *OT["(%F_FGY;YY(_K?':1%0OWK]5T>=<BR0V^9! FO&P@M<B
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M#&FJV5HFG@.$&!IT^RB9'^RIRVRQ6'LP?18L[%51XO[P+G&@8T(]Y8IA381
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M<5MN&&D@_['SG Z@YY915W+IRSK_F$UFZ6*QCI\LI?U^M7R4*'7OCO1MNCB
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M:S6V(J'4/M<[\B,M/N3+\,\TG<WN["J+V)Z.#Y@ IIPR0A)I-(?:*FVWJ4H
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MY4<Y2DW0%"SQ1'+"-1!F1['!,<KY:W5X= .[UF5Q'ED&.(8>>^0(($B:L.:
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MS"=_7.>S()Y%J9K7*@!2=XC$""Z0]P9K1Z4"AE!M=CNCU(,]_7OM-_8="6
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M]X;$FW+3I8Q4SCW+H(WQ?X\]J*AS/+7'][[P=9(?] #G+#7(E#=!TFJ,J%?
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M4Q78C7>+TIF8AVKU+U'E!K;S[*JTY+]3X'8OO=Y4VT?3?IIH]9"2>K!C@CU
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M0C+J @LXXN%(!=!#5_&%*Q)337+LF#L=(R^#K4.^]XS'0_<E59/$*0]MF#3
MD"(8F+4KP"*D%# FX\S8TS*WC9RFS.Q/FUVLRZENZY/72F2YITL2%/XR&9QE
M)'"$26F#95!1R *Y9^R4:OMP:XG'?:+H_>7?\ORBG/0V/G.W*=HLR&XR7<LT
M_#S+MGYB=9,7R^F_C\6SQP^>@'6.?>*1L3*L8T.TWG$-.7_.^4;BD?0"-'L5
M1W\GXR(+WU5F!K1ATY[EZPIZ6[X=/"X/]$N0\I0;X(A5T@#/B#.^HM41&:-]
MC7U3;!UZ;7*ZMUBV;!;&O/I;-@]6^JQ<"1<WT_FTY,1R>IL=AU>] 1(,(1 (
M,DL-$-IYROBV))100N.8BL5C?V_6.LXZ87EO[W,>[+2E5ZUV*>+#'1,JL+%>
M4*^L%MXZI'6EORH7E\YV[&_$6@=8JZP>RE1H8"(D5AMEJ:064<4)(IQY45'$
M!(VQ),=>L:$3!2R"N;W=WFW<TO.K6C&:+[1.L ML*;.X!IN)*8T<<F!'EXHJ
MC#/V>Y&V[<EX]O9ZZ;N9Y;&[W4VK1$)%F4664$X1%YQPR"HZH*$Q;H>Q'TRM
MP^1DMO:8$ZD*0=OZ8I^61-M<76_:?4Z_98MWT_E:#N&8S8*8R_KHCT?9O%UX
MERVORYONLA3J^F;MZ*55+[-(UE><1"KGE$,&.:?13AG@$,8H]F,_.MN&]WC%
MUN_R"91ME0<=3)S+Z?'[V6<]$@4$YX9"03&SSG.NS+8^L-!(LYB@W%?P-+D#
M6,:R>-POV9UU0ABIH+;",LJ4 JJBA3(,(N#2_'GQZ][%8AC;%TBJ5)P?LF+]
MZ+3&M=*^+@DA5C*!'9($2HL0<;IRL^A@*L5X4!N_$W[E.TU+/!X*13I=3"<-
M(+1NGWAHA+86<!>V4\Z,!/?;J",\9NL9^^5/O+R/ .@4#@^%'CN=K98'BZGO
MZ9$ B+F& %H=OHEHA,,2VW'+RA@$C?T.IW,$G<;COC#TCVQZ=1VFIVZ#A7"5
M_;8J,TN_OWR62*'&^=9TJ$0J+[! )!SLA-IPQ'M MQPQUO.8Z@:-LQB\\G.O
M8]Z/#8W'SLE&XR3!D,6!\4IIIH0,B]22ZE[58&L&2P;= PZ[P\V) #U%(@.C
M<[O!-TD;U'"DA&LJ!-#46Q^HIT1[4T5:FJ"/Q/@BQGX^#XW0EF0RP*N*0,>'
M0,B)3R46U7I99)._7.6WOUYDT\U2"3\\72'AHV3]A0?4A&=MDO(Y'I# !IXI
MIB6@!& '4! :X1["6N=_*U.W^62U+KL0OFC/S!\V203VS"MD@C'@)1$:<FZW
M$Q>!J'-\KQ\AO;P5+M;;Y$\6_?]9I45@Y>SN8_8U+_;A=T_K)*CSTEE-,=""
M F=9.*0J4KB6@[U6'S,&XGC8,1P^5$G-;-#0CX#A4=O$E^G!J'0XL,8YS#&'
MHB+#01ZS-XPU3*U=7,2PLV-4K/-^3#>I>FOL$D^;)YPPP["$09?EE@I(@=P1
M XB+<?1&7>2/&0Z13.P($6Z^#&O)3V=;/7$/$IXV2Q!DA&K-C"PM&@P-9[*:
M/&,V)N%55/[M,2(@DGF=2OYC=K6.EITO?TM?C./9US1AI0-0 \XPY-(31@!B
MNV,.1R6%'>NU<IMPB.)FIY H77I%V*'64EE[]DR^FB^+.Y-?'$;(P9X)!1R%
MK4Y2'&@5PA@E^)9$:6S4Z]:HO-7CQ4B;_.P4,I_3;V\N E.FE\%X+R=;XS#9
MTR<)3%'2<X(=1%!@A8FC%5D ZI@KG*A+Y/'"I!U.=@H0=7$11++8_O-V.L_@
M07"\T#[!P;P._[/&!&4)"H\E<Q4Y-&C40]VRC!<8\5SL&12H(2A0(H4%RECN
MJ5B[UHGQ>$<.YS%:" 3?"RJ:LK$/5)CPX_OB<_[G2P^.#[1.>-CK&,3 6N\A
MH3+L?7YW+ 8Z8Q QHI*H'2#B9";V@8>U^O.^^%#DM]/YY+ >^G*7<!YJ;;PW
M$@/FA(>^],=LB1+8Q1P@\.R\FRURL@]X?,@7RW3V_Z9?CQHI+W5(UL]!&8->
M!+N+A .QO 3;$*04<%$7(5'>SM%#(X:/'0&CW,=4D:4'H/"P22)<L)N<IY@K
MCXPO8Z10-6FM953.B;-S9T9PKB-QOPT"F7VXSN>'79A/FR5&6>8I<QAI98D5
M$MIJ$U,2JJAHF;/S849RKR/1;S,WWT'TY?-T.=NWVI\V2Y#TX0B3C",NM"+
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M]DI0TU3(>?ML[0LRNSU:W^U^_,]I5H3OO[Y[F]UFLR-G7;T!$@N9)8  R95
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M/VJ4..^HE)YA#H.>1IU5Q%8S4X'DX938P0SQVL+*6^+J"(RAUBQQHZUQ'@C
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M8KQSH[^O'UQ[Z%U^<?&;I\STZ/)]OUHNED%)G\ZO-N%W!Z,W^YE"(@T@3@.
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M)QAD&XR4],O+/G>0A^;_PZVQ-.)WJUZO[__:?=9H [G^19$EYA+,G&:<<*E
M@>85-4G 36J)AAI_&HQD],# H?B"9:O=EW]5=E1;K(NWUF(O@TY))U2:LY7&
M 3.>A5T_XL"MEKC6W7TC,1B.-!CK]'U1!&TIUI@(*0UQ&L$^LI+H*Q5I8BA,
MW:>LB\RN#84K^)C+2'BW2'JQ^)B@L0T5_K)?R9D682=&12=L\AHX8HGAW!'F
M#7+[=3J+\10+]@<"G&573.H9C&<[?)T<%R$9Y-0K0JETF%E#)*+56J5@4VZ4
MU H$ZL'J*F)G[,!5I'=]-8M;5WPO[I;?RJGO[;HZ?;C.C8X.4'F=NR6!A4"4
M,AI$M6Z&[91WZ98 \;RM5LM$S^9W%W?IF5_^42R*U>PNS=_<_C5?S$NC9#/_
M7NR7L#X+NXN>$[DP3'KEA086L-;>4EW10B'5Y KMH4==NP%@E^3/!<5VS)!?
M3O1XZ^A-T5&*F0*)I HA&*FL/M!3*#?E0X1A69'],C9;;^3= HK;E]>W%_83
M^*_W@,@84.ND<X)R$51 P52K]RHQ9<)F0F] >MHAN0M.Y0]B5O<??)PG&GU.
MOUULS,W-\GZQ29O6A^7=_&;>8VK+\ZG4"$0>'Q3!!!N<=M13+"43B!"VSXTB
MGII:VT%'UMXI^M<Z/:GU@.B5),(ZBK0P(A"LK%<5!2SE39J8#EUSM(&+I\9=
M%T0?J!*PL_77\O\RW>_[[&X;(EW<_LP)*'^W.]N8CKYP5@2+G# XZ$"]\P&8
M!8^0P#Q]U*>^.%AW)=T3(YZPIOXAPXGQT6-""")*X& 4MXD605;K9PSKOK1%
M=@51&PA'SP#:(W,N8Q9F=[-%:6$51=V _K$A$0O+J+"$8\>)Y00"Y=4*C<"]
M;3M=NUZM<'W9"9'[A-'94/SQ05%!VC>E1L0KSZDBC#JH5AD<SGHO>/=0:L[L
M&NBYBK*Y\/-A57R;S6^K0%F2IFU]@;U?E?0SZW6Q.1\$K?^0*$@(*G%*0AF(
M<R",#'LJ"&Y\UA[$_>#K4C@L,]'ZZJY,ORX7-[NWOUM\3S^7JQ_5K(XBI][
MZ @N[\\VUB#)L3%!2E*M0'#6Q$)J%& </%HZH6\NG?3RMEXGP'UF9!2&2P_
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M,J"&(MC_HOSQQVQ=_/=__3]02P,$%     @ )#BG4 B&-0F,=0$ ./$0 !(
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M;\+9J]+](I2W@NJ?;J"Y0<2T7<"KY:=9(NK]/TFB2$8QPQ2UZ75V29GJ"[*
MID_(G:O"-.,/3ZB\QBC(>^R9%=B H&H:Q@(,;8BXY_%;:XW,('A/]_16HLX?
MEU<)]=*QL,%^B^]H$O$^'75.J',AACKJ?!%U'C!=M75)EPD<X=.;GO^3]CME
M6"-N%N"G$S8OBKYTAEIGJ.U.P&A5ZNP,M<Y0VUWJ[+1ZI]7?AC(/F*K:NJ2N
M%R3B]A[S<?+Q=X92+_$'CU_H'0UG9,^DSVDT&F>IZ(#V:Z6?!_%4G"P N2.
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MZ>EE-NX_=ASU1ASU@M5J Z\5K$9&"?/<T%>.=?[+01IQ.VRH,(]YE?CR=HB
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M.QK9$1K9;MTY(]]4[U9]QU;]92&E3>X'+W?P\@-!>6[ ^4AXRKQ]SZ)%3TS
M_"10$U"M5 G=JN^AD%]5KQ^H,#\(;?T<,<S]U)QR>3I6@P/[-!>N16J_EN%7
M0=HBVCE(\^/UM="885P0O35.LW@X2UQ#<<,++?(/BP[EB\K&Z:OYN^;>FPZ\
MA*9U;RU %.TKOG2<]K_1Y)(_6GUS/[AC!%S%%7_B;,QFS9,F*W0S'2E(8QE!
M[>3'I3T_B?^:F<;LBRHCV#2*AT'4.,9B2&<'>?*NLFD"VD*\7.84V+B&1?OJ
MV*Y[XT+,+7QA-'XJQF8Q-6(?5WRE$/EAN!#Z2I]E;_\8/)RPQ8K'B4_3_.N
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M!)^>EO4;\^H#YU>_.Q==Y8&V*^,6@7J@=L=!51Y K@R(2EP30UW1+,LP70T
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MFQ1<#"UC_A(:L0X5J_05-*"F=47Z=X;7=U6AMHV'$9QF/CBV @Q#U1V5F !
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M\B@IOQ<F>^R.D!T\?*U9RY8<(?N6E/5/4\[6/>F_P0< H#3R$NG."\?TDX1
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MRI>,&,\<7R?4^WGLW; IG7CAO?>8LJ$^#I("&D_P:LKK6 ,%*PXA6+$P^VH
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ML0%U8JLJMES3M8")@%(F$LDZTMT72:QMY -HNR&X]B=>V57QV/TJ'MK&JGA
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MR"(-$4.QC#F [N^X=O<1Q]9N9PGM'P6>IYL [)5YZ,'"\ZBN B\+&KNT' B
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M]ND TP$?"AG7M0%Y-LZF7WTMP"F:V3OV)$6W,H :022B-B8)80)P;5F3QH&
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M!UP@3:!&"9&U!L:&Z$W&KL-)GO2NU/LTO$&?@S[OJL\"M Q\0@ HH)':&@N
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M!7 *X-0+.'4:X!(H.!"<J-BZF(;$+$Y8X^>H!-@!@1/JKPZ%RI$ )*!30*>
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M;';F(.TL>Q-U[_AY-9U-BN:7SCYF#F$=L'ZNL=D!H;_IF1.F15Y$Q<KA7.J
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M\4F/7/AZ]-IVDH6J@Z__>EE9&5QQV. AC:).^U0#.58$8IPPG5"E6>- $*L
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MS'&/+A3Z['7WH#&-T4VK&&I]0JU/J/4)M3X#V5S>C;,N% (==2'0(X0B:,^
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M[QC8.'E-T*7C;!/O(86M $2OZISEB(2P 2"Q(D\Q"*LDF*J2U\-2.?LMO$S
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M[MM): :!%P2FD0 3%@Q9-^R5*"VV4"@+8G!ABJ-()L2"ZZ\<N$E9L7K8CQS
M_4[0C;GA01B?,]#4 W6#X;@&YS<D2'%6UHM["P34\IP#GKO4Z$57;3V,=3L
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MKNO[91Q?D[&G_&2^QT9H*])Z9R%*^25HV;=Q\BV&T[N;$/$^UOY8C'*A:=N
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M(C3CP/8BQTLB5TRW,RQ7/R3'>#.VM7:A[K.#P8E+'!.7.)Z-OXB9[G3M"IW
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MJR4E>RTIJ1>K,T\5 ,<$_CA^KNAZ7:F2KMJQZ8>.:3B!86F^$WH"ZJ'E>'N
M>B\?VQ+JJ_D,>X/ZB7D=+_-:U%N?5T]E'_'R'_,YZ/O#OBK)KV U@0Z-+).H
M0OD-<+W>;MGN?K1KOU"^7OZFY,#-.7=/43L!'$_G@&7S?#[):L+X,>P!9#CP
M^BH;9@!Q)LYKE OX.^H_:7'___R7JVO.3S40^!2053R4/8,]&X-C]86"BOVB
M\IZEP[%8#CEQ%'@ WC><E#66EL[0 ?O0"[EP8G>0:0 7DAW WL6O5\9I9Q[
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MF1J(GJ&2;&0QGS^9UPI.-IS24*^^>9%*4XM\^& "9']^.1R7DZP^_Q58!]S
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M-*?AI6^[F<UI>.EQ-+-Y\>&E U"LA]F,1<N8Z"3W;BM(4XIEGH:<'KX[SDN
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M ^DJNR^!\#5=X?#I=_GARE'HU0SW,<D'#K!%.ZSW4\Z^A'_]H)3LQ)'7,QK
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M)X!BY!K-* J3YEA+G +>P--@86WWS;RNFAE+OQRF%(V[$F7*'*'P=6QRZF+
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MC4G,F:-W(^ZTB#<%)?&09 T*L-*^H,Y#X:H\,<,9YR.4D0*I%P-V[6 =W (
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M9%Z KDJN8R1U?V2#$*/B(.@G;KQ;(F^KU=A'2GV%C!L.P')O>3,51)$GWHT
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M9?=ZG9WQI ](M1R!!CERFFP.['[W.5IHU319TV39:)@]; QJDCPHDMS[^EY
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M?A\YF,)W7\C_!NQV@/.'M4= G>X,*!66^Y 9'2'0_)W( %/+QTRD4C@'H\6
MC;_(C^JY$WBA:\!A&_C??%B3(/&0)N'4QA%65;J.9^<G@*."Q(9#C?#E, PU
M:#%04U?N2N#>5@Y2^@M(4AC%MN; =DC1U+9KNG1][#=#V*[[0)=^RC"'VQVK
MMX?^I+MUQVH.7Z^5;?]@NK.^?G^L=O-@-NN06QAF0;YQJT"Y)![U.=#"PHJP
M-PEJ 3 XX-%O(L8_#*V+^\Q-2Y9+$4Y<-A6DDJF:1'_O@YJ:NVCA.%$DP'Q8
M@F)R_YU),REQE/>^EW:Z/#LT]M #G$Y).& WP.%66H2\'A)YY<P/E3@ G%6>
MS<\M\S4[DF)S7Z18:1+<4R/>?73TJ+X2RU!7JD[888W8G;@542Q[(M!CLLT5
MJQ-NKB# Y2!]4CDN_!0&MVZ$8AP/0ZX@=K[O9/+?5)T'7K-+RIV*$%#O);7?
MR@4"#<:+_'/I(1KG@_([(WDZ;5J7-GTR.P#GF[V0M5>PFLI+PZR9. UA/3YZ
M@CAIX&OX @-3X.'S6FEQX+2F*UL+)R1ZPC^F;@26)7SK@HR=D*WYRI:1[/D:
M+<!@FSF>ESD=%7<#,;8M@J1L8=@;[AZ&R_Q7XH2Q",^M$;;]2^UJ.FEX_ZWC
M)?+7V&7&\2<8MW)</\(F,C,1DOJ!!\F:C,SFK=@+%YM-X;GX@8H(TF[/Q)3B
M!Z:0VNC>@^_Q,$PW%O ;]53U%<U[<U'4;DL+">.4)B*,81NYS6T4(QTBZ>%*
MW;EO_1..*)JZW%J]^HO>T(75:C2;O[F=UHUF7ZK1;*NS-WLG._/?W'\E[A3%
M&?+-I8-P>1XVP.,8?SGK;+"?V/@HVDE?[%,MVMQAE5);)D[$\7CZAX#] _&.
MATX?%EJYN_8+;#=;^VC6MZ]X76L?'>V=N/P<KL1$X'71_MP:C&AM/]>0NO8&
MD<NZ.5@)C--38&P2).KH%\ -8#-YQ%*&'R1[],*D@M"=NS[0$%A12!IT9S=L
M6%.0DQCK)ML2-F:*B@R^6@$3+L $X6F!#G,C&:]+WPWS 54FUI+RK%F"S85I
M1"-&-W;\;SS+&4S I\_0_'#CA)4CCY#&])P5W\;AHL[ OO%<:D(=K@*R]MPH
M2JBU\,=MGMT]\YUC/HI/+F*T@J<"I$F>@'H_:36P0R,1V9OSHAL3-)7.,&,
MPY;5<"C?_?*1KM*43#7N2JLCRW9S]O;,>L1;NM<B]<WF3HS13X\_2..M=:/
MHH2/W&SK1H%/'^SU^ZT4)CS5K>(>LVEOIQM<-0H2WBHY;"K'NJW;Y3:S^H5X
M9.O^E>L'^*IYPSND!9=;[?Z Q3OVL+M7R-S7/;XZ[;]FW3?"NIVNW>B7J@VM
MYO'M$PJ[LEKW0U%(YJ<=S;9:1E5^?6_F+-\(F@Q=;'[%Y,PDY#L:(WCJS(4_
M<?.W-,?>>F'0M[O[U4>UM?B:DNK8R'-@]QIU.[CJB=)+?;DT%>/C[ C7;+7M
M3JL,:$9E1>!;DG05):IVPVYTRR!^5UQP';QQ."J^ J_!V,Q?M'MV>P]H!8>
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MAX7SC:M""']@;#3&6)A@;9@J:0Y]H T%"J]H%;,P6!HG. :I)T(X,PXM^/,
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M5 ('CHJTE+EWAP<_I=",\K+)$>?[QW2R:!$1*@ JV7$2I^^:4!46HELS,DQ
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M BJUS*K76L=4/CAK7FB?8ZL5.=N*B>FJ@>F4WH0?HQ]Y!SZX"T=XUJ_GUJ?
M6R]%&*R"Q LBV_IP?E5Y$7YLHJQBY'X@Y%Q@E=1D79/U$9*U[@=$%YY;\LEJ
MZJZI^R"I^]X\R*I3=>UAU6NMO<G:FWS3WN365H[5D]?')K<J1ML'0KL%5DA-
MPS4-'SH-<[V0S*!&+Y'_J?->^<_-\J'['N,_P._D?^1^D]8597ZTU6P_B!2M
M04&*UO]2?XR#Z?J7__V?/R[BI??+_P=02P,$%     @ )#BG4+NJ?(K!'P
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MBJK_FXI*G!PG*:J)RJ]TP?-T:!1^=B3QM2H:"5F5(V DY0PI'A8<JT0-B0/
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M@,R 3>7C!U4]E_BA3N>(DR4(/)2CK$.DF<@"K@4X#6@VUB4>/N#/=*0(,2,
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M([ CN.2/L!9B@H4%54I9@.0O-X3I?5\YAI-SPV\PRQ PJ, ,O<.EXTZM.//
M%8,O'9OTRF 3QP/K>1"*/J%DL(Y0.(,$<QO)"0LG]RW-IJD1'/SO*)%Z7/@L
MQX::-5(IV_9R"%A2U#,A,YL6CKE% V#0%%*9<WV@U8-"9$Q^82-UZN$97R<D
M$Y =;$@L2$8SJS0.<<P@-WAL5DI>R[X:<#V-D4L^.[01%[*EBQXR@C1,VSHW
M(Q\K&2."!@E;"%_SY_;<K,!__-,.QTE]/M:\WG"A)C*W\O.DF44UD#HI.*WD
M]O4WX>M0&4%SR%Q=9=]4$0[5X>._8U 5'W.*1TV[F%=V7BQ?>GPW#K#:+*"]
MI**A,^E%.3>3K"B GZ]14O]*F^L70/TY&9IG\E&Y_2<#E[IAM>MY\=XT(%#B
M^J@.\)V3]"I+JI3*E0*5+B#SV^H'X(CGY?P/:?XT >EF@O1RBT/0IZ_3RN17
MS$(VTIJ=S2G(Q@0$%-C=LVG%]6"G%UR-U&>:CG\XHU&:"=V%HQ9G*]8SBHV&
M,@];;A)#3.90(Y&X 16J#4LK1%D(\YI$&O9_1!H>SI26L%I,]5$6!P$K7]Q+
M-41<!FT.WR^Q8MN-%E+>&2,F)=[BC_4F'U97C9(J5N3)-1XE+MTHG+.)T_%&
M=3>/30UM5UL_9E,DCXY5-E_L;&'&A.$A#151!7XEC##2.HH))G65TZR>P5 $
M(JMM>5X#IU0QHX(/X;-QW0UT#J:,HVH&R/,Q=3W1>9"\4LLF0479I R:%VTJ
M--GR=4A_Z+E/Y)$*"C<>YS>9JU$BG:JE/,1(E?O(&BO9S!2M]9 BJ<834-3&
M%C>;0BB%XP6D&U8F<S$:@01*E!=*9+IG453E35G<1AOKHMBO=!CBR^31'KL[
MJO0/5N=!N>55X^A7JJ"D:\RO\]&*FTMACK@4YH*J7L*9,2IA"FM&*FF+5M=I
M@JU_)[/:BDDPP2TV(058NM4L;1F,Z:+@=$]3KBS"7@(V%Z3%_T3Y;MKN!S=/
M,@OPZ<;7*H]T(6T:736A6C%]/5\\=Z-$WK"AHXX86?'G?&N,-BZE$OVNS0QY
MSBDV1W)FDHA]0+%FQ=<10AQQFI[&&INT!-; X==!E7O',,:TFN#4Q*1UL8$
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M<:NX'Q4\RZFY0SWH,?4&/$+A"@UL%'X\KE*3S'/KY=ZNQ,<WM>7;WGS9+:J
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M9#_TLWCV[L]OMT?E.'GW_U!+ P04    "  D.*=0@NF1C'8(  ".-   %P
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MD9Q=\[*'3@88IN#6Q H2#1A,P9G0>$K2V.J4PU*0>K@L!)!$200M+:@D(QK
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M$IB M;:>+P>-_P=?]@Z_DS!T"PESR@TL!KAQ*<>W05W&;"B@J5E_"*8E0PX
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M+3(P,C P,S,Q7VQA8BYX;6Q02P$"% ,4    "  D.*=0L&BH!?1E  !F804
M%0              @ %\!@$ =FYD82TR,#(P,#,S,5]P<F4N>&UL4$L! A0#
M%     @ )#BG4 B&-0F,=0$ ./$0 !(              ( !HVP! '9N9&$S
M,S$R,#(P,3!Q+FAT;5!+ 0(4 Q0    ( "0XIU"[JGR*P1\  ,.]   8
M          "  5_B @!V;F1A97@Q,#0R,S,Q,C R,#$P<2YH=&U02P$"% ,4
M    "  D.*=0@NF1C'8(  ".-   %P              @ %6 @, =FYD865X
M,S$Q,S,Q,C R,#$P<2YH=&U02P$"% ,4    "  D.*=0;[QFA( (  !D-
M%P              @ $!"P, =FYD865X,S$R,S,Q,C R,#$P<2YH=&U02P$"
M% ,4    "  D.*=01G@98X<&  ![)   %P              @ &V$P, =FYD
J865X,S(Q,S,Q,C R,#$P<2YH=&U02P4&      H "@"@ @  <AH#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6894598096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - (Stock-Based Compensation) - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember', window );">2006 Plan and 2016 Plan | Outstanding options and RSUs granted (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber', window );">Shares subject to outstanding options and RSUs (in shares)</a></td>
<td class="nump">6,335,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixteenPlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares of common stock available for future grant (in shares)</a></td>
<td class="nump">2,153,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including vested and non-vested options, as of the balance sheet, plus the number of non-vested restricted stock units outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsRSUOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnda_TwoThousandSixPlanAndTwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vnda_StockOptionsAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vnda_StockOptionsAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vnda_TwoThousandSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vnda_TwoThousandSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882766912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity Plan (Detail) - Restricted Stock Units (RSU)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares Unvested</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1,649,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">745,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(136,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(498,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,760,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Price/Share Unvested</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">11.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">18.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">16.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6882323776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 1,320<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory, current</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrentAbstract', window );"><strong>Non-Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryRawMaterialsNetOfReservesNonCurrent', window );">Raw materials</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryWorkInProcessNetOfReservesNonCurrent', window );">Work-in-process</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent', window );">Finished goods</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Total inventory, non-current</a></td>
<td class="nump">2,542<span></span>
</td>
<td class="nump">2,824<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vnda_Inventory', window );">Total inventory</a></td>
<td class="nump">$ 3,862<span></span>
</td>
<td class="nump">$ 3,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_Inventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_Inventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryFinishedGoodsNetOfReservesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finished goods inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryFinishedGoodsNetOfReservesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryRawMaterialsNetOfReservesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Raw materials inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryRawMaterialsNetOfReservesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vnda_InventoryWorkInProcessNetOfReservesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Work in process inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vnda_InventoryWorkInProcessNetOfReservesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vnda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6880661776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Sales by Product (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 47,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_HetliozMember', window );">HETLIOZ&#174; product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">35,336<span></span>
</td>
<td class="nump">28,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vnda_FanaptMember', window );">Fanapt&#174; product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 22,664<span></span>
</td>
<td class="nump">$ 18,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_HetliozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_HetliozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vnda_FanaptMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vnda_FanaptMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796667936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than two years:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,014</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>87,572</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122,964</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>572</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(110</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,386</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>246,364</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,186</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(174</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s available-for-sale marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which all have contractual maturities of less than two years:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Market</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. Treasury and government agencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>88,601</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129,860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>130,055</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total marketable securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>266,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6883635584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the Company&#8217;s accounts payable and accrued liabilities as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consulting and other professional fees</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,636</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,376</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,893</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Royalties payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,912</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,904</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Compensation and employee benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,597</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,795</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accounts payable and accrued liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796671440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded income tax expense of&#160;$</span><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span><span style="font-family:inherit;font-size:10pt;"> million&#160;and less than </span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;">, respectively. The income tax expense for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> was primarily driven by the estimated effective tax rate for the year and the discrete impact of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of net shortfall tax expense related to stock-based compensation activity during the quarter. As a result of the tax valuation allowance against deferred tax assets in the U.S., there was no benefit for federal income taxes associated with the loss before taxes for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">. Income taxes were recorded related to certain U.S. state and foreign jurisdictions for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span style="font-family:inherit;font-size:10pt;">The Company assesses the need for a valuation allowance against its deferred tax asset each quarter through the review of all available positive and negative evidence. Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more likely than not that some portion of the deferred tax assets will not be realized. The analysis depends on historical and projected taxable income. Projected taxable income includes significant assumptions related to revenue, commercial expenses and research and development activities. During the third quarter of 2019, after considering all available positive and negative evidence, including but not limited to cumulative income in recent periods, historical, current and future projected results and significant risks and uncertainties related to forecasts, the Company concluded that it was more likely than not that substantially all of its deferred tax assets in the U.S. are realizable in future periods. A valuation allowance was retained against certain U.S. federal tax attributes with short carryforward periods and District of Columbia state deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">March&#160;31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
